(function(){const c=document.createElement("link").relList;if(c&&c.supports&&c.supports("modulepreload"))return;for(const _ of document.querySelectorAll('link[rel="modulepreload"]'))u(_);new MutationObserver(_=>{for(const E of _)if(E.type==="childList")for(const O of E.addedNodes)O.tagName==="LINK"&&O.rel==="modulepreload"&&u(O)}).observe(document,{childList:!0,subtree:!0});function d(_){const E={};return _.integrity&&(E.integrity=_.integrity),_.referrerPolicy&&(E.referrerPolicy=_.referrerPolicy),_.crossOrigin==="use-credentials"?E.credentials="include":_.crossOrigin==="anonymous"?E.credentials="omit":E.credentials="same-origin",E}function u(_){if(_.ep)return;_.ep=!0;const E=d(_);fetch(_.href,E)}})();var ol={exports:{}},An={};/**
 * @license React
 * react-jsx-runtime.production.js
 *
 * Copyright (c) Meta Platforms, Inc. and affiliates.
 *
 * This source code is licensed under the MIT license found in the
 * LICENSE file in the root directory of this source tree.
 */var cd;function Xf(){if(cd)return An;cd=1;var m=Symbol.for("react.transitional.element"),c=Symbol.for("react.fragment");function d(u,_,E){var O=null;if(E!==void 0&&(O=""+E),_.key!==void 0&&(O=""+_.key),"key"in _){E={};for(var P in _)P!=="key"&&(E[P]=_[P])}else E=_;return _=E.ref,{$$typeof:m,type:u,key:O,ref:_!==void 0?_:null,props:E}}return An.Fragment=c,An.jsx=d,An.jsxs=d,An}var md;function Kf(){return md||(md=1,ol.exports=Xf()),ol.exports}var s=Kf(),rl={exports:{}},me={};/**
 * @license React
 * react.production.js
 *
 * Copyright (c) Meta Platforms, Inc. and affiliates.
 *
 * This source code is licensed under the MIT license found in the
 * LICENSE file in the root directory of this source tree.
 */var ud;function Qf(){if(ud)return me;ud=1;var m=Symbol.for("react.transitional.element"),c=Symbol.for("react.portal"),d=Symbol.for("react.fragment"),u=Symbol.for("react.strict_mode"),_=Symbol.for("react.profiler"),E=Symbol.for("react.consumer"),O=Symbol.for("react.context"),P=Symbol.for("react.forward_ref"),L=Symbol.for("react.suspense"),y=Symbol.for("react.memo"),z=Symbol.for("react.lazy"),q=Symbol.iterator;function ie(f){return f===null||typeof f!="object"?null:(f=q&&f[q]||f["@@iterator"],typeof f=="function"?f:null)}var B={isMounted:function(){return!1},enqueueForceUpdate:function(){},enqueueReplaceState:function(){},enqueueSetState:function(){}},Q=Object.assign,H={};function Y(f,R,T){this.props=f,this.context=R,this.refs=H,this.updater=T||B}Y.prototype.isReactComponent={},Y.prototype.setState=function(f,R){if(typeof f!="object"&&typeof f!="function"&&f!=null)throw Error("takes an object of state variables to update or a function which returns an object of state variables.");this.updater.enqueueSetState(this,f,R,"setState")},Y.prototype.forceUpdate=function(f){this.updater.enqueueForceUpdate(this,f,"forceUpdate")};function M(){}M.prototype=Y.prototype;function V(f,R,T){this.props=f,this.context=R,this.refs=H,this.updater=T||B}var X=V.prototype=new M;X.constructor=V,Q(X,Y.prototype),X.isPureReactComponent=!0;var Z=Array.isArray,K={H:null,A:null,T:null,S:null,V:null},G=Object.prototype.hasOwnProperty;function F(f,R,T,C,I,U){return T=U.ref,{$$typeof:m,type:f,key:R,ref:T!==void 0?T:null,props:U}}function se(f,R){return F(f.type,R,void 0,void 0,void 0,f.props)}function w(f){return typeof f=="object"&&f!==null&&f.$$typeof===m}function ue(f){var R={"=":"=0",":":"=2"};return"$"+f.replace(/[=:]/g,function(T){return R[T]})}var le=/\/+/g;function W(f,R){return typeof f=="object"&&f!==null&&f.key!=null?ue(""+f.key):R.toString(36)}function re(){}function de(f){switch(f.status){case"fulfilled":return f.value;case"rejected":throw f.reason;default:switch(typeof f.status=="string"?f.then(re,re):(f.status="pending",f.then(function(R){f.status==="pending"&&(f.status="fulfilled",f.value=R)},function(R){f.status==="pending"&&(f.status="rejected",f.reason=R)})),f.status){case"fulfilled":return f.value;case"rejected":throw f.reason}}throw f}function ce(f,R,T,C,I){var U=typeof f;(U==="undefined"||U==="boolean")&&(f=null);var ee=!1;if(f===null)ee=!0;else switch(U){case"bigint":case"string":case"number":ee=!0;break;case"object":switch(f.$$typeof){case m:case c:ee=!0;break;case z:return ee=f._init,ce(ee(f._payload),R,T,C,I)}}if(ee)return I=I(f),ee=C===""?"."+W(f,0):C,Z(I)?(T="",ee!=null&&(T=ee.replace(le,"$&/")+"/"),ce(I,R,T,"",function(Ft){return Ft})):I!=null&&(w(I)&&(I=se(I,T+(I.key==null||f&&f.key===I.key?"":(""+I.key).replace(le,"$&/")+"/")+ee)),R.push(I)),1;ee=0;var Te=C===""?".":C+":";if(Z(f))for(var je=0;je<f.length;je++)C=f[je],U=Te+W(C,je),ee+=ce(C,R,T,U,I);else if(je=ie(f),typeof je=="function")for(f=je.call(f),je=0;!(C=f.next()).done;)C=C.value,U=Te+W(C,je++),ee+=ce(C,R,T,U,I);else if(U==="object"){if(typeof f.then=="function")return ce(de(f),R,T,C,I);throw R=String(f),Error("Objects are not valid as a React child (found: "+(R==="[object Object]"?"object with keys {"+Object.keys(f).join(", ")+"}":R)+"). If you meant to render a collection of children, use an array instead.")}return ee}function x(f,R,T){if(f==null)return f;var C=[],I=0;return ce(f,C,"","",function(U){return R.call(T,U,I++)}),C}function D(f){if(f._status===-1){var R=f._result;R=R(),R.then(function(T){(f._status===0||f._status===-1)&&(f._status=1,f._result=T)},function(T){(f._status===0||f._status===-1)&&(f._status=2,f._result=T)}),f._status===-1&&(f._status=0,f._result=R)}if(f._status===1)return f._result.default;throw f._result}var $=typeof reportError=="function"?reportError:function(f){if(typeof window=="object"&&typeof window.ErrorEvent=="function"){var R=new window.ErrorEvent("error",{bubbles:!0,cancelable:!0,message:typeof f=="object"&&f!==null&&typeof f.message=="string"?String(f.message):String(f),error:f});if(!window.dispatchEvent(R))return}else if(typeof process=="object"&&typeof process.emit=="function"){process.emit("uncaughtException",f);return}console.error(f)};function fe(){}return me.Children={map:x,forEach:function(f,R,T){x(f,function(){R.apply(this,arguments)},T)},count:function(f){var R=0;return x(f,function(){R++}),R},toArray:function(f){return x(f,function(R){return R})||[]},only:function(f){if(!w(f))throw Error("React.Children.only expected to receive a single React element child.");return f}},me.Component=Y,me.Fragment=d,me.Profiler=_,me.PureComponent=V,me.StrictMode=u,me.Suspense=L,me.__CLIENT_INTERNALS_DO_NOT_USE_OR_WARN_USERS_THEY_CANNOT_UPGRADE=K,me.__COMPILER_RUNTIME={__proto__:null,c:function(f){return K.H.useMemoCache(f)}},me.cache=function(f){return function(){return f.apply(null,arguments)}},me.cloneElement=function(f,R,T){if(f==null)throw Error("The argument must be a React element, but you passed "+f+".");var C=Q({},f.props),I=f.key,U=void 0;if(R!=null)for(ee in R.ref!==void 0&&(U=void 0),R.key!==void 0&&(I=""+R.key),R)!G.call(R,ee)||ee==="key"||ee==="__self"||ee==="__source"||ee==="ref"&&R.ref===void 0||(C[ee]=R[ee]);var ee=arguments.length-2;if(ee===1)C.children=T;else if(1<ee){for(var Te=Array(ee),je=0;je<ee;je++)Te[je]=arguments[je+2];C.children=Te}return F(f.type,I,void 0,void 0,U,C)},me.createContext=function(f){return f={$$typeof:O,_currentValue:f,_currentValue2:f,_threadCount:0,Provider:null,Consumer:null},f.Provider=f,f.Consumer={$$typeof:E,_context:f},f},me.createElement=function(f,R,T){var C,I={},U=null;if(R!=null)for(C in R.key!==void 0&&(U=""+R.key),R)G.call(R,C)&&C!=="key"&&C!=="__self"&&C!=="__source"&&(I[C]=R[C]);var ee=arguments.length-2;if(ee===1)I.children=T;else if(1<ee){for(var Te=Array(ee),je=0;je<ee;je++)Te[je]=arguments[je+2];I.children=Te}if(f&&f.defaultProps)for(C in ee=f.defaultProps,ee)I[C]===void 0&&(I[C]=ee[C]);return F(f,U,void 0,void 0,null,I)},me.createRef=function(){return{current:null}},me.forwardRef=function(f){return{$$typeof:P,render:f}},me.isValidElement=w,me.lazy=function(f){return{$$typeof:z,_payload:{_status:-1,_result:f},_init:D}},me.memo=function(f,R){return{$$typeof:y,type:f,compare:R===void 0?null:R}},me.startTransition=function(f){var R=K.T,T={};K.T=T;try{var C=f(),I=K.S;I!==null&&I(T,C),typeof C=="object"&&C!==null&&typeof C.then=="function"&&C.then(fe,$)}catch(U){$(U)}finally{K.T=R}},me.unstable_useCacheRefresh=function(){return K.H.useCacheRefresh()},me.use=function(f){return K.H.use(f)},me.useActionState=function(f,R,T){return K.H.useActionState(f,R,T)},me.useCallback=function(f,R){return K.H.useCallback(f,R)},me.useContext=function(f){return K.H.useContext(f)},me.useDebugValue=function(){},me.useDeferredValue=function(f,R){return K.H.useDeferredValue(f,R)},me.useEffect=function(f,R,T){var C=K.H;if(typeof T=="function")throw Error("useEffect CRUD overload is not enabled in this build of React.");return C.useEffect(f,R)},me.useId=function(){return K.H.useId()},me.useImperativeHandle=function(f,R,T){return K.H.useImperativeHandle(f,R,T)},me.useInsertionEffect=function(f,R){return K.H.useInsertionEffect(f,R)},me.useLayoutEffect=function(f,R){return K.H.useLayoutEffect(f,R)},me.useMemo=function(f,R){return K.H.useMemo(f,R)},me.useOptimistic=function(f,R){return K.H.useOptimistic(f,R)},me.useReducer=function(f,R,T){return K.H.useReducer(f,R,T)},me.useRef=function(f){return K.H.useRef(f)},me.useState=function(f){return K.H.useState(f)},me.useSyncExternalStore=function(f,R,T){return K.H.useSyncExternalStore(f,R,T)},me.useTransition=function(){return K.H.useTransition()},me.version="19.1.0",me}var dd;function bl(){return dd||(dd=1,rl.exports=Qf()),rl.exports}var _e=bl(),ll={exports:{}},En={},cl={exports:{}},ml={};/**
 * @license React
 * scheduler.production.js
 *
 * Copyright (c) Meta Platforms, Inc. and affiliates.
 *
 * This source code is licensed under the MIT license found in the
 * LICENSE file in the root directory of this source tree.
 */var pd;function Zf(){return pd||(pd=1,function(m){function c(x,D){var $=x.length;x.push(D);e:for(;0<$;){var fe=$-1>>>1,f=x[fe];if(0<_(f,D))x[fe]=D,x[$]=f,$=fe;else break e}}function d(x){return x.length===0?null:x[0]}function u(x){if(x.length===0)return null;var D=x[0],$=x.pop();if($!==D){x[0]=$;e:for(var fe=0,f=x.length,R=f>>>1;fe<R;){var T=2*(fe+1)-1,C=x[T],I=T+1,U=x[I];if(0>_(C,$))I<f&&0>_(U,C)?(x[fe]=U,x[I]=$,fe=I):(x[fe]=C,x[T]=$,fe=T);else if(I<f&&0>_(U,$))x[fe]=U,x[I]=$,fe=I;else break e}}return D}function _(x,D){var $=x.sortIndex-D.sortIndex;return $!==0?$:x.id-D.id}if(m.unstable_now=void 0,typeof performance=="object"&&typeof performance.now=="function"){var E=performance;m.unstable_now=function(){return E.now()}}else{var O=Date,P=O.now();m.unstable_now=function(){return O.now()-P}}var L=[],y=[],z=1,q=null,ie=3,B=!1,Q=!1,H=!1,Y=!1,M=typeof setTimeout=="function"?setTimeout:null,V=typeof clearTimeout=="function"?clearTimeout:null,X=typeof setImmediate<"u"?setImmediate:null;function Z(x){for(var D=d(y);D!==null;){if(D.callback===null)u(y);else if(D.startTime<=x)u(y),D.sortIndex=D.expirationTime,c(L,D);else break;D=d(y)}}function K(x){if(H=!1,Z(x),!Q)if(d(L)!==null)Q=!0,G||(G=!0,W());else{var D=d(y);D!==null&&ce(K,D.startTime-x)}}var G=!1,F=-1,se=5,w=-1;function ue(){return Y?!0:!(m.unstable_now()-w<se)}function le(){if(Y=!1,G){var x=m.unstable_now();w=x;var D=!0;try{e:{Q=!1,H&&(H=!1,V(F),F=-1),B=!0;var $=ie;try{t:{for(Z(x),q=d(L);q!==null&&!(q.expirationTime>x&&ue());){var fe=q.callback;if(typeof fe=="function"){q.callback=null,ie=q.priorityLevel;var f=fe(q.expirationTime<=x);if(x=m.unstable_now(),typeof f=="function"){q.callback=f,Z(x),D=!0;break t}q===d(L)&&u(L),Z(x)}else u(L);q=d(L)}if(q!==null)D=!0;else{var R=d(y);R!==null&&ce(K,R.startTime-x),D=!1}}break e}finally{q=null,ie=$,B=!1}D=void 0}}finally{D?W():G=!1}}}var W;if(typeof X=="function")W=function(){X(le)};else if(typeof MessageChannel<"u"){var re=new MessageChannel,de=re.port2;re.port1.onmessage=le,W=function(){de.postMessage(null)}}else W=function(){M(le,0)};function ce(x,D){F=M(function(){x(m.unstable_now())},D)}m.unstable_IdlePriority=5,m.unstable_ImmediatePriority=1,m.unstable_LowPriority=4,m.unstable_NormalPriority=3,m.unstable_Profiling=null,m.unstable_UserBlockingPriority=2,m.unstable_cancelCallback=function(x){x.callback=null},m.unstable_forceFrameRate=function(x){0>x||125<x?console.error("forceFrameRate takes a positive int between 0 and 125, forcing frame rates higher than 125 fps is not supported"):se=0<x?Math.floor(1e3/x):5},m.unstable_getCurrentPriorityLevel=function(){return ie},m.unstable_next=function(x){switch(ie){case 1:case 2:case 3:var D=3;break;default:D=ie}var $=ie;ie=D;try{return x()}finally{ie=$}},m.unstable_requestPaint=function(){Y=!0},m.unstable_runWithPriority=function(x,D){switch(x){case 1:case 2:case 3:case 4:case 5:break;default:x=3}var $=ie;ie=x;try{return D()}finally{ie=$}},m.unstable_scheduleCallback=function(x,D,$){var fe=m.unstable_now();switch(typeof $=="object"&&$!==null?($=$.delay,$=typeof $=="number"&&0<$?fe+$:fe):$=fe,x){case 1:var f=-1;break;case 2:f=250;break;case 5:f=1073741823;break;case 4:f=1e4;break;default:f=5e3}return f=$+f,x={id:z++,callback:D,priorityLevel:x,startTime:$,expirationTime:f,sortIndex:-1},$>fe?(x.sortIndex=$,c(y,x),d(L)===null&&x===d(y)&&(H?(V(F),F=-1):H=!0,ce(K,$-fe))):(x.sortIndex=f,c(L,x),Q||B||(Q=!0,G||(G=!0,W()))),x},m.unstable_shouldYield=ue,m.unstable_wrapCallback=function(x){var D=ie;return function(){var $=ie;ie=D;try{return x.apply(this,arguments)}finally{ie=$}}}}(ml)),ml}var fd;function Jf(){return fd||(fd=1,cl.exports=Zf()),cl.exports}var ul={exports:{}},Fe={};/**
 * @license React
 * react-dom.production.js
 *
 * Copyright (c) Meta Platforms, Inc. and affiliates.
 *
 * This source code is licensed under the MIT license found in the
 * LICENSE file in the root directory of this source tree.
 */var bd;function Ff(){if(bd)return Fe;bd=1;var m=bl();function c(L){var y="https://react.dev/errors/"+L;if(1<arguments.length){y+="?args[]="+encodeURIComponent(arguments[1]);for(var z=2;z<arguments.length;z++)y+="&args[]="+encodeURIComponent(arguments[z])}return"Minified React error #"+L+"; visit "+y+" for the full message or use the non-minified dev environment for full errors and additional helpful warnings."}function d(){}var u={d:{f:d,r:function(){throw Error(c(522))},D:d,C:d,L:d,m:d,X:d,S:d,M:d},p:0,findDOMNode:null},_=Symbol.for("react.portal");function E(L,y,z){var q=3<arguments.length&&arguments[3]!==void 0?arguments[3]:null;return{$$typeof:_,key:q==null?null:""+q,children:L,containerInfo:y,implementation:z}}var O=m.__CLIENT_INTERNALS_DO_NOT_USE_OR_WARN_USERS_THEY_CANNOT_UPGRADE;function P(L,y){if(L==="font")return"";if(typeof y=="string")return y==="use-credentials"?y:""}return Fe.__DOM_INTERNALS_DO_NOT_USE_OR_WARN_USERS_THEY_CANNOT_UPGRADE=u,Fe.createPortal=function(L,y){var z=2<arguments.length&&arguments[2]!==void 0?arguments[2]:null;if(!y||y.nodeType!==1&&y.nodeType!==9&&y.nodeType!==11)throw Error(c(299));return E(L,y,null,z)},Fe.flushSync=function(L){var y=O.T,z=u.p;try{if(O.T=null,u.p=2,L)return L()}finally{O.T=y,u.p=z,u.d.f()}},Fe.preconnect=function(L,y){typeof L=="string"&&(y?(y=y.crossOrigin,y=typeof y=="string"?y==="use-credentials"?y:"":void 0):y=null,u.d.C(L,y))},Fe.prefetchDNS=function(L){typeof L=="string"&&u.d.D(L)},Fe.preinit=function(L,y){if(typeof L=="string"&&y&&typeof y.as=="string"){var z=y.as,q=P(z,y.crossOrigin),ie=typeof y.integrity=="string"?y.integrity:void 0,B=typeof y.fetchPriority=="string"?y.fetchPriority:void 0;z==="style"?u.d.S(L,typeof y.precedence=="string"?y.precedence:void 0,{crossOrigin:q,integrity:ie,fetchPriority:B}):z==="script"&&u.d.X(L,{crossOrigin:q,integrity:ie,fetchPriority:B,nonce:typeof y.nonce=="string"?y.nonce:void 0})}},Fe.preinitModule=function(L,y){if(typeof L=="string")if(typeof y=="object"&&y!==null){if(y.as==null||y.as==="script"){var z=P(y.as,y.crossOrigin);u.d.M(L,{crossOrigin:z,integrity:typeof y.integrity=="string"?y.integrity:void 0,nonce:typeof y.nonce=="string"?y.nonce:void 0})}}else y==null&&u.d.M(L)},Fe.preload=function(L,y){if(typeof L=="string"&&typeof y=="object"&&y!==null&&typeof y.as=="string"){var z=y.as,q=P(z,y.crossOrigin);u.d.L(L,z,{crossOrigin:q,integrity:typeof y.integrity=="string"?y.integrity:void 0,nonce:typeof y.nonce=="string"?y.nonce:void 0,type:typeof y.type=="string"?y.type:void 0,fetchPriority:typeof y.fetchPriority=="string"?y.fetchPriority:void 0,referrerPolicy:typeof y.referrerPolicy=="string"?y.referrerPolicy:void 0,imageSrcSet:typeof y.imageSrcSet=="string"?y.imageSrcSet:void 0,imageSizes:typeof y.imageSizes=="string"?y.imageSizes:void 0,media:typeof y.media=="string"?y.media:void 0})}},Fe.preloadModule=function(L,y){if(typeof L=="string")if(y){var z=P(y.as,y.crossOrigin);u.d.m(L,{as:typeof y.as=="string"&&y.as!=="script"?y.as:void 0,crossOrigin:z,integrity:typeof y.integrity=="string"?y.integrity:void 0})}else u.d.m(L)},Fe.requestFormReset=function(L){u.d.r(L)},Fe.unstable_batchedUpdates=function(L,y){return L(y)},Fe.useFormState=function(L,y,z){return O.H.useFormState(L,y,z)},Fe.useFormStatus=function(){return O.H.useHostTransitionStatus()},Fe.version="19.1.0",Fe}var gd;function $f(){if(gd)return ul.exports;gd=1;function m(){if(!(typeof __REACT_DEVTOOLS_GLOBAL_HOOK__>"u"||typeof __REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE!="function"))try{__REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE(m)}catch(c){console.error(c)}}return m(),ul.exports=Ff(),ul.exports}/**
 * @license React
 * react-dom-client.production.js
 *
 * Copyright (c) Meta Platforms, Inc. and affiliates.
 *
 * This source code is licensed under the MIT license found in the
 * LICENSE file in the root directory of this source tree.
 */var hd;function Wf(){if(hd)return En;hd=1;var m=Jf(),c=bl(),d=$f();function u(e){var t="https://react.dev/errors/"+e;if(1<arguments.length){t+="?args[]="+encodeURIComponent(arguments[1]);for(var i=2;i<arguments.length;i++)t+="&args[]="+encodeURIComponent(arguments[i])}return"Minified React error #"+e+"; visit "+t+" for the full message or use the non-minified dev environment for full errors and additional helpful warnings."}function _(e){return!(!e||e.nodeType!==1&&e.nodeType!==9&&e.nodeType!==11)}function E(e){var t=e,i=e;if(e.alternate)for(;t.return;)t=t.return;else{e=t;do t=e,(t.flags&4098)!==0&&(i=t.return),e=t.return;while(e)}return t.tag===3?i:null}function O(e){if(e.tag===13){var t=e.memoizedState;if(t===null&&(e=e.alternate,e!==null&&(t=e.memoizedState)),t!==null)return t.dehydrated}return null}function P(e){if(E(e)!==e)throw Error(u(188))}function L(e){var t=e.alternate;if(!t){if(t=E(e),t===null)throw Error(u(188));return t!==e?null:e}for(var i=e,a=t;;){var n=i.return;if(n===null)break;var o=n.alternate;if(o===null){if(a=n.return,a!==null){i=a;continue}break}if(n.child===o.child){for(o=n.child;o;){if(o===i)return P(n),e;if(o===a)return P(n),t;o=o.sibling}throw Error(u(188))}if(i.return!==a.return)i=n,a=o;else{for(var r=!1,l=n.child;l;){if(l===i){r=!0,i=n,a=o;break}if(l===a){r=!0,a=n,i=o;break}l=l.sibling}if(!r){for(l=o.child;l;){if(l===i){r=!0,i=o,a=n;break}if(l===a){r=!0,a=o,i=n;break}l=l.sibling}if(!r)throw Error(u(189))}}if(i.alternate!==a)throw Error(u(190))}if(i.tag!==3)throw Error(u(188));return i.stateNode.current===i?e:t}function y(e){var t=e.tag;if(t===5||t===26||t===27||t===6)return e;for(e=e.child;e!==null;){if(t=y(e),t!==null)return t;e=e.sibling}return null}var z=Object.assign,q=Symbol.for("react.element"),ie=Symbol.for("react.transitional.element"),B=Symbol.for("react.portal"),Q=Symbol.for("react.fragment"),H=Symbol.for("react.strict_mode"),Y=Symbol.for("react.profiler"),M=Symbol.for("react.provider"),V=Symbol.for("react.consumer"),X=Symbol.for("react.context"),Z=Symbol.for("react.forward_ref"),K=Symbol.for("react.suspense"),G=Symbol.for("react.suspense_list"),F=Symbol.for("react.memo"),se=Symbol.for("react.lazy"),w=Symbol.for("react.activity"),ue=Symbol.for("react.memo_cache_sentinel"),le=Symbol.iterator;function W(e){return e===null||typeof e!="object"?null:(e=le&&e[le]||e["@@iterator"],typeof e=="function"?e:null)}var re=Symbol.for("react.client.reference");function de(e){if(e==null)return null;if(typeof e=="function")return e.$$typeof===re?null:e.displayName||e.name||null;if(typeof e=="string")return e;switch(e){case Q:return"Fragment";case Y:return"Profiler";case H:return"StrictMode";case K:return"Suspense";case G:return"SuspenseList";case w:return"Activity"}if(typeof e=="object")switch(e.$$typeof){case B:return"Portal";case X:return(e.displayName||"Context")+".Provider";case V:return(e._context.displayName||"Context")+".Consumer";case Z:var t=e.render;return e=e.displayName,e||(e=t.displayName||t.name||"",e=e!==""?"ForwardRef("+e+")":"ForwardRef"),e;case F:return t=e.displayName||null,t!==null?t:de(e.type)||"Memo";case se:t=e._payload,e=e._init;try{return de(e(t))}catch{}}return null}var ce=Array.isArray,x=c.__CLIENT_INTERNALS_DO_NOT_USE_OR_WARN_USERS_THEY_CANNOT_UPGRADE,D=d.__DOM_INTERNALS_DO_NOT_USE_OR_WARN_USERS_THEY_CANNOT_UPGRADE,$={pending:!1,data:null,method:null,action:null},fe=[],f=-1;function R(e){return{current:e}}function T(e){0>f||(e.current=fe[f],fe[f]=null,f--)}function C(e,t){f++,fe[f]=e.current,e.current=t}var I=R(null),U=R(null),ee=R(null),Te=R(null);function je(e,t){switch(C(ee,t),C(U,e),C(I,null),t.nodeType){case 9:case 11:e=(e=t.documentElement)&&(e=e.namespaceURI)?Ou(e):0;break;default:if(e=t.tagName,t=t.namespaceURI)t=Ou(t),e=Pu(t,e);else switch(e){case"svg":e=1;break;case"math":e=2;break;default:e=0}}T(I),C(I,e)}function Ft(){T(I),T(U),T(ee)}function Gs(e){e.memoizedState!==null&&C(Te,e);var t=I.current,i=Pu(t,e.type);t!==i&&(C(U,e),C(I,i))}function jn(e){U.current===e&&(T(I),T(U)),Te.current===e&&(T(Te),xn._currentValue=$)}var Ys=Object.prototype.hasOwnProperty,Xs=m.unstable_scheduleCallback,Ks=m.unstable_cancelCallback,_d=m.unstable_shouldYield,Cd=m.unstable_requestPaint,At=m.unstable_now,Nd=m.unstable_getCurrentPriorityLevel,hl=m.unstable_ImmediatePriority,yl=m.unstable_UserBlockingPriority,Rn=m.unstable_NormalPriority,Ad=m.unstable_LowPriority,vl=m.unstable_IdlePriority,Ed=m.log,jd=m.unstable_setDisableYieldValue,ja=null,nt=null;function $t(e){if(typeof Ed=="function"&&jd(e),nt&&typeof nt.setStrictMode=="function")try{nt.setStrictMode(ja,e)}catch{}}var st=Math.clz32?Math.clz32:Dd,Rd=Math.log,Td=Math.LN2;function Dd(e){return e>>>=0,e===0?32:31-(Rd(e)/Td|0)|0}var Tn=256,Dn=4194304;function Si(e){var t=e&42;if(t!==0)return t;switch(e&-e){case 1:return 1;case 2:return 2;case 4:return 4;case 8:return 8;case 16:return 16;case 32:return 32;case 64:return 64;case 128:return 128;case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:return e&4194048;case 4194304:case 8388608:case 16777216:case 33554432:return e&62914560;case 67108864:return 67108864;case 134217728:return 134217728;case 268435456:return 268435456;case 536870912:return 536870912;case 1073741824:return 0;default:return e}}function Ln(e,t,i){var a=e.pendingLanes;if(a===0)return 0;var n=0,o=e.suspendedLanes,r=e.pingedLanes;e=e.warmLanes;var l=a&134217727;return l!==0?(a=l&~o,a!==0?n=Si(a):(r&=l,r!==0?n=Si(r):i||(i=l&~e,i!==0&&(n=Si(i))))):(l=a&~o,l!==0?n=Si(l):r!==0?n=Si(r):i||(i=a&~e,i!==0&&(n=Si(i)))),n===0?0:t!==0&&t!==n&&(t&o)===0&&(o=n&-n,i=t&-t,o>=i||o===32&&(i&4194048)!==0)?t:n}function Ra(e,t){return(e.pendingLanes&~(e.suspendedLanes&~e.pingedLanes)&t)===0}function Ld(e,t){switch(e){case 1:case 2:case 4:case 8:case 64:return t+250;case 16:case 32:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:return t+5e3;case 4194304:case 8388608:case 16777216:case 33554432:return-1;case 67108864:case 134217728:case 268435456:case 536870912:case 1073741824:return-1;default:return-1}}function kl(){var e=Tn;return Tn<<=1,(Tn&4194048)===0&&(Tn=256),e}function xl(){var e=Dn;return Dn<<=1,(Dn&62914560)===0&&(Dn=4194304),e}function Qs(e){for(var t=[],i=0;31>i;i++)t.push(e);return t}function Ta(e,t){e.pendingLanes|=t,t!==268435456&&(e.suspendedLanes=0,e.pingedLanes=0,e.warmLanes=0)}function Md(e,t,i,a,n,o){var r=e.pendingLanes;e.pendingLanes=i,e.suspendedLanes=0,e.pingedLanes=0,e.warmLanes=0,e.expiredLanes&=i,e.entangledLanes&=i,e.errorRecoveryDisabledLanes&=i,e.shellSuspendCounter=0;var l=e.entanglements,p=e.expirationTimes,v=e.hiddenUpdates;for(i=r&~i;0<i;){var N=31-st(i),j=1<<N;l[N]=0,p[N]=-1;var k=v[N];if(k!==null)for(v[N]=null,N=0;N<k.length;N++){var S=k[N];S!==null&&(S.lane&=-536870913)}i&=~j}a!==0&&Sl(e,a,0),o!==0&&n===0&&e.tag!==0&&(e.suspendedLanes|=o&~(r&~t))}function Sl(e,t,i){e.pendingLanes|=t,e.suspendedLanes&=~t;var a=31-st(t);e.entangledLanes|=t,e.entanglements[a]=e.entanglements[a]|1073741824|i&4194090}function _l(e,t){var i=e.entangledLanes|=t;for(e=e.entanglements;i;){var a=31-st(i),n=1<<a;n&t|e[a]&t&&(e[a]|=t),i&=~n}}function Zs(e){switch(e){case 2:e=1;break;case 8:e=4;break;case 32:e=16;break;case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:case 4194304:case 8388608:case 16777216:case 33554432:e=128;break;case 268435456:e=134217728;break;default:e=0}return e}function Js(e){return e&=-e,2<e?8<e?(e&134217727)!==0?32:268435456:8:2}function Cl(){var e=D.p;return e!==0?e:(e=window.event,e===void 0?32:ad(e.type))}function zd(e,t){var i=D.p;try{return D.p=e,t()}finally{D.p=i}}var Wt=Math.random().toString(36).slice(2),Ze="__reactFiber$"+Wt,We="__reactProps$"+Wt,Hi="__reactContainer$"+Wt,Fs="__reactEvents$"+Wt,Id="__reactListeners$"+Wt,qd="__reactHandles$"+Wt,Nl="__reactResources$"+Wt,Da="__reactMarker$"+Wt;function $s(e){delete e[Ze],delete e[We],delete e[Fs],delete e[Id],delete e[qd]}function Gi(e){var t=e[Ze];if(t)return t;for(var i=e.parentNode;i;){if(t=i[Hi]||i[Ze]){if(i=t.alternate,t.child!==null||i!==null&&i.child!==null)for(e=Uu(e);e!==null;){if(i=e[Ze])return i;e=Uu(e)}return t}e=i,i=e.parentNode}return null}function Yi(e){if(e=e[Ze]||e[Hi]){var t=e.tag;if(t===5||t===6||t===13||t===26||t===27||t===3)return e}return null}function La(e){var t=e.tag;if(t===5||t===26||t===27||t===6)return e.stateNode;throw Error(u(33))}function Xi(e){var t=e[Nl];return t||(t=e[Nl]={hoistableStyles:new Map,hoistableScripts:new Map}),t}function Ue(e){e[Da]=!0}var Al=new Set,El={};function _i(e,t){Ki(e,t),Ki(e+"Capture",t)}function Ki(e,t){for(El[e]=t,e=0;e<t.length;e++)Al.add(t[e])}var Od=RegExp("^[:A-Z_a-z\\u00C0-\\u00D6\\u00D8-\\u00F6\\u00F8-\\u02FF\\u0370-\\u037D\\u037F-\\u1FFF\\u200C-\\u200D\\u2070-\\u218F\\u2C00-\\u2FEF\\u3001-\\uD7FF\\uF900-\\uFDCF\\uFDF0-\\uFFFD][:A-Z_a-z\\u00C0-\\u00D6\\u00D8-\\u00F6\\u00F8-\\u02FF\\u0370-\\u037D\\u037F-\\u1FFF\\u200C-\\u200D\\u2070-\\u218F\\u2C00-\\u2FEF\\u3001-\\uD7FF\\uF900-\\uFDCF\\uFDF0-\\uFFFD\\-.0-9\\u00B7\\u0300-\\u036F\\u203F-\\u2040]*$"),jl={},Rl={};function Pd(e){return Ys.call(Rl,e)?!0:Ys.call(jl,e)?!1:Od.test(e)?Rl[e]=!0:(jl[e]=!0,!1)}function Mn(e,t,i){if(Pd(t))if(i===null)e.removeAttribute(t);else{switch(typeof i){case"undefined":case"function":case"symbol":e.removeAttribute(t);return;case"boolean":var a=t.toLowerCase().slice(0,5);if(a!=="data-"&&a!=="aria-"){e.removeAttribute(t);return}}e.setAttribute(t,""+i)}}function zn(e,t,i){if(i===null)e.removeAttribute(t);else{switch(typeof i){case"undefined":case"function":case"symbol":case"boolean":e.removeAttribute(t);return}e.setAttribute(t,""+i)}}function zt(e,t,i,a){if(a===null)e.removeAttribute(i);else{switch(typeof a){case"undefined":case"function":case"symbol":case"boolean":e.removeAttribute(i);return}e.setAttributeNS(t,i,""+a)}}var Ws,Tl;function Qi(e){if(Ws===void 0)try{throw Error()}catch(i){var t=i.stack.trim().match(/\n( *(at )?)/);Ws=t&&t[1]||"",Tl=-1<i.stack.indexOf(`
    at`)?" (<anonymous>)":-1<i.stack.indexOf("@")?"@unknown:0:0":""}return`
`+Ws+e+Tl}var eo=!1;function to(e,t){if(!e||eo)return"";eo=!0;var i=Error.prepareStackTrace;Error.prepareStackTrace=void 0;try{var a={DetermineComponentFrameRoot:function(){try{if(t){var j=function(){throw Error()};if(Object.defineProperty(j.prototype,"props",{set:function(){throw Error()}}),typeof Reflect=="object"&&Reflect.construct){try{Reflect.construct(j,[])}catch(S){var k=S}Reflect.construct(e,[],j)}else{try{j.call()}catch(S){k=S}e.call(j.prototype)}}else{try{throw Error()}catch(S){k=S}(j=e())&&typeof j.catch=="function"&&j.catch(function(){})}}catch(S){if(S&&k&&typeof S.stack=="string")return[S.stack,k.stack]}return[null,null]}};a.DetermineComponentFrameRoot.displayName="DetermineComponentFrameRoot";var n=Object.getOwnPropertyDescriptor(a.DetermineComponentFrameRoot,"name");n&&n.configurable&&Object.defineProperty(a.DetermineComponentFrameRoot,"name",{value:"DetermineComponentFrameRoot"});var o=a.DetermineComponentFrameRoot(),r=o[0],l=o[1];if(r&&l){var p=r.split(`
`),v=l.split(`
`);for(n=a=0;a<p.length&&!p[a].includes("DetermineComponentFrameRoot");)a++;for(;n<v.length&&!v[n].includes("DetermineComponentFrameRoot");)n++;if(a===p.length||n===v.length)for(a=p.length-1,n=v.length-1;1<=a&&0<=n&&p[a]!==v[n];)n--;for(;1<=a&&0<=n;a--,n--)if(p[a]!==v[n]){if(a!==1||n!==1)do if(a--,n--,0>n||p[a]!==v[n]){var N=`
`+p[a].replace(" at new "," at ");return e.displayName&&N.includes("<anonymous>")&&(N=N.replace("<anonymous>",e.displayName)),N}while(1<=a&&0<=n);break}}}finally{eo=!1,Error.prepareStackTrace=i}return(i=e?e.displayName||e.name:"")?Qi(i):""}function Bd(e){switch(e.tag){case 26:case 27:case 5:return Qi(e.type);case 16:return Qi("Lazy");case 13:return Qi("Suspense");case 19:return Qi("SuspenseList");case 0:case 15:return to(e.type,!1);case 11:return to(e.type.render,!1);case 1:return to(e.type,!0);case 31:return Qi("Activity");default:return""}}function Dl(e){try{var t="";do t+=Bd(e),e=e.return;while(e);return t}catch(i){return`
Error generating stack: `+i.message+`
`+i.stack}}function pt(e){switch(typeof e){case"bigint":case"boolean":case"number":case"string":case"undefined":return e;case"object":return e;default:return""}}function Ll(e){var t=e.type;return(e=e.nodeName)&&e.toLowerCase()==="input"&&(t==="checkbox"||t==="radio")}function wd(e){var t=Ll(e)?"checked":"value",i=Object.getOwnPropertyDescriptor(e.constructor.prototype,t),a=""+e[t];if(!e.hasOwnProperty(t)&&typeof i<"u"&&typeof i.get=="function"&&typeof i.set=="function"){var n=i.get,o=i.set;return Object.defineProperty(e,t,{configurable:!0,get:function(){return n.call(this)},set:function(r){a=""+r,o.call(this,r)}}),Object.defineProperty(e,t,{enumerable:i.enumerable}),{getValue:function(){return a},setValue:function(r){a=""+r},stopTracking:function(){e._valueTracker=null,delete e[t]}}}}function In(e){e._valueTracker||(e._valueTracker=wd(e))}function Ml(e){if(!e)return!1;var t=e._valueTracker;if(!t)return!0;var i=t.getValue(),a="";return e&&(a=Ll(e)?e.checked?"true":"false":e.value),e=a,e!==i?(t.setValue(e),!0):!1}function qn(e){if(e=e||(typeof document<"u"?document:void 0),typeof e>"u")return null;try{return e.activeElement||e.body}catch{return e.body}}var Vd=/[\n"\\]/g;function ft(e){return e.replace(Vd,function(t){return"\\"+t.charCodeAt(0).toString(16)+" "})}function io(e,t,i,a,n,o,r,l){e.name="",r!=null&&typeof r!="function"&&typeof r!="symbol"&&typeof r!="boolean"?e.type=r:e.removeAttribute("type"),t!=null?r==="number"?(t===0&&e.value===""||e.value!=t)&&(e.value=""+pt(t)):e.value!==""+pt(t)&&(e.value=""+pt(t)):r!=="submit"&&r!=="reset"||e.removeAttribute("value"),t!=null?ao(e,r,pt(t)):i!=null?ao(e,r,pt(i)):a!=null&&e.removeAttribute("value"),n==null&&o!=null&&(e.defaultChecked=!!o),n!=null&&(e.checked=n&&typeof n!="function"&&typeof n!="symbol"),l!=null&&typeof l!="function"&&typeof l!="symbol"&&typeof l!="boolean"?e.name=""+pt(l):e.removeAttribute("name")}function zl(e,t,i,a,n,o,r,l){if(o!=null&&typeof o!="function"&&typeof o!="symbol"&&typeof o!="boolean"&&(e.type=o),t!=null||i!=null){if(!(o!=="submit"&&o!=="reset"||t!=null))return;i=i!=null?""+pt(i):"",t=t!=null?""+pt(t):i,l||t===e.value||(e.value=t),e.defaultValue=t}a=a??n,a=typeof a!="function"&&typeof a!="symbol"&&!!a,e.checked=l?e.checked:!!a,e.defaultChecked=!!a,r!=null&&typeof r!="function"&&typeof r!="symbol"&&typeof r!="boolean"&&(e.name=r)}function ao(e,t,i){t==="number"&&qn(e.ownerDocument)===e||e.defaultValue===""+i||(e.defaultValue=""+i)}function Zi(e,t,i,a){if(e=e.options,t){t={};for(var n=0;n<i.length;n++)t["$"+i[n]]=!0;for(i=0;i<e.length;i++)n=t.hasOwnProperty("$"+e[i].value),e[i].selected!==n&&(e[i].selected=n),n&&a&&(e[i].defaultSelected=!0)}else{for(i=""+pt(i),t=null,n=0;n<e.length;n++){if(e[n].value===i){e[n].selected=!0,a&&(e[n].defaultSelected=!0);return}t!==null||e[n].disabled||(t=e[n])}t!==null&&(t.selected=!0)}}function Il(e,t,i){if(t!=null&&(t=""+pt(t),t!==e.value&&(e.value=t),i==null)){e.defaultValue!==t&&(e.defaultValue=t);return}e.defaultValue=i!=null?""+pt(i):""}function ql(e,t,i,a){if(t==null){if(a!=null){if(i!=null)throw Error(u(92));if(ce(a)){if(1<a.length)throw Error(u(93));a=a[0]}i=a}i==null&&(i=""),t=i}i=pt(t),e.defaultValue=i,a=e.textContent,a===i&&a!==""&&a!==null&&(e.value=a)}function Ji(e,t){if(t){var i=e.firstChild;if(i&&i===e.lastChild&&i.nodeType===3){i.nodeValue=t;return}}e.textContent=t}var Ud=new Set("animationIterationCount aspectRatio borderImageOutset borderImageSlice borderImageWidth boxFlex boxFlexGroup boxOrdinalGroup columnCount columns flex flexGrow flexPositive flexShrink flexNegative flexOrder gridArea gridRow gridRowEnd gridRowSpan gridRowStart gridColumn gridColumnEnd gridColumnSpan gridColumnStart fontWeight lineClamp lineHeight opacity order orphans scale tabSize widows zIndex zoom fillOpacity floodOpacity stopOpacity strokeDasharray strokeDashoffset strokeMiterlimit strokeOpacity strokeWidth MozAnimationIterationCount MozBoxFlex MozBoxFlexGroup MozLineClamp msAnimationIterationCount msFlex msZoom msFlexGrow msFlexNegative msFlexOrder msFlexPositive msFlexShrink msGridColumn msGridColumnSpan msGridRow msGridRowSpan WebkitAnimationIterationCount WebkitBoxFlex WebKitBoxFlexGroup WebkitBoxOrdinalGroup WebkitColumnCount WebkitColumns WebkitFlex WebkitFlexGrow WebkitFlexPositive WebkitFlexShrink WebkitLineClamp".split(" "));function Ol(e,t,i){var a=t.indexOf("--")===0;i==null||typeof i=="boolean"||i===""?a?e.setProperty(t,""):t==="float"?e.cssFloat="":e[t]="":a?e.setProperty(t,i):typeof i!="number"||i===0||Ud.has(t)?t==="float"?e.cssFloat=i:e[t]=(""+i).trim():e[t]=i+"px"}function Pl(e,t,i){if(t!=null&&typeof t!="object")throw Error(u(62));if(e=e.style,i!=null){for(var a in i)!i.hasOwnProperty(a)||t!=null&&t.hasOwnProperty(a)||(a.indexOf("--")===0?e.setProperty(a,""):a==="float"?e.cssFloat="":e[a]="");for(var n in t)a=t[n],t.hasOwnProperty(n)&&i[n]!==a&&Ol(e,n,a)}else for(var o in t)t.hasOwnProperty(o)&&Ol(e,o,t[o])}function no(e){if(e.indexOf("-")===-1)return!1;switch(e){case"annotation-xml":case"color-profile":case"font-face":case"font-face-src":case"font-face-uri":case"font-face-format":case"font-face-name":case"missing-glyph":return!1;default:return!0}}var Hd=new Map([["acceptCharset","accept-charset"],["htmlFor","for"],["httpEquiv","http-equiv"],["crossOrigin","crossorigin"],["accentHeight","accent-height"],["alignmentBaseline","alignment-baseline"],["arabicForm","arabic-form"],["baselineShift","baseline-shift"],["capHeight","cap-height"],["clipPath","clip-path"],["clipRule","clip-rule"],["colorInterpolation","color-interpolation"],["colorInterpolationFilters","color-interpolation-filters"],["colorProfile","color-profile"],["colorRendering","color-rendering"],["dominantBaseline","dominant-baseline"],["enableBackground","enable-background"],["fillOpacity","fill-opacity"],["fillRule","fill-rule"],["floodColor","flood-color"],["floodOpacity","flood-opacity"],["fontFamily","font-family"],["fontSize","font-size"],["fontSizeAdjust","font-size-adjust"],["fontStretch","font-stretch"],["fontStyle","font-style"],["fontVariant","font-variant"],["fontWeight","font-weight"],["glyphName","glyph-name"],["glyphOrientationHorizontal","glyph-orientation-horizontal"],["glyphOrientationVertical","glyph-orientation-vertical"],["horizAdvX","horiz-adv-x"],["horizOriginX","horiz-origin-x"],["imageRendering","image-rendering"],["letterSpacing","letter-spacing"],["lightingColor","lighting-color"],["markerEnd","marker-end"],["markerMid","marker-mid"],["markerStart","marker-start"],["overlinePosition","overline-position"],["overlineThickness","overline-thickness"],["paintOrder","paint-order"],["panose-1","panose-1"],["pointerEvents","pointer-events"],["renderingIntent","rendering-intent"],["shapeRendering","shape-rendering"],["stopColor","stop-color"],["stopOpacity","stop-opacity"],["strikethroughPosition","strikethrough-position"],["strikethroughThickness","strikethrough-thickness"],["strokeDasharray","stroke-dasharray"],["strokeDashoffset","stroke-dashoffset"],["strokeLinecap","stroke-linecap"],["strokeLinejoin","stroke-linejoin"],["strokeMiterlimit","stroke-miterlimit"],["strokeOpacity","stroke-opacity"],["strokeWidth","stroke-width"],["textAnchor","text-anchor"],["textDecoration","text-decoration"],["textRendering","text-rendering"],["transformOrigin","transform-origin"],["underlinePosition","underline-position"],["underlineThickness","underline-thickness"],["unicodeBidi","unicode-bidi"],["unicodeRange","unicode-range"],["unitsPerEm","units-per-em"],["vAlphabetic","v-alphabetic"],["vHanging","v-hanging"],["vIdeographic","v-ideographic"],["vMathematical","v-mathematical"],["vectorEffect","vector-effect"],["vertAdvY","vert-adv-y"],["vertOriginX","vert-origin-x"],["vertOriginY","vert-origin-y"],["wordSpacing","word-spacing"],["writingMode","writing-mode"],["xmlnsXlink","xmlns:xlink"],["xHeight","x-height"]]),Gd=/^[\u0000-\u001F ]*j[\r\n\t]*a[\r\n\t]*v[\r\n\t]*a[\r\n\t]*s[\r\n\t]*c[\r\n\t]*r[\r\n\t]*i[\r\n\t]*p[\r\n\t]*t[\r\n\t]*:/i;function On(e){return Gd.test(""+e)?"javascript:throw new Error('React has blocked a javascript: URL as a security precaution.')":e}var so=null;function oo(e){return e=e.target||e.srcElement||window,e.correspondingUseElement&&(e=e.correspondingUseElement),e.nodeType===3?e.parentNode:e}var Fi=null,$i=null;function Bl(e){var t=Yi(e);if(t&&(e=t.stateNode)){var i=e[We]||null;e:switch(e=t.stateNode,t.type){case"input":if(io(e,i.value,i.defaultValue,i.defaultValue,i.checked,i.defaultChecked,i.type,i.name),t=i.name,i.type==="radio"&&t!=null){for(i=e;i.parentNode;)i=i.parentNode;for(i=i.querySelectorAll('input[name="'+ft(""+t)+'"][type="radio"]'),t=0;t<i.length;t++){var a=i[t];if(a!==e&&a.form===e.form){var n=a[We]||null;if(!n)throw Error(u(90));io(a,n.value,n.defaultValue,n.defaultValue,n.checked,n.defaultChecked,n.type,n.name)}}for(t=0;t<i.length;t++)a=i[t],a.form===e.form&&Ml(a)}break e;case"textarea":Il(e,i.value,i.defaultValue);break e;case"select":t=i.value,t!=null&&Zi(e,!!i.multiple,t,!1)}}}var ro=!1;function wl(e,t,i){if(ro)return e(t,i);ro=!0;try{var a=e(t);return a}finally{if(ro=!1,(Fi!==null||$i!==null)&&(Ss(),Fi&&(t=Fi,e=$i,$i=Fi=null,Bl(t),e)))for(t=0;t<e.length;t++)Bl(e[t])}}function Ma(e,t){var i=e.stateNode;if(i===null)return null;var a=i[We]||null;if(a===null)return null;i=a[t];e:switch(t){case"onClick":case"onClickCapture":case"onDoubleClick":case"onDoubleClickCapture":case"onMouseDown":case"onMouseDownCapture":case"onMouseMove":case"onMouseMoveCapture":case"onMouseUp":case"onMouseUpCapture":case"onMouseEnter":(a=!a.disabled)||(e=e.type,a=!(e==="button"||e==="input"||e==="select"||e==="textarea")),e=!a;break e;default:e=!1}if(e)return null;if(i&&typeof i!="function")throw Error(u(231,t,typeof i));return i}var It=!(typeof window>"u"||typeof window.document>"u"||typeof window.document.createElement>"u"),lo=!1;if(It)try{var za={};Object.defineProperty(za,"passive",{get:function(){lo=!0}}),window.addEventListener("test",za,za),window.removeEventListener("test",za,za)}catch{lo=!1}var ei=null,co=null,Pn=null;function Vl(){if(Pn)return Pn;var e,t=co,i=t.length,a,n="value"in ei?ei.value:ei.textContent,o=n.length;for(e=0;e<i&&t[e]===n[e];e++);var r=i-e;for(a=1;a<=r&&t[i-a]===n[o-a];a++);return Pn=n.slice(e,1<a?1-a:void 0)}function Bn(e){var t=e.keyCode;return"charCode"in e?(e=e.charCode,e===0&&t===13&&(e=13)):e=t,e===10&&(e=13),32<=e||e===13?e:0}function wn(){return!0}function Ul(){return!1}function et(e){function t(i,a,n,o,r){this._reactName=i,this._targetInst=n,this.type=a,this.nativeEvent=o,this.target=r,this.currentTarget=null;for(var l in e)e.hasOwnProperty(l)&&(i=e[l],this[l]=i?i(o):o[l]);return this.isDefaultPrevented=(o.defaultPrevented!=null?o.defaultPrevented:o.returnValue===!1)?wn:Ul,this.isPropagationStopped=Ul,this}return z(t.prototype,{preventDefault:function(){this.defaultPrevented=!0;var i=this.nativeEvent;i&&(i.preventDefault?i.preventDefault():typeof i.returnValue!="unknown"&&(i.returnValue=!1),this.isDefaultPrevented=wn)},stopPropagation:function(){var i=this.nativeEvent;i&&(i.stopPropagation?i.stopPropagation():typeof i.cancelBubble!="unknown"&&(i.cancelBubble=!0),this.isPropagationStopped=wn)},persist:function(){},isPersistent:wn}),t}var Ci={eventPhase:0,bubbles:0,cancelable:0,timeStamp:function(e){return e.timeStamp||Date.now()},defaultPrevented:0,isTrusted:0},Vn=et(Ci),Ia=z({},Ci,{view:0,detail:0}),Yd=et(Ia),mo,uo,qa,Un=z({},Ia,{screenX:0,screenY:0,clientX:0,clientY:0,pageX:0,pageY:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,getModifierState:fo,button:0,buttons:0,relatedTarget:function(e){return e.relatedTarget===void 0?e.fromElement===e.srcElement?e.toElement:e.fromElement:e.relatedTarget},movementX:function(e){return"movementX"in e?e.movementX:(e!==qa&&(qa&&e.type==="mousemove"?(mo=e.screenX-qa.screenX,uo=e.screenY-qa.screenY):uo=mo=0,qa=e),mo)},movementY:function(e){return"movementY"in e?e.movementY:uo}}),Hl=et(Un),Xd=z({},Un,{dataTransfer:0}),Kd=et(Xd),Qd=z({},Ia,{relatedTarget:0}),po=et(Qd),Zd=z({},Ci,{animationName:0,elapsedTime:0,pseudoElement:0}),Jd=et(Zd),Fd=z({},Ci,{clipboardData:function(e){return"clipboardData"in e?e.clipboardData:window.clipboardData}}),$d=et(Fd),Wd=z({},Ci,{data:0}),Gl=et(Wd),ep={Esc:"Escape",Spacebar:" ",Left:"ArrowLeft",Up:"ArrowUp",Right:"ArrowRight",Down:"ArrowDown",Del:"Delete",Win:"OS",Menu:"ContextMenu",Apps:"ContextMenu",Scroll:"ScrollLock",MozPrintableKey:"Unidentified"},tp={8:"Backspace",9:"Tab",12:"Clear",13:"Enter",16:"Shift",17:"Control",18:"Alt",19:"Pause",20:"CapsLock",27:"Escape",32:" ",33:"PageUp",34:"PageDown",35:"End",36:"Home",37:"ArrowLeft",38:"ArrowUp",39:"ArrowRight",40:"ArrowDown",45:"Insert",46:"Delete",112:"F1",113:"F2",114:"F3",115:"F4",116:"F5",117:"F6",118:"F7",119:"F8",120:"F9",121:"F10",122:"F11",123:"F12",144:"NumLock",145:"ScrollLock",224:"Meta"},ip={Alt:"altKey",Control:"ctrlKey",Meta:"metaKey",Shift:"shiftKey"};function ap(e){var t=this.nativeEvent;return t.getModifierState?t.getModifierState(e):(e=ip[e])?!!t[e]:!1}function fo(){return ap}var np=z({},Ia,{key:function(e){if(e.key){var t=ep[e.key]||e.key;if(t!=="Unidentified")return t}return e.type==="keypress"?(e=Bn(e),e===13?"Enter":String.fromCharCode(e)):e.type==="keydown"||e.type==="keyup"?tp[e.keyCode]||"Unidentified":""},code:0,location:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,repeat:0,locale:0,getModifierState:fo,charCode:function(e){return e.type==="keypress"?Bn(e):0},keyCode:function(e){return e.type==="keydown"||e.type==="keyup"?e.keyCode:0},which:function(e){return e.type==="keypress"?Bn(e):e.type==="keydown"||e.type==="keyup"?e.keyCode:0}}),sp=et(np),op=z({},Un,{pointerId:0,width:0,height:0,pressure:0,tangentialPressure:0,tiltX:0,tiltY:0,twist:0,pointerType:0,isPrimary:0}),Yl=et(op),rp=z({},Ia,{touches:0,targetTouches:0,changedTouches:0,altKey:0,metaKey:0,ctrlKey:0,shiftKey:0,getModifierState:fo}),lp=et(rp),cp=z({},Ci,{propertyName:0,elapsedTime:0,pseudoElement:0}),mp=et(cp),up=z({},Un,{deltaX:function(e){return"deltaX"in e?e.deltaX:"wheelDeltaX"in e?-e.wheelDeltaX:0},deltaY:function(e){return"deltaY"in e?e.deltaY:"wheelDeltaY"in e?-e.wheelDeltaY:"wheelDelta"in e?-e.wheelDelta:0},deltaZ:0,deltaMode:0}),dp=et(up),pp=z({},Ci,{newState:0,oldState:0}),fp=et(pp),bp=[9,13,27,32],bo=It&&"CompositionEvent"in window,Oa=null;It&&"documentMode"in document&&(Oa=document.documentMode);var gp=It&&"TextEvent"in window&&!Oa,Xl=It&&(!bo||Oa&&8<Oa&&11>=Oa),Kl=" ",Ql=!1;function Zl(e,t){switch(e){case"keyup":return bp.indexOf(t.keyCode)!==-1;case"keydown":return t.keyCode!==229;case"keypress":case"mousedown":case"focusout":return!0;default:return!1}}function Jl(e){return e=e.detail,typeof e=="object"&&"data"in e?e.data:null}var Wi=!1;function hp(e,t){switch(e){case"compositionend":return Jl(t);case"keypress":return t.which!==32?null:(Ql=!0,Kl);case"textInput":return e=t.data,e===Kl&&Ql?null:e;default:return null}}function yp(e,t){if(Wi)return e==="compositionend"||!bo&&Zl(e,t)?(e=Vl(),Pn=co=ei=null,Wi=!1,e):null;switch(e){case"paste":return null;case"keypress":if(!(t.ctrlKey||t.altKey||t.metaKey)||t.ctrlKey&&t.altKey){if(t.char&&1<t.char.length)return t.char;if(t.which)return String.fromCharCode(t.which)}return null;case"compositionend":return Xl&&t.locale!=="ko"?null:t.data;default:return null}}var vp={color:!0,date:!0,datetime:!0,"datetime-local":!0,email:!0,month:!0,number:!0,password:!0,range:!0,search:!0,tel:!0,text:!0,time:!0,url:!0,week:!0};function Fl(e){var t=e&&e.nodeName&&e.nodeName.toLowerCase();return t==="input"?!!vp[e.type]:t==="textarea"}function $l(e,t,i,a){Fi?$i?$i.push(a):$i=[a]:Fi=a,t=js(t,"onChange"),0<t.length&&(i=new Vn("onChange","change",null,i,a),e.push({event:i,listeners:t}))}var Pa=null,Ba=null;function kp(e){Lu(e,0)}function Hn(e){var t=La(e);if(Ml(t))return e}function Wl(e,t){if(e==="change")return t}var ec=!1;if(It){var go;if(It){var ho="oninput"in document;if(!ho){var tc=document.createElement("div");tc.setAttribute("oninput","return;"),ho=typeof tc.oninput=="function"}go=ho}else go=!1;ec=go&&(!document.documentMode||9<document.documentMode)}function ic(){Pa&&(Pa.detachEvent("onpropertychange",ac),Ba=Pa=null)}function ac(e){if(e.propertyName==="value"&&Hn(Ba)){var t=[];$l(t,Ba,e,oo(e)),wl(kp,t)}}function xp(e,t,i){e==="focusin"?(ic(),Pa=t,Ba=i,Pa.attachEvent("onpropertychange",ac)):e==="focusout"&&ic()}function Sp(e){if(e==="selectionchange"||e==="keyup"||e==="keydown")return Hn(Ba)}function _p(e,t){if(e==="click")return Hn(t)}function Cp(e,t){if(e==="input"||e==="change")return Hn(t)}function Np(e,t){return e===t&&(e!==0||1/e===1/t)||e!==e&&t!==t}var ot=typeof Object.is=="function"?Object.is:Np;function wa(e,t){if(ot(e,t))return!0;if(typeof e!="object"||e===null||typeof t!="object"||t===null)return!1;var i=Object.keys(e),a=Object.keys(t);if(i.length!==a.length)return!1;for(a=0;a<i.length;a++){var n=i[a];if(!Ys.call(t,n)||!ot(e[n],t[n]))return!1}return!0}function nc(e){for(;e&&e.firstChild;)e=e.firstChild;return e}function sc(e,t){var i=nc(e);e=0;for(var a;i;){if(i.nodeType===3){if(a=e+i.textContent.length,e<=t&&a>=t)return{node:i,offset:t-e};e=a}e:{for(;i;){if(i.nextSibling){i=i.nextSibling;break e}i=i.parentNode}i=void 0}i=nc(i)}}function oc(e,t){return e&&t?e===t?!0:e&&e.nodeType===3?!1:t&&t.nodeType===3?oc(e,t.parentNode):"contains"in e?e.contains(t):e.compareDocumentPosition?!!(e.compareDocumentPosition(t)&16):!1:!1}function rc(e){e=e!=null&&e.ownerDocument!=null&&e.ownerDocument.defaultView!=null?e.ownerDocument.defaultView:window;for(var t=qn(e.document);t instanceof e.HTMLIFrameElement;){try{var i=typeof t.contentWindow.location.href=="string"}catch{i=!1}if(i)e=t.contentWindow;else break;t=qn(e.document)}return t}function yo(e){var t=e&&e.nodeName&&e.nodeName.toLowerCase();return t&&(t==="input"&&(e.type==="text"||e.type==="search"||e.type==="tel"||e.type==="url"||e.type==="password")||t==="textarea"||e.contentEditable==="true")}var Ap=It&&"documentMode"in document&&11>=document.documentMode,ea=null,vo=null,Va=null,ko=!1;function lc(e,t,i){var a=i.window===i?i.document:i.nodeType===9?i:i.ownerDocument;ko||ea==null||ea!==qn(a)||(a=ea,"selectionStart"in a&&yo(a)?a={start:a.selectionStart,end:a.selectionEnd}:(a=(a.ownerDocument&&a.ownerDocument.defaultView||window).getSelection(),a={anchorNode:a.anchorNode,anchorOffset:a.anchorOffset,focusNode:a.focusNode,focusOffset:a.focusOffset}),Va&&wa(Va,a)||(Va=a,a=js(vo,"onSelect"),0<a.length&&(t=new Vn("onSelect","select",null,t,i),e.push({event:t,listeners:a}),t.target=ea)))}function Ni(e,t){var i={};return i[e.toLowerCase()]=t.toLowerCase(),i["Webkit"+e]="webkit"+t,i["Moz"+e]="moz"+t,i}var ta={animationend:Ni("Animation","AnimationEnd"),animationiteration:Ni("Animation","AnimationIteration"),animationstart:Ni("Animation","AnimationStart"),transitionrun:Ni("Transition","TransitionRun"),transitionstart:Ni("Transition","TransitionStart"),transitioncancel:Ni("Transition","TransitionCancel"),transitionend:Ni("Transition","TransitionEnd")},xo={},cc={};It&&(cc=document.createElement("div").style,"AnimationEvent"in window||(delete ta.animationend.animation,delete ta.animationiteration.animation,delete ta.animationstart.animation),"TransitionEvent"in window||delete ta.transitionend.transition);function Ai(e){if(xo[e])return xo[e];if(!ta[e])return e;var t=ta[e],i;for(i in t)if(t.hasOwnProperty(i)&&i in cc)return xo[e]=t[i];return e}var mc=Ai("animationend"),uc=Ai("animationiteration"),dc=Ai("animationstart"),Ep=Ai("transitionrun"),jp=Ai("transitionstart"),Rp=Ai("transitioncancel"),pc=Ai("transitionend"),fc=new Map,So="abort auxClick beforeToggle cancel canPlay canPlayThrough click close contextMenu copy cut drag dragEnd dragEnter dragExit dragLeave dragOver dragStart drop durationChange emptied encrypted ended error gotPointerCapture input invalid keyDown keyPress keyUp load loadedData loadedMetadata loadStart lostPointerCapture mouseDown mouseMove mouseOut mouseOver mouseUp paste pause play playing pointerCancel pointerDown pointerMove pointerOut pointerOver pointerUp progress rateChange reset resize seeked seeking stalled submit suspend timeUpdate touchCancel touchEnd touchStart volumeChange scroll toggle touchMove waiting wheel".split(" ");So.push("scrollEnd");function St(e,t){fc.set(e,t),_i(t,[e])}var bc=new WeakMap;function bt(e,t){if(typeof e=="object"&&e!==null){var i=bc.get(e);return i!==void 0?i:(t={value:e,source:t,stack:Dl(t)},bc.set(e,t),t)}return{value:e,source:t,stack:Dl(t)}}var gt=[],ia=0,_o=0;function Gn(){for(var e=ia,t=_o=ia=0;t<e;){var i=gt[t];gt[t++]=null;var a=gt[t];gt[t++]=null;var n=gt[t];gt[t++]=null;var o=gt[t];if(gt[t++]=null,a!==null&&n!==null){var r=a.pending;r===null?n.next=n:(n.next=r.next,r.next=n),a.pending=n}o!==0&&gc(i,n,o)}}function Yn(e,t,i,a){gt[ia++]=e,gt[ia++]=t,gt[ia++]=i,gt[ia++]=a,_o|=a,e.lanes|=a,e=e.alternate,e!==null&&(e.lanes|=a)}function Co(e,t,i,a){return Yn(e,t,i,a),Xn(e)}function aa(e,t){return Yn(e,null,null,t),Xn(e)}function gc(e,t,i){e.lanes|=i;var a=e.alternate;a!==null&&(a.lanes|=i);for(var n=!1,o=e.return;o!==null;)o.childLanes|=i,a=o.alternate,a!==null&&(a.childLanes|=i),o.tag===22&&(e=o.stateNode,e===null||e._visibility&1||(n=!0)),e=o,o=o.return;return e.tag===3?(o=e.stateNode,n&&t!==null&&(n=31-st(i),e=o.hiddenUpdates,a=e[n],a===null?e[n]=[t]:a.push(t),t.lane=i|536870912),o):null}function Xn(e){if(50<pn)throw pn=0,Tr=null,Error(u(185));for(var t=e.return;t!==null;)e=t,t=e.return;return e.tag===3?e.stateNode:null}var na={};function Tp(e,t,i,a){this.tag=e,this.key=i,this.sibling=this.child=this.return=this.stateNode=this.type=this.elementType=null,this.index=0,this.refCleanup=this.ref=null,this.pendingProps=t,this.dependencies=this.memoizedState=this.updateQueue=this.memoizedProps=null,this.mode=a,this.subtreeFlags=this.flags=0,this.deletions=null,this.childLanes=this.lanes=0,this.alternate=null}function rt(e,t,i,a){return new Tp(e,t,i,a)}function No(e){return e=e.prototype,!(!e||!e.isReactComponent)}function qt(e,t){var i=e.alternate;return i===null?(i=rt(e.tag,t,e.key,e.mode),i.elementType=e.elementType,i.type=e.type,i.stateNode=e.stateNode,i.alternate=e,e.alternate=i):(i.pendingProps=t,i.type=e.type,i.flags=0,i.subtreeFlags=0,i.deletions=null),i.flags=e.flags&65011712,i.childLanes=e.childLanes,i.lanes=e.lanes,i.child=e.child,i.memoizedProps=e.memoizedProps,i.memoizedState=e.memoizedState,i.updateQueue=e.updateQueue,t=e.dependencies,i.dependencies=t===null?null:{lanes:t.lanes,firstContext:t.firstContext},i.sibling=e.sibling,i.index=e.index,i.ref=e.ref,i.refCleanup=e.refCleanup,i}function hc(e,t){e.flags&=65011714;var i=e.alternate;return i===null?(e.childLanes=0,e.lanes=t,e.child=null,e.subtreeFlags=0,e.memoizedProps=null,e.memoizedState=null,e.updateQueue=null,e.dependencies=null,e.stateNode=null):(e.childLanes=i.childLanes,e.lanes=i.lanes,e.child=i.child,e.subtreeFlags=0,e.deletions=null,e.memoizedProps=i.memoizedProps,e.memoizedState=i.memoizedState,e.updateQueue=i.updateQueue,e.type=i.type,t=i.dependencies,e.dependencies=t===null?null:{lanes:t.lanes,firstContext:t.firstContext}),e}function Kn(e,t,i,a,n,o){var r=0;if(a=e,typeof e=="function")No(e)&&(r=1);else if(typeof e=="string")r=Mf(e,i,I.current)?26:e==="html"||e==="head"||e==="body"?27:5;else e:switch(e){case w:return e=rt(31,i,t,n),e.elementType=w,e.lanes=o,e;case Q:return Ei(i.children,n,o,t);case H:r=8,n|=24;break;case Y:return e=rt(12,i,t,n|2),e.elementType=Y,e.lanes=o,e;case K:return e=rt(13,i,t,n),e.elementType=K,e.lanes=o,e;case G:return e=rt(19,i,t,n),e.elementType=G,e.lanes=o,e;default:if(typeof e=="object"&&e!==null)switch(e.$$typeof){case M:case X:r=10;break e;case V:r=9;break e;case Z:r=11;break e;case F:r=14;break e;case se:r=16,a=null;break e}r=29,i=Error(u(130,e===null?"null":typeof e,"")),a=null}return t=rt(r,i,t,n),t.elementType=e,t.type=a,t.lanes=o,t}function Ei(e,t,i,a){return e=rt(7,e,a,t),e.lanes=i,e}function Ao(e,t,i){return e=rt(6,e,null,t),e.lanes=i,e}function Eo(e,t,i){return t=rt(4,e.children!==null?e.children:[],e.key,t),t.lanes=i,t.stateNode={containerInfo:e.containerInfo,pendingChildren:null,implementation:e.implementation},t}var sa=[],oa=0,Qn=null,Zn=0,ht=[],yt=0,ji=null,Ot=1,Pt="";function Ri(e,t){sa[oa++]=Zn,sa[oa++]=Qn,Qn=e,Zn=t}function yc(e,t,i){ht[yt++]=Ot,ht[yt++]=Pt,ht[yt++]=ji,ji=e;var a=Ot;e=Pt;var n=32-st(a)-1;a&=~(1<<n),i+=1;var o=32-st(t)+n;if(30<o){var r=n-n%5;o=(a&(1<<r)-1).toString(32),a>>=r,n-=r,Ot=1<<32-st(t)+n|i<<n|a,Pt=o+e}else Ot=1<<o|i<<n|a,Pt=e}function jo(e){e.return!==null&&(Ri(e,1),yc(e,1,0))}function Ro(e){for(;e===Qn;)Qn=sa[--oa],sa[oa]=null,Zn=sa[--oa],sa[oa]=null;for(;e===ji;)ji=ht[--yt],ht[yt]=null,Pt=ht[--yt],ht[yt]=null,Ot=ht[--yt],ht[yt]=null}var $e=null,Me=null,ke=!1,Ti=null,Et=!1,To=Error(u(519));function Di(e){var t=Error(u(418,""));throw Ga(bt(t,e)),To}function vc(e){var t=e.stateNode,i=e.type,a=e.memoizedProps;switch(t[Ze]=e,t[We]=a,i){case"dialog":he("cancel",t),he("close",t);break;case"iframe":case"object":case"embed":he("load",t);break;case"video":case"audio":for(i=0;i<bn.length;i++)he(bn[i],t);break;case"source":he("error",t);break;case"img":case"image":case"link":he("error",t),he("load",t);break;case"details":he("toggle",t);break;case"input":he("invalid",t),zl(t,a.value,a.defaultValue,a.checked,a.defaultChecked,a.type,a.name,!0),In(t);break;case"select":he("invalid",t);break;case"textarea":he("invalid",t),ql(t,a.value,a.defaultValue,a.children),In(t)}i=a.children,typeof i!="string"&&typeof i!="number"&&typeof i!="bigint"||t.textContent===""+i||a.suppressHydrationWarning===!0||qu(t.textContent,i)?(a.popover!=null&&(he("beforetoggle",t),he("toggle",t)),a.onScroll!=null&&he("scroll",t),a.onScrollEnd!=null&&he("scrollend",t),a.onClick!=null&&(t.onclick=Rs),t=!0):t=!1,t||Di(e)}function kc(e){for($e=e.return;$e;)switch($e.tag){case 5:case 13:Et=!1;return;case 27:case 3:Et=!0;return;default:$e=$e.return}}function Ua(e){if(e!==$e)return!1;if(!ke)return kc(e),ke=!0,!1;var t=e.tag,i;if((i=t!==3&&t!==27)&&((i=t===5)&&(i=e.type,i=!(i!=="form"&&i!=="button")||Xr(e.type,e.memoizedProps)),i=!i),i&&Me&&Di(e),kc(e),t===13){if(e=e.memoizedState,e=e!==null?e.dehydrated:null,!e)throw Error(u(317));e:{for(e=e.nextSibling,t=0;e;){if(e.nodeType===8)if(i=e.data,i==="/$"){if(t===0){Me=Ct(e.nextSibling);break e}t--}else i!=="$"&&i!=="$!"&&i!=="$?"||t++;e=e.nextSibling}Me=null}}else t===27?(t=Me,gi(e.type)?(e=Jr,Jr=null,Me=e):Me=t):Me=$e?Ct(e.stateNode.nextSibling):null;return!0}function Ha(){Me=$e=null,ke=!1}function xc(){var e=Ti;return e!==null&&(at===null?at=e:at.push.apply(at,e),Ti=null),e}function Ga(e){Ti===null?Ti=[e]:Ti.push(e)}var Do=R(null),Li=null,Bt=null;function ti(e,t,i){C(Do,t._currentValue),t._currentValue=i}function wt(e){e._currentValue=Do.current,T(Do)}function Lo(e,t,i){for(;e!==null;){var a=e.alternate;if((e.childLanes&t)!==t?(e.childLanes|=t,a!==null&&(a.childLanes|=t)):a!==null&&(a.childLanes&t)!==t&&(a.childLanes|=t),e===i)break;e=e.return}}function Mo(e,t,i,a){var n=e.child;for(n!==null&&(n.return=e);n!==null;){var o=n.dependencies;if(o!==null){var r=n.child;o=o.firstContext;e:for(;o!==null;){var l=o;o=n;for(var p=0;p<t.length;p++)if(l.context===t[p]){o.lanes|=i,l=o.alternate,l!==null&&(l.lanes|=i),Lo(o.return,i,e),a||(r=null);break e}o=l.next}}else if(n.tag===18){if(r=n.return,r===null)throw Error(u(341));r.lanes|=i,o=r.alternate,o!==null&&(o.lanes|=i),Lo(r,i,e),r=null}else r=n.child;if(r!==null)r.return=n;else for(r=n;r!==null;){if(r===e){r=null;break}if(n=r.sibling,n!==null){n.return=r.return,r=n;break}r=r.return}n=r}}function Ya(e,t,i,a){e=null;for(var n=t,o=!1;n!==null;){if(!o){if((n.flags&524288)!==0)o=!0;else if((n.flags&262144)!==0)break}if(n.tag===10){var r=n.alternate;if(r===null)throw Error(u(387));if(r=r.memoizedProps,r!==null){var l=n.type;ot(n.pendingProps.value,r.value)||(e!==null?e.push(l):e=[l])}}else if(n===Te.current){if(r=n.alternate,r===null)throw Error(u(387));r.memoizedState.memoizedState!==n.memoizedState.memoizedState&&(e!==null?e.push(xn):e=[xn])}n=n.return}e!==null&&Mo(t,e,i,a),t.flags|=262144}function Jn(e){for(e=e.firstContext;e!==null;){if(!ot(e.context._currentValue,e.memoizedValue))return!0;e=e.next}return!1}function Mi(e){Li=e,Bt=null,e=e.dependencies,e!==null&&(e.firstContext=null)}function Je(e){return Sc(Li,e)}function Fn(e,t){return Li===null&&Mi(e),Sc(e,t)}function Sc(e,t){var i=t._currentValue;if(t={context:t,memoizedValue:i,next:null},Bt===null){if(e===null)throw Error(u(308));Bt=t,e.dependencies={lanes:0,firstContext:t},e.flags|=524288}else Bt=Bt.next=t;return i}var Dp=typeof AbortController<"u"?AbortController:function(){var e=[],t=this.signal={aborted:!1,addEventListener:function(i,a){e.push(a)}};this.abort=function(){t.aborted=!0,e.forEach(function(i){return i()})}},Lp=m.unstable_scheduleCallback,Mp=m.unstable_NormalPriority,we={$$typeof:X,Consumer:null,Provider:null,_currentValue:null,_currentValue2:null,_threadCount:0};function zo(){return{controller:new Dp,data:new Map,refCount:0}}function Xa(e){e.refCount--,e.refCount===0&&Lp(Mp,function(){e.controller.abort()})}var Ka=null,Io=0,ra=0,la=null;function zp(e,t){if(Ka===null){var i=Ka=[];Io=0,ra=Or(),la={status:"pending",value:void 0,then:function(a){i.push(a)}}}return Io++,t.then(_c,_c),t}function _c(){if(--Io===0&&Ka!==null){la!==null&&(la.status="fulfilled");var e=Ka;Ka=null,ra=0,la=null;for(var t=0;t<e.length;t++)(0,e[t])()}}function Ip(e,t){var i=[],a={status:"pending",value:null,reason:null,then:function(n){i.push(n)}};return e.then(function(){a.status="fulfilled",a.value=t;for(var n=0;n<i.length;n++)(0,i[n])(t)},function(n){for(a.status="rejected",a.reason=n,n=0;n<i.length;n++)(0,i[n])(void 0)}),a}var Cc=x.S;x.S=function(e,t){typeof t=="object"&&t!==null&&typeof t.then=="function"&&zp(e,t),Cc!==null&&Cc(e,t)};var zi=R(null);function qo(){var e=zi.current;return e!==null?e:Re.pooledCache}function $n(e,t){t===null?C(zi,zi.current):C(zi,t.pool)}function Nc(){var e=qo();return e===null?null:{parent:we._currentValue,pool:e}}var Qa=Error(u(460)),Ac=Error(u(474)),Wn=Error(u(542)),Oo={then:function(){}};function Ec(e){return e=e.status,e==="fulfilled"||e==="rejected"}function es(){}function jc(e,t,i){switch(i=e[i],i===void 0?e.push(t):i!==t&&(t.then(es,es),t=i),t.status){case"fulfilled":return t.value;case"rejected":throw e=t.reason,Tc(e),e;default:if(typeof t.status=="string")t.then(es,es);else{if(e=Re,e!==null&&100<e.shellSuspendCounter)throw Error(u(482));e=t,e.status="pending",e.then(function(a){if(t.status==="pending"){var n=t;n.status="fulfilled",n.value=a}},function(a){if(t.status==="pending"){var n=t;n.status="rejected",n.reason=a}})}switch(t.status){case"fulfilled":return t.value;case"rejected":throw e=t.reason,Tc(e),e}throw Za=t,Qa}}var Za=null;function Rc(){if(Za===null)throw Error(u(459));var e=Za;return Za=null,e}function Tc(e){if(e===Qa||e===Wn)throw Error(u(483))}var ii=!1;function Po(e){e.updateQueue={baseState:e.memoizedState,firstBaseUpdate:null,lastBaseUpdate:null,shared:{pending:null,lanes:0,hiddenCallbacks:null},callbacks:null}}function Bo(e,t){e=e.updateQueue,t.updateQueue===e&&(t.updateQueue={baseState:e.baseState,firstBaseUpdate:e.firstBaseUpdate,lastBaseUpdate:e.lastBaseUpdate,shared:e.shared,callbacks:null})}function ai(e){return{lane:e,tag:0,payload:null,callback:null,next:null}}function ni(e,t,i){var a=e.updateQueue;if(a===null)return null;if(a=a.shared,(xe&2)!==0){var n=a.pending;return n===null?t.next=t:(t.next=n.next,n.next=t),a.pending=t,t=Xn(e),gc(e,null,i),t}return Yn(e,a,t,i),Xn(e)}function Ja(e,t,i){if(t=t.updateQueue,t!==null&&(t=t.shared,(i&4194048)!==0)){var a=t.lanes;a&=e.pendingLanes,i|=a,t.lanes=i,_l(e,i)}}function wo(e,t){var i=e.updateQueue,a=e.alternate;if(a!==null&&(a=a.updateQueue,i===a)){var n=null,o=null;if(i=i.firstBaseUpdate,i!==null){do{var r={lane:i.lane,tag:i.tag,payload:i.payload,callback:null,next:null};o===null?n=o=r:o=o.next=r,i=i.next}while(i!==null);o===null?n=o=t:o=o.next=t}else n=o=t;i={baseState:a.baseState,firstBaseUpdate:n,lastBaseUpdate:o,shared:a.shared,callbacks:a.callbacks},e.updateQueue=i;return}e=i.lastBaseUpdate,e===null?i.firstBaseUpdate=t:e.next=t,i.lastBaseUpdate=t}var Vo=!1;function Fa(){if(Vo){var e=la;if(e!==null)throw e}}function $a(e,t,i,a){Vo=!1;var n=e.updateQueue;ii=!1;var o=n.firstBaseUpdate,r=n.lastBaseUpdate,l=n.shared.pending;if(l!==null){n.shared.pending=null;var p=l,v=p.next;p.next=null,r===null?o=v:r.next=v,r=p;var N=e.alternate;N!==null&&(N=N.updateQueue,l=N.lastBaseUpdate,l!==r&&(l===null?N.firstBaseUpdate=v:l.next=v,N.lastBaseUpdate=p))}if(o!==null){var j=n.baseState;r=0,N=v=p=null,l=o;do{var k=l.lane&-536870913,S=k!==l.lane;if(S?(ye&k)===k:(a&k)===k){k!==0&&k===ra&&(Vo=!0),N!==null&&(N=N.next={lane:0,tag:l.tag,payload:l.payload,callback:null,next:null});e:{var oe=e,ae=l;k=t;var Ae=i;switch(ae.tag){case 1:if(oe=ae.payload,typeof oe=="function"){j=oe.call(Ae,j,k);break e}j=oe;break e;case 3:oe.flags=oe.flags&-65537|128;case 0:if(oe=ae.payload,k=typeof oe=="function"?oe.call(Ae,j,k):oe,k==null)break e;j=z({},j,k);break e;case 2:ii=!0}}k=l.callback,k!==null&&(e.flags|=64,S&&(e.flags|=8192),S=n.callbacks,S===null?n.callbacks=[k]:S.push(k))}else S={lane:k,tag:l.tag,payload:l.payload,callback:l.callback,next:null},N===null?(v=N=S,p=j):N=N.next=S,r|=k;if(l=l.next,l===null){if(l=n.shared.pending,l===null)break;S=l,l=S.next,S.next=null,n.lastBaseUpdate=S,n.shared.pending=null}}while(!0);N===null&&(p=j),n.baseState=p,n.firstBaseUpdate=v,n.lastBaseUpdate=N,o===null&&(n.shared.lanes=0),di|=r,e.lanes=r,e.memoizedState=j}}function Dc(e,t){if(typeof e!="function")throw Error(u(191,e));e.call(t)}function Lc(e,t){var i=e.callbacks;if(i!==null)for(e.callbacks=null,e=0;e<i.length;e++)Dc(i[e],t)}var ca=R(null),ts=R(0);function Mc(e,t){e=Kt,C(ts,e),C(ca,t),Kt=e|t.baseLanes}function Uo(){C(ts,Kt),C(ca,ca.current)}function Ho(){Kt=ts.current,T(ca),T(ts)}var si=0,pe=null,Ce=null,Oe=null,is=!1,ma=!1,Ii=!1,as=0,Wa=0,ua=null,qp=0;function Ie(){throw Error(u(321))}function Go(e,t){if(t===null)return!1;for(var i=0;i<t.length&&i<e.length;i++)if(!ot(e[i],t[i]))return!1;return!0}function Yo(e,t,i,a,n,o){return si=o,pe=t,t.memoizedState=null,t.updateQueue=null,t.lanes=0,x.H=e===null||e.memoizedState===null?gm:hm,Ii=!1,o=i(a,n),Ii=!1,ma&&(o=Ic(t,i,a,n)),zc(e),o}function zc(e){x.H=cs;var t=Ce!==null&&Ce.next!==null;if(si=0,Oe=Ce=pe=null,is=!1,Wa=0,ua=null,t)throw Error(u(300));e===null||He||(e=e.dependencies,e!==null&&Jn(e)&&(He=!0))}function Ic(e,t,i,a){pe=e;var n=0;do{if(ma&&(ua=null),Wa=0,ma=!1,25<=n)throw Error(u(301));if(n+=1,Oe=Ce=null,e.updateQueue!=null){var o=e.updateQueue;o.lastEffect=null,o.events=null,o.stores=null,o.memoCache!=null&&(o.memoCache.index=0)}x.H=Hp,o=t(i,a)}while(ma);return o}function Op(){var e=x.H,t=e.useState()[0];return t=typeof t.then=="function"?en(t):t,e=e.useState()[0],(Ce!==null?Ce.memoizedState:null)!==e&&(pe.flags|=1024),t}function Xo(){var e=as!==0;return as=0,e}function Ko(e,t,i){t.updateQueue=e.updateQueue,t.flags&=-2053,e.lanes&=~i}function Qo(e){if(is){for(e=e.memoizedState;e!==null;){var t=e.queue;t!==null&&(t.pending=null),e=e.next}is=!1}si=0,Oe=Ce=pe=null,ma=!1,Wa=as=0,ua=null}function tt(){var e={memoizedState:null,baseState:null,baseQueue:null,queue:null,next:null};return Oe===null?pe.memoizedState=Oe=e:Oe=Oe.next=e,Oe}function Pe(){if(Ce===null){var e=pe.alternate;e=e!==null?e.memoizedState:null}else e=Ce.next;var t=Oe===null?pe.memoizedState:Oe.next;if(t!==null)Oe=t,Ce=e;else{if(e===null)throw pe.alternate===null?Error(u(467)):Error(u(310));Ce=e,e={memoizedState:Ce.memoizedState,baseState:Ce.baseState,baseQueue:Ce.baseQueue,queue:Ce.queue,next:null},Oe===null?pe.memoizedState=Oe=e:Oe=Oe.next=e}return Oe}function Zo(){return{lastEffect:null,events:null,stores:null,memoCache:null}}function en(e){var t=Wa;return Wa+=1,ua===null&&(ua=[]),e=jc(ua,e,t),t=pe,(Oe===null?t.memoizedState:Oe.next)===null&&(t=t.alternate,x.H=t===null||t.memoizedState===null?gm:hm),e}function ns(e){if(e!==null&&typeof e=="object"){if(typeof e.then=="function")return en(e);if(e.$$typeof===X)return Je(e)}throw Error(u(438,String(e)))}function Jo(e){var t=null,i=pe.updateQueue;if(i!==null&&(t=i.memoCache),t==null){var a=pe.alternate;a!==null&&(a=a.updateQueue,a!==null&&(a=a.memoCache,a!=null&&(t={data:a.data.map(function(n){return n.slice()}),index:0})))}if(t==null&&(t={data:[],index:0}),i===null&&(i=Zo(),pe.updateQueue=i),i.memoCache=t,i=t.data[t.index],i===void 0)for(i=t.data[t.index]=Array(e),a=0;a<e;a++)i[a]=ue;return t.index++,i}function Vt(e,t){return typeof t=="function"?t(e):t}function ss(e){var t=Pe();return Fo(t,Ce,e)}function Fo(e,t,i){var a=e.queue;if(a===null)throw Error(u(311));a.lastRenderedReducer=i;var n=e.baseQueue,o=a.pending;if(o!==null){if(n!==null){var r=n.next;n.next=o.next,o.next=r}t.baseQueue=n=o,a.pending=null}if(o=e.baseState,n===null)e.memoizedState=o;else{t=n.next;var l=r=null,p=null,v=t,N=!1;do{var j=v.lane&-536870913;if(j!==v.lane?(ye&j)===j:(si&j)===j){var k=v.revertLane;if(k===0)p!==null&&(p=p.next={lane:0,revertLane:0,action:v.action,hasEagerState:v.hasEagerState,eagerState:v.eagerState,next:null}),j===ra&&(N=!0);else if((si&k)===k){v=v.next,k===ra&&(N=!0);continue}else j={lane:0,revertLane:v.revertLane,action:v.action,hasEagerState:v.hasEagerState,eagerState:v.eagerState,next:null},p===null?(l=p=j,r=o):p=p.next=j,pe.lanes|=k,di|=k;j=v.action,Ii&&i(o,j),o=v.hasEagerState?v.eagerState:i(o,j)}else k={lane:j,revertLane:v.revertLane,action:v.action,hasEagerState:v.hasEagerState,eagerState:v.eagerState,next:null},p===null?(l=p=k,r=o):p=p.next=k,pe.lanes|=j,di|=j;v=v.next}while(v!==null&&v!==t);if(p===null?r=o:p.next=l,!ot(o,e.memoizedState)&&(He=!0,N&&(i=la,i!==null)))throw i;e.memoizedState=o,e.baseState=r,e.baseQueue=p,a.lastRenderedState=o}return n===null&&(a.lanes=0),[e.memoizedState,a.dispatch]}function $o(e){var t=Pe(),i=t.queue;if(i===null)throw Error(u(311));i.lastRenderedReducer=e;var a=i.dispatch,n=i.pending,o=t.memoizedState;if(n!==null){i.pending=null;var r=n=n.next;do o=e(o,r.action),r=r.next;while(r!==n);ot(o,t.memoizedState)||(He=!0),t.memoizedState=o,t.baseQueue===null&&(t.baseState=o),i.lastRenderedState=o}return[o,a]}function qc(e,t,i){var a=pe,n=Pe(),o=ke;if(o){if(i===void 0)throw Error(u(407));i=i()}else i=t();var r=!ot((Ce||n).memoizedState,i);r&&(n.memoizedState=i,He=!0),n=n.queue;var l=Bc.bind(null,a,n,e);if(tn(2048,8,l,[e]),n.getSnapshot!==t||r||Oe!==null&&Oe.memoizedState.tag&1){if(a.flags|=2048,da(9,os(),Pc.bind(null,a,n,i,t),null),Re===null)throw Error(u(349));o||(si&124)!==0||Oc(a,t,i)}return i}function Oc(e,t,i){e.flags|=16384,e={getSnapshot:t,value:i},t=pe.updateQueue,t===null?(t=Zo(),pe.updateQueue=t,t.stores=[e]):(i=t.stores,i===null?t.stores=[e]:i.push(e))}function Pc(e,t,i,a){t.value=i,t.getSnapshot=a,wc(t)&&Vc(e)}function Bc(e,t,i){return i(function(){wc(t)&&Vc(e)})}function wc(e){var t=e.getSnapshot;e=e.value;try{var i=t();return!ot(e,i)}catch{return!0}}function Vc(e){var t=aa(e,2);t!==null&&dt(t,e,2)}function Wo(e){var t=tt();if(typeof e=="function"){var i=e;if(e=i(),Ii){$t(!0);try{i()}finally{$t(!1)}}}return t.memoizedState=t.baseState=e,t.queue={pending:null,lanes:0,dispatch:null,lastRenderedReducer:Vt,lastRenderedState:e},t}function Uc(e,t,i,a){return e.baseState=i,Fo(e,Ce,typeof a=="function"?a:Vt)}function Pp(e,t,i,a,n){if(ls(e))throw Error(u(485));if(e=t.action,e!==null){var o={payload:n,action:e,next:null,isTransition:!0,status:"pending",value:null,reason:null,listeners:[],then:function(r){o.listeners.push(r)}};x.T!==null?i(!0):o.isTransition=!1,a(o),i=t.pending,i===null?(o.next=t.pending=o,Hc(t,o)):(o.next=i.next,t.pending=i.next=o)}}function Hc(e,t){var i=t.action,a=t.payload,n=e.state;if(t.isTransition){var o=x.T,r={};x.T=r;try{var l=i(n,a),p=x.S;p!==null&&p(r,l),Gc(e,t,l)}catch(v){er(e,t,v)}finally{x.T=o}}else try{o=i(n,a),Gc(e,t,o)}catch(v){er(e,t,v)}}function Gc(e,t,i){i!==null&&typeof i=="object"&&typeof i.then=="function"?i.then(function(a){Yc(e,t,a)},function(a){return er(e,t,a)}):Yc(e,t,i)}function Yc(e,t,i){t.status="fulfilled",t.value=i,Xc(t),e.state=i,t=e.pending,t!==null&&(i=t.next,i===t?e.pending=null:(i=i.next,t.next=i,Hc(e,i)))}function er(e,t,i){var a=e.pending;if(e.pending=null,a!==null){a=a.next;do t.status="rejected",t.reason=i,Xc(t),t=t.next;while(t!==a)}e.action=null}function Xc(e){e=e.listeners;for(var t=0;t<e.length;t++)(0,e[t])()}function Kc(e,t){return t}function Qc(e,t){if(ke){var i=Re.formState;if(i!==null){e:{var a=pe;if(ke){if(Me){t:{for(var n=Me,o=Et;n.nodeType!==8;){if(!o){n=null;break t}if(n=Ct(n.nextSibling),n===null){n=null;break t}}o=n.data,n=o==="F!"||o==="F"?n:null}if(n){Me=Ct(n.nextSibling),a=n.data==="F!";break e}}Di(a)}a=!1}a&&(t=i[0])}}return i=tt(),i.memoizedState=i.baseState=t,a={pending:null,lanes:0,dispatch:null,lastRenderedReducer:Kc,lastRenderedState:t},i.queue=a,i=pm.bind(null,pe,a),a.dispatch=i,a=Wo(!1),o=sr.bind(null,pe,!1,a.queue),a=tt(),n={state:t,dispatch:null,action:e,pending:null},a.queue=n,i=Pp.bind(null,pe,n,o,i),n.dispatch=i,a.memoizedState=e,[t,i,!1]}function Zc(e){var t=Pe();return Jc(t,Ce,e)}function Jc(e,t,i){if(t=Fo(e,t,Kc)[0],e=ss(Vt)[0],typeof t=="object"&&t!==null&&typeof t.then=="function")try{var a=en(t)}catch(r){throw r===Qa?Wn:r}else a=t;t=Pe();var n=t.queue,o=n.dispatch;return i!==t.memoizedState&&(pe.flags|=2048,da(9,os(),Bp.bind(null,n,i),null)),[a,o,e]}function Bp(e,t){e.action=t}function Fc(e){var t=Pe(),i=Ce;if(i!==null)return Jc(t,i,e);Pe(),t=t.memoizedState,i=Pe();var a=i.queue.dispatch;return i.memoizedState=e,[t,a,!1]}function da(e,t,i,a){return e={tag:e,create:i,deps:a,inst:t,next:null},t=pe.updateQueue,t===null&&(t=Zo(),pe.updateQueue=t),i=t.lastEffect,i===null?t.lastEffect=e.next=e:(a=i.next,i.next=e,e.next=a,t.lastEffect=e),e}function os(){return{destroy:void 0,resource:void 0}}function $c(){return Pe().memoizedState}function rs(e,t,i,a){var n=tt();a=a===void 0?null:a,pe.flags|=e,n.memoizedState=da(1|t,os(),i,a)}function tn(e,t,i,a){var n=Pe();a=a===void 0?null:a;var o=n.memoizedState.inst;Ce!==null&&a!==null&&Go(a,Ce.memoizedState.deps)?n.memoizedState=da(t,o,i,a):(pe.flags|=e,n.memoizedState=da(1|t,o,i,a))}function Wc(e,t){rs(8390656,8,e,t)}function em(e,t){tn(2048,8,e,t)}function tm(e,t){return tn(4,2,e,t)}function im(e,t){return tn(4,4,e,t)}function am(e,t){if(typeof t=="function"){e=e();var i=t(e);return function(){typeof i=="function"?i():t(null)}}if(t!=null)return e=e(),t.current=e,function(){t.current=null}}function nm(e,t,i){i=i!=null?i.concat([e]):null,tn(4,4,am.bind(null,t,e),i)}function tr(){}function sm(e,t){var i=Pe();t=t===void 0?null:t;var a=i.memoizedState;return t!==null&&Go(t,a[1])?a[0]:(i.memoizedState=[e,t],e)}function om(e,t){var i=Pe();t=t===void 0?null:t;var a=i.memoizedState;if(t!==null&&Go(t,a[1]))return a[0];if(a=e(),Ii){$t(!0);try{e()}finally{$t(!1)}}return i.memoizedState=[a,t],a}function ir(e,t,i){return i===void 0||(si&1073741824)!==0?e.memoizedState=t:(e.memoizedState=i,e=cu(),pe.lanes|=e,di|=e,i)}function rm(e,t,i,a){return ot(i,t)?i:ca.current!==null?(e=ir(e,i,a),ot(e,t)||(He=!0),e):(si&42)===0?(He=!0,e.memoizedState=i):(e=cu(),pe.lanes|=e,di|=e,t)}function lm(e,t,i,a,n){var o=D.p;D.p=o!==0&&8>o?o:8;var r=x.T,l={};x.T=l,sr(e,!1,t,i);try{var p=n(),v=x.S;if(v!==null&&v(l,p),p!==null&&typeof p=="object"&&typeof p.then=="function"){var N=Ip(p,a);an(e,t,N,ut(e))}else an(e,t,a,ut(e))}catch(j){an(e,t,{then:function(){},status:"rejected",reason:j},ut())}finally{D.p=o,x.T=r}}function wp(){}function ar(e,t,i,a){if(e.tag!==5)throw Error(u(476));var n=cm(e).queue;lm(e,n,t,$,i===null?wp:function(){return mm(e),i(a)})}function cm(e){var t=e.memoizedState;if(t!==null)return t;t={memoizedState:$,baseState:$,baseQueue:null,queue:{pending:null,lanes:0,dispatch:null,lastRenderedReducer:Vt,lastRenderedState:$},next:null};var i={};return t.next={memoizedState:i,baseState:i,baseQueue:null,queue:{pending:null,lanes:0,dispatch:null,lastRenderedReducer:Vt,lastRenderedState:i},next:null},e.memoizedState=t,e=e.alternate,e!==null&&(e.memoizedState=t),t}function mm(e){var t=cm(e).next.queue;an(e,t,{},ut())}function nr(){return Je(xn)}function um(){return Pe().memoizedState}function dm(){return Pe().memoizedState}function Vp(e){for(var t=e.return;t!==null;){switch(t.tag){case 24:case 3:var i=ut();e=ai(i);var a=ni(t,e,i);a!==null&&(dt(a,t,i),Ja(a,t,i)),t={cache:zo()},e.payload=t;return}t=t.return}}function Up(e,t,i){var a=ut();i={lane:a,revertLane:0,action:i,hasEagerState:!1,eagerState:null,next:null},ls(e)?fm(t,i):(i=Co(e,t,i,a),i!==null&&(dt(i,e,a),bm(i,t,a)))}function pm(e,t,i){var a=ut();an(e,t,i,a)}function an(e,t,i,a){var n={lane:a,revertLane:0,action:i,hasEagerState:!1,eagerState:null,next:null};if(ls(e))fm(t,n);else{var o=e.alternate;if(e.lanes===0&&(o===null||o.lanes===0)&&(o=t.lastRenderedReducer,o!==null))try{var r=t.lastRenderedState,l=o(r,i);if(n.hasEagerState=!0,n.eagerState=l,ot(l,r))return Yn(e,t,n,0),Re===null&&Gn(),!1}catch{}finally{}if(i=Co(e,t,n,a),i!==null)return dt(i,e,a),bm(i,t,a),!0}return!1}function sr(e,t,i,a){if(a={lane:2,revertLane:Or(),action:a,hasEagerState:!1,eagerState:null,next:null},ls(e)){if(t)throw Error(u(479))}else t=Co(e,i,a,2),t!==null&&dt(t,e,2)}function ls(e){var t=e.alternate;return e===pe||t!==null&&t===pe}function fm(e,t){ma=is=!0;var i=e.pending;i===null?t.next=t:(t.next=i.next,i.next=t),e.pending=t}function bm(e,t,i){if((i&4194048)!==0){var a=t.lanes;a&=e.pendingLanes,i|=a,t.lanes=i,_l(e,i)}}var cs={readContext:Je,use:ns,useCallback:Ie,useContext:Ie,useEffect:Ie,useImperativeHandle:Ie,useLayoutEffect:Ie,useInsertionEffect:Ie,useMemo:Ie,useReducer:Ie,useRef:Ie,useState:Ie,useDebugValue:Ie,useDeferredValue:Ie,useTransition:Ie,useSyncExternalStore:Ie,useId:Ie,useHostTransitionStatus:Ie,useFormState:Ie,useActionState:Ie,useOptimistic:Ie,useMemoCache:Ie,useCacheRefresh:Ie},gm={readContext:Je,use:ns,useCallback:function(e,t){return tt().memoizedState=[e,t===void 0?null:t],e},useContext:Je,useEffect:Wc,useImperativeHandle:function(e,t,i){i=i!=null?i.concat([e]):null,rs(4194308,4,am.bind(null,t,e),i)},useLayoutEffect:function(e,t){return rs(4194308,4,e,t)},useInsertionEffect:function(e,t){rs(4,2,e,t)},useMemo:function(e,t){var i=tt();t=t===void 0?null:t;var a=e();if(Ii){$t(!0);try{e()}finally{$t(!1)}}return i.memoizedState=[a,t],a},useReducer:function(e,t,i){var a=tt();if(i!==void 0){var n=i(t);if(Ii){$t(!0);try{i(t)}finally{$t(!1)}}}else n=t;return a.memoizedState=a.baseState=n,e={pending:null,lanes:0,dispatch:null,lastRenderedReducer:e,lastRenderedState:n},a.queue=e,e=e.dispatch=Up.bind(null,pe,e),[a.memoizedState,e]},useRef:function(e){var t=tt();return e={current:e},t.memoizedState=e},useState:function(e){e=Wo(e);var t=e.queue,i=pm.bind(null,pe,t);return t.dispatch=i,[e.memoizedState,i]},useDebugValue:tr,useDeferredValue:function(e,t){var i=tt();return ir(i,e,t)},useTransition:function(){var e=Wo(!1);return e=lm.bind(null,pe,e.queue,!0,!1),tt().memoizedState=e,[!1,e]},useSyncExternalStore:function(e,t,i){var a=pe,n=tt();if(ke){if(i===void 0)throw Error(u(407));i=i()}else{if(i=t(),Re===null)throw Error(u(349));(ye&124)!==0||Oc(a,t,i)}n.memoizedState=i;var o={value:i,getSnapshot:t};return n.queue=o,Wc(Bc.bind(null,a,o,e),[e]),a.flags|=2048,da(9,os(),Pc.bind(null,a,o,i,t),null),i},useId:function(){var e=tt(),t=Re.identifierPrefix;if(ke){var i=Pt,a=Ot;i=(a&~(1<<32-st(a)-1)).toString(32)+i,t="«"+t+"R"+i,i=as++,0<i&&(t+="H"+i.toString(32)),t+="»"}else i=qp++,t="«"+t+"r"+i.toString(32)+"»";return e.memoizedState=t},useHostTransitionStatus:nr,useFormState:Qc,useActionState:Qc,useOptimistic:function(e){var t=tt();t.memoizedState=t.baseState=e;var i={pending:null,lanes:0,dispatch:null,lastRenderedReducer:null,lastRenderedState:null};return t.queue=i,t=sr.bind(null,pe,!0,i),i.dispatch=t,[e,t]},useMemoCache:Jo,useCacheRefresh:function(){return tt().memoizedState=Vp.bind(null,pe)}},hm={readContext:Je,use:ns,useCallback:sm,useContext:Je,useEffect:em,useImperativeHandle:nm,useInsertionEffect:tm,useLayoutEffect:im,useMemo:om,useReducer:ss,useRef:$c,useState:function(){return ss(Vt)},useDebugValue:tr,useDeferredValue:function(e,t){var i=Pe();return rm(i,Ce.memoizedState,e,t)},useTransition:function(){var e=ss(Vt)[0],t=Pe().memoizedState;return[typeof e=="boolean"?e:en(e),t]},useSyncExternalStore:qc,useId:um,useHostTransitionStatus:nr,useFormState:Zc,useActionState:Zc,useOptimistic:function(e,t){var i=Pe();return Uc(i,Ce,e,t)},useMemoCache:Jo,useCacheRefresh:dm},Hp={readContext:Je,use:ns,useCallback:sm,useContext:Je,useEffect:em,useImperativeHandle:nm,useInsertionEffect:tm,useLayoutEffect:im,useMemo:om,useReducer:$o,useRef:$c,useState:function(){return $o(Vt)},useDebugValue:tr,useDeferredValue:function(e,t){var i=Pe();return Ce===null?ir(i,e,t):rm(i,Ce.memoizedState,e,t)},useTransition:function(){var e=$o(Vt)[0],t=Pe().memoizedState;return[typeof e=="boolean"?e:en(e),t]},useSyncExternalStore:qc,useId:um,useHostTransitionStatus:nr,useFormState:Fc,useActionState:Fc,useOptimistic:function(e,t){var i=Pe();return Ce!==null?Uc(i,Ce,e,t):(i.baseState=e,[e,i.queue.dispatch])},useMemoCache:Jo,useCacheRefresh:dm},pa=null,nn=0;function ms(e){var t=nn;return nn+=1,pa===null&&(pa=[]),jc(pa,e,t)}function sn(e,t){t=t.props.ref,e.ref=t!==void 0?t:null}function us(e,t){throw t.$$typeof===q?Error(u(525)):(e=Object.prototype.toString.call(t),Error(u(31,e==="[object Object]"?"object with keys {"+Object.keys(t).join(", ")+"}":e)))}function ym(e){var t=e._init;return t(e._payload)}function vm(e){function t(g,b){if(e){var h=g.deletions;h===null?(g.deletions=[b],g.flags|=16):h.push(b)}}function i(g,b){if(!e)return null;for(;b!==null;)t(g,b),b=b.sibling;return null}function a(g){for(var b=new Map;g!==null;)g.key!==null?b.set(g.key,g):b.set(g.index,g),g=g.sibling;return b}function n(g,b){return g=qt(g,b),g.index=0,g.sibling=null,g}function o(g,b,h){return g.index=h,e?(h=g.alternate,h!==null?(h=h.index,h<b?(g.flags|=67108866,b):h):(g.flags|=67108866,b)):(g.flags|=1048576,b)}function r(g){return e&&g.alternate===null&&(g.flags|=67108866),g}function l(g,b,h,A){return b===null||b.tag!==6?(b=Ao(h,g.mode,A),b.return=g,b):(b=n(b,h),b.return=g,b)}function p(g,b,h,A){var J=h.type;return J===Q?N(g,b,h.props.children,A,h.key):b!==null&&(b.elementType===J||typeof J=="object"&&J!==null&&J.$$typeof===se&&ym(J)===b.type)?(b=n(b,h.props),sn(b,h),b.return=g,b):(b=Kn(h.type,h.key,h.props,null,g.mode,A),sn(b,h),b.return=g,b)}function v(g,b,h,A){return b===null||b.tag!==4||b.stateNode.containerInfo!==h.containerInfo||b.stateNode.implementation!==h.implementation?(b=Eo(h,g.mode,A),b.return=g,b):(b=n(b,h.children||[]),b.return=g,b)}function N(g,b,h,A,J){return b===null||b.tag!==7?(b=Ei(h,g.mode,A,J),b.return=g,b):(b=n(b,h),b.return=g,b)}function j(g,b,h){if(typeof b=="string"&&b!==""||typeof b=="number"||typeof b=="bigint")return b=Ao(""+b,g.mode,h),b.return=g,b;if(typeof b=="object"&&b!==null){switch(b.$$typeof){case ie:return h=Kn(b.type,b.key,b.props,null,g.mode,h),sn(h,b),h.return=g,h;case B:return b=Eo(b,g.mode,h),b.return=g,b;case se:var A=b._init;return b=A(b._payload),j(g,b,h)}if(ce(b)||W(b))return b=Ei(b,g.mode,h,null),b.return=g,b;if(typeof b.then=="function")return j(g,ms(b),h);if(b.$$typeof===X)return j(g,Fn(g,b),h);us(g,b)}return null}function k(g,b,h,A){var J=b!==null?b.key:null;if(typeof h=="string"&&h!==""||typeof h=="number"||typeof h=="bigint")return J!==null?null:l(g,b,""+h,A);if(typeof h=="object"&&h!==null){switch(h.$$typeof){case ie:return h.key===J?p(g,b,h,A):null;case B:return h.key===J?v(g,b,h,A):null;case se:return J=h._init,h=J(h._payload),k(g,b,h,A)}if(ce(h)||W(h))return J!==null?null:N(g,b,h,A,null);if(typeof h.then=="function")return k(g,b,ms(h),A);if(h.$$typeof===X)return k(g,b,Fn(g,h),A);us(g,h)}return null}function S(g,b,h,A,J){if(typeof A=="string"&&A!==""||typeof A=="number"||typeof A=="bigint")return g=g.get(h)||null,l(b,g,""+A,J);if(typeof A=="object"&&A!==null){switch(A.$$typeof){case ie:return g=g.get(A.key===null?h:A.key)||null,p(b,g,A,J);case B:return g=g.get(A.key===null?h:A.key)||null,v(b,g,A,J);case se:var be=A._init;return A=be(A._payload),S(g,b,h,A,J)}if(ce(A)||W(A))return g=g.get(h)||null,N(b,g,A,J,null);if(typeof A.then=="function")return S(g,b,h,ms(A),J);if(A.$$typeof===X)return S(g,b,h,Fn(b,A),J);us(b,A)}return null}function oe(g,b,h,A){for(var J=null,be=null,te=b,ne=b=0,Ye=null;te!==null&&ne<h.length;ne++){te.index>ne?(Ye=te,te=null):Ye=te.sibling;var ve=k(g,te,h[ne],A);if(ve===null){te===null&&(te=Ye);break}e&&te&&ve.alternate===null&&t(g,te),b=o(ve,b,ne),be===null?J=ve:be.sibling=ve,be=ve,te=Ye}if(ne===h.length)return i(g,te),ke&&Ri(g,ne),J;if(te===null){for(;ne<h.length;ne++)te=j(g,h[ne],A),te!==null&&(b=o(te,b,ne),be===null?J=te:be.sibling=te,be=te);return ke&&Ri(g,ne),J}for(te=a(te);ne<h.length;ne++)Ye=S(te,g,ne,h[ne],A),Ye!==null&&(e&&Ye.alternate!==null&&te.delete(Ye.key===null?ne:Ye.key),b=o(Ye,b,ne),be===null?J=Ye:be.sibling=Ye,be=Ye);return e&&te.forEach(function(xi){return t(g,xi)}),ke&&Ri(g,ne),J}function ae(g,b,h,A){if(h==null)throw Error(u(151));for(var J=null,be=null,te=b,ne=b=0,Ye=null,ve=h.next();te!==null&&!ve.done;ne++,ve=h.next()){te.index>ne?(Ye=te,te=null):Ye=te.sibling;var xi=k(g,te,ve.value,A);if(xi===null){te===null&&(te=Ye);break}e&&te&&xi.alternate===null&&t(g,te),b=o(xi,b,ne),be===null?J=xi:be.sibling=xi,be=xi,te=Ye}if(ve.done)return i(g,te),ke&&Ri(g,ne),J;if(te===null){for(;!ve.done;ne++,ve=h.next())ve=j(g,ve.value,A),ve!==null&&(b=o(ve,b,ne),be===null?J=ve:be.sibling=ve,be=ve);return ke&&Ri(g,ne),J}for(te=a(te);!ve.done;ne++,ve=h.next())ve=S(te,g,ne,ve.value,A),ve!==null&&(e&&ve.alternate!==null&&te.delete(ve.key===null?ne:ve.key),b=o(ve,b,ne),be===null?J=ve:be.sibling=ve,be=ve);return e&&te.forEach(function(Yf){return t(g,Yf)}),ke&&Ri(g,ne),J}function Ae(g,b,h,A){if(typeof h=="object"&&h!==null&&h.type===Q&&h.key===null&&(h=h.props.children),typeof h=="object"&&h!==null){switch(h.$$typeof){case ie:e:{for(var J=h.key;b!==null;){if(b.key===J){if(J=h.type,J===Q){if(b.tag===7){i(g,b.sibling),A=n(b,h.props.children),A.return=g,g=A;break e}}else if(b.elementType===J||typeof J=="object"&&J!==null&&J.$$typeof===se&&ym(J)===b.type){i(g,b.sibling),A=n(b,h.props),sn(A,h),A.return=g,g=A;break e}i(g,b);break}else t(g,b);b=b.sibling}h.type===Q?(A=Ei(h.props.children,g.mode,A,h.key),A.return=g,g=A):(A=Kn(h.type,h.key,h.props,null,g.mode,A),sn(A,h),A.return=g,g=A)}return r(g);case B:e:{for(J=h.key;b!==null;){if(b.key===J)if(b.tag===4&&b.stateNode.containerInfo===h.containerInfo&&b.stateNode.implementation===h.implementation){i(g,b.sibling),A=n(b,h.children||[]),A.return=g,g=A;break e}else{i(g,b);break}else t(g,b);b=b.sibling}A=Eo(h,g.mode,A),A.return=g,g=A}return r(g);case se:return J=h._init,h=J(h._payload),Ae(g,b,h,A)}if(ce(h))return oe(g,b,h,A);if(W(h)){if(J=W(h),typeof J!="function")throw Error(u(150));return h=J.call(h),ae(g,b,h,A)}if(typeof h.then=="function")return Ae(g,b,ms(h),A);if(h.$$typeof===X)return Ae(g,b,Fn(g,h),A);us(g,h)}return typeof h=="string"&&h!==""||typeof h=="number"||typeof h=="bigint"?(h=""+h,b!==null&&b.tag===6?(i(g,b.sibling),A=n(b,h),A.return=g,g=A):(i(g,b),A=Ao(h,g.mode,A),A.return=g,g=A),r(g)):i(g,b)}return function(g,b,h,A){try{nn=0;var J=Ae(g,b,h,A);return pa=null,J}catch(te){if(te===Qa||te===Wn)throw te;var be=rt(29,te,null,g.mode);return be.lanes=A,be.return=g,be}finally{}}}var fa=vm(!0),km=vm(!1),vt=R(null),jt=null;function oi(e){var t=e.alternate;C(Ve,Ve.current&1),C(vt,e),jt===null&&(t===null||ca.current!==null||t.memoizedState!==null)&&(jt=e)}function xm(e){if(e.tag===22){if(C(Ve,Ve.current),C(vt,e),jt===null){var t=e.alternate;t!==null&&t.memoizedState!==null&&(jt=e)}}else ri()}function ri(){C(Ve,Ve.current),C(vt,vt.current)}function Ut(e){T(vt),jt===e&&(jt=null),T(Ve)}var Ve=R(0);function ds(e){for(var t=e;t!==null;){if(t.tag===13){var i=t.memoizedState;if(i!==null&&(i=i.dehydrated,i===null||i.data==="$?"||Zr(i)))return t}else if(t.tag===19&&t.memoizedProps.revealOrder!==void 0){if((t.flags&128)!==0)return t}else if(t.child!==null){t.child.return=t,t=t.child;continue}if(t===e)break;for(;t.sibling===null;){if(t.return===null||t.return===e)return null;t=t.return}t.sibling.return=t.return,t=t.sibling}return null}function or(e,t,i,a){t=e.memoizedState,i=i(a,t),i=i==null?t:z({},t,i),e.memoizedState=i,e.lanes===0&&(e.updateQueue.baseState=i)}var rr={enqueueSetState:function(e,t,i){e=e._reactInternals;var a=ut(),n=ai(a);n.payload=t,i!=null&&(n.callback=i),t=ni(e,n,a),t!==null&&(dt(t,e,a),Ja(t,e,a))},enqueueReplaceState:function(e,t,i){e=e._reactInternals;var a=ut(),n=ai(a);n.tag=1,n.payload=t,i!=null&&(n.callback=i),t=ni(e,n,a),t!==null&&(dt(t,e,a),Ja(t,e,a))},enqueueForceUpdate:function(e,t){e=e._reactInternals;var i=ut(),a=ai(i);a.tag=2,t!=null&&(a.callback=t),t=ni(e,a,i),t!==null&&(dt(t,e,i),Ja(t,e,i))}};function Sm(e,t,i,a,n,o,r){return e=e.stateNode,typeof e.shouldComponentUpdate=="function"?e.shouldComponentUpdate(a,o,r):t.prototype&&t.prototype.isPureReactComponent?!wa(i,a)||!wa(n,o):!0}function _m(e,t,i,a){e=t.state,typeof t.componentWillReceiveProps=="function"&&t.componentWillReceiveProps(i,a),typeof t.UNSAFE_componentWillReceiveProps=="function"&&t.UNSAFE_componentWillReceiveProps(i,a),t.state!==e&&rr.enqueueReplaceState(t,t.state,null)}function qi(e,t){var i=t;if("ref"in t){i={};for(var a in t)a!=="ref"&&(i[a]=t[a])}if(e=e.defaultProps){i===t&&(i=z({},i));for(var n in e)i[n]===void 0&&(i[n]=e[n])}return i}var ps=typeof reportError=="function"?reportError:function(e){if(typeof window=="object"&&typeof window.ErrorEvent=="function"){var t=new window.ErrorEvent("error",{bubbles:!0,cancelable:!0,message:typeof e=="object"&&e!==null&&typeof e.message=="string"?String(e.message):String(e),error:e});if(!window.dispatchEvent(t))return}else if(typeof process=="object"&&typeof process.emit=="function"){process.emit("uncaughtException",e);return}console.error(e)};function Cm(e){ps(e)}function Nm(e){console.error(e)}function Am(e){ps(e)}function fs(e,t){try{var i=e.onUncaughtError;i(t.value,{componentStack:t.stack})}catch(a){setTimeout(function(){throw a})}}function Em(e,t,i){try{var a=e.onCaughtError;a(i.value,{componentStack:i.stack,errorBoundary:t.tag===1?t.stateNode:null})}catch(n){setTimeout(function(){throw n})}}function lr(e,t,i){return i=ai(i),i.tag=3,i.payload={element:null},i.callback=function(){fs(e,t)},i}function jm(e){return e=ai(e),e.tag=3,e}function Rm(e,t,i,a){var n=i.type.getDerivedStateFromError;if(typeof n=="function"){var o=a.value;e.payload=function(){return n(o)},e.callback=function(){Em(t,i,a)}}var r=i.stateNode;r!==null&&typeof r.componentDidCatch=="function"&&(e.callback=function(){Em(t,i,a),typeof n!="function"&&(pi===null?pi=new Set([this]):pi.add(this));var l=a.stack;this.componentDidCatch(a.value,{componentStack:l!==null?l:""})})}function Gp(e,t,i,a,n){if(i.flags|=32768,a!==null&&typeof a=="object"&&typeof a.then=="function"){if(t=i.alternate,t!==null&&Ya(t,i,n,!0),i=vt.current,i!==null){switch(i.tag){case 13:return jt===null?Lr():i.alternate===null&&ze===0&&(ze=3),i.flags&=-257,i.flags|=65536,i.lanes=n,a===Oo?i.flags|=16384:(t=i.updateQueue,t===null?i.updateQueue=new Set([a]):t.add(a),zr(e,a,n)),!1;case 22:return i.flags|=65536,a===Oo?i.flags|=16384:(t=i.updateQueue,t===null?(t={transitions:null,markerInstances:null,retryQueue:new Set([a])},i.updateQueue=t):(i=t.retryQueue,i===null?t.retryQueue=new Set([a]):i.add(a)),zr(e,a,n)),!1}throw Error(u(435,i.tag))}return zr(e,a,n),Lr(),!1}if(ke)return t=vt.current,t!==null?((t.flags&65536)===0&&(t.flags|=256),t.flags|=65536,t.lanes=n,a!==To&&(e=Error(u(422),{cause:a}),Ga(bt(e,i)))):(a!==To&&(t=Error(u(423),{cause:a}),Ga(bt(t,i))),e=e.current.alternate,e.flags|=65536,n&=-n,e.lanes|=n,a=bt(a,i),n=lr(e.stateNode,a,n),wo(e,n),ze!==4&&(ze=2)),!1;var o=Error(u(520),{cause:a});if(o=bt(o,i),dn===null?dn=[o]:dn.push(o),ze!==4&&(ze=2),t===null)return!0;a=bt(a,i),i=t;do{switch(i.tag){case 3:return i.flags|=65536,e=n&-n,i.lanes|=e,e=lr(i.stateNode,a,e),wo(i,e),!1;case 1:if(t=i.type,o=i.stateNode,(i.flags&128)===0&&(typeof t.getDerivedStateFromError=="function"||o!==null&&typeof o.componentDidCatch=="function"&&(pi===null||!pi.has(o))))return i.flags|=65536,n&=-n,i.lanes|=n,n=jm(n),Rm(n,e,i,a),wo(i,n),!1}i=i.return}while(i!==null);return!1}var Tm=Error(u(461)),He=!1;function Xe(e,t,i,a){t.child=e===null?km(t,null,i,a):fa(t,e.child,i,a)}function Dm(e,t,i,a,n){i=i.render;var o=t.ref;if("ref"in a){var r={};for(var l in a)l!=="ref"&&(r[l]=a[l])}else r=a;return Mi(t),a=Yo(e,t,i,r,o,n),l=Xo(),e!==null&&!He?(Ko(e,t,n),Ht(e,t,n)):(ke&&l&&jo(t),t.flags|=1,Xe(e,t,a,n),t.child)}function Lm(e,t,i,a,n){if(e===null){var o=i.type;return typeof o=="function"&&!No(o)&&o.defaultProps===void 0&&i.compare===null?(t.tag=15,t.type=o,Mm(e,t,o,a,n)):(e=Kn(i.type,null,a,t,t.mode,n),e.ref=t.ref,e.return=t,t.child=e)}if(o=e.child,!gr(e,n)){var r=o.memoizedProps;if(i=i.compare,i=i!==null?i:wa,i(r,a)&&e.ref===t.ref)return Ht(e,t,n)}return t.flags|=1,e=qt(o,a),e.ref=t.ref,e.return=t,t.child=e}function Mm(e,t,i,a,n){if(e!==null){var o=e.memoizedProps;if(wa(o,a)&&e.ref===t.ref)if(He=!1,t.pendingProps=a=o,gr(e,n))(e.flags&131072)!==0&&(He=!0);else return t.lanes=e.lanes,Ht(e,t,n)}return cr(e,t,i,a,n)}function zm(e,t,i){var a=t.pendingProps,n=a.children,o=e!==null?e.memoizedState:null;if(a.mode==="hidden"){if((t.flags&128)!==0){if(a=o!==null?o.baseLanes|i:i,e!==null){for(n=t.child=e.child,o=0;n!==null;)o=o|n.lanes|n.childLanes,n=n.sibling;t.childLanes=o&~a}else t.childLanes=0,t.child=null;return Im(e,t,a,i)}if((i&536870912)!==0)t.memoizedState={baseLanes:0,cachePool:null},e!==null&&$n(t,o!==null?o.cachePool:null),o!==null?Mc(t,o):Uo(),xm(t);else return t.lanes=t.childLanes=536870912,Im(e,t,o!==null?o.baseLanes|i:i,i)}else o!==null?($n(t,o.cachePool),Mc(t,o),ri(),t.memoizedState=null):(e!==null&&$n(t,null),Uo(),ri());return Xe(e,t,n,i),t.child}function Im(e,t,i,a){var n=qo();return n=n===null?null:{parent:we._currentValue,pool:n},t.memoizedState={baseLanes:i,cachePool:n},e!==null&&$n(t,null),Uo(),xm(t),e!==null&&Ya(e,t,a,!0),null}function bs(e,t){var i=t.ref;if(i===null)e!==null&&e.ref!==null&&(t.flags|=4194816);else{if(typeof i!="function"&&typeof i!="object")throw Error(u(284));(e===null||e.ref!==i)&&(t.flags|=4194816)}}function cr(e,t,i,a,n){return Mi(t),i=Yo(e,t,i,a,void 0,n),a=Xo(),e!==null&&!He?(Ko(e,t,n),Ht(e,t,n)):(ke&&a&&jo(t),t.flags|=1,Xe(e,t,i,n),t.child)}function qm(e,t,i,a,n,o){return Mi(t),t.updateQueue=null,i=Ic(t,a,i,n),zc(e),a=Xo(),e!==null&&!He?(Ko(e,t,o),Ht(e,t,o)):(ke&&a&&jo(t),t.flags|=1,Xe(e,t,i,o),t.child)}function Om(e,t,i,a,n){if(Mi(t),t.stateNode===null){var o=na,r=i.contextType;typeof r=="object"&&r!==null&&(o=Je(r)),o=new i(a,o),t.memoizedState=o.state!==null&&o.state!==void 0?o.state:null,o.updater=rr,t.stateNode=o,o._reactInternals=t,o=t.stateNode,o.props=a,o.state=t.memoizedState,o.refs={},Po(t),r=i.contextType,o.context=typeof r=="object"&&r!==null?Je(r):na,o.state=t.memoizedState,r=i.getDerivedStateFromProps,typeof r=="function"&&(or(t,i,r,a),o.state=t.memoizedState),typeof i.getDerivedStateFromProps=="function"||typeof o.getSnapshotBeforeUpdate=="function"||typeof o.UNSAFE_componentWillMount!="function"&&typeof o.componentWillMount!="function"||(r=o.state,typeof o.componentWillMount=="function"&&o.componentWillMount(),typeof o.UNSAFE_componentWillMount=="function"&&o.UNSAFE_componentWillMount(),r!==o.state&&rr.enqueueReplaceState(o,o.state,null),$a(t,a,o,n),Fa(),o.state=t.memoizedState),typeof o.componentDidMount=="function"&&(t.flags|=4194308),a=!0}else if(e===null){o=t.stateNode;var l=t.memoizedProps,p=qi(i,l);o.props=p;var v=o.context,N=i.contextType;r=na,typeof N=="object"&&N!==null&&(r=Je(N));var j=i.getDerivedStateFromProps;N=typeof j=="function"||typeof o.getSnapshotBeforeUpdate=="function",l=t.pendingProps!==l,N||typeof o.UNSAFE_componentWillReceiveProps!="function"&&typeof o.componentWillReceiveProps!="function"||(l||v!==r)&&_m(t,o,a,r),ii=!1;var k=t.memoizedState;o.state=k,$a(t,a,o,n),Fa(),v=t.memoizedState,l||k!==v||ii?(typeof j=="function"&&(or(t,i,j,a),v=t.memoizedState),(p=ii||Sm(t,i,p,a,k,v,r))?(N||typeof o.UNSAFE_componentWillMount!="function"&&typeof o.componentWillMount!="function"||(typeof o.componentWillMount=="function"&&o.componentWillMount(),typeof o.UNSAFE_componentWillMount=="function"&&o.UNSAFE_componentWillMount()),typeof o.componentDidMount=="function"&&(t.flags|=4194308)):(typeof o.componentDidMount=="function"&&(t.flags|=4194308),t.memoizedProps=a,t.memoizedState=v),o.props=a,o.state=v,o.context=r,a=p):(typeof o.componentDidMount=="function"&&(t.flags|=4194308),a=!1)}else{o=t.stateNode,Bo(e,t),r=t.memoizedProps,N=qi(i,r),o.props=N,j=t.pendingProps,k=o.context,v=i.contextType,p=na,typeof v=="object"&&v!==null&&(p=Je(v)),l=i.getDerivedStateFromProps,(v=typeof l=="function"||typeof o.getSnapshotBeforeUpdate=="function")||typeof o.UNSAFE_componentWillReceiveProps!="function"&&typeof o.componentWillReceiveProps!="function"||(r!==j||k!==p)&&_m(t,o,a,p),ii=!1,k=t.memoizedState,o.state=k,$a(t,a,o,n),Fa();var S=t.memoizedState;r!==j||k!==S||ii||e!==null&&e.dependencies!==null&&Jn(e.dependencies)?(typeof l=="function"&&(or(t,i,l,a),S=t.memoizedState),(N=ii||Sm(t,i,N,a,k,S,p)||e!==null&&e.dependencies!==null&&Jn(e.dependencies))?(v||typeof o.UNSAFE_componentWillUpdate!="function"&&typeof o.componentWillUpdate!="function"||(typeof o.componentWillUpdate=="function"&&o.componentWillUpdate(a,S,p),typeof o.UNSAFE_componentWillUpdate=="function"&&o.UNSAFE_componentWillUpdate(a,S,p)),typeof o.componentDidUpdate=="function"&&(t.flags|=4),typeof o.getSnapshotBeforeUpdate=="function"&&(t.flags|=1024)):(typeof o.componentDidUpdate!="function"||r===e.memoizedProps&&k===e.memoizedState||(t.flags|=4),typeof o.getSnapshotBeforeUpdate!="function"||r===e.memoizedProps&&k===e.memoizedState||(t.flags|=1024),t.memoizedProps=a,t.memoizedState=S),o.props=a,o.state=S,o.context=p,a=N):(typeof o.componentDidUpdate!="function"||r===e.memoizedProps&&k===e.memoizedState||(t.flags|=4),typeof o.getSnapshotBeforeUpdate!="function"||r===e.memoizedProps&&k===e.memoizedState||(t.flags|=1024),a=!1)}return o=a,bs(e,t),a=(t.flags&128)!==0,o||a?(o=t.stateNode,i=a&&typeof i.getDerivedStateFromError!="function"?null:o.render(),t.flags|=1,e!==null&&a?(t.child=fa(t,e.child,null,n),t.child=fa(t,null,i,n)):Xe(e,t,i,n),t.memoizedState=o.state,e=t.child):e=Ht(e,t,n),e}function Pm(e,t,i,a){return Ha(),t.flags|=256,Xe(e,t,i,a),t.child}var mr={dehydrated:null,treeContext:null,retryLane:0,hydrationErrors:null};function ur(e){return{baseLanes:e,cachePool:Nc()}}function dr(e,t,i){return e=e!==null?e.childLanes&~i:0,t&&(e|=kt),e}function Bm(e,t,i){var a=t.pendingProps,n=!1,o=(t.flags&128)!==0,r;if((r=o)||(r=e!==null&&e.memoizedState===null?!1:(Ve.current&2)!==0),r&&(n=!0,t.flags&=-129),r=(t.flags&32)!==0,t.flags&=-33,e===null){if(ke){if(n?oi(t):ri(),ke){var l=Me,p;if(p=l){e:{for(p=l,l=Et;p.nodeType!==8;){if(!l){l=null;break e}if(p=Ct(p.nextSibling),p===null){l=null;break e}}l=p}l!==null?(t.memoizedState={dehydrated:l,treeContext:ji!==null?{id:Ot,overflow:Pt}:null,retryLane:536870912,hydrationErrors:null},p=rt(18,null,null,0),p.stateNode=l,p.return=t,t.child=p,$e=t,Me=null,p=!0):p=!1}p||Di(t)}if(l=t.memoizedState,l!==null&&(l=l.dehydrated,l!==null))return Zr(l)?t.lanes=32:t.lanes=536870912,null;Ut(t)}return l=a.children,a=a.fallback,n?(ri(),n=t.mode,l=gs({mode:"hidden",children:l},n),a=Ei(a,n,i,null),l.return=t,a.return=t,l.sibling=a,t.child=l,n=t.child,n.memoizedState=ur(i),n.childLanes=dr(e,r,i),t.memoizedState=mr,a):(oi(t),pr(t,l))}if(p=e.memoizedState,p!==null&&(l=p.dehydrated,l!==null)){if(o)t.flags&256?(oi(t),t.flags&=-257,t=fr(e,t,i)):t.memoizedState!==null?(ri(),t.child=e.child,t.flags|=128,t=null):(ri(),n=a.fallback,l=t.mode,a=gs({mode:"visible",children:a.children},l),n=Ei(n,l,i,null),n.flags|=2,a.return=t,n.return=t,a.sibling=n,t.child=a,fa(t,e.child,null,i),a=t.child,a.memoizedState=ur(i),a.childLanes=dr(e,r,i),t.memoizedState=mr,t=n);else if(oi(t),Zr(l)){if(r=l.nextSibling&&l.nextSibling.dataset,r)var v=r.dgst;r=v,a=Error(u(419)),a.stack="",a.digest=r,Ga({value:a,source:null,stack:null}),t=fr(e,t,i)}else if(He||Ya(e,t,i,!1),r=(i&e.childLanes)!==0,He||r){if(r=Re,r!==null&&(a=i&-i,a=(a&42)!==0?1:Zs(a),a=(a&(r.suspendedLanes|i))!==0?0:a,a!==0&&a!==p.retryLane))throw p.retryLane=a,aa(e,a),dt(r,e,a),Tm;l.data==="$?"||Lr(),t=fr(e,t,i)}else l.data==="$?"?(t.flags|=192,t.child=e.child,t=null):(e=p.treeContext,Me=Ct(l.nextSibling),$e=t,ke=!0,Ti=null,Et=!1,e!==null&&(ht[yt++]=Ot,ht[yt++]=Pt,ht[yt++]=ji,Ot=e.id,Pt=e.overflow,ji=t),t=pr(t,a.children),t.flags|=4096);return t}return n?(ri(),n=a.fallback,l=t.mode,p=e.child,v=p.sibling,a=qt(p,{mode:"hidden",children:a.children}),a.subtreeFlags=p.subtreeFlags&65011712,v!==null?n=qt(v,n):(n=Ei(n,l,i,null),n.flags|=2),n.return=t,a.return=t,a.sibling=n,t.child=a,a=n,n=t.child,l=e.child.memoizedState,l===null?l=ur(i):(p=l.cachePool,p!==null?(v=we._currentValue,p=p.parent!==v?{parent:v,pool:v}:p):p=Nc(),l={baseLanes:l.baseLanes|i,cachePool:p}),n.memoizedState=l,n.childLanes=dr(e,r,i),t.memoizedState=mr,a):(oi(t),i=e.child,e=i.sibling,i=qt(i,{mode:"visible",children:a.children}),i.return=t,i.sibling=null,e!==null&&(r=t.deletions,r===null?(t.deletions=[e],t.flags|=16):r.push(e)),t.child=i,t.memoizedState=null,i)}function pr(e,t){return t=gs({mode:"visible",children:t},e.mode),t.return=e,e.child=t}function gs(e,t){return e=rt(22,e,null,t),e.lanes=0,e.stateNode={_visibility:1,_pendingMarkers:null,_retryCache:null,_transitions:null},e}function fr(e,t,i){return fa(t,e.child,null,i),e=pr(t,t.pendingProps.children),e.flags|=2,t.memoizedState=null,e}function wm(e,t,i){e.lanes|=t;var a=e.alternate;a!==null&&(a.lanes|=t),Lo(e.return,t,i)}function br(e,t,i,a,n){var o=e.memoizedState;o===null?e.memoizedState={isBackwards:t,rendering:null,renderingStartTime:0,last:a,tail:i,tailMode:n}:(o.isBackwards=t,o.rendering=null,o.renderingStartTime=0,o.last=a,o.tail=i,o.tailMode=n)}function Vm(e,t,i){var a=t.pendingProps,n=a.revealOrder,o=a.tail;if(Xe(e,t,a.children,i),a=Ve.current,(a&2)!==0)a=a&1|2,t.flags|=128;else{if(e!==null&&(e.flags&128)!==0)e:for(e=t.child;e!==null;){if(e.tag===13)e.memoizedState!==null&&wm(e,i,t);else if(e.tag===19)wm(e,i,t);else if(e.child!==null){e.child.return=e,e=e.child;continue}if(e===t)break e;for(;e.sibling===null;){if(e.return===null||e.return===t)break e;e=e.return}e.sibling.return=e.return,e=e.sibling}a&=1}switch(C(Ve,a),n){case"forwards":for(i=t.child,n=null;i!==null;)e=i.alternate,e!==null&&ds(e)===null&&(n=i),i=i.sibling;i=n,i===null?(n=t.child,t.child=null):(n=i.sibling,i.sibling=null),br(t,!1,n,i,o);break;case"backwards":for(i=null,n=t.child,t.child=null;n!==null;){if(e=n.alternate,e!==null&&ds(e)===null){t.child=n;break}e=n.sibling,n.sibling=i,i=n,n=e}br(t,!0,i,null,o);break;case"together":br(t,!1,null,null,void 0);break;default:t.memoizedState=null}return t.child}function Ht(e,t,i){if(e!==null&&(t.dependencies=e.dependencies),di|=t.lanes,(i&t.childLanes)===0)if(e!==null){if(Ya(e,t,i,!1),(i&t.childLanes)===0)return null}else return null;if(e!==null&&t.child!==e.child)throw Error(u(153));if(t.child!==null){for(e=t.child,i=qt(e,e.pendingProps),t.child=i,i.return=t;e.sibling!==null;)e=e.sibling,i=i.sibling=qt(e,e.pendingProps),i.return=t;i.sibling=null}return t.child}function gr(e,t){return(e.lanes&t)!==0?!0:(e=e.dependencies,!!(e!==null&&Jn(e)))}function Yp(e,t,i){switch(t.tag){case 3:je(t,t.stateNode.containerInfo),ti(t,we,e.memoizedState.cache),Ha();break;case 27:case 5:Gs(t);break;case 4:je(t,t.stateNode.containerInfo);break;case 10:ti(t,t.type,t.memoizedProps.value);break;case 13:var a=t.memoizedState;if(a!==null)return a.dehydrated!==null?(oi(t),t.flags|=128,null):(i&t.child.childLanes)!==0?Bm(e,t,i):(oi(t),e=Ht(e,t,i),e!==null?e.sibling:null);oi(t);break;case 19:var n=(e.flags&128)!==0;if(a=(i&t.childLanes)!==0,a||(Ya(e,t,i,!1),a=(i&t.childLanes)!==0),n){if(a)return Vm(e,t,i);t.flags|=128}if(n=t.memoizedState,n!==null&&(n.rendering=null,n.tail=null,n.lastEffect=null),C(Ve,Ve.current),a)break;return null;case 22:case 23:return t.lanes=0,zm(e,t,i);case 24:ti(t,we,e.memoizedState.cache)}return Ht(e,t,i)}function Um(e,t,i){if(e!==null)if(e.memoizedProps!==t.pendingProps)He=!0;else{if(!gr(e,i)&&(t.flags&128)===0)return He=!1,Yp(e,t,i);He=(e.flags&131072)!==0}else He=!1,ke&&(t.flags&1048576)!==0&&yc(t,Zn,t.index);switch(t.lanes=0,t.tag){case 16:e:{e=t.pendingProps;var a=t.elementType,n=a._init;if(a=n(a._payload),t.type=a,typeof a=="function")No(a)?(e=qi(a,e),t.tag=1,t=Om(null,t,a,e,i)):(t.tag=0,t=cr(null,t,a,e,i));else{if(a!=null){if(n=a.$$typeof,n===Z){t.tag=11,t=Dm(null,t,a,e,i);break e}else if(n===F){t.tag=14,t=Lm(null,t,a,e,i);break e}}throw t=de(a)||a,Error(u(306,t,""))}}return t;case 0:return cr(e,t,t.type,t.pendingProps,i);case 1:return a=t.type,n=qi(a,t.pendingProps),Om(e,t,a,n,i);case 3:e:{if(je(t,t.stateNode.containerInfo),e===null)throw Error(u(387));a=t.pendingProps;var o=t.memoizedState;n=o.element,Bo(e,t),$a(t,a,null,i);var r=t.memoizedState;if(a=r.cache,ti(t,we,a),a!==o.cache&&Mo(t,[we],i,!0),Fa(),a=r.element,o.isDehydrated)if(o={element:a,isDehydrated:!1,cache:r.cache},t.updateQueue.baseState=o,t.memoizedState=o,t.flags&256){t=Pm(e,t,a,i);break e}else if(a!==n){n=bt(Error(u(424)),t),Ga(n),t=Pm(e,t,a,i);break e}else{switch(e=t.stateNode.containerInfo,e.nodeType){case 9:e=e.body;break;default:e=e.nodeName==="HTML"?e.ownerDocument.body:e}for(Me=Ct(e.firstChild),$e=t,ke=!0,Ti=null,Et=!0,i=km(t,null,a,i),t.child=i;i;)i.flags=i.flags&-3|4096,i=i.sibling}else{if(Ha(),a===n){t=Ht(e,t,i);break e}Xe(e,t,a,i)}t=t.child}return t;case 26:return bs(e,t),e===null?(i=Xu(t.type,null,t.pendingProps,null))?t.memoizedState=i:ke||(i=t.type,e=t.pendingProps,a=Ts(ee.current).createElement(i),a[Ze]=t,a[We]=e,Qe(a,i,e),Ue(a),t.stateNode=a):t.memoizedState=Xu(t.type,e.memoizedProps,t.pendingProps,e.memoizedState),null;case 27:return Gs(t),e===null&&ke&&(a=t.stateNode=Hu(t.type,t.pendingProps,ee.current),$e=t,Et=!0,n=Me,gi(t.type)?(Jr=n,Me=Ct(a.firstChild)):Me=n),Xe(e,t,t.pendingProps.children,i),bs(e,t),e===null&&(t.flags|=4194304),t.child;case 5:return e===null&&ke&&((n=a=Me)&&(a=kf(a,t.type,t.pendingProps,Et),a!==null?(t.stateNode=a,$e=t,Me=Ct(a.firstChild),Et=!1,n=!0):n=!1),n||Di(t)),Gs(t),n=t.type,o=t.pendingProps,r=e!==null?e.memoizedProps:null,a=o.children,Xr(n,o)?a=null:r!==null&&Xr(n,r)&&(t.flags|=32),t.memoizedState!==null&&(n=Yo(e,t,Op,null,null,i),xn._currentValue=n),bs(e,t),Xe(e,t,a,i),t.child;case 6:return e===null&&ke&&((e=i=Me)&&(i=xf(i,t.pendingProps,Et),i!==null?(t.stateNode=i,$e=t,Me=null,e=!0):e=!1),e||Di(t)),null;case 13:return Bm(e,t,i);case 4:return je(t,t.stateNode.containerInfo),a=t.pendingProps,e===null?t.child=fa(t,null,a,i):Xe(e,t,a,i),t.child;case 11:return Dm(e,t,t.type,t.pendingProps,i);case 7:return Xe(e,t,t.pendingProps,i),t.child;case 8:return Xe(e,t,t.pendingProps.children,i),t.child;case 12:return Xe(e,t,t.pendingProps.children,i),t.child;case 10:return a=t.pendingProps,ti(t,t.type,a.value),Xe(e,t,a.children,i),t.child;case 9:return n=t.type._context,a=t.pendingProps.children,Mi(t),n=Je(n),a=a(n),t.flags|=1,Xe(e,t,a,i),t.child;case 14:return Lm(e,t,t.type,t.pendingProps,i);case 15:return Mm(e,t,t.type,t.pendingProps,i);case 19:return Vm(e,t,i);case 31:return a=t.pendingProps,i=t.mode,a={mode:a.mode,children:a.children},e===null?(i=gs(a,i),i.ref=t.ref,t.child=i,i.return=t,t=i):(i=qt(e.child,a),i.ref=t.ref,t.child=i,i.return=t,t=i),t;case 22:return zm(e,t,i);case 24:return Mi(t),a=Je(we),e===null?(n=qo(),n===null&&(n=Re,o=zo(),n.pooledCache=o,o.refCount++,o!==null&&(n.pooledCacheLanes|=i),n=o),t.memoizedState={parent:a,cache:n},Po(t),ti(t,we,n)):((e.lanes&i)!==0&&(Bo(e,t),$a(t,null,null,i),Fa()),n=e.memoizedState,o=t.memoizedState,n.parent!==a?(n={parent:a,cache:a},t.memoizedState=n,t.lanes===0&&(t.memoizedState=t.updateQueue.baseState=n),ti(t,we,a)):(a=o.cache,ti(t,we,a),a!==n.cache&&Mo(t,[we],i,!0))),Xe(e,t,t.pendingProps.children,i),t.child;case 29:throw t.pendingProps}throw Error(u(156,t.tag))}function Gt(e){e.flags|=4}function Hm(e,t){if(t.type!=="stylesheet"||(t.state.loading&4)!==0)e.flags&=-16777217;else if(e.flags|=16777216,!Fu(t)){if(t=vt.current,t!==null&&((ye&4194048)===ye?jt!==null:(ye&62914560)!==ye&&(ye&536870912)===0||t!==jt))throw Za=Oo,Ac;e.flags|=8192}}function hs(e,t){t!==null&&(e.flags|=4),e.flags&16384&&(t=e.tag!==22?xl():536870912,e.lanes|=t,ya|=t)}function on(e,t){if(!ke)switch(e.tailMode){case"hidden":t=e.tail;for(var i=null;t!==null;)t.alternate!==null&&(i=t),t=t.sibling;i===null?e.tail=null:i.sibling=null;break;case"collapsed":i=e.tail;for(var a=null;i!==null;)i.alternate!==null&&(a=i),i=i.sibling;a===null?t||e.tail===null?e.tail=null:e.tail.sibling=null:a.sibling=null}}function Le(e){var t=e.alternate!==null&&e.alternate.child===e.child,i=0,a=0;if(t)for(var n=e.child;n!==null;)i|=n.lanes|n.childLanes,a|=n.subtreeFlags&65011712,a|=n.flags&65011712,n.return=e,n=n.sibling;else for(n=e.child;n!==null;)i|=n.lanes|n.childLanes,a|=n.subtreeFlags,a|=n.flags,n.return=e,n=n.sibling;return e.subtreeFlags|=a,e.childLanes=i,t}function Xp(e,t,i){var a=t.pendingProps;switch(Ro(t),t.tag){case 31:case 16:case 15:case 0:case 11:case 7:case 8:case 12:case 9:case 14:return Le(t),null;case 1:return Le(t),null;case 3:return i=t.stateNode,a=null,e!==null&&(a=e.memoizedState.cache),t.memoizedState.cache!==a&&(t.flags|=2048),wt(we),Ft(),i.pendingContext&&(i.context=i.pendingContext,i.pendingContext=null),(e===null||e.child===null)&&(Ua(t)?Gt(t):e===null||e.memoizedState.isDehydrated&&(t.flags&256)===0||(t.flags|=1024,xc())),Le(t),null;case 26:return i=t.memoizedState,e===null?(Gt(t),i!==null?(Le(t),Hm(t,i)):(Le(t),t.flags&=-16777217)):i?i!==e.memoizedState?(Gt(t),Le(t),Hm(t,i)):(Le(t),t.flags&=-16777217):(e.memoizedProps!==a&&Gt(t),Le(t),t.flags&=-16777217),null;case 27:jn(t),i=ee.current;var n=t.type;if(e!==null&&t.stateNode!=null)e.memoizedProps!==a&&Gt(t);else{if(!a){if(t.stateNode===null)throw Error(u(166));return Le(t),null}e=I.current,Ua(t)?vc(t):(e=Hu(n,a,i),t.stateNode=e,Gt(t))}return Le(t),null;case 5:if(jn(t),i=t.type,e!==null&&t.stateNode!=null)e.memoizedProps!==a&&Gt(t);else{if(!a){if(t.stateNode===null)throw Error(u(166));return Le(t),null}if(e=I.current,Ua(t))vc(t);else{switch(n=Ts(ee.current),e){case 1:e=n.createElementNS("http://www.w3.org/2000/svg",i);break;case 2:e=n.createElementNS("http://www.w3.org/1998/Math/MathML",i);break;default:switch(i){case"svg":e=n.createElementNS("http://www.w3.org/2000/svg",i);break;case"math":e=n.createElementNS("http://www.w3.org/1998/Math/MathML",i);break;case"script":e=n.createElement("div"),e.innerHTML="<script><\/script>",e=e.removeChild(e.firstChild);break;case"select":e=typeof a.is=="string"?n.createElement("select",{is:a.is}):n.createElement("select"),a.multiple?e.multiple=!0:a.size&&(e.size=a.size);break;default:e=typeof a.is=="string"?n.createElement(i,{is:a.is}):n.createElement(i)}}e[Ze]=t,e[We]=a;e:for(n=t.child;n!==null;){if(n.tag===5||n.tag===6)e.appendChild(n.stateNode);else if(n.tag!==4&&n.tag!==27&&n.child!==null){n.child.return=n,n=n.child;continue}if(n===t)break e;for(;n.sibling===null;){if(n.return===null||n.return===t)break e;n=n.return}n.sibling.return=n.return,n=n.sibling}t.stateNode=e;e:switch(Qe(e,i,a),i){case"button":case"input":case"select":case"textarea":e=!!a.autoFocus;break e;case"img":e=!0;break e;default:e=!1}e&&Gt(t)}}return Le(t),t.flags&=-16777217,null;case 6:if(e&&t.stateNode!=null)e.memoizedProps!==a&&Gt(t);else{if(typeof a!="string"&&t.stateNode===null)throw Error(u(166));if(e=ee.current,Ua(t)){if(e=t.stateNode,i=t.memoizedProps,a=null,n=$e,n!==null)switch(n.tag){case 27:case 5:a=n.memoizedProps}e[Ze]=t,e=!!(e.nodeValue===i||a!==null&&a.suppressHydrationWarning===!0||qu(e.nodeValue,i)),e||Di(t)}else e=Ts(e).createTextNode(a),e[Ze]=t,t.stateNode=e}return Le(t),null;case 13:if(a=t.memoizedState,e===null||e.memoizedState!==null&&e.memoizedState.dehydrated!==null){if(n=Ua(t),a!==null&&a.dehydrated!==null){if(e===null){if(!n)throw Error(u(318));if(n=t.memoizedState,n=n!==null?n.dehydrated:null,!n)throw Error(u(317));n[Ze]=t}else Ha(),(t.flags&128)===0&&(t.memoizedState=null),t.flags|=4;Le(t),n=!1}else n=xc(),e!==null&&e.memoizedState!==null&&(e.memoizedState.hydrationErrors=n),n=!0;if(!n)return t.flags&256?(Ut(t),t):(Ut(t),null)}if(Ut(t),(t.flags&128)!==0)return t.lanes=i,t;if(i=a!==null,e=e!==null&&e.memoizedState!==null,i){a=t.child,n=null,a.alternate!==null&&a.alternate.memoizedState!==null&&a.alternate.memoizedState.cachePool!==null&&(n=a.alternate.memoizedState.cachePool.pool);var o=null;a.memoizedState!==null&&a.memoizedState.cachePool!==null&&(o=a.memoizedState.cachePool.pool),o!==n&&(a.flags|=2048)}return i!==e&&i&&(t.child.flags|=8192),hs(t,t.updateQueue),Le(t),null;case 4:return Ft(),e===null&&Vr(t.stateNode.containerInfo),Le(t),null;case 10:return wt(t.type),Le(t),null;case 19:if(T(Ve),n=t.memoizedState,n===null)return Le(t),null;if(a=(t.flags&128)!==0,o=n.rendering,o===null)if(a)on(n,!1);else{if(ze!==0||e!==null&&(e.flags&128)!==0)for(e=t.child;e!==null;){if(o=ds(e),o!==null){for(t.flags|=128,on(n,!1),e=o.updateQueue,t.updateQueue=e,hs(t,e),t.subtreeFlags=0,e=i,i=t.child;i!==null;)hc(i,e),i=i.sibling;return C(Ve,Ve.current&1|2),t.child}e=e.sibling}n.tail!==null&&At()>ks&&(t.flags|=128,a=!0,on(n,!1),t.lanes=4194304)}else{if(!a)if(e=ds(o),e!==null){if(t.flags|=128,a=!0,e=e.updateQueue,t.updateQueue=e,hs(t,e),on(n,!0),n.tail===null&&n.tailMode==="hidden"&&!o.alternate&&!ke)return Le(t),null}else 2*At()-n.renderingStartTime>ks&&i!==536870912&&(t.flags|=128,a=!0,on(n,!1),t.lanes=4194304);n.isBackwards?(o.sibling=t.child,t.child=o):(e=n.last,e!==null?e.sibling=o:t.child=o,n.last=o)}return n.tail!==null?(t=n.tail,n.rendering=t,n.tail=t.sibling,n.renderingStartTime=At(),t.sibling=null,e=Ve.current,C(Ve,a?e&1|2:e&1),t):(Le(t),null);case 22:case 23:return Ut(t),Ho(),a=t.memoizedState!==null,e!==null?e.memoizedState!==null!==a&&(t.flags|=8192):a&&(t.flags|=8192),a?(i&536870912)!==0&&(t.flags&128)===0&&(Le(t),t.subtreeFlags&6&&(t.flags|=8192)):Le(t),i=t.updateQueue,i!==null&&hs(t,i.retryQueue),i=null,e!==null&&e.memoizedState!==null&&e.memoizedState.cachePool!==null&&(i=e.memoizedState.cachePool.pool),a=null,t.memoizedState!==null&&t.memoizedState.cachePool!==null&&(a=t.memoizedState.cachePool.pool),a!==i&&(t.flags|=2048),e!==null&&T(zi),null;case 24:return i=null,e!==null&&(i=e.memoizedState.cache),t.memoizedState.cache!==i&&(t.flags|=2048),wt(we),Le(t),null;case 25:return null;case 30:return null}throw Error(u(156,t.tag))}function Kp(e,t){switch(Ro(t),t.tag){case 1:return e=t.flags,e&65536?(t.flags=e&-65537|128,t):null;case 3:return wt(we),Ft(),e=t.flags,(e&65536)!==0&&(e&128)===0?(t.flags=e&-65537|128,t):null;case 26:case 27:case 5:return jn(t),null;case 13:if(Ut(t),e=t.memoizedState,e!==null&&e.dehydrated!==null){if(t.alternate===null)throw Error(u(340));Ha()}return e=t.flags,e&65536?(t.flags=e&-65537|128,t):null;case 19:return T(Ve),null;case 4:return Ft(),null;case 10:return wt(t.type),null;case 22:case 23:return Ut(t),Ho(),e!==null&&T(zi),e=t.flags,e&65536?(t.flags=e&-65537|128,t):null;case 24:return wt(we),null;case 25:return null;default:return null}}function Gm(e,t){switch(Ro(t),t.tag){case 3:wt(we),Ft();break;case 26:case 27:case 5:jn(t);break;case 4:Ft();break;case 13:Ut(t);break;case 19:T(Ve);break;case 10:wt(t.type);break;case 22:case 23:Ut(t),Ho(),e!==null&&T(zi);break;case 24:wt(we)}}function rn(e,t){try{var i=t.updateQueue,a=i!==null?i.lastEffect:null;if(a!==null){var n=a.next;i=n;do{if((i.tag&e)===e){a=void 0;var o=i.create,r=i.inst;a=o(),r.destroy=a}i=i.next}while(i!==n)}}catch(l){Ee(t,t.return,l)}}function li(e,t,i){try{var a=t.updateQueue,n=a!==null?a.lastEffect:null;if(n!==null){var o=n.next;a=o;do{if((a.tag&e)===e){var r=a.inst,l=r.destroy;if(l!==void 0){r.destroy=void 0,n=t;var p=i,v=l;try{v()}catch(N){Ee(n,p,N)}}}a=a.next}while(a!==o)}}catch(N){Ee(t,t.return,N)}}function Ym(e){var t=e.updateQueue;if(t!==null){var i=e.stateNode;try{Lc(t,i)}catch(a){Ee(e,e.return,a)}}}function Xm(e,t,i){i.props=qi(e.type,e.memoizedProps),i.state=e.memoizedState;try{i.componentWillUnmount()}catch(a){Ee(e,t,a)}}function ln(e,t){try{var i=e.ref;if(i!==null){switch(e.tag){case 26:case 27:case 5:var a=e.stateNode;break;case 30:a=e.stateNode;break;default:a=e.stateNode}typeof i=="function"?e.refCleanup=i(a):i.current=a}}catch(n){Ee(e,t,n)}}function Rt(e,t){var i=e.ref,a=e.refCleanup;if(i!==null)if(typeof a=="function")try{a()}catch(n){Ee(e,t,n)}finally{e.refCleanup=null,e=e.alternate,e!=null&&(e.refCleanup=null)}else if(typeof i=="function")try{i(null)}catch(n){Ee(e,t,n)}else i.current=null}function Km(e){var t=e.type,i=e.memoizedProps,a=e.stateNode;try{e:switch(t){case"button":case"input":case"select":case"textarea":i.autoFocus&&a.focus();break e;case"img":i.src?a.src=i.src:i.srcSet&&(a.srcset=i.srcSet)}}catch(n){Ee(e,e.return,n)}}function hr(e,t,i){try{var a=e.stateNode;bf(a,e.type,i,t),a[We]=t}catch(n){Ee(e,e.return,n)}}function Qm(e){return e.tag===5||e.tag===3||e.tag===26||e.tag===27&&gi(e.type)||e.tag===4}function yr(e){e:for(;;){for(;e.sibling===null;){if(e.return===null||Qm(e.return))return null;e=e.return}for(e.sibling.return=e.return,e=e.sibling;e.tag!==5&&e.tag!==6&&e.tag!==18;){if(e.tag===27&&gi(e.type)||e.flags&2||e.child===null||e.tag===4)continue e;e.child.return=e,e=e.child}if(!(e.flags&2))return e.stateNode}}function vr(e,t,i){var a=e.tag;if(a===5||a===6)e=e.stateNode,t?(i.nodeType===9?i.body:i.nodeName==="HTML"?i.ownerDocument.body:i).insertBefore(e,t):(t=i.nodeType===9?i.body:i.nodeName==="HTML"?i.ownerDocument.body:i,t.appendChild(e),i=i._reactRootContainer,i!=null||t.onclick!==null||(t.onclick=Rs));else if(a!==4&&(a===27&&gi(e.type)&&(i=e.stateNode,t=null),e=e.child,e!==null))for(vr(e,t,i),e=e.sibling;e!==null;)vr(e,t,i),e=e.sibling}function ys(e,t,i){var a=e.tag;if(a===5||a===6)e=e.stateNode,t?i.insertBefore(e,t):i.appendChild(e);else if(a!==4&&(a===27&&gi(e.type)&&(i=e.stateNode),e=e.child,e!==null))for(ys(e,t,i),e=e.sibling;e!==null;)ys(e,t,i),e=e.sibling}function Zm(e){var t=e.stateNode,i=e.memoizedProps;try{for(var a=e.type,n=t.attributes;n.length;)t.removeAttributeNode(n[0]);Qe(t,a,i),t[Ze]=e,t[We]=i}catch(o){Ee(e,e.return,o)}}var Yt=!1,qe=!1,kr=!1,Jm=typeof WeakSet=="function"?WeakSet:Set,Ge=null;function Qp(e,t){if(e=e.containerInfo,Gr=qs,e=rc(e),yo(e)){if("selectionStart"in e)var i={start:e.selectionStart,end:e.selectionEnd};else e:{i=(i=e.ownerDocument)&&i.defaultView||window;var a=i.getSelection&&i.getSelection();if(a&&a.rangeCount!==0){i=a.anchorNode;var n=a.anchorOffset,o=a.focusNode;a=a.focusOffset;try{i.nodeType,o.nodeType}catch{i=null;break e}var r=0,l=-1,p=-1,v=0,N=0,j=e,k=null;t:for(;;){for(var S;j!==i||n!==0&&j.nodeType!==3||(l=r+n),j!==o||a!==0&&j.nodeType!==3||(p=r+a),j.nodeType===3&&(r+=j.nodeValue.length),(S=j.firstChild)!==null;)k=j,j=S;for(;;){if(j===e)break t;if(k===i&&++v===n&&(l=r),k===o&&++N===a&&(p=r),(S=j.nextSibling)!==null)break;j=k,k=j.parentNode}j=S}i=l===-1||p===-1?null:{start:l,end:p}}else i=null}i=i||{start:0,end:0}}else i=null;for(Yr={focusedElem:e,selectionRange:i},qs=!1,Ge=t;Ge!==null;)if(t=Ge,e=t.child,(t.subtreeFlags&1024)!==0&&e!==null)e.return=t,Ge=e;else for(;Ge!==null;){switch(t=Ge,o=t.alternate,e=t.flags,t.tag){case 0:break;case 11:case 15:break;case 1:if((e&1024)!==0&&o!==null){e=void 0,i=t,n=o.memoizedProps,o=o.memoizedState,a=i.stateNode;try{var oe=qi(i.type,n,i.elementType===i.type);e=a.getSnapshotBeforeUpdate(oe,o),a.__reactInternalSnapshotBeforeUpdate=e}catch(ae){Ee(i,i.return,ae)}}break;case 3:if((e&1024)!==0){if(e=t.stateNode.containerInfo,i=e.nodeType,i===9)Qr(e);else if(i===1)switch(e.nodeName){case"HEAD":case"HTML":case"BODY":Qr(e);break;default:e.textContent=""}}break;case 5:case 26:case 27:case 6:case 4:case 17:break;default:if((e&1024)!==0)throw Error(u(163))}if(e=t.sibling,e!==null){e.return=t.return,Ge=e;break}Ge=t.return}}function Fm(e,t,i){var a=i.flags;switch(i.tag){case 0:case 11:case 15:ci(e,i),a&4&&rn(5,i);break;case 1:if(ci(e,i),a&4)if(e=i.stateNode,t===null)try{e.componentDidMount()}catch(r){Ee(i,i.return,r)}else{var n=qi(i.type,t.memoizedProps);t=t.memoizedState;try{e.componentDidUpdate(n,t,e.__reactInternalSnapshotBeforeUpdate)}catch(r){Ee(i,i.return,r)}}a&64&&Ym(i),a&512&&ln(i,i.return);break;case 3:if(ci(e,i),a&64&&(e=i.updateQueue,e!==null)){if(t=null,i.child!==null)switch(i.child.tag){case 27:case 5:t=i.child.stateNode;break;case 1:t=i.child.stateNode}try{Lc(e,t)}catch(r){Ee(i,i.return,r)}}break;case 27:t===null&&a&4&&Zm(i);case 26:case 5:ci(e,i),t===null&&a&4&&Km(i),a&512&&ln(i,i.return);break;case 12:ci(e,i);break;case 13:ci(e,i),a&4&&eu(e,i),a&64&&(e=i.memoizedState,e!==null&&(e=e.dehydrated,e!==null&&(i=nf.bind(null,i),Sf(e,i))));break;case 22:if(a=i.memoizedState!==null||Yt,!a){t=t!==null&&t.memoizedState!==null||qe,n=Yt;var o=qe;Yt=a,(qe=t)&&!o?mi(e,i,(i.subtreeFlags&8772)!==0):ci(e,i),Yt=n,qe=o}break;case 30:break;default:ci(e,i)}}function $m(e){var t=e.alternate;t!==null&&(e.alternate=null,$m(t)),e.child=null,e.deletions=null,e.sibling=null,e.tag===5&&(t=e.stateNode,t!==null&&$s(t)),e.stateNode=null,e.return=null,e.dependencies=null,e.memoizedProps=null,e.memoizedState=null,e.pendingProps=null,e.stateNode=null,e.updateQueue=null}var De=null,it=!1;function Xt(e,t,i){for(i=i.child;i!==null;)Wm(e,t,i),i=i.sibling}function Wm(e,t,i){if(nt&&typeof nt.onCommitFiberUnmount=="function")try{nt.onCommitFiberUnmount(ja,i)}catch{}switch(i.tag){case 26:qe||Rt(i,t),Xt(e,t,i),i.memoizedState?i.memoizedState.count--:i.stateNode&&(i=i.stateNode,i.parentNode.removeChild(i));break;case 27:qe||Rt(i,t);var a=De,n=it;gi(i.type)&&(De=i.stateNode,it=!1),Xt(e,t,i),hn(i.stateNode),De=a,it=n;break;case 5:qe||Rt(i,t);case 6:if(a=De,n=it,De=null,Xt(e,t,i),De=a,it=n,De!==null)if(it)try{(De.nodeType===9?De.body:De.nodeName==="HTML"?De.ownerDocument.body:De).removeChild(i.stateNode)}catch(o){Ee(i,t,o)}else try{De.removeChild(i.stateNode)}catch(o){Ee(i,t,o)}break;case 18:De!==null&&(it?(e=De,Vu(e.nodeType===9?e.body:e.nodeName==="HTML"?e.ownerDocument.body:e,i.stateNode),Nn(e)):Vu(De,i.stateNode));break;case 4:a=De,n=it,De=i.stateNode.containerInfo,it=!0,Xt(e,t,i),De=a,it=n;break;case 0:case 11:case 14:case 15:qe||li(2,i,t),qe||li(4,i,t),Xt(e,t,i);break;case 1:qe||(Rt(i,t),a=i.stateNode,typeof a.componentWillUnmount=="function"&&Xm(i,t,a)),Xt(e,t,i);break;case 21:Xt(e,t,i);break;case 22:qe=(a=qe)||i.memoizedState!==null,Xt(e,t,i),qe=a;break;default:Xt(e,t,i)}}function eu(e,t){if(t.memoizedState===null&&(e=t.alternate,e!==null&&(e=e.memoizedState,e!==null&&(e=e.dehydrated,e!==null))))try{Nn(e)}catch(i){Ee(t,t.return,i)}}function Zp(e){switch(e.tag){case 13:case 19:var t=e.stateNode;return t===null&&(t=e.stateNode=new Jm),t;case 22:return e=e.stateNode,t=e._retryCache,t===null&&(t=e._retryCache=new Jm),t;default:throw Error(u(435,e.tag))}}function xr(e,t){var i=Zp(e);t.forEach(function(a){var n=sf.bind(null,e,a);i.has(a)||(i.add(a),a.then(n,n))})}function lt(e,t){var i=t.deletions;if(i!==null)for(var a=0;a<i.length;a++){var n=i[a],o=e,r=t,l=r;e:for(;l!==null;){switch(l.tag){case 27:if(gi(l.type)){De=l.stateNode,it=!1;break e}break;case 5:De=l.stateNode,it=!1;break e;case 3:case 4:De=l.stateNode.containerInfo,it=!0;break e}l=l.return}if(De===null)throw Error(u(160));Wm(o,r,n),De=null,it=!1,o=n.alternate,o!==null&&(o.return=null),n.return=null}if(t.subtreeFlags&13878)for(t=t.child;t!==null;)tu(t,e),t=t.sibling}var _t=null;function tu(e,t){var i=e.alternate,a=e.flags;switch(e.tag){case 0:case 11:case 14:case 15:lt(t,e),ct(e),a&4&&(li(3,e,e.return),rn(3,e),li(5,e,e.return));break;case 1:lt(t,e),ct(e),a&512&&(qe||i===null||Rt(i,i.return)),a&64&&Yt&&(e=e.updateQueue,e!==null&&(a=e.callbacks,a!==null&&(i=e.shared.hiddenCallbacks,e.shared.hiddenCallbacks=i===null?a:i.concat(a))));break;case 26:var n=_t;if(lt(t,e),ct(e),a&512&&(qe||i===null||Rt(i,i.return)),a&4){var o=i!==null?i.memoizedState:null;if(a=e.memoizedState,i===null)if(a===null)if(e.stateNode===null){e:{a=e.type,i=e.memoizedProps,n=n.ownerDocument||n;t:switch(a){case"title":o=n.getElementsByTagName("title")[0],(!o||o[Da]||o[Ze]||o.namespaceURI==="http://www.w3.org/2000/svg"||o.hasAttribute("itemprop"))&&(o=n.createElement(a),n.head.insertBefore(o,n.querySelector("head > title"))),Qe(o,a,i),o[Ze]=e,Ue(o),a=o;break e;case"link":var r=Zu("link","href",n).get(a+(i.href||""));if(r){for(var l=0;l<r.length;l++)if(o=r[l],o.getAttribute("href")===(i.href==null||i.href===""?null:i.href)&&o.getAttribute("rel")===(i.rel==null?null:i.rel)&&o.getAttribute("title")===(i.title==null?null:i.title)&&o.getAttribute("crossorigin")===(i.crossOrigin==null?null:i.crossOrigin)){r.splice(l,1);break t}}o=n.createElement(a),Qe(o,a,i),n.head.appendChild(o);break;case"meta":if(r=Zu("meta","content",n).get(a+(i.content||""))){for(l=0;l<r.length;l++)if(o=r[l],o.getAttribute("content")===(i.content==null?null:""+i.content)&&o.getAttribute("name")===(i.name==null?null:i.name)&&o.getAttribute("property")===(i.property==null?null:i.property)&&o.getAttribute("http-equiv")===(i.httpEquiv==null?null:i.httpEquiv)&&o.getAttribute("charset")===(i.charSet==null?null:i.charSet)){r.splice(l,1);break t}}o=n.createElement(a),Qe(o,a,i),n.head.appendChild(o);break;default:throw Error(u(468,a))}o[Ze]=e,Ue(o),a=o}e.stateNode=a}else Ju(n,e.type,e.stateNode);else e.stateNode=Qu(n,a,e.memoizedProps);else o!==a?(o===null?i.stateNode!==null&&(i=i.stateNode,i.parentNode.removeChild(i)):o.count--,a===null?Ju(n,e.type,e.stateNode):Qu(n,a,e.memoizedProps)):a===null&&e.stateNode!==null&&hr(e,e.memoizedProps,i.memoizedProps)}break;case 27:lt(t,e),ct(e),a&512&&(qe||i===null||Rt(i,i.return)),i!==null&&a&4&&hr(e,e.memoizedProps,i.memoizedProps);break;case 5:if(lt(t,e),ct(e),a&512&&(qe||i===null||Rt(i,i.return)),e.flags&32){n=e.stateNode;try{Ji(n,"")}catch(S){Ee(e,e.return,S)}}a&4&&e.stateNode!=null&&(n=e.memoizedProps,hr(e,n,i!==null?i.memoizedProps:n)),a&1024&&(kr=!0);break;case 6:if(lt(t,e),ct(e),a&4){if(e.stateNode===null)throw Error(u(162));a=e.memoizedProps,i=e.stateNode;try{i.nodeValue=a}catch(S){Ee(e,e.return,S)}}break;case 3:if(Ms=null,n=_t,_t=Ds(t.containerInfo),lt(t,e),_t=n,ct(e),a&4&&i!==null&&i.memoizedState.isDehydrated)try{Nn(t.containerInfo)}catch(S){Ee(e,e.return,S)}kr&&(kr=!1,iu(e));break;case 4:a=_t,_t=Ds(e.stateNode.containerInfo),lt(t,e),ct(e),_t=a;break;case 12:lt(t,e),ct(e);break;case 13:lt(t,e),ct(e),e.child.flags&8192&&e.memoizedState!==null!=(i!==null&&i.memoizedState!==null)&&(Er=At()),a&4&&(a=e.updateQueue,a!==null&&(e.updateQueue=null,xr(e,a)));break;case 22:n=e.memoizedState!==null;var p=i!==null&&i.memoizedState!==null,v=Yt,N=qe;if(Yt=v||n,qe=N||p,lt(t,e),qe=N,Yt=v,ct(e),a&8192)e:for(t=e.stateNode,t._visibility=n?t._visibility&-2:t._visibility|1,n&&(i===null||p||Yt||qe||Oi(e)),i=null,t=e;;){if(t.tag===5||t.tag===26){if(i===null){p=i=t;try{if(o=p.stateNode,n)r=o.style,typeof r.setProperty=="function"?r.setProperty("display","none","important"):r.display="none";else{l=p.stateNode;var j=p.memoizedProps.style,k=j!=null&&j.hasOwnProperty("display")?j.display:null;l.style.display=k==null||typeof k=="boolean"?"":(""+k).trim()}}catch(S){Ee(p,p.return,S)}}}else if(t.tag===6){if(i===null){p=t;try{p.stateNode.nodeValue=n?"":p.memoizedProps}catch(S){Ee(p,p.return,S)}}}else if((t.tag!==22&&t.tag!==23||t.memoizedState===null||t===e)&&t.child!==null){t.child.return=t,t=t.child;continue}if(t===e)break e;for(;t.sibling===null;){if(t.return===null||t.return===e)break e;i===t&&(i=null),t=t.return}i===t&&(i=null),t.sibling.return=t.return,t=t.sibling}a&4&&(a=e.updateQueue,a!==null&&(i=a.retryQueue,i!==null&&(a.retryQueue=null,xr(e,i))));break;case 19:lt(t,e),ct(e),a&4&&(a=e.updateQueue,a!==null&&(e.updateQueue=null,xr(e,a)));break;case 30:break;case 21:break;default:lt(t,e),ct(e)}}function ct(e){var t=e.flags;if(t&2){try{for(var i,a=e.return;a!==null;){if(Qm(a)){i=a;break}a=a.return}if(i==null)throw Error(u(160));switch(i.tag){case 27:var n=i.stateNode,o=yr(e);ys(e,o,n);break;case 5:var r=i.stateNode;i.flags&32&&(Ji(r,""),i.flags&=-33);var l=yr(e);ys(e,l,r);break;case 3:case 4:var p=i.stateNode.containerInfo,v=yr(e);vr(e,v,p);break;default:throw Error(u(161))}}catch(N){Ee(e,e.return,N)}e.flags&=-3}t&4096&&(e.flags&=-4097)}function iu(e){if(e.subtreeFlags&1024)for(e=e.child;e!==null;){var t=e;iu(t),t.tag===5&&t.flags&1024&&t.stateNode.reset(),e=e.sibling}}function ci(e,t){if(t.subtreeFlags&8772)for(t=t.child;t!==null;)Fm(e,t.alternate,t),t=t.sibling}function Oi(e){for(e=e.child;e!==null;){var t=e;switch(t.tag){case 0:case 11:case 14:case 15:li(4,t,t.return),Oi(t);break;case 1:Rt(t,t.return);var i=t.stateNode;typeof i.componentWillUnmount=="function"&&Xm(t,t.return,i),Oi(t);break;case 27:hn(t.stateNode);case 26:case 5:Rt(t,t.return),Oi(t);break;case 22:t.memoizedState===null&&Oi(t);break;case 30:Oi(t);break;default:Oi(t)}e=e.sibling}}function mi(e,t,i){for(i=i&&(t.subtreeFlags&8772)!==0,t=t.child;t!==null;){var a=t.alternate,n=e,o=t,r=o.flags;switch(o.tag){case 0:case 11:case 15:mi(n,o,i),rn(4,o);break;case 1:if(mi(n,o,i),a=o,n=a.stateNode,typeof n.componentDidMount=="function")try{n.componentDidMount()}catch(v){Ee(a,a.return,v)}if(a=o,n=a.updateQueue,n!==null){var l=a.stateNode;try{var p=n.shared.hiddenCallbacks;if(p!==null)for(n.shared.hiddenCallbacks=null,n=0;n<p.length;n++)Dc(p[n],l)}catch(v){Ee(a,a.return,v)}}i&&r&64&&Ym(o),ln(o,o.return);break;case 27:Zm(o);case 26:case 5:mi(n,o,i),i&&a===null&&r&4&&Km(o),ln(o,o.return);break;case 12:mi(n,o,i);break;case 13:mi(n,o,i),i&&r&4&&eu(n,o);break;case 22:o.memoizedState===null&&mi(n,o,i),ln(o,o.return);break;case 30:break;default:mi(n,o,i)}t=t.sibling}}function Sr(e,t){var i=null;e!==null&&e.memoizedState!==null&&e.memoizedState.cachePool!==null&&(i=e.memoizedState.cachePool.pool),e=null,t.memoizedState!==null&&t.memoizedState.cachePool!==null&&(e=t.memoizedState.cachePool.pool),e!==i&&(e!=null&&e.refCount++,i!=null&&Xa(i))}function _r(e,t){e=null,t.alternate!==null&&(e=t.alternate.memoizedState.cache),t=t.memoizedState.cache,t!==e&&(t.refCount++,e!=null&&Xa(e))}function Tt(e,t,i,a){if(t.subtreeFlags&10256)for(t=t.child;t!==null;)au(e,t,i,a),t=t.sibling}function au(e,t,i,a){var n=t.flags;switch(t.tag){case 0:case 11:case 15:Tt(e,t,i,a),n&2048&&rn(9,t);break;case 1:Tt(e,t,i,a);break;case 3:Tt(e,t,i,a),n&2048&&(e=null,t.alternate!==null&&(e=t.alternate.memoizedState.cache),t=t.memoizedState.cache,t!==e&&(t.refCount++,e!=null&&Xa(e)));break;case 12:if(n&2048){Tt(e,t,i,a),e=t.stateNode;try{var o=t.memoizedProps,r=o.id,l=o.onPostCommit;typeof l=="function"&&l(r,t.alternate===null?"mount":"update",e.passiveEffectDuration,-0)}catch(p){Ee(t,t.return,p)}}else Tt(e,t,i,a);break;case 13:Tt(e,t,i,a);break;case 23:break;case 22:o=t.stateNode,r=t.alternate,t.memoizedState!==null?o._visibility&2?Tt(e,t,i,a):cn(e,t):o._visibility&2?Tt(e,t,i,a):(o._visibility|=2,ba(e,t,i,a,(t.subtreeFlags&10256)!==0)),n&2048&&Sr(r,t);break;case 24:Tt(e,t,i,a),n&2048&&_r(t.alternate,t);break;default:Tt(e,t,i,a)}}function ba(e,t,i,a,n){for(n=n&&(t.subtreeFlags&10256)!==0,t=t.child;t!==null;){var o=e,r=t,l=i,p=a,v=r.flags;switch(r.tag){case 0:case 11:case 15:ba(o,r,l,p,n),rn(8,r);break;case 23:break;case 22:var N=r.stateNode;r.memoizedState!==null?N._visibility&2?ba(o,r,l,p,n):cn(o,r):(N._visibility|=2,ba(o,r,l,p,n)),n&&v&2048&&Sr(r.alternate,r);break;case 24:ba(o,r,l,p,n),n&&v&2048&&_r(r.alternate,r);break;default:ba(o,r,l,p,n)}t=t.sibling}}function cn(e,t){if(t.subtreeFlags&10256)for(t=t.child;t!==null;){var i=e,a=t,n=a.flags;switch(a.tag){case 22:cn(i,a),n&2048&&Sr(a.alternate,a);break;case 24:cn(i,a),n&2048&&_r(a.alternate,a);break;default:cn(i,a)}t=t.sibling}}var mn=8192;function ga(e){if(e.subtreeFlags&mn)for(e=e.child;e!==null;)nu(e),e=e.sibling}function nu(e){switch(e.tag){case 26:ga(e),e.flags&mn&&e.memoizedState!==null&&If(_t,e.memoizedState,e.memoizedProps);break;case 5:ga(e);break;case 3:case 4:var t=_t;_t=Ds(e.stateNode.containerInfo),ga(e),_t=t;break;case 22:e.memoizedState===null&&(t=e.alternate,t!==null&&t.memoizedState!==null?(t=mn,mn=16777216,ga(e),mn=t):ga(e));break;default:ga(e)}}function su(e){var t=e.alternate;if(t!==null&&(e=t.child,e!==null)){t.child=null;do t=e.sibling,e.sibling=null,e=t;while(e!==null)}}function un(e){var t=e.deletions;if((e.flags&16)!==0){if(t!==null)for(var i=0;i<t.length;i++){var a=t[i];Ge=a,ru(a,e)}su(e)}if(e.subtreeFlags&10256)for(e=e.child;e!==null;)ou(e),e=e.sibling}function ou(e){switch(e.tag){case 0:case 11:case 15:un(e),e.flags&2048&&li(9,e,e.return);break;case 3:un(e);break;case 12:un(e);break;case 22:var t=e.stateNode;e.memoizedState!==null&&t._visibility&2&&(e.return===null||e.return.tag!==13)?(t._visibility&=-3,vs(e)):un(e);break;default:un(e)}}function vs(e){var t=e.deletions;if((e.flags&16)!==0){if(t!==null)for(var i=0;i<t.length;i++){var a=t[i];Ge=a,ru(a,e)}su(e)}for(e=e.child;e!==null;){switch(t=e,t.tag){case 0:case 11:case 15:li(8,t,t.return),vs(t);break;case 22:i=t.stateNode,i._visibility&2&&(i._visibility&=-3,vs(t));break;default:vs(t)}e=e.sibling}}function ru(e,t){for(;Ge!==null;){var i=Ge;switch(i.tag){case 0:case 11:case 15:li(8,i,t);break;case 23:case 22:if(i.memoizedState!==null&&i.memoizedState.cachePool!==null){var a=i.memoizedState.cachePool.pool;a!=null&&a.refCount++}break;case 24:Xa(i.memoizedState.cache)}if(a=i.child,a!==null)a.return=i,Ge=a;else e:for(i=e;Ge!==null;){a=Ge;var n=a.sibling,o=a.return;if($m(a),a===i){Ge=null;break e}if(n!==null){n.return=o,Ge=n;break e}Ge=o}}}var Jp={getCacheForType:function(e){var t=Je(we),i=t.data.get(e);return i===void 0&&(i=e(),t.data.set(e,i)),i}},Fp=typeof WeakMap=="function"?WeakMap:Map,xe=0,Re=null,ge=null,ye=0,Se=0,mt=null,ui=!1,ha=!1,Cr=!1,Kt=0,ze=0,di=0,Pi=0,Nr=0,kt=0,ya=0,dn=null,at=null,Ar=!1,Er=0,ks=1/0,xs=null,pi=null,Ke=0,fi=null,va=null,ka=0,jr=0,Rr=null,lu=null,pn=0,Tr=null;function ut(){if((xe&2)!==0&&ye!==0)return ye&-ye;if(x.T!==null){var e=ra;return e!==0?e:Or()}return Cl()}function cu(){kt===0&&(kt=(ye&536870912)===0||ke?kl():536870912);var e=vt.current;return e!==null&&(e.flags|=32),kt}function dt(e,t,i){(e===Re&&(Se===2||Se===9)||e.cancelPendingCommit!==null)&&(xa(e,0),bi(e,ye,kt,!1)),Ta(e,i),((xe&2)===0||e!==Re)&&(e===Re&&((xe&2)===0&&(Pi|=i),ze===4&&bi(e,ye,kt,!1)),Dt(e))}function mu(e,t,i){if((xe&6)!==0)throw Error(u(327));var a=!i&&(t&124)===0&&(t&e.expiredLanes)===0||Ra(e,t),n=a?ef(e,t):Mr(e,t,!0),o=a;do{if(n===0){ha&&!a&&bi(e,t,0,!1);break}else{if(i=e.current.alternate,o&&!$p(i)){n=Mr(e,t,!1),o=!1;continue}if(n===2){if(o=t,e.errorRecoveryDisabledLanes&o)var r=0;else r=e.pendingLanes&-536870913,r=r!==0?r:r&536870912?536870912:0;if(r!==0){t=r;e:{var l=e;n=dn;var p=l.current.memoizedState.isDehydrated;if(p&&(xa(l,r).flags|=256),r=Mr(l,r,!1),r!==2){if(Cr&&!p){l.errorRecoveryDisabledLanes|=o,Pi|=o,n=4;break e}o=at,at=n,o!==null&&(at===null?at=o:at.push.apply(at,o))}n=r}if(o=!1,n!==2)continue}}if(n===1){xa(e,0),bi(e,t,0,!0);break}e:{switch(a=e,o=n,o){case 0:case 1:throw Error(u(345));case 4:if((t&4194048)!==t)break;case 6:bi(a,t,kt,!ui);break e;case 2:at=null;break;case 3:case 5:break;default:throw Error(u(329))}if((t&62914560)===t&&(n=Er+300-At(),10<n)){if(bi(a,t,kt,!ui),Ln(a,0,!0)!==0)break e;a.timeoutHandle=Bu(uu.bind(null,a,i,at,xs,Ar,t,kt,Pi,ya,ui,o,2,-0,0),n);break e}uu(a,i,at,xs,Ar,t,kt,Pi,ya,ui,o,0,-0,0)}}break}while(!0);Dt(e)}function uu(e,t,i,a,n,o,r,l,p,v,N,j,k,S){if(e.timeoutHandle=-1,j=t.subtreeFlags,(j&8192||(j&16785408)===16785408)&&(kn={stylesheets:null,count:0,unsuspend:zf},nu(t),j=qf(),j!==null)){e.cancelPendingCommit=j(yu.bind(null,e,t,o,i,a,n,r,l,p,N,1,k,S)),bi(e,o,r,!v);return}yu(e,t,o,i,a,n,r,l,p)}function $p(e){for(var t=e;;){var i=t.tag;if((i===0||i===11||i===15)&&t.flags&16384&&(i=t.updateQueue,i!==null&&(i=i.stores,i!==null)))for(var a=0;a<i.length;a++){var n=i[a],o=n.getSnapshot;n=n.value;try{if(!ot(o(),n))return!1}catch{return!1}}if(i=t.child,t.subtreeFlags&16384&&i!==null)i.return=t,t=i;else{if(t===e)break;for(;t.sibling===null;){if(t.return===null||t.return===e)return!0;t=t.return}t.sibling.return=t.return,t=t.sibling}}return!0}function bi(e,t,i,a){t&=~Nr,t&=~Pi,e.suspendedLanes|=t,e.pingedLanes&=~t,a&&(e.warmLanes|=t),a=e.expirationTimes;for(var n=t;0<n;){var o=31-st(n),r=1<<o;a[o]=-1,n&=~r}i!==0&&Sl(e,i,t)}function Ss(){return(xe&6)===0?(fn(0),!1):!0}function Dr(){if(ge!==null){if(Se===0)var e=ge.return;else e=ge,Bt=Li=null,Qo(e),pa=null,nn=0,e=ge;for(;e!==null;)Gm(e.alternate,e),e=e.return;ge=null}}function xa(e,t){var i=e.timeoutHandle;i!==-1&&(e.timeoutHandle=-1,hf(i)),i=e.cancelPendingCommit,i!==null&&(e.cancelPendingCommit=null,i()),Dr(),Re=e,ge=i=qt(e.current,null),ye=t,Se=0,mt=null,ui=!1,ha=Ra(e,t),Cr=!1,ya=kt=Nr=Pi=di=ze=0,at=dn=null,Ar=!1,(t&8)!==0&&(t|=t&32);var a=e.entangledLanes;if(a!==0)for(e=e.entanglements,a&=t;0<a;){var n=31-st(a),o=1<<n;t|=e[n],a&=~o}return Kt=t,Gn(),i}function du(e,t){pe=null,x.H=cs,t===Qa||t===Wn?(t=Rc(),Se=3):t===Ac?(t=Rc(),Se=4):Se=t===Tm?8:t!==null&&typeof t=="object"&&typeof t.then=="function"?6:1,mt=t,ge===null&&(ze=1,fs(e,bt(t,e.current)))}function pu(){var e=x.H;return x.H=cs,e===null?cs:e}function fu(){var e=x.A;return x.A=Jp,e}function Lr(){ze=4,ui||(ye&4194048)!==ye&&vt.current!==null||(ha=!0),(di&134217727)===0&&(Pi&134217727)===0||Re===null||bi(Re,ye,kt,!1)}function Mr(e,t,i){var a=xe;xe|=2;var n=pu(),o=fu();(Re!==e||ye!==t)&&(xs=null,xa(e,t)),t=!1;var r=ze;e:do try{if(Se!==0&&ge!==null){var l=ge,p=mt;switch(Se){case 8:Dr(),r=6;break e;case 3:case 2:case 9:case 6:vt.current===null&&(t=!0);var v=Se;if(Se=0,mt=null,Sa(e,l,p,v),i&&ha){r=0;break e}break;default:v=Se,Se=0,mt=null,Sa(e,l,p,v)}}Wp(),r=ze;break}catch(N){du(e,N)}while(!0);return t&&e.shellSuspendCounter++,Bt=Li=null,xe=a,x.H=n,x.A=o,ge===null&&(Re=null,ye=0,Gn()),r}function Wp(){for(;ge!==null;)bu(ge)}function ef(e,t){var i=xe;xe|=2;var a=pu(),n=fu();Re!==e||ye!==t?(xs=null,ks=At()+500,xa(e,t)):ha=Ra(e,t);e:do try{if(Se!==0&&ge!==null){t=ge;var o=mt;t:switch(Se){case 1:Se=0,mt=null,Sa(e,t,o,1);break;case 2:case 9:if(Ec(o)){Se=0,mt=null,gu(t);break}t=function(){Se!==2&&Se!==9||Re!==e||(Se=7),Dt(e)},o.then(t,t);break e;case 3:Se=7;break e;case 4:Se=5;break e;case 7:Ec(o)?(Se=0,mt=null,gu(t)):(Se=0,mt=null,Sa(e,t,o,7));break;case 5:var r=null;switch(ge.tag){case 26:r=ge.memoizedState;case 5:case 27:var l=ge;if(!r||Fu(r)){Se=0,mt=null;var p=l.sibling;if(p!==null)ge=p;else{var v=l.return;v!==null?(ge=v,_s(v)):ge=null}break t}}Se=0,mt=null,Sa(e,t,o,5);break;case 6:Se=0,mt=null,Sa(e,t,o,6);break;case 8:Dr(),ze=6;break e;default:throw Error(u(462))}}tf();break}catch(N){du(e,N)}while(!0);return Bt=Li=null,x.H=a,x.A=n,xe=i,ge!==null?0:(Re=null,ye=0,Gn(),ze)}function tf(){for(;ge!==null&&!_d();)bu(ge)}function bu(e){var t=Um(e.alternate,e,Kt);e.memoizedProps=e.pendingProps,t===null?_s(e):ge=t}function gu(e){var t=e,i=t.alternate;switch(t.tag){case 15:case 0:t=qm(i,t,t.pendingProps,t.type,void 0,ye);break;case 11:t=qm(i,t,t.pendingProps,t.type.render,t.ref,ye);break;case 5:Qo(t);default:Gm(i,t),t=ge=hc(t,Kt),t=Um(i,t,Kt)}e.memoizedProps=e.pendingProps,t===null?_s(e):ge=t}function Sa(e,t,i,a){Bt=Li=null,Qo(t),pa=null,nn=0;var n=t.return;try{if(Gp(e,n,t,i,ye)){ze=1,fs(e,bt(i,e.current)),ge=null;return}}catch(o){if(n!==null)throw ge=n,o;ze=1,fs(e,bt(i,e.current)),ge=null;return}t.flags&32768?(ke||a===1?e=!0:ha||(ye&536870912)!==0?e=!1:(ui=e=!0,(a===2||a===9||a===3||a===6)&&(a=vt.current,a!==null&&a.tag===13&&(a.flags|=16384))),hu(t,e)):_s(t)}function _s(e){var t=e;do{if((t.flags&32768)!==0){hu(t,ui);return}e=t.return;var i=Xp(t.alternate,t,Kt);if(i!==null){ge=i;return}if(t=t.sibling,t!==null){ge=t;return}ge=t=e}while(t!==null);ze===0&&(ze=5)}function hu(e,t){do{var i=Kp(e.alternate,e);if(i!==null){i.flags&=32767,ge=i;return}if(i=e.return,i!==null&&(i.flags|=32768,i.subtreeFlags=0,i.deletions=null),!t&&(e=e.sibling,e!==null)){ge=e;return}ge=e=i}while(e!==null);ze=6,ge=null}function yu(e,t,i,a,n,o,r,l,p){e.cancelPendingCommit=null;do Cs();while(Ke!==0);if((xe&6)!==0)throw Error(u(327));if(t!==null){if(t===e.current)throw Error(u(177));if(o=t.lanes|t.childLanes,o|=_o,Md(e,i,o,r,l,p),e===Re&&(ge=Re=null,ye=0),va=t,fi=e,ka=i,jr=o,Rr=n,lu=a,(t.subtreeFlags&10256)!==0||(t.flags&10256)!==0?(e.callbackNode=null,e.callbackPriority=0,of(Rn,function(){return _u(),null})):(e.callbackNode=null,e.callbackPriority=0),a=(t.flags&13878)!==0,(t.subtreeFlags&13878)!==0||a){a=x.T,x.T=null,n=D.p,D.p=2,r=xe,xe|=4;try{Qp(e,t,i)}finally{xe=r,D.p=n,x.T=a}}Ke=1,vu(),ku(),xu()}}function vu(){if(Ke===1){Ke=0;var e=fi,t=va,i=(t.flags&13878)!==0;if((t.subtreeFlags&13878)!==0||i){i=x.T,x.T=null;var a=D.p;D.p=2;var n=xe;xe|=4;try{tu(t,e);var o=Yr,r=rc(e.containerInfo),l=o.focusedElem,p=o.selectionRange;if(r!==l&&l&&l.ownerDocument&&oc(l.ownerDocument.documentElement,l)){if(p!==null&&yo(l)){var v=p.start,N=p.end;if(N===void 0&&(N=v),"selectionStart"in l)l.selectionStart=v,l.selectionEnd=Math.min(N,l.value.length);else{var j=l.ownerDocument||document,k=j&&j.defaultView||window;if(k.getSelection){var S=k.getSelection(),oe=l.textContent.length,ae=Math.min(p.start,oe),Ae=p.end===void 0?ae:Math.min(p.end,oe);!S.extend&&ae>Ae&&(r=Ae,Ae=ae,ae=r);var g=sc(l,ae),b=sc(l,Ae);if(g&&b&&(S.rangeCount!==1||S.anchorNode!==g.node||S.anchorOffset!==g.offset||S.focusNode!==b.node||S.focusOffset!==b.offset)){var h=j.createRange();h.setStart(g.node,g.offset),S.removeAllRanges(),ae>Ae?(S.addRange(h),S.extend(b.node,b.offset)):(h.setEnd(b.node,b.offset),S.addRange(h))}}}}for(j=[],S=l;S=S.parentNode;)S.nodeType===1&&j.push({element:S,left:S.scrollLeft,top:S.scrollTop});for(typeof l.focus=="function"&&l.focus(),l=0;l<j.length;l++){var A=j[l];A.element.scrollLeft=A.left,A.element.scrollTop=A.top}}qs=!!Gr,Yr=Gr=null}finally{xe=n,D.p=a,x.T=i}}e.current=t,Ke=2}}function ku(){if(Ke===2){Ke=0;var e=fi,t=va,i=(t.flags&8772)!==0;if((t.subtreeFlags&8772)!==0||i){i=x.T,x.T=null;var a=D.p;D.p=2;var n=xe;xe|=4;try{Fm(e,t.alternate,t)}finally{xe=n,D.p=a,x.T=i}}Ke=3}}function xu(){if(Ke===4||Ke===3){Ke=0,Cd();var e=fi,t=va,i=ka,a=lu;(t.subtreeFlags&10256)!==0||(t.flags&10256)!==0?Ke=5:(Ke=0,va=fi=null,Su(e,e.pendingLanes));var n=e.pendingLanes;if(n===0&&(pi=null),Js(i),t=t.stateNode,nt&&typeof nt.onCommitFiberRoot=="function")try{nt.onCommitFiberRoot(ja,t,void 0,(t.current.flags&128)===128)}catch{}if(a!==null){t=x.T,n=D.p,D.p=2,x.T=null;try{for(var o=e.onRecoverableError,r=0;r<a.length;r++){var l=a[r];o(l.value,{componentStack:l.stack})}}finally{x.T=t,D.p=n}}(ka&3)!==0&&Cs(),Dt(e),n=e.pendingLanes,(i&4194090)!==0&&(n&42)!==0?e===Tr?pn++:(pn=0,Tr=e):pn=0,fn(0)}}function Su(e,t){(e.pooledCacheLanes&=t)===0&&(t=e.pooledCache,t!=null&&(e.pooledCache=null,Xa(t)))}function Cs(e){return vu(),ku(),xu(),_u()}function _u(){if(Ke!==5)return!1;var e=fi,t=jr;jr=0;var i=Js(ka),a=x.T,n=D.p;try{D.p=32>i?32:i,x.T=null,i=Rr,Rr=null;var o=fi,r=ka;if(Ke=0,va=fi=null,ka=0,(xe&6)!==0)throw Error(u(331));var l=xe;if(xe|=4,ou(o.current),au(o,o.current,r,i),xe=l,fn(0,!1),nt&&typeof nt.onPostCommitFiberRoot=="function")try{nt.onPostCommitFiberRoot(ja,o)}catch{}return!0}finally{D.p=n,x.T=a,Su(e,t)}}function Cu(e,t,i){t=bt(i,t),t=lr(e.stateNode,t,2),e=ni(e,t,2),e!==null&&(Ta(e,2),Dt(e))}function Ee(e,t,i){if(e.tag===3)Cu(e,e,i);else for(;t!==null;){if(t.tag===3){Cu(t,e,i);break}else if(t.tag===1){var a=t.stateNode;if(typeof t.type.getDerivedStateFromError=="function"||typeof a.componentDidCatch=="function"&&(pi===null||!pi.has(a))){e=bt(i,e),i=jm(2),a=ni(t,i,2),a!==null&&(Rm(i,a,t,e),Ta(a,2),Dt(a));break}}t=t.return}}function zr(e,t,i){var a=e.pingCache;if(a===null){a=e.pingCache=new Fp;var n=new Set;a.set(t,n)}else n=a.get(t),n===void 0&&(n=new Set,a.set(t,n));n.has(i)||(Cr=!0,n.add(i),e=af.bind(null,e,t,i),t.then(e,e))}function af(e,t,i){var a=e.pingCache;a!==null&&a.delete(t),e.pingedLanes|=e.suspendedLanes&i,e.warmLanes&=~i,Re===e&&(ye&i)===i&&(ze===4||ze===3&&(ye&62914560)===ye&&300>At()-Er?(xe&2)===0&&xa(e,0):Nr|=i,ya===ye&&(ya=0)),Dt(e)}function Nu(e,t){t===0&&(t=xl()),e=aa(e,t),e!==null&&(Ta(e,t),Dt(e))}function nf(e){var t=e.memoizedState,i=0;t!==null&&(i=t.retryLane),Nu(e,i)}function sf(e,t){var i=0;switch(e.tag){case 13:var a=e.stateNode,n=e.memoizedState;n!==null&&(i=n.retryLane);break;case 19:a=e.stateNode;break;case 22:a=e.stateNode._retryCache;break;default:throw Error(u(314))}a!==null&&a.delete(t),Nu(e,i)}function of(e,t){return Xs(e,t)}var Ns=null,_a=null,Ir=!1,As=!1,qr=!1,Bi=0;function Dt(e){e!==_a&&e.next===null&&(_a===null?Ns=_a=e:_a=_a.next=e),As=!0,Ir||(Ir=!0,lf())}function fn(e,t){if(!qr&&As){qr=!0;do for(var i=!1,a=Ns;a!==null;){if(e!==0){var n=a.pendingLanes;if(n===0)var o=0;else{var r=a.suspendedLanes,l=a.pingedLanes;o=(1<<31-st(42|e)+1)-1,o&=n&~(r&~l),o=o&201326741?o&201326741|1:o?o|2:0}o!==0&&(i=!0,Ru(a,o))}else o=ye,o=Ln(a,a===Re?o:0,a.cancelPendingCommit!==null||a.timeoutHandle!==-1),(o&3)===0||Ra(a,o)||(i=!0,Ru(a,o));a=a.next}while(i);qr=!1}}function rf(){Au()}function Au(){As=Ir=!1;var e=0;Bi!==0&&(gf()&&(e=Bi),Bi=0);for(var t=At(),i=null,a=Ns;a!==null;){var n=a.next,o=Eu(a,t);o===0?(a.next=null,i===null?Ns=n:i.next=n,n===null&&(_a=i)):(i=a,(e!==0||(o&3)!==0)&&(As=!0)),a=n}fn(e)}function Eu(e,t){for(var i=e.suspendedLanes,a=e.pingedLanes,n=e.expirationTimes,o=e.pendingLanes&-62914561;0<o;){var r=31-st(o),l=1<<r,p=n[r];p===-1?((l&i)===0||(l&a)!==0)&&(n[r]=Ld(l,t)):p<=t&&(e.expiredLanes|=l),o&=~l}if(t=Re,i=ye,i=Ln(e,e===t?i:0,e.cancelPendingCommit!==null||e.timeoutHandle!==-1),a=e.callbackNode,i===0||e===t&&(Se===2||Se===9)||e.cancelPendingCommit!==null)return a!==null&&a!==null&&Ks(a),e.callbackNode=null,e.callbackPriority=0;if((i&3)===0||Ra(e,i)){if(t=i&-i,t===e.callbackPriority)return t;switch(a!==null&&Ks(a),Js(i)){case 2:case 8:i=yl;break;case 32:i=Rn;break;case 268435456:i=vl;break;default:i=Rn}return a=ju.bind(null,e),i=Xs(i,a),e.callbackPriority=t,e.callbackNode=i,t}return a!==null&&a!==null&&Ks(a),e.callbackPriority=2,e.callbackNode=null,2}function ju(e,t){if(Ke!==0&&Ke!==5)return e.callbackNode=null,e.callbackPriority=0,null;var i=e.callbackNode;if(Cs()&&e.callbackNode!==i)return null;var a=ye;return a=Ln(e,e===Re?a:0,e.cancelPendingCommit!==null||e.timeoutHandle!==-1),a===0?null:(mu(e,a,t),Eu(e,At()),e.callbackNode!=null&&e.callbackNode===i?ju.bind(null,e):null)}function Ru(e,t){if(Cs())return null;mu(e,t,!0)}function lf(){yf(function(){(xe&6)!==0?Xs(hl,rf):Au()})}function Or(){return Bi===0&&(Bi=kl()),Bi}function Tu(e){return e==null||typeof e=="symbol"||typeof e=="boolean"?null:typeof e=="function"?e:On(""+e)}function Du(e,t){var i=t.ownerDocument.createElement("input");return i.name=t.name,i.value=t.value,e.id&&i.setAttribute("form",e.id),t.parentNode.insertBefore(i,t),e=new FormData(e),i.parentNode.removeChild(i),e}function cf(e,t,i,a,n){if(t==="submit"&&i&&i.stateNode===n){var o=Tu((n[We]||null).action),r=a.submitter;r&&(t=(t=r[We]||null)?Tu(t.formAction):r.getAttribute("formAction"),t!==null&&(o=t,r=null));var l=new Vn("action","action",null,a,n);e.push({event:l,listeners:[{instance:null,listener:function(){if(a.defaultPrevented){if(Bi!==0){var p=r?Du(n,r):new FormData(n);ar(i,{pending:!0,data:p,method:n.method,action:o},null,p)}}else typeof o=="function"&&(l.preventDefault(),p=r?Du(n,r):new FormData(n),ar(i,{pending:!0,data:p,method:n.method,action:o},o,p))},currentTarget:n}]})}}for(var Pr=0;Pr<So.length;Pr++){var Br=So[Pr],mf=Br.toLowerCase(),uf=Br[0].toUpperCase()+Br.slice(1);St(mf,"on"+uf)}St(mc,"onAnimationEnd"),St(uc,"onAnimationIteration"),St(dc,"onAnimationStart"),St("dblclick","onDoubleClick"),St("focusin","onFocus"),St("focusout","onBlur"),St(Ep,"onTransitionRun"),St(jp,"onTransitionStart"),St(Rp,"onTransitionCancel"),St(pc,"onTransitionEnd"),Ki("onMouseEnter",["mouseout","mouseover"]),Ki("onMouseLeave",["mouseout","mouseover"]),Ki("onPointerEnter",["pointerout","pointerover"]),Ki("onPointerLeave",["pointerout","pointerover"]),_i("onChange","change click focusin focusout input keydown keyup selectionchange".split(" ")),_i("onSelect","focusout contextmenu dragend focusin keydown keyup mousedown mouseup selectionchange".split(" ")),_i("onBeforeInput",["compositionend","keypress","textInput","paste"]),_i("onCompositionEnd","compositionend focusout keydown keypress keyup mousedown".split(" ")),_i("onCompositionStart","compositionstart focusout keydown keypress keyup mousedown".split(" ")),_i("onCompositionUpdate","compositionupdate focusout keydown keypress keyup mousedown".split(" "));var bn="abort canplay canplaythrough durationchange emptied encrypted ended error loadeddata loadedmetadata loadstart pause play playing progress ratechange resize seeked seeking stalled suspend timeupdate volumechange waiting".split(" "),df=new Set("beforetoggle cancel close invalid load scroll scrollend toggle".split(" ").concat(bn));function Lu(e,t){t=(t&4)!==0;for(var i=0;i<e.length;i++){var a=e[i],n=a.event;a=a.listeners;e:{var o=void 0;if(t)for(var r=a.length-1;0<=r;r--){var l=a[r],p=l.instance,v=l.currentTarget;if(l=l.listener,p!==o&&n.isPropagationStopped())break e;o=l,n.currentTarget=v;try{o(n)}catch(N){ps(N)}n.currentTarget=null,o=p}else for(r=0;r<a.length;r++){if(l=a[r],p=l.instance,v=l.currentTarget,l=l.listener,p!==o&&n.isPropagationStopped())break e;o=l,n.currentTarget=v;try{o(n)}catch(N){ps(N)}n.currentTarget=null,o=p}}}}function he(e,t){var i=t[Fs];i===void 0&&(i=t[Fs]=new Set);var a=e+"__bubble";i.has(a)||(Mu(t,e,2,!1),i.add(a))}function wr(e,t,i){var a=0;t&&(a|=4),Mu(i,e,a,t)}var Es="_reactListening"+Math.random().toString(36).slice(2);function Vr(e){if(!e[Es]){e[Es]=!0,Al.forEach(function(i){i!=="selectionchange"&&(df.has(i)||wr(i,!1,e),wr(i,!0,e))});var t=e.nodeType===9?e:e.ownerDocument;t===null||t[Es]||(t[Es]=!0,wr("selectionchange",!1,t))}}function Mu(e,t,i,a){switch(ad(t)){case 2:var n=Bf;break;case 8:n=wf;break;default:n=tl}i=n.bind(null,t,i,e),n=void 0,!lo||t!=="touchstart"&&t!=="touchmove"&&t!=="wheel"||(n=!0),a?n!==void 0?e.addEventListener(t,i,{capture:!0,passive:n}):e.addEventListener(t,i,!0):n!==void 0?e.addEventListener(t,i,{passive:n}):e.addEventListener(t,i,!1)}function Ur(e,t,i,a,n){var o=a;if((t&1)===0&&(t&2)===0&&a!==null)e:for(;;){if(a===null)return;var r=a.tag;if(r===3||r===4){var l=a.stateNode.containerInfo;if(l===n)break;if(r===4)for(r=a.return;r!==null;){var p=r.tag;if((p===3||p===4)&&r.stateNode.containerInfo===n)return;r=r.return}for(;l!==null;){if(r=Gi(l),r===null)return;if(p=r.tag,p===5||p===6||p===26||p===27){a=o=r;continue e}l=l.parentNode}}a=a.return}wl(function(){var v=o,N=oo(i),j=[];e:{var k=fc.get(e);if(k!==void 0){var S=Vn,oe=e;switch(e){case"keypress":if(Bn(i)===0)break e;case"keydown":case"keyup":S=sp;break;case"focusin":oe="focus",S=po;break;case"focusout":oe="blur",S=po;break;case"beforeblur":case"afterblur":S=po;break;case"click":if(i.button===2)break e;case"auxclick":case"dblclick":case"mousedown":case"mousemove":case"mouseup":case"mouseout":case"mouseover":case"contextmenu":S=Hl;break;case"drag":case"dragend":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"dragstart":case"drop":S=Kd;break;case"touchcancel":case"touchend":case"touchmove":case"touchstart":S=lp;break;case mc:case uc:case dc:S=Jd;break;case pc:S=mp;break;case"scroll":case"scrollend":S=Yd;break;case"wheel":S=dp;break;case"copy":case"cut":case"paste":S=$d;break;case"gotpointercapture":case"lostpointercapture":case"pointercancel":case"pointerdown":case"pointermove":case"pointerout":case"pointerover":case"pointerup":S=Yl;break;case"toggle":case"beforetoggle":S=fp}var ae=(t&4)!==0,Ae=!ae&&(e==="scroll"||e==="scrollend"),g=ae?k!==null?k+"Capture":null:k;ae=[];for(var b=v,h;b!==null;){var A=b;if(h=A.stateNode,A=A.tag,A!==5&&A!==26&&A!==27||h===null||g===null||(A=Ma(b,g),A!=null&&ae.push(gn(b,A,h))),Ae)break;b=b.return}0<ae.length&&(k=new S(k,oe,null,i,N),j.push({event:k,listeners:ae}))}}if((t&7)===0){e:{if(k=e==="mouseover"||e==="pointerover",S=e==="mouseout"||e==="pointerout",k&&i!==so&&(oe=i.relatedTarget||i.fromElement)&&(Gi(oe)||oe[Hi]))break e;if((S||k)&&(k=N.window===N?N:(k=N.ownerDocument)?k.defaultView||k.parentWindow:window,S?(oe=i.relatedTarget||i.toElement,S=v,oe=oe?Gi(oe):null,oe!==null&&(Ae=E(oe),ae=oe.tag,oe!==Ae||ae!==5&&ae!==27&&ae!==6)&&(oe=null)):(S=null,oe=v),S!==oe)){if(ae=Hl,A="onMouseLeave",g="onMouseEnter",b="mouse",(e==="pointerout"||e==="pointerover")&&(ae=Yl,A="onPointerLeave",g="onPointerEnter",b="pointer"),Ae=S==null?k:La(S),h=oe==null?k:La(oe),k=new ae(A,b+"leave",S,i,N),k.target=Ae,k.relatedTarget=h,A=null,Gi(N)===v&&(ae=new ae(g,b+"enter",oe,i,N),ae.target=h,ae.relatedTarget=Ae,A=ae),Ae=A,S&&oe)t:{for(ae=S,g=oe,b=0,h=ae;h;h=Ca(h))b++;for(h=0,A=g;A;A=Ca(A))h++;for(;0<b-h;)ae=Ca(ae),b--;for(;0<h-b;)g=Ca(g),h--;for(;b--;){if(ae===g||g!==null&&ae===g.alternate)break t;ae=Ca(ae),g=Ca(g)}ae=null}else ae=null;S!==null&&zu(j,k,S,ae,!1),oe!==null&&Ae!==null&&zu(j,Ae,oe,ae,!0)}}e:{if(k=v?La(v):window,S=k.nodeName&&k.nodeName.toLowerCase(),S==="select"||S==="input"&&k.type==="file")var J=Wl;else if(Fl(k))if(ec)J=Cp;else{J=Sp;var be=xp}else S=k.nodeName,!S||S.toLowerCase()!=="input"||k.type!=="checkbox"&&k.type!=="radio"?v&&no(v.elementType)&&(J=Wl):J=_p;if(J&&(J=J(e,v))){$l(j,J,i,N);break e}be&&be(e,k,v),e==="focusout"&&v&&k.type==="number"&&v.memoizedProps.value!=null&&ao(k,"number",k.value)}switch(be=v?La(v):window,e){case"focusin":(Fl(be)||be.contentEditable==="true")&&(ea=be,vo=v,Va=null);break;case"focusout":Va=vo=ea=null;break;case"mousedown":ko=!0;break;case"contextmenu":case"mouseup":case"dragend":ko=!1,lc(j,i,N);break;case"selectionchange":if(Ap)break;case"keydown":case"keyup":lc(j,i,N)}var te;if(bo)e:{switch(e){case"compositionstart":var ne="onCompositionStart";break e;case"compositionend":ne="onCompositionEnd";break e;case"compositionupdate":ne="onCompositionUpdate";break e}ne=void 0}else Wi?Zl(e,i)&&(ne="onCompositionEnd"):e==="keydown"&&i.keyCode===229&&(ne="onCompositionStart");ne&&(Xl&&i.locale!=="ko"&&(Wi||ne!=="onCompositionStart"?ne==="onCompositionEnd"&&Wi&&(te=Vl()):(ei=N,co="value"in ei?ei.value:ei.textContent,Wi=!0)),be=js(v,ne),0<be.length&&(ne=new Gl(ne,e,null,i,N),j.push({event:ne,listeners:be}),te?ne.data=te:(te=Jl(i),te!==null&&(ne.data=te)))),(te=gp?hp(e,i):yp(e,i))&&(ne=js(v,"onBeforeInput"),0<ne.length&&(be=new Gl("onBeforeInput","beforeinput",null,i,N),j.push({event:be,listeners:ne}),be.data=te)),cf(j,e,v,i,N)}Lu(j,t)})}function gn(e,t,i){return{instance:e,listener:t,currentTarget:i}}function js(e,t){for(var i=t+"Capture",a=[];e!==null;){var n=e,o=n.stateNode;if(n=n.tag,n!==5&&n!==26&&n!==27||o===null||(n=Ma(e,i),n!=null&&a.unshift(gn(e,n,o)),n=Ma(e,t),n!=null&&a.push(gn(e,n,o))),e.tag===3)return a;e=e.return}return[]}function Ca(e){if(e===null)return null;do e=e.return;while(e&&e.tag!==5&&e.tag!==27);return e||null}function zu(e,t,i,a,n){for(var o=t._reactName,r=[];i!==null&&i!==a;){var l=i,p=l.alternate,v=l.stateNode;if(l=l.tag,p!==null&&p===a)break;l!==5&&l!==26&&l!==27||v===null||(p=v,n?(v=Ma(i,o),v!=null&&r.unshift(gn(i,v,p))):n||(v=Ma(i,o),v!=null&&r.push(gn(i,v,p)))),i=i.return}r.length!==0&&e.push({event:t,listeners:r})}var pf=/\r\n?/g,ff=/\u0000|\uFFFD/g;function Iu(e){return(typeof e=="string"?e:""+e).replace(pf,`
`).replace(ff,"")}function qu(e,t){return t=Iu(t),Iu(e)===t}function Rs(){}function Ne(e,t,i,a,n,o){switch(i){case"children":typeof a=="string"?t==="body"||t==="textarea"&&a===""||Ji(e,a):(typeof a=="number"||typeof a=="bigint")&&t!=="body"&&Ji(e,""+a);break;case"className":zn(e,"class",a);break;case"tabIndex":zn(e,"tabindex",a);break;case"dir":case"role":case"viewBox":case"width":case"height":zn(e,i,a);break;case"style":Pl(e,a,o);break;case"data":if(t!=="object"){zn(e,"data",a);break}case"src":case"href":if(a===""&&(t!=="a"||i!=="href")){e.removeAttribute(i);break}if(a==null||typeof a=="function"||typeof a=="symbol"||typeof a=="boolean"){e.removeAttribute(i);break}a=On(""+a),e.setAttribute(i,a);break;case"action":case"formAction":if(typeof a=="function"){e.setAttribute(i,"javascript:throw new Error('A React form was unexpectedly submitted. If you called form.submit() manually, consider using form.requestSubmit() instead. If you\\'re trying to use event.stopPropagation() in a submit event handler, consider also calling event.preventDefault().')");break}else typeof o=="function"&&(i==="formAction"?(t!=="input"&&Ne(e,t,"name",n.name,n,null),Ne(e,t,"formEncType",n.formEncType,n,null),Ne(e,t,"formMethod",n.formMethod,n,null),Ne(e,t,"formTarget",n.formTarget,n,null)):(Ne(e,t,"encType",n.encType,n,null),Ne(e,t,"method",n.method,n,null),Ne(e,t,"target",n.target,n,null)));if(a==null||typeof a=="symbol"||typeof a=="boolean"){e.removeAttribute(i);break}a=On(""+a),e.setAttribute(i,a);break;case"onClick":a!=null&&(e.onclick=Rs);break;case"onScroll":a!=null&&he("scroll",e);break;case"onScrollEnd":a!=null&&he("scrollend",e);break;case"dangerouslySetInnerHTML":if(a!=null){if(typeof a!="object"||!("__html"in a))throw Error(u(61));if(i=a.__html,i!=null){if(n.children!=null)throw Error(u(60));e.innerHTML=i}}break;case"multiple":e.multiple=a&&typeof a!="function"&&typeof a!="symbol";break;case"muted":e.muted=a&&typeof a!="function"&&typeof a!="symbol";break;case"suppressContentEditableWarning":case"suppressHydrationWarning":case"defaultValue":case"defaultChecked":case"innerHTML":case"ref":break;case"autoFocus":break;case"xlinkHref":if(a==null||typeof a=="function"||typeof a=="boolean"||typeof a=="symbol"){e.removeAttribute("xlink:href");break}i=On(""+a),e.setAttributeNS("http://www.w3.org/1999/xlink","xlink:href",i);break;case"contentEditable":case"spellCheck":case"draggable":case"value":case"autoReverse":case"externalResourcesRequired":case"focusable":case"preserveAlpha":a!=null&&typeof a!="function"&&typeof a!="symbol"?e.setAttribute(i,""+a):e.removeAttribute(i);break;case"inert":case"allowFullScreen":case"async":case"autoPlay":case"controls":case"default":case"defer":case"disabled":case"disablePictureInPicture":case"disableRemotePlayback":case"formNoValidate":case"hidden":case"loop":case"noModule":case"noValidate":case"open":case"playsInline":case"readOnly":case"required":case"reversed":case"scoped":case"seamless":case"itemScope":a&&typeof a!="function"&&typeof a!="symbol"?e.setAttribute(i,""):e.removeAttribute(i);break;case"capture":case"download":a===!0?e.setAttribute(i,""):a!==!1&&a!=null&&typeof a!="function"&&typeof a!="symbol"?e.setAttribute(i,a):e.removeAttribute(i);break;case"cols":case"rows":case"size":case"span":a!=null&&typeof a!="function"&&typeof a!="symbol"&&!isNaN(a)&&1<=a?e.setAttribute(i,a):e.removeAttribute(i);break;case"rowSpan":case"start":a==null||typeof a=="function"||typeof a=="symbol"||isNaN(a)?e.removeAttribute(i):e.setAttribute(i,a);break;case"popover":he("beforetoggle",e),he("toggle",e),Mn(e,"popover",a);break;case"xlinkActuate":zt(e,"http://www.w3.org/1999/xlink","xlink:actuate",a);break;case"xlinkArcrole":zt(e,"http://www.w3.org/1999/xlink","xlink:arcrole",a);break;case"xlinkRole":zt(e,"http://www.w3.org/1999/xlink","xlink:role",a);break;case"xlinkShow":zt(e,"http://www.w3.org/1999/xlink","xlink:show",a);break;case"xlinkTitle":zt(e,"http://www.w3.org/1999/xlink","xlink:title",a);break;case"xlinkType":zt(e,"http://www.w3.org/1999/xlink","xlink:type",a);break;case"xmlBase":zt(e,"http://www.w3.org/XML/1998/namespace","xml:base",a);break;case"xmlLang":zt(e,"http://www.w3.org/XML/1998/namespace","xml:lang",a);break;case"xmlSpace":zt(e,"http://www.w3.org/XML/1998/namespace","xml:space",a);break;case"is":Mn(e,"is",a);break;case"innerText":case"textContent":break;default:(!(2<i.length)||i[0]!=="o"&&i[0]!=="O"||i[1]!=="n"&&i[1]!=="N")&&(i=Hd.get(i)||i,Mn(e,i,a))}}function Hr(e,t,i,a,n,o){switch(i){case"style":Pl(e,a,o);break;case"dangerouslySetInnerHTML":if(a!=null){if(typeof a!="object"||!("__html"in a))throw Error(u(61));if(i=a.__html,i!=null){if(n.children!=null)throw Error(u(60));e.innerHTML=i}}break;case"children":typeof a=="string"?Ji(e,a):(typeof a=="number"||typeof a=="bigint")&&Ji(e,""+a);break;case"onScroll":a!=null&&he("scroll",e);break;case"onScrollEnd":a!=null&&he("scrollend",e);break;case"onClick":a!=null&&(e.onclick=Rs);break;case"suppressContentEditableWarning":case"suppressHydrationWarning":case"innerHTML":case"ref":break;case"innerText":case"textContent":break;default:if(!El.hasOwnProperty(i))e:{if(i[0]==="o"&&i[1]==="n"&&(n=i.endsWith("Capture"),t=i.slice(2,n?i.length-7:void 0),o=e[We]||null,o=o!=null?o[i]:null,typeof o=="function"&&e.removeEventListener(t,o,n),typeof a=="function")){typeof o!="function"&&o!==null&&(i in e?e[i]=null:e.hasAttribute(i)&&e.removeAttribute(i)),e.addEventListener(t,a,n);break e}i in e?e[i]=a:a===!0?e.setAttribute(i,""):Mn(e,i,a)}}}function Qe(e,t,i){switch(t){case"div":case"span":case"svg":case"path":case"a":case"g":case"p":case"li":break;case"img":he("error",e),he("load",e);var a=!1,n=!1,o;for(o in i)if(i.hasOwnProperty(o)){var r=i[o];if(r!=null)switch(o){case"src":a=!0;break;case"srcSet":n=!0;break;case"children":case"dangerouslySetInnerHTML":throw Error(u(137,t));default:Ne(e,t,o,r,i,null)}}n&&Ne(e,t,"srcSet",i.srcSet,i,null),a&&Ne(e,t,"src",i.src,i,null);return;case"input":he("invalid",e);var l=o=r=n=null,p=null,v=null;for(a in i)if(i.hasOwnProperty(a)){var N=i[a];if(N!=null)switch(a){case"name":n=N;break;case"type":r=N;break;case"checked":p=N;break;case"defaultChecked":v=N;break;case"value":o=N;break;case"defaultValue":l=N;break;case"children":case"dangerouslySetInnerHTML":if(N!=null)throw Error(u(137,t));break;default:Ne(e,t,a,N,i,null)}}zl(e,o,l,p,v,r,n,!1),In(e);return;case"select":he("invalid",e),a=r=o=null;for(n in i)if(i.hasOwnProperty(n)&&(l=i[n],l!=null))switch(n){case"value":o=l;break;case"defaultValue":r=l;break;case"multiple":a=l;default:Ne(e,t,n,l,i,null)}t=o,i=r,e.multiple=!!a,t!=null?Zi(e,!!a,t,!1):i!=null&&Zi(e,!!a,i,!0);return;case"textarea":he("invalid",e),o=n=a=null;for(r in i)if(i.hasOwnProperty(r)&&(l=i[r],l!=null))switch(r){case"value":a=l;break;case"defaultValue":n=l;break;case"children":o=l;break;case"dangerouslySetInnerHTML":if(l!=null)throw Error(u(91));break;default:Ne(e,t,r,l,i,null)}ql(e,a,n,o),In(e);return;case"option":for(p in i)if(i.hasOwnProperty(p)&&(a=i[p],a!=null))switch(p){case"selected":e.selected=a&&typeof a!="function"&&typeof a!="symbol";break;default:Ne(e,t,p,a,i,null)}return;case"dialog":he("beforetoggle",e),he("toggle",e),he("cancel",e),he("close",e);break;case"iframe":case"object":he("load",e);break;case"video":case"audio":for(a=0;a<bn.length;a++)he(bn[a],e);break;case"image":he("error",e),he("load",e);break;case"details":he("toggle",e);break;case"embed":case"source":case"link":he("error",e),he("load",e);case"area":case"base":case"br":case"col":case"hr":case"keygen":case"meta":case"param":case"track":case"wbr":case"menuitem":for(v in i)if(i.hasOwnProperty(v)&&(a=i[v],a!=null))switch(v){case"children":case"dangerouslySetInnerHTML":throw Error(u(137,t));default:Ne(e,t,v,a,i,null)}return;default:if(no(t)){for(N in i)i.hasOwnProperty(N)&&(a=i[N],a!==void 0&&Hr(e,t,N,a,i,void 0));return}}for(l in i)i.hasOwnProperty(l)&&(a=i[l],a!=null&&Ne(e,t,l,a,i,null))}function bf(e,t,i,a){switch(t){case"div":case"span":case"svg":case"path":case"a":case"g":case"p":case"li":break;case"input":var n=null,o=null,r=null,l=null,p=null,v=null,N=null;for(S in i){var j=i[S];if(i.hasOwnProperty(S)&&j!=null)switch(S){case"checked":break;case"value":break;case"defaultValue":p=j;default:a.hasOwnProperty(S)||Ne(e,t,S,null,a,j)}}for(var k in a){var S=a[k];if(j=i[k],a.hasOwnProperty(k)&&(S!=null||j!=null))switch(k){case"type":o=S;break;case"name":n=S;break;case"checked":v=S;break;case"defaultChecked":N=S;break;case"value":r=S;break;case"defaultValue":l=S;break;case"children":case"dangerouslySetInnerHTML":if(S!=null)throw Error(u(137,t));break;default:S!==j&&Ne(e,t,k,S,a,j)}}io(e,r,l,p,v,N,o,n);return;case"select":S=r=l=k=null;for(o in i)if(p=i[o],i.hasOwnProperty(o)&&p!=null)switch(o){case"value":break;case"multiple":S=p;default:a.hasOwnProperty(o)||Ne(e,t,o,null,a,p)}for(n in a)if(o=a[n],p=i[n],a.hasOwnProperty(n)&&(o!=null||p!=null))switch(n){case"value":k=o;break;case"defaultValue":l=o;break;case"multiple":r=o;default:o!==p&&Ne(e,t,n,o,a,p)}t=l,i=r,a=S,k!=null?Zi(e,!!i,k,!1):!!a!=!!i&&(t!=null?Zi(e,!!i,t,!0):Zi(e,!!i,i?[]:"",!1));return;case"textarea":S=k=null;for(l in i)if(n=i[l],i.hasOwnProperty(l)&&n!=null&&!a.hasOwnProperty(l))switch(l){case"value":break;case"children":break;default:Ne(e,t,l,null,a,n)}for(r in a)if(n=a[r],o=i[r],a.hasOwnProperty(r)&&(n!=null||o!=null))switch(r){case"value":k=n;break;case"defaultValue":S=n;break;case"children":break;case"dangerouslySetInnerHTML":if(n!=null)throw Error(u(91));break;default:n!==o&&Ne(e,t,r,n,a,o)}Il(e,k,S);return;case"option":for(var oe in i)if(k=i[oe],i.hasOwnProperty(oe)&&k!=null&&!a.hasOwnProperty(oe))switch(oe){case"selected":e.selected=!1;break;default:Ne(e,t,oe,null,a,k)}for(p in a)if(k=a[p],S=i[p],a.hasOwnProperty(p)&&k!==S&&(k!=null||S!=null))switch(p){case"selected":e.selected=k&&typeof k!="function"&&typeof k!="symbol";break;default:Ne(e,t,p,k,a,S)}return;case"img":case"link":case"area":case"base":case"br":case"col":case"embed":case"hr":case"keygen":case"meta":case"param":case"source":case"track":case"wbr":case"menuitem":for(var ae in i)k=i[ae],i.hasOwnProperty(ae)&&k!=null&&!a.hasOwnProperty(ae)&&Ne(e,t,ae,null,a,k);for(v in a)if(k=a[v],S=i[v],a.hasOwnProperty(v)&&k!==S&&(k!=null||S!=null))switch(v){case"children":case"dangerouslySetInnerHTML":if(k!=null)throw Error(u(137,t));break;default:Ne(e,t,v,k,a,S)}return;default:if(no(t)){for(var Ae in i)k=i[Ae],i.hasOwnProperty(Ae)&&k!==void 0&&!a.hasOwnProperty(Ae)&&Hr(e,t,Ae,void 0,a,k);for(N in a)k=a[N],S=i[N],!a.hasOwnProperty(N)||k===S||k===void 0&&S===void 0||Hr(e,t,N,k,a,S);return}}for(var g in i)k=i[g],i.hasOwnProperty(g)&&k!=null&&!a.hasOwnProperty(g)&&Ne(e,t,g,null,a,k);for(j in a)k=a[j],S=i[j],!a.hasOwnProperty(j)||k===S||k==null&&S==null||Ne(e,t,j,k,a,S)}var Gr=null,Yr=null;function Ts(e){return e.nodeType===9?e:e.ownerDocument}function Ou(e){switch(e){case"http://www.w3.org/2000/svg":return 1;case"http://www.w3.org/1998/Math/MathML":return 2;default:return 0}}function Pu(e,t){if(e===0)switch(t){case"svg":return 1;case"math":return 2;default:return 0}return e===1&&t==="foreignObject"?0:e}function Xr(e,t){return e==="textarea"||e==="noscript"||typeof t.children=="string"||typeof t.children=="number"||typeof t.children=="bigint"||typeof t.dangerouslySetInnerHTML=="object"&&t.dangerouslySetInnerHTML!==null&&t.dangerouslySetInnerHTML.__html!=null}var Kr=null;function gf(){var e=window.event;return e&&e.type==="popstate"?e===Kr?!1:(Kr=e,!0):(Kr=null,!1)}var Bu=typeof setTimeout=="function"?setTimeout:void 0,hf=typeof clearTimeout=="function"?clearTimeout:void 0,wu=typeof Promise=="function"?Promise:void 0,yf=typeof queueMicrotask=="function"?queueMicrotask:typeof wu<"u"?function(e){return wu.resolve(null).then(e).catch(vf)}:Bu;function vf(e){setTimeout(function(){throw e})}function gi(e){return e==="head"}function Vu(e,t){var i=t,a=0,n=0;do{var o=i.nextSibling;if(e.removeChild(i),o&&o.nodeType===8)if(i=o.data,i==="/$"){if(0<a&&8>a){i=a;var r=e.ownerDocument;if(i&1&&hn(r.documentElement),i&2&&hn(r.body),i&4)for(i=r.head,hn(i),r=i.firstChild;r;){var l=r.nextSibling,p=r.nodeName;r[Da]||p==="SCRIPT"||p==="STYLE"||p==="LINK"&&r.rel.toLowerCase()==="stylesheet"||i.removeChild(r),r=l}}if(n===0){e.removeChild(o),Nn(t);return}n--}else i==="$"||i==="$?"||i==="$!"?n++:a=i.charCodeAt(0)-48;else a=0;i=o}while(i);Nn(t)}function Qr(e){var t=e.firstChild;for(t&&t.nodeType===10&&(t=t.nextSibling);t;){var i=t;switch(t=t.nextSibling,i.nodeName){case"HTML":case"HEAD":case"BODY":Qr(i),$s(i);continue;case"SCRIPT":case"STYLE":continue;case"LINK":if(i.rel.toLowerCase()==="stylesheet")continue}e.removeChild(i)}}function kf(e,t,i,a){for(;e.nodeType===1;){var n=i;if(e.nodeName.toLowerCase()!==t.toLowerCase()){if(!a&&(e.nodeName!=="INPUT"||e.type!=="hidden"))break}else if(a){if(!e[Da])switch(t){case"meta":if(!e.hasAttribute("itemprop"))break;return e;case"link":if(o=e.getAttribute("rel"),o==="stylesheet"&&e.hasAttribute("data-precedence"))break;if(o!==n.rel||e.getAttribute("href")!==(n.href==null||n.href===""?null:n.href)||e.getAttribute("crossorigin")!==(n.crossOrigin==null?null:n.crossOrigin)||e.getAttribute("title")!==(n.title==null?null:n.title))break;return e;case"style":if(e.hasAttribute("data-precedence"))break;return e;case"script":if(o=e.getAttribute("src"),(o!==(n.src==null?null:n.src)||e.getAttribute("type")!==(n.type==null?null:n.type)||e.getAttribute("crossorigin")!==(n.crossOrigin==null?null:n.crossOrigin))&&o&&e.hasAttribute("async")&&!e.hasAttribute("itemprop"))break;return e;default:return e}}else if(t==="input"&&e.type==="hidden"){var o=n.name==null?null:""+n.name;if(n.type==="hidden"&&e.getAttribute("name")===o)return e}else return e;if(e=Ct(e.nextSibling),e===null)break}return null}function xf(e,t,i){if(t==="")return null;for(;e.nodeType!==3;)if((e.nodeType!==1||e.nodeName!=="INPUT"||e.type!=="hidden")&&!i||(e=Ct(e.nextSibling),e===null))return null;return e}function Zr(e){return e.data==="$!"||e.data==="$?"&&e.ownerDocument.readyState==="complete"}function Sf(e,t){var i=e.ownerDocument;if(e.data!=="$?"||i.readyState==="complete")t();else{var a=function(){t(),i.removeEventListener("DOMContentLoaded",a)};i.addEventListener("DOMContentLoaded",a),e._reactRetry=a}}function Ct(e){for(;e!=null;e=e.nextSibling){var t=e.nodeType;if(t===1||t===3)break;if(t===8){if(t=e.data,t==="$"||t==="$!"||t==="$?"||t==="F!"||t==="F")break;if(t==="/$")return null}}return e}var Jr=null;function Uu(e){e=e.previousSibling;for(var t=0;e;){if(e.nodeType===8){var i=e.data;if(i==="$"||i==="$!"||i==="$?"){if(t===0)return e;t--}else i==="/$"&&t++}e=e.previousSibling}return null}function Hu(e,t,i){switch(t=Ts(i),e){case"html":if(e=t.documentElement,!e)throw Error(u(452));return e;case"head":if(e=t.head,!e)throw Error(u(453));return e;case"body":if(e=t.body,!e)throw Error(u(454));return e;default:throw Error(u(451))}}function hn(e){for(var t=e.attributes;t.length;)e.removeAttributeNode(t[0]);$s(e)}var xt=new Map,Gu=new Set;function Ds(e){return typeof e.getRootNode=="function"?e.getRootNode():e.nodeType===9?e:e.ownerDocument}var Qt=D.d;D.d={f:_f,r:Cf,D:Nf,C:Af,L:Ef,m:jf,X:Tf,S:Rf,M:Df};function _f(){var e=Qt.f(),t=Ss();return e||t}function Cf(e){var t=Yi(e);t!==null&&t.tag===5&&t.type==="form"?mm(t):Qt.r(e)}var Na=typeof document>"u"?null:document;function Yu(e,t,i){var a=Na;if(a&&typeof t=="string"&&t){var n=ft(t);n='link[rel="'+e+'"][href="'+n+'"]',typeof i=="string"&&(n+='[crossorigin="'+i+'"]'),Gu.has(n)||(Gu.add(n),e={rel:e,crossOrigin:i,href:t},a.querySelector(n)===null&&(t=a.createElement("link"),Qe(t,"link",e),Ue(t),a.head.appendChild(t)))}}function Nf(e){Qt.D(e),Yu("dns-prefetch",e,null)}function Af(e,t){Qt.C(e,t),Yu("preconnect",e,t)}function Ef(e,t,i){Qt.L(e,t,i);var a=Na;if(a&&e&&t){var n='link[rel="preload"][as="'+ft(t)+'"]';t==="image"&&i&&i.imageSrcSet?(n+='[imagesrcset="'+ft(i.imageSrcSet)+'"]',typeof i.imageSizes=="string"&&(n+='[imagesizes="'+ft(i.imageSizes)+'"]')):n+='[href="'+ft(e)+'"]';var o=n;switch(t){case"style":o=Aa(e);break;case"script":o=Ea(e)}xt.has(o)||(e=z({rel:"preload",href:t==="image"&&i&&i.imageSrcSet?void 0:e,as:t},i),xt.set(o,e),a.querySelector(n)!==null||t==="style"&&a.querySelector(yn(o))||t==="script"&&a.querySelector(vn(o))||(t=a.createElement("link"),Qe(t,"link",e),Ue(t),a.head.appendChild(t)))}}function jf(e,t){Qt.m(e,t);var i=Na;if(i&&e){var a=t&&typeof t.as=="string"?t.as:"script",n='link[rel="modulepreload"][as="'+ft(a)+'"][href="'+ft(e)+'"]',o=n;switch(a){case"audioworklet":case"paintworklet":case"serviceworker":case"sharedworker":case"worker":case"script":o=Ea(e)}if(!xt.has(o)&&(e=z({rel:"modulepreload",href:e},t),xt.set(o,e),i.querySelector(n)===null)){switch(a){case"audioworklet":case"paintworklet":case"serviceworker":case"sharedworker":case"worker":case"script":if(i.querySelector(vn(o)))return}a=i.createElement("link"),Qe(a,"link",e),Ue(a),i.head.appendChild(a)}}}function Rf(e,t,i){Qt.S(e,t,i);var a=Na;if(a&&e){var n=Xi(a).hoistableStyles,o=Aa(e);t=t||"default";var r=n.get(o);if(!r){var l={loading:0,preload:null};if(r=a.querySelector(yn(o)))l.loading=5;else{e=z({rel:"stylesheet",href:e,"data-precedence":t},i),(i=xt.get(o))&&Fr(e,i);var p=r=a.createElement("link");Ue(p),Qe(p,"link",e),p._p=new Promise(function(v,N){p.onload=v,p.onerror=N}),p.addEventListener("load",function(){l.loading|=1}),p.addEventListener("error",function(){l.loading|=2}),l.loading|=4,Ls(r,t,a)}r={type:"stylesheet",instance:r,count:1,state:l},n.set(o,r)}}}function Tf(e,t){Qt.X(e,t);var i=Na;if(i&&e){var a=Xi(i).hoistableScripts,n=Ea(e),o=a.get(n);o||(o=i.querySelector(vn(n)),o||(e=z({src:e,async:!0},t),(t=xt.get(n))&&$r(e,t),o=i.createElement("script"),Ue(o),Qe(o,"link",e),i.head.appendChild(o)),o={type:"script",instance:o,count:1,state:null},a.set(n,o))}}function Df(e,t){Qt.M(e,t);var i=Na;if(i&&e){var a=Xi(i).hoistableScripts,n=Ea(e),o=a.get(n);o||(o=i.querySelector(vn(n)),o||(e=z({src:e,async:!0,type:"module"},t),(t=xt.get(n))&&$r(e,t),o=i.createElement("script"),Ue(o),Qe(o,"link",e),i.head.appendChild(o)),o={type:"script",instance:o,count:1,state:null},a.set(n,o))}}function Xu(e,t,i,a){var n=(n=ee.current)?Ds(n):null;if(!n)throw Error(u(446));switch(e){case"meta":case"title":return null;case"style":return typeof i.precedence=="string"&&typeof i.href=="string"?(t=Aa(i.href),i=Xi(n).hoistableStyles,a=i.get(t),a||(a={type:"style",instance:null,count:0,state:null},i.set(t,a)),a):{type:"void",instance:null,count:0,state:null};case"link":if(i.rel==="stylesheet"&&typeof i.href=="string"&&typeof i.precedence=="string"){e=Aa(i.href);var o=Xi(n).hoistableStyles,r=o.get(e);if(r||(n=n.ownerDocument||n,r={type:"stylesheet",instance:null,count:0,state:{loading:0,preload:null}},o.set(e,r),(o=n.querySelector(yn(e)))&&!o._p&&(r.instance=o,r.state.loading=5),xt.has(e)||(i={rel:"preload",as:"style",href:i.href,crossOrigin:i.crossOrigin,integrity:i.integrity,media:i.media,hrefLang:i.hrefLang,referrerPolicy:i.referrerPolicy},xt.set(e,i),o||Lf(n,e,i,r.state))),t&&a===null)throw Error(u(528,""));return r}if(t&&a!==null)throw Error(u(529,""));return null;case"script":return t=i.async,i=i.src,typeof i=="string"&&t&&typeof t!="function"&&typeof t!="symbol"?(t=Ea(i),i=Xi(n).hoistableScripts,a=i.get(t),a||(a={type:"script",instance:null,count:0,state:null},i.set(t,a)),a):{type:"void",instance:null,count:0,state:null};default:throw Error(u(444,e))}}function Aa(e){return'href="'+ft(e)+'"'}function yn(e){return'link[rel="stylesheet"]['+e+"]"}function Ku(e){return z({},e,{"data-precedence":e.precedence,precedence:null})}function Lf(e,t,i,a){e.querySelector('link[rel="preload"][as="style"]['+t+"]")?a.loading=1:(t=e.createElement("link"),a.preload=t,t.addEventListener("load",function(){return a.loading|=1}),t.addEventListener("error",function(){return a.loading|=2}),Qe(t,"link",i),Ue(t),e.head.appendChild(t))}function Ea(e){return'[src="'+ft(e)+'"]'}function vn(e){return"script[async]"+e}function Qu(e,t,i){if(t.count++,t.instance===null)switch(t.type){case"style":var a=e.querySelector('style[data-href~="'+ft(i.href)+'"]');if(a)return t.instance=a,Ue(a),a;var n=z({},i,{"data-href":i.href,"data-precedence":i.precedence,href:null,precedence:null});return a=(e.ownerDocument||e).createElement("style"),Ue(a),Qe(a,"style",n),Ls(a,i.precedence,e),t.instance=a;case"stylesheet":n=Aa(i.href);var o=e.querySelector(yn(n));if(o)return t.state.loading|=4,t.instance=o,Ue(o),o;a=Ku(i),(n=xt.get(n))&&Fr(a,n),o=(e.ownerDocument||e).createElement("link"),Ue(o);var r=o;return r._p=new Promise(function(l,p){r.onload=l,r.onerror=p}),Qe(o,"link",a),t.state.loading|=4,Ls(o,i.precedence,e),t.instance=o;case"script":return o=Ea(i.src),(n=e.querySelector(vn(o)))?(t.instance=n,Ue(n),n):(a=i,(n=xt.get(o))&&(a=z({},i),$r(a,n)),e=e.ownerDocument||e,n=e.createElement("script"),Ue(n),Qe(n,"link",a),e.head.appendChild(n),t.instance=n);case"void":return null;default:throw Error(u(443,t.type))}else t.type==="stylesheet"&&(t.state.loading&4)===0&&(a=t.instance,t.state.loading|=4,Ls(a,i.precedence,e));return t.instance}function Ls(e,t,i){for(var a=i.querySelectorAll('link[rel="stylesheet"][data-precedence],style[data-precedence]'),n=a.length?a[a.length-1]:null,o=n,r=0;r<a.length;r++){var l=a[r];if(l.dataset.precedence===t)o=l;else if(o!==n)break}o?o.parentNode.insertBefore(e,o.nextSibling):(t=i.nodeType===9?i.head:i,t.insertBefore(e,t.firstChild))}function Fr(e,t){e.crossOrigin==null&&(e.crossOrigin=t.crossOrigin),e.referrerPolicy==null&&(e.referrerPolicy=t.referrerPolicy),e.title==null&&(e.title=t.title)}function $r(e,t){e.crossOrigin==null&&(e.crossOrigin=t.crossOrigin),e.referrerPolicy==null&&(e.referrerPolicy=t.referrerPolicy),e.integrity==null&&(e.integrity=t.integrity)}var Ms=null;function Zu(e,t,i){if(Ms===null){var a=new Map,n=Ms=new Map;n.set(i,a)}else n=Ms,a=n.get(i),a||(a=new Map,n.set(i,a));if(a.has(e))return a;for(a.set(e,null),i=i.getElementsByTagName(e),n=0;n<i.length;n++){var o=i[n];if(!(o[Da]||o[Ze]||e==="link"&&o.getAttribute("rel")==="stylesheet")&&o.namespaceURI!=="http://www.w3.org/2000/svg"){var r=o.getAttribute(t)||"";r=e+r;var l=a.get(r);l?l.push(o):a.set(r,[o])}}return a}function Ju(e,t,i){e=e.ownerDocument||e,e.head.insertBefore(i,t==="title"?e.querySelector("head > title"):null)}function Mf(e,t,i){if(i===1||t.itemProp!=null)return!1;switch(e){case"meta":case"title":return!0;case"style":if(typeof t.precedence!="string"||typeof t.href!="string"||t.href==="")break;return!0;case"link":if(typeof t.rel!="string"||typeof t.href!="string"||t.href===""||t.onLoad||t.onError)break;switch(t.rel){case"stylesheet":return e=t.disabled,typeof t.precedence=="string"&&e==null;default:return!0}case"script":if(t.async&&typeof t.async!="function"&&typeof t.async!="symbol"&&!t.onLoad&&!t.onError&&t.src&&typeof t.src=="string")return!0}return!1}function Fu(e){return!(e.type==="stylesheet"&&(e.state.loading&3)===0)}var kn=null;function zf(){}function If(e,t,i){if(kn===null)throw Error(u(475));var a=kn;if(t.type==="stylesheet"&&(typeof i.media!="string"||matchMedia(i.media).matches!==!1)&&(t.state.loading&4)===0){if(t.instance===null){var n=Aa(i.href),o=e.querySelector(yn(n));if(o){e=o._p,e!==null&&typeof e=="object"&&typeof e.then=="function"&&(a.count++,a=zs.bind(a),e.then(a,a)),t.state.loading|=4,t.instance=o,Ue(o);return}o=e.ownerDocument||e,i=Ku(i),(n=xt.get(n))&&Fr(i,n),o=o.createElement("link"),Ue(o);var r=o;r._p=new Promise(function(l,p){r.onload=l,r.onerror=p}),Qe(o,"link",i),t.instance=o}a.stylesheets===null&&(a.stylesheets=new Map),a.stylesheets.set(t,e),(e=t.state.preload)&&(t.state.loading&3)===0&&(a.count++,t=zs.bind(a),e.addEventListener("load",t),e.addEventListener("error",t))}}function qf(){if(kn===null)throw Error(u(475));var e=kn;return e.stylesheets&&e.count===0&&Wr(e,e.stylesheets),0<e.count?function(t){var i=setTimeout(function(){if(e.stylesheets&&Wr(e,e.stylesheets),e.unsuspend){var a=e.unsuspend;e.unsuspend=null,a()}},6e4);return e.unsuspend=t,function(){e.unsuspend=null,clearTimeout(i)}}:null}function zs(){if(this.count--,this.count===0){if(this.stylesheets)Wr(this,this.stylesheets);else if(this.unsuspend){var e=this.unsuspend;this.unsuspend=null,e()}}}var Is=null;function Wr(e,t){e.stylesheets=null,e.unsuspend!==null&&(e.count++,Is=new Map,t.forEach(Of,e),Is=null,zs.call(e))}function Of(e,t){if(!(t.state.loading&4)){var i=Is.get(e);if(i)var a=i.get(null);else{i=new Map,Is.set(e,i);for(var n=e.querySelectorAll("link[data-precedence],style[data-precedence]"),o=0;o<n.length;o++){var r=n[o];(r.nodeName==="LINK"||r.getAttribute("media")!=="not all")&&(i.set(r.dataset.precedence,r),a=r)}a&&i.set(null,a)}n=t.instance,r=n.getAttribute("data-precedence"),o=i.get(r)||a,o===a&&i.set(null,n),i.set(r,n),this.count++,a=zs.bind(this),n.addEventListener("load",a),n.addEventListener("error",a),o?o.parentNode.insertBefore(n,o.nextSibling):(e=e.nodeType===9?e.head:e,e.insertBefore(n,e.firstChild)),t.state.loading|=4}}var xn={$$typeof:X,Provider:null,Consumer:null,_currentValue:$,_currentValue2:$,_threadCount:0};function Pf(e,t,i,a,n,o,r,l){this.tag=1,this.containerInfo=e,this.pingCache=this.current=this.pendingChildren=null,this.timeoutHandle=-1,this.callbackNode=this.next=this.pendingContext=this.context=this.cancelPendingCommit=null,this.callbackPriority=0,this.expirationTimes=Qs(-1),this.entangledLanes=this.shellSuspendCounter=this.errorRecoveryDisabledLanes=this.expiredLanes=this.warmLanes=this.pingedLanes=this.suspendedLanes=this.pendingLanes=0,this.entanglements=Qs(0),this.hiddenUpdates=Qs(null),this.identifierPrefix=a,this.onUncaughtError=n,this.onCaughtError=o,this.onRecoverableError=r,this.pooledCache=null,this.pooledCacheLanes=0,this.formState=l,this.incompleteTransitions=new Map}function $u(e,t,i,a,n,o,r,l,p,v,N,j){return e=new Pf(e,t,i,r,l,p,v,j),t=1,o===!0&&(t|=24),o=rt(3,null,null,t),e.current=o,o.stateNode=e,t=zo(),t.refCount++,e.pooledCache=t,t.refCount++,o.memoizedState={element:a,isDehydrated:i,cache:t},Po(o),e}function Wu(e){return e?(e=na,e):na}function ed(e,t,i,a,n,o){n=Wu(n),a.context===null?a.context=n:a.pendingContext=n,a=ai(t),a.payload={element:i},o=o===void 0?null:o,o!==null&&(a.callback=o),i=ni(e,a,t),i!==null&&(dt(i,e,t),Ja(i,e,t))}function td(e,t){if(e=e.memoizedState,e!==null&&e.dehydrated!==null){var i=e.retryLane;e.retryLane=i!==0&&i<t?i:t}}function el(e,t){td(e,t),(e=e.alternate)&&td(e,t)}function id(e){if(e.tag===13){var t=aa(e,67108864);t!==null&&dt(t,e,67108864),el(e,67108864)}}var qs=!0;function Bf(e,t,i,a){var n=x.T;x.T=null;var o=D.p;try{D.p=2,tl(e,t,i,a)}finally{D.p=o,x.T=n}}function wf(e,t,i,a){var n=x.T;x.T=null;var o=D.p;try{D.p=8,tl(e,t,i,a)}finally{D.p=o,x.T=n}}function tl(e,t,i,a){if(qs){var n=il(a);if(n===null)Ur(e,t,a,Os,i),nd(e,a);else if(Uf(n,e,t,i,a))a.stopPropagation();else if(nd(e,a),t&4&&-1<Vf.indexOf(e)){for(;n!==null;){var o=Yi(n);if(o!==null)switch(o.tag){case 3:if(o=o.stateNode,o.current.memoizedState.isDehydrated){var r=Si(o.pendingLanes);if(r!==0){var l=o;for(l.pendingLanes|=2,l.entangledLanes|=2;r;){var p=1<<31-st(r);l.entanglements[1]|=p,r&=~p}Dt(o),(xe&6)===0&&(ks=At()+500,fn(0))}}break;case 13:l=aa(o,2),l!==null&&dt(l,o,2),Ss(),el(o,2)}if(o=il(a),o===null&&Ur(e,t,a,Os,i),o===n)break;n=o}n!==null&&a.stopPropagation()}else Ur(e,t,a,null,i)}}function il(e){return e=oo(e),al(e)}var Os=null;function al(e){if(Os=null,e=Gi(e),e!==null){var t=E(e);if(t===null)e=null;else{var i=t.tag;if(i===13){if(e=O(t),e!==null)return e;e=null}else if(i===3){if(t.stateNode.current.memoizedState.isDehydrated)return t.tag===3?t.stateNode.containerInfo:null;e=null}else t!==e&&(e=null)}}return Os=e,null}function ad(e){switch(e){case"beforetoggle":case"cancel":case"click":case"close":case"contextmenu":case"copy":case"cut":case"auxclick":case"dblclick":case"dragend":case"dragstart":case"drop":case"focusin":case"focusout":case"input":case"invalid":case"keydown":case"keypress":case"keyup":case"mousedown":case"mouseup":case"paste":case"pause":case"play":case"pointercancel":case"pointerdown":case"pointerup":case"ratechange":case"reset":case"resize":case"seeked":case"submit":case"toggle":case"touchcancel":case"touchend":case"touchstart":case"volumechange":case"change":case"selectionchange":case"textInput":case"compositionstart":case"compositionend":case"compositionupdate":case"beforeblur":case"afterblur":case"beforeinput":case"blur":case"fullscreenchange":case"focus":case"hashchange":case"popstate":case"select":case"selectstart":return 2;case"drag":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"mousemove":case"mouseout":case"mouseover":case"pointermove":case"pointerout":case"pointerover":case"scroll":case"touchmove":case"wheel":case"mouseenter":case"mouseleave":case"pointerenter":case"pointerleave":return 8;case"message":switch(Nd()){case hl:return 2;case yl:return 8;case Rn:case Ad:return 32;case vl:return 268435456;default:return 32}default:return 32}}var nl=!1,hi=null,yi=null,vi=null,Sn=new Map,_n=new Map,ki=[],Vf="mousedown mouseup touchcancel touchend touchstart auxclick dblclick pointercancel pointerdown pointerup dragend dragstart drop compositionend compositionstart keydown keypress keyup input textInput copy cut paste click change contextmenu reset".split(" ");function nd(e,t){switch(e){case"focusin":case"focusout":hi=null;break;case"dragenter":case"dragleave":yi=null;break;case"mouseover":case"mouseout":vi=null;break;case"pointerover":case"pointerout":Sn.delete(t.pointerId);break;case"gotpointercapture":case"lostpointercapture":_n.delete(t.pointerId)}}function Cn(e,t,i,a,n,o){return e===null||e.nativeEvent!==o?(e={blockedOn:t,domEventName:i,eventSystemFlags:a,nativeEvent:o,targetContainers:[n]},t!==null&&(t=Yi(t),t!==null&&id(t)),e):(e.eventSystemFlags|=a,t=e.targetContainers,n!==null&&t.indexOf(n)===-1&&t.push(n),e)}function Uf(e,t,i,a,n){switch(t){case"focusin":return hi=Cn(hi,e,t,i,a,n),!0;case"dragenter":return yi=Cn(yi,e,t,i,a,n),!0;case"mouseover":return vi=Cn(vi,e,t,i,a,n),!0;case"pointerover":var o=n.pointerId;return Sn.set(o,Cn(Sn.get(o)||null,e,t,i,a,n)),!0;case"gotpointercapture":return o=n.pointerId,_n.set(o,Cn(_n.get(o)||null,e,t,i,a,n)),!0}return!1}function sd(e){var t=Gi(e.target);if(t!==null){var i=E(t);if(i!==null){if(t=i.tag,t===13){if(t=O(i),t!==null){e.blockedOn=t,zd(e.priority,function(){if(i.tag===13){var a=ut();a=Zs(a);var n=aa(i,a);n!==null&&dt(n,i,a),el(i,a)}});return}}else if(t===3&&i.stateNode.current.memoizedState.isDehydrated){e.blockedOn=i.tag===3?i.stateNode.containerInfo:null;return}}}e.blockedOn=null}function Ps(e){if(e.blockedOn!==null)return!1;for(var t=e.targetContainers;0<t.length;){var i=il(e.nativeEvent);if(i===null){i=e.nativeEvent;var a=new i.constructor(i.type,i);so=a,i.target.dispatchEvent(a),so=null}else return t=Yi(i),t!==null&&id(t),e.blockedOn=i,!1;t.shift()}return!0}function od(e,t,i){Ps(e)&&i.delete(t)}function Hf(){nl=!1,hi!==null&&Ps(hi)&&(hi=null),yi!==null&&Ps(yi)&&(yi=null),vi!==null&&Ps(vi)&&(vi=null),Sn.forEach(od),_n.forEach(od)}function Bs(e,t){e.blockedOn===t&&(e.blockedOn=null,nl||(nl=!0,m.unstable_scheduleCallback(m.unstable_NormalPriority,Hf)))}var ws=null;function rd(e){ws!==e&&(ws=e,m.unstable_scheduleCallback(m.unstable_NormalPriority,function(){ws===e&&(ws=null);for(var t=0;t<e.length;t+=3){var i=e[t],a=e[t+1],n=e[t+2];if(typeof a!="function"){if(al(a||i)===null)continue;break}var o=Yi(i);o!==null&&(e.splice(t,3),t-=3,ar(o,{pending:!0,data:n,method:i.method,action:a},a,n))}}))}function Nn(e){function t(p){return Bs(p,e)}hi!==null&&Bs(hi,e),yi!==null&&Bs(yi,e),vi!==null&&Bs(vi,e),Sn.forEach(t),_n.forEach(t);for(var i=0;i<ki.length;i++){var a=ki[i];a.blockedOn===e&&(a.blockedOn=null)}for(;0<ki.length&&(i=ki[0],i.blockedOn===null);)sd(i),i.blockedOn===null&&ki.shift();if(i=(e.ownerDocument||e).$$reactFormReplay,i!=null)for(a=0;a<i.length;a+=3){var n=i[a],o=i[a+1],r=n[We]||null;if(typeof o=="function")r||rd(i);else if(r){var l=null;if(o&&o.hasAttribute("formAction")){if(n=o,r=o[We]||null)l=r.formAction;else if(al(n)!==null)continue}else l=r.action;typeof l=="function"?i[a+1]=l:(i.splice(a,3),a-=3),rd(i)}}}function sl(e){this._internalRoot=e}Vs.prototype.render=sl.prototype.render=function(e){var t=this._internalRoot;if(t===null)throw Error(u(409));var i=t.current,a=ut();ed(i,a,e,t,null,null)},Vs.prototype.unmount=sl.prototype.unmount=function(){var e=this._internalRoot;if(e!==null){this._internalRoot=null;var t=e.containerInfo;ed(e.current,2,null,e,null,null),Ss(),t[Hi]=null}};function Vs(e){this._internalRoot=e}Vs.prototype.unstable_scheduleHydration=function(e){if(e){var t=Cl();e={blockedOn:null,target:e,priority:t};for(var i=0;i<ki.length&&t!==0&&t<ki[i].priority;i++);ki.splice(i,0,e),i===0&&sd(e)}};var ld=c.version;if(ld!=="19.1.0")throw Error(u(527,ld,"19.1.0"));D.findDOMNode=function(e){var t=e._reactInternals;if(t===void 0)throw typeof e.render=="function"?Error(u(188)):(e=Object.keys(e).join(","),Error(u(268,e)));return e=L(t),e=e!==null?y(e):null,e=e===null?null:e.stateNode,e};var Gf={bundleType:0,version:"19.1.0",rendererPackageName:"react-dom",currentDispatcherRef:x,reconcilerVersion:"19.1.0"};if(typeof __REACT_DEVTOOLS_GLOBAL_HOOK__<"u"){var Us=__REACT_DEVTOOLS_GLOBAL_HOOK__;if(!Us.isDisabled&&Us.supportsFiber)try{ja=Us.inject(Gf),nt=Us}catch{}}return En.createRoot=function(e,t){if(!_(e))throw Error(u(299));var i=!1,a="",n=Cm,o=Nm,r=Am,l=null;return t!=null&&(t.unstable_strictMode===!0&&(i=!0),t.identifierPrefix!==void 0&&(a=t.identifierPrefix),t.onUncaughtError!==void 0&&(n=t.onUncaughtError),t.onCaughtError!==void 0&&(o=t.onCaughtError),t.onRecoverableError!==void 0&&(r=t.onRecoverableError),t.unstable_transitionCallbacks!==void 0&&(l=t.unstable_transitionCallbacks)),t=$u(e,1,!1,null,null,i,a,n,o,r,l,null),e[Hi]=t.current,Vr(e),new sl(t)},En.hydrateRoot=function(e,t,i){if(!_(e))throw Error(u(299));var a=!1,n="",o=Cm,r=Nm,l=Am,p=null,v=null;return i!=null&&(i.unstable_strictMode===!0&&(a=!0),i.identifierPrefix!==void 0&&(n=i.identifierPrefix),i.onUncaughtError!==void 0&&(o=i.onUncaughtError),i.onCaughtError!==void 0&&(r=i.onCaughtError),i.onRecoverableError!==void 0&&(l=i.onRecoverableError),i.unstable_transitionCallbacks!==void 0&&(p=i.unstable_transitionCallbacks),i.formState!==void 0&&(v=i.formState)),t=$u(e,1,!0,t,i??null,a,n,o,r,l,p,v),t.context=Wu(null),i=t.current,a=ut(),a=Zs(a),n=ai(a),n.callback=null,ni(i,n,a),i=a,t.current.lanes=i,Ta(t,i),Dt(t),e[Hi]=t.current,Vr(e),new Vs(t)},En.version="19.1.0",En}var yd;function eb(){if(yd)return ll.exports;yd=1;function m(){if(!(typeof __REACT_DEVTOOLS_GLOBAL_HOOK__>"u"||typeof __REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE!="function"))try{__REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE(m)}catch(c){console.error(c)}}return m(),ll.exports=Wf(),ll.exports}var tb=eb();const ib=({title:m,content:c})=>{const[d,u]=_e.useState(!1),_=()=>{u(!d)};return s.jsxs("div",{className:"border border-slate-200 rounded-lg",children:[s.jsxs("button",{onClick:_,className:"w-full text-left p-4 bg-slate-100 hover:bg-slate-200 rounded-lg font-semibold flex justify-between items-center",children:[s.jsx("span",{children:m}),s.jsx("span",{className:`transform transition-transform duration-300 ${d?"rotate-180":""}`,children:"▼"})]}),d&&s.jsx("div",{className:"bg-white border-t border-slate-200 rounded-b-lg p-4",children:s.jsx("div",{className:"text-sm text-slate-700",children:c})})]})},ab=({onSelectSection:m})=>{var ie,B,Q,H,Y;const[c,d]=_e.useState("resumen"),[u,_]=_e.useState("p_aeruginosa"),[E,O]=_e.useState(null),[P,L]=_e.useState(null),y={topPathogens:{labels:["E. coli","S. aureus","K. pneumoniae","P. aeruginosa","A. baumannii"],data:[4e3,3100,2600,2e3,1500]},pathogens:{p_aeruginosa:{name:"Pseudomonas aeruginosa",burden:"4ta causa de muerte por RAM en Colombia (2,000 muertes en 2019). Prevalencia en UCI aumentó de 8% a 11% (2018-2021). 2do agente en Neumonía Asociada a Ventilador (20.7%) y Bacteriemia (10.5%) en UCI de adultos (2023).",resistance:{labels:["Pip-Tazo","Ceftazidima","Cefepime","Imipenem","Meropenem","Ciprofloxacina","Amikacina"],datasets:[{label:"% Resistencia",data:[35,30,30,28,28,30,30],backgroundColor:"rgba(13, 148, 136, 0.6)",borderColor:"rgba(13, 148, 136, 1)",borderWidth:1,sources:["GREBO 2018-21","GREBO 2001-03","GREBO 2001-03","INS 2022","INS 2022","GREBO 2001-03","GREBO 2001-03"]}]},intrinsic:["Ampicilina","Amoxi-Clav","Cefalosp. 1ra-2da gen","Tetraciclinas","TMP-SMX","Cloranfenicol"],considerations:"TENDENCIA CRÍTICA: Se ha demostrado un aumento estadísticamente significativo en la resistencia a Piperacilina-Tazobactam y Carbapenems a nivel nacional (2018-2021). La eficacia de estas terapias clave está disminuyendo activamente."},e_coli:{name:"Escherichia coli",burden:"1ra causa de muerte por RAM en Colombia (4,000 muertes en 2019). Constituye 26-28% de todos los aislados bacterianos. Principal agente en ITU asociada a catéter en UCI (25.6% en 2023).",resistance:{labels:["Cefalosp. 3ra Gen","Ciprofloxacina"],datasets:[{label:"% Resistencia",data:[28.6,25],backgroundColor:"rgba(13, 148, 136, 0.6)",borderColor:"rgba(13, 148, 136, 1)",borderWidth:1,sources:["INS 2022","GREBO 2001-03"]}]},intrinsic:[],considerations:"La resistencia a Cefalosporinas de 3ra Gen es un marcador de producción de BLEE. Datos de diferentes fuentes muestran tasas entre 20-28.6%, indicando una alta prevalencia de BLEE."},k_pneumoniae:{name:"Klebsiella pneumoniae",burden:"3ra causa de muerte por RAM en Colombia (2,600 muertes en 2019). Prevalencia en UCI aumentó de 15% a 18% (2018-2021). Agente predominante en Bacteriemia (19.9%) y NAV (29.8%) en UCI de adultos (2023).",resistance:{labels:["Ceftriaxona","Carbapenems"],datasets:[{label:"% Resistencia",data:[31,15],backgroundColor:"rgba(13, 148, 136, 0.6)",borderColor:"rgba(13, 148, 136, 1)",borderWidth:1,sources:["Expertos 2022","INS-GREBO"]}]},intrinsic:["Ampicilina"],considerations:"La resistencia a carbapenems es una amenaza crítica y creciente a nivel nacional, a menudo mediada por carbapenemasas como KPC, cuya diseminación en Bogotá fue documentada desde 2008."},s_aureus:{name:"Staphylococcus aureus",burden:"2da causa de muerte por RAM en Colombia (3,100 muertes en 2019). Constituye 10-11% de todos los aislados bacterianos.",resistance:{labels:["Infección Clínica","UCI Bogotá","Portadores Sanos"],datasets:[{label:"% Resistencia SARM",data:[43,62,20],backgroundColor:"rgba(13, 148, 136, 0.6)",borderColor:"rgba(13, 148, 136, 1)",borderWidth:1,sources:["Expertos 2022","GREBO 2001-03","Expertos 2022"]}]},intrinsic:["Aztreonam","Polimixinas"],considerations:"La prevalencia de SARM es alta y depende del contexto: 43% en infecciones clínicas, pero puede superar el 60% en UCI. Esto requiere el uso empírico de terapias alternativas como vancomicina en pacientes críticos."},a_baumannii:{name:"Acinetobacter baumannii",burden:"5ta causa de muerte por RAM en Colombia (1,500 muertes en 2019). Patógeno formidable casi exclusivo de entornos de UCI.",resistance:{labels:["Carbapenems"],datasets:[{label:"% Resistencia",data:[45],backgroundColor:"rgba(13, 148, 136, 0.6)",borderColor:"rgba(13, 148, 136, 1)",borderWidth:1,sources:["INS 2022"]}]},intrinsic:["Ampicilina","Cefalosp. 1ra-2da gen","Ertapenem"],considerations:"Patógeno nosocomial con tasas de resistencia a carbapenémicos extremadamente altas (>45%), lo que limita severamente las opciones terapéuticas y lo convierte en una amenaza crítica."}},crossResistanceData:[{title:"Producción de BLEE (ESBL)",content:"En E. coli, K. pneumoniae, P. mirabilis. Implica resistencia a todas las penicilinas, todas las cefalosporinas (1ra-4ta gen), y aztreonam, sin importar el resultado in vitro. Los carbapenems permanecen activos."},{title:"Producción de Carbapenemasa (ej. KPC)",content:"En Enterobacterales, P. aeruginosa, A. baumannii. Implica resistencia a todos los beta-lactámicos (penicilinas, cefalosporinas, carbapenems). El tratamiento requiere agentes noveles o terapia combinada."},{title:"S. aureus Meticilino-Resistente (SARM)",content:"En S. aureus. Implica resistencia a todos los beta-lactámicos (excepto ceftarolina). Usar Cefoxitin como marcador. Opciones terapéuticas incluyen vancomicina, daptomicina, linezolid."},{title:"Resistencia a Fluoroquinolonas de Alto Nivel",content:"En Enterobacterales, P. aeruginosa. Implica alta probabilidad de resistencia a todas las fluoroquinolonas (ciprofloxacina, levofloxacina, etc.). No se recomienda probar una segunda fluoroquinolona."}]};_e.useEffect(()=>(typeof window<"u"&&window.Chart&&setTimeout(()=>{z()},100),()=>{P&&(P.destroy(),L(null)),E&&(E.destroy(),O(null))}),[c]);const z=()=>{if(P&&(P.destroy(),L(null)),E&&(E.destroy(),O(null)),c==="resumen"){const M=document.getElementById("topPathogensChart");if(M){const V=window.Chart.getChart(M);V&&V.destroy();const X=new window.Chart(M,{type:"bar",data:{labels:y.topPathogens.labels,datasets:[{label:"Muertes Asociadas",data:y.topPathogens.data,backgroundColor:"rgba(13, 148, 136, 0.6)",borderColor:"rgba(13, 148, 136, 1)",borderWidth:1}]},options:{indexAxis:"y",responsive:!0,maintainAspectRatio:!1,plugins:{legend:{display:!1},tooltip:{callbacks:{label:Z=>` ${Z.raw.toLocaleString()} muertes`}}},scales:{x:{beginAtZero:!0,title:{display:!0,text:"Número de Muertes (Estimado 2019)"}}}}});L(X)}}c==="patogenos"&&q()},q=()=>{const M=y.pathogens[u];if(!M)return;const V=document.getElementById("resistanceChart");if(V){const X=window.Chart.getChart(V);X&&X.destroy();const Z=new window.Chart(V,{type:"bar",data:M.resistance,options:{responsive:!0,maintainAspectRatio:!1,scales:{y:{beginAtZero:!0,max:100,title:{display:!0,text:"% Resistencia"}}},plugins:{legend:{display:M.resistance.datasets.length>1},tooltip:{callbacks:{label:K=>` ${K.dataset.label||""}: ${K.raw}%`,afterLabel:K=>`Fuente: ${K.dataset.sources?K.dataset.sources[K.dataIndex]:""}`}}}}});O(Z)}};return _e.useEffect(()=>{c==="patogenos"&&u&&q()},[u,c]),s.jsxs("div",{className:"min-h-full bg-slate-50 text-slate-800",children:[s.jsx("header",{className:"bg-white shadow-sm border-b border-slate-200",children:s.jsx("div",{className:"max-w-7xl mx-auto px-4 sm:px-6 lg:px-8 py-6",children:s.jsxs("div",{className:"text-center",children:[s.jsx("h1",{className:"text-4xl font-bold text-teal-700 mb-2",children:"Guía Interactiva de Resistencia Antimicrobiana"}),s.jsx("p",{className:"text-xl text-slate-600 mb-1",children:"Colombia - Versión Alpha"}),s.jsx("p",{className:"text-sm text-slate-500",children:"Sistema integrado de apoyo clínico y vigilancia epidemiológica"})]})})}),s.jsxs("main",{className:"max-w-6xl mx-auto px-4 sm:px-6 lg:px-8 py-12",children:[s.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-8 mb-16",children:[s.jsx("div",{onClick:()=>m("antibiogram"),className:"bg-white rounded-2xl shadow-lg border border-slate-200 p-8 hover:shadow-xl transition-all duration-300 cursor-pointer group",children:s.jsxs("div",{className:"text-center",children:[s.jsx("div",{className:"w-20 h-20 bg-indigo-100 rounded-full flex items-center justify-center mx-auto mb-6 group-hover:bg-indigo-200 transition-colors",children:s.jsx("span",{className:"text-4xl",children:"🧬"})}),s.jsx("h2",{className:"text-2xl font-bold text-slate-900 mb-4",children:"Antibiograma Inteligente"}),s.jsx("p",{className:"text-slate-600 mb-6",children:"Sistema de apoyo para la toma de decisiones clínicas en el tratamiento de infecciones. Interpretación avanzada de antibiogramas con algoritmos de detección de resistencia."}),s.jsxs("div",{className:"space-y-2 text-sm text-slate-500 text-left",children:[s.jsxs("div",{className:"flex items-center",children:[s.jsx("span",{className:"w-2 h-2 bg-green-500 rounded-full mr-3"}),s.jsx("span",{children:"Interpretación CLSI automatizada"})]}),s.jsxs("div",{className:"flex items-center",children:[s.jsx("span",{className:"w-2 h-2 bg-green-500 rounded-full mr-3"}),s.jsx("span",{children:"Detección de patrones de resistencia"})]}),s.jsxs("div",{className:"flex items-center",children:[s.jsx("span",{className:"w-2 h-2 bg-green-500 rounded-full mr-3"}),s.jsx("span",{children:"Recomendaciones terapéuticas inteligentes"})]}),s.jsxs("div",{className:"flex items-center",children:[s.jsx("span",{className:"w-2 h-2 bg-green-500 rounded-full mr-3"}),s.jsx("span",{children:"Ajustes por función renal/hepática"})]})]}),s.jsx("button",{className:"mt-6 w-full bg-indigo-600 text-white py-3 px-6 rounded-lg font-semibold hover:bg-indigo-700 transition-colors",children:"Acceder al Antibiograma"})]})}),s.jsx("div",{className:"bg-gray-100 rounded-2xl shadow-lg border border-gray-300 p-8 opacity-75 relative",children:s.jsxs("div",{className:"text-center",children:[s.jsx("div",{className:"w-20 h-20 bg-gray-200 rounded-full flex items-center justify-center mx-auto mb-6",children:s.jsx("span",{className:"text-4xl",children:"🚧"})}),s.jsx("h2",{className:"text-2xl font-bold text-gray-600 mb-4",children:"Guía de Síndromes"}),s.jsxs("div",{className:"bg-yellow-50 border border-yellow-200 rounded-lg p-4 mb-6",children:[s.jsx("p",{className:"text-yellow-800 font-semibold text-sm mb-2",children:"🔨 En Construcción"}),s.jsx("p",{className:"text-yellow-700 text-sm",children:"Esta sección estará disponible próximamente con atlas epidemiológico completo."})]}),s.jsx("p",{className:"text-gray-500 mb-6",children:"Atlas epidemiológico de resistencia antimicrobiana en Colombia. Datos actualizados de vigilancia nacional, perfiles de patógenos y tendencias críticas."}),s.jsxs("div",{className:"space-y-2 text-sm text-gray-400 text-left",children:[s.jsxs("div",{className:"flex items-center",children:[s.jsx("span",{className:"w-2 h-2 bg-gray-400 rounded-full mr-3"}),s.jsx("span",{children:"Panorama nacional de RAM"})]}),s.jsxs("div",{className:"flex items-center",children:[s.jsx("span",{className:"w-2 h-2 bg-gray-400 rounded-full mr-3"}),s.jsx("span",{children:"Perfiles de resistencia por patógeno"})]}),s.jsxs("div",{className:"flex items-center",children:[s.jsx("span",{className:"w-2 h-2 bg-gray-400 rounded-full mr-3"}),s.jsx("span",{children:"Triangulación de datos de vigilancia"})]}),s.jsxs("div",{className:"flex items-center",children:[s.jsx("span",{className:"w-2 h-2 bg-gray-400 rounded-full mr-3"}),s.jsx("span",{children:"Resistencia cruzada y fenotipos"})]})]}),s.jsx("button",{className:"mt-6 w-full bg-gray-400 text-white py-3 px-6 rounded-lg font-semibold cursor-not-allowed",disabled:!0,children:"Próximamente Disponible"})]})})]}),s.jsxs("div",{className:"mb-8",children:[s.jsx("h3",{className:"text-2xl font-bold text-slate-900 mb-6 text-center",children:"Atlas Epidemiológico Nacional"}),s.jsxs("div",{className:"flex flex-wrap justify-center gap-4 mb-8",children:[s.jsx("button",{onClick:()=>d("resumen"),className:`px-6 py-3 rounded-lg font-medium transition-all ${c==="resumen"?"bg-teal-600 text-white":"bg-white text-slate-600 hover:bg-slate-100 border border-slate-200"}`,children:"🏠 Resumen Nacional"}),s.jsx("button",{onClick:()=>d("patogenos"),className:`px-6 py-3 rounded-lg font-medium transition-all ${c==="patogenos"?"bg-teal-600 text-white":"bg-white text-slate-600 hover:bg-slate-100 border border-slate-200"}`,children:"🦠 Perfiles de Patógenos"}),s.jsx("button",{onClick:()=>d("principios"),className:`px-6 py-3 rounded-lg font-medium transition-all ${c==="principios"?"bg-teal-600 text-white":"bg-white text-slate-600 hover:bg-slate-100 border border-slate-200"}`,children:"🔬 Principios Clave"})]})]}),c==="resumen"&&s.jsxs("div",{className:"space-y-8",children:[s.jsxs("header",{className:"mb-8",children:[s.jsx("h2",{className:"text-3xl font-bold text-slate-900",children:"Panorama de la Resistencia Antimicrobiana en Colombia"}),s.jsx("p",{className:"mt-2 text-slate-600",children:"Un resumen del impacto, los patógenos clave y los sistemas de vigilancia que definen el desafío de la RAM en el país."})]}),s.jsxs("div",{className:"bg-white p-6 rounded-lg shadow-sm border border-slate-200",children:[s.jsx("h3",{className:"text-xl font-semibold text-slate-900 mb-4",children:"Carga de Mortalidad por RAM en Colombia (Datos 2019)"}),s.jsx("p",{className:"text-slate-600 mb-6",children:"La resistencia antimicrobiana es una de las principales causas de muerte en Colombia, superando la mortalidad combinada de varias enfermedades crónicas. Los datos del IHME de 2019 revelan la escala del problema."}),s.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-6",children:[s.jsxs("div",{className:"bg-red-50 p-6 rounded-lg border border-red-200",children:[s.jsx("h4",{className:"font-semibold text-red-800 mb-2",children:"Mortalidad Asociada a la RAM"}),s.jsx("p",{className:"text-4xl font-bold text-red-600",children:"18,200"}),s.jsx("p",{className:"text-red-700",children:"muertes en las que una infección resistente fue un factor contribuyente."})]}),s.jsxs("div",{className:"bg-red-50 p-6 rounded-lg border border-red-200",children:[s.jsx("h4",{className:"font-semibold text-red-800 mb-2",children:"Mortalidad Atribuible a la RAM"}),s.jsx("p",{className:"text-4xl font-bold text-red-700",children:"4,700"}),s.jsx("p",{className:"text-red-700",children:"muertes directamente causadas por la infección resistente."})]})]})]}),s.jsxs("div",{className:"bg-white p-6 rounded-lg shadow-sm border border-slate-200",children:[s.jsx("h3",{className:"text-xl font-semibold text-slate-900 mb-4",children:"Patógenos con Mayor Mortalidad Asociada en Colombia (2019)"}),s.jsx("div",{className:"chart-container",style:{position:"relative",height:"350px",maxHeight:"40vh"},children:s.jsx("canvas",{id:"topPathogensChart"})}),s.jsx("p",{className:"text-xs text-center text-slate-500 mt-2",children:"Fuente: IHME 2019. Pase el cursor sobre las barras para ver el número de muertes."})]}),s.jsxs("div",{className:"bg-white p-6 rounded-lg shadow-sm border border-slate-200",children:[s.jsx("h3",{className:"text-xl font-semibold text-slate-900 mb-4",children:"Arquitectura de la Vigilancia de la RAM en Colombia"}),s.jsx("p",{className:"text-slate-600 mb-6",children:'Colombia utiliza un enfoque de "Una Salud" y triangulación de datos, integrando información de múltiples niveles. Para un antibiograma local, es crucial priorizar datos locales, contextualizarlos con datos nacionales y compararlos con benchmarks regionales.'}),s.jsxs("div",{className:"grid grid-cols-1 sm:grid-cols-2 lg:grid-cols-3 gap-4 text-center",children:[s.jsxs("div",{className:"p-4 bg-teal-50 border border-teal-200 rounded-lg",children:[s.jsx("h4",{className:"font-semibold text-teal-800",children:"Local (GREBO)"}),s.jsx("p",{className:"text-sm text-teal-700",children:"Red de hospitales en Bogotá. Provee datos de alta granularidad, especialmente de UCI, que suelen mostrar tasas de resistencia más altas que el promedio nacional."})]}),s.jsxs("div",{className:"p-4 bg-blue-50 border border-blue-200 rounded-lg",children:[s.jsx("h4",{className:"font-semibold text-blue-800",children:"Nacional (INS/SIVIGILA)"}),s.jsx("p",{className:"text-sm text-blue-700",children:"Sistema de reporte obligatorio nacional. Provee la data oficial del país. Nota: Sufrió una brecha de reportes en 2020 durante la pandemia."})]}),s.jsxs("div",{className:"p-4 bg-indigo-50 border border-indigo-200 rounded-lg",children:[s.jsx("h4",{className:"font-semibold text-indigo-800",children:"Regional (PAHO/ReLAVRA+)"}),s.jsx("p",{className:"text-sm text-indigo-700",children:"Red latinoamericana que agrega datos de 20 países. Permite la comparación y el benchmarking regional. Usa CLSI como estándar."})]})]})]})]}),c==="patogenos"&&s.jsxs("div",{className:"space-y-6",children:[s.jsxs("header",{className:"mb-8",children:[s.jsx("h2",{className:"text-3xl font-bold text-slate-900",children:"Perfiles de Resistencia por Patógeno"}),s.jsx("p",{className:"mt-2 text-slate-600",children:"Seleccione un patógeno para visualizar su perfil de resistencia, carga epidemiológica y consideraciones clave, basado en la triangulación de datos de vigilancia colombianos."})]}),s.jsxs("div",{className:"mb-6 bg-white p-4 rounded-lg shadow-sm border border-slate-200",children:[s.jsx("label",{htmlFor:"pathogen-select",className:"block text-sm font-medium text-slate-700 mb-2",children:"Seleccionar Patógeno:"}),s.jsxs("select",{id:"pathogen-select",value:u,onChange:M=>_(M.target.value),className:"w-full md:w-1/2 p-2 border border-slate-300 rounded-md shadow-sm focus:ring-teal-500 focus:border-teal-500",children:[s.jsx("option",{value:"p_aeruginosa",children:"Pseudomonas aeruginosa"}),s.jsx("option",{value:"e_coli",children:"Escherichia coli"}),s.jsx("option",{value:"k_pneumoniae",children:"Klebsiella pneumoniae"}),s.jsx("option",{value:"s_aureus",children:"Staphylococcus aureus"}),s.jsx("option",{value:"a_baumannii",children:"Acinetobacter baumannii"})]})]}),s.jsxs("div",{className:"grid grid-cols-1 lg:grid-cols-3 gap-6",children:[s.jsxs("div",{className:"lg:col-span-2 bg-white p-6 rounded-lg shadow-sm border border-slate-200",children:[s.jsxs("h3",{className:"text-xl font-semibold text-slate-900 mb-4",children:["Perfil de Resistencia para ",(ie=y.pathogens[u])==null?void 0:ie.name]}),s.jsx("div",{className:"chart-container",style:{position:"relative",height:"400px"},children:s.jsx("canvas",{id:"resistanceChart"})}),s.jsx("p",{className:"text-xs text-center text-slate-500 mt-2",children:"Pase el cursor sobre las barras para ver el porcentaje y la fuente del dato."})]}),s.jsxs("div",{className:"space-y-6",children:[s.jsxs("div",{className:"bg-white p-6 rounded-lg shadow-sm border border-slate-200",children:[s.jsx("h4",{className:"font-semibold text-slate-900 mb-2",children:"Carga Epidemiológica"}),s.jsx("p",{className:"text-sm text-slate-600",children:(B=y.pathogens[u])==null?void 0:B.burden})]}),s.jsxs("div",{className:"bg-white p-6 rounded-lg shadow-sm border border-slate-200",children:[s.jsx("h4",{className:"font-semibold text-slate-900 mb-2",children:"Consideraciones Clave y Tendencias"}),s.jsx("p",{className:"text-sm text-slate-600",children:(Q=y.pathogens[u])==null?void 0:Q.considerations})]}),s.jsxs("div",{className:"bg-white p-6 rounded-lg shadow-sm border border-slate-200",children:[s.jsx("h4",{className:"font-semibold text-slate-900 mb-2",children:"Resistencia Intrínseca"}),s.jsx("p",{className:"text-sm text-slate-600 mb-2",children:"Este patógeno es naturalmente resistente a los siguientes agentes. No deben ser usados."}),s.jsx("ul",{className:"list-disc list-inside text-sm text-slate-600 space-y-1",children:((Y=(H=y.pathogens[u])==null?void 0:H.intrinsic)==null?void 0:Y.length)>0?y.pathogens[u].intrinsic.map((M,V)=>s.jsx("li",{children:M},V)):s.jsx("li",{children:"Ninguna resistencia intrínseca común a destacar."})})]})]})]})]}),c==="principios"&&s.jsxs("div",{className:"space-y-8",children:[s.jsxs("header",{className:"mb-8",children:[s.jsx("h2",{className:"text-3xl font-bold text-slate-900",children:"Principios Clave y Hallazgos del Informe"}),s.jsx("p",{className:"mt-2 text-slate-600",children:"Conceptos y conclusiones fundamentales del análisis de la resistencia en Colombia para la interpretación y uso adecuado de los datos."})]}),s.jsxs("div",{className:"bg-white p-6 rounded-lg shadow-sm border border-slate-200",children:[s.jsx("h3",{className:"text-xl font-semibold text-slate-900 mb-4",children:"Hallazgos y Tendencias Críticas del Informe"}),s.jsx("p",{className:"text-slate-600 mb-6",children:"El análisis de los datos de vigilancia colombianos revela varias tendencias y conclusiones que son cruciales para la práctica clínica y la salud pública."}),s.jsxs("div",{className:"space-y-4",children:[s.jsxs("div",{className:"flex items-start gap-4 p-4 bg-amber-50 border-l-4 border-amber-500 rounded-r-lg",children:[s.jsx("span",{className:"text-2xl mt-1",children:"📈"}),s.jsxs("div",{children:[s.jsx("h4",{className:"font-bold text-amber-800",children:"Tendencia de Alarma: Resistencia Creciente en P. aeruginosa"}),s.jsx("p",{className:"text-sm text-amber-700",children:"El hallazgo más consistente y estadísticamente significativo del período 2018-2021 fue el aumento de la resistencia de P. aeruginosa a Piperacilina-Tazobactam y Carbapenems. La eficacia de estas terapias de primera línea está disminuyendo activamente a nivel nacional."})]})]}),s.jsxs("div",{className:"flex items-start gap-4 p-4 bg-sky-50 border-l-4 border-sky-500 rounded-r-lg",children:[s.jsx("span",{className:"text-2xl mt-1",children:"💉"}),s.jsxs("div",{children:[s.jsx("h4",{className:"font-bold text-sky-800",children:"Impacto de la Vigilancia en Políticas Públicas: Caso S. pneumoniae"}),s.jsx("p",{className:"text-sm text-sky-700",children:"La vigilancia demostró que la alta resistencia a penicilina y ceftriaxona en niños estaba ligada al serotipo 19A, no cubierto por la vacuna PCV10. Este dato fue fundamental para impulsar el cambio de la política nacional de vacunación a la PCV13."})]})]}),s.jsxs("div",{className:"flex items-start gap-4 p-4 bg-violet-50 border-l-4 border-violet-500 rounded-r-lg",children:[s.jsx("span",{className:"text-2xl mt-1",children:"🧩"}),s.jsxs("div",{children:[s.jsx("h4",{className:"font-bold text-violet-800",children:"El Imperativo de la Triangulación de Datos"}),s.jsx("p",{className:"text-sm text-violet-700",children:"Un antibiograma local preciso no puede basarse en una sola fuente. Es esencial triangular la información: priorizar los datos locales, contextualizarlos con los datos nacionales, y compararlos con los benchmarks regionales."})]})]})]})]}),s.jsxs("div",{className:"bg-white p-6 rounded-lg shadow-sm border border-slate-200",children:[s.jsx("h3",{className:"text-xl font-semibold text-slate-900 mb-4",children:"Resistencia Cruzada: Interpretando Fenotipos Complejos"}),s.jsx("p",{className:"text-slate-600 mb-4",children:"Un único mecanismo de resistencia puede conferir insensibilidad a múltiples fármacos. Reconocer estos fenotipos es clave para la interpretación. Haga clic en cada fenotipo para ver los detalles."}),s.jsx("div",{className:"space-y-2",children:y.crossResistanceData.map((M,V)=>s.jsx(ib,{title:M.title,content:M.content},V))})]}),s.jsxs("div",{className:"bg-white p-6 rounded-lg shadow-sm border border-slate-200",children:[s.jsx("h3",{className:"text-xl font-semibold text-slate-900 mb-4",children:"Estrategias de Reporte Avanzadas (Stewardship)"}),s.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-6",children:[s.jsxs("div",{children:[s.jsx("h4",{className:"font-semibold text-slate-800",children:"Reporte en Cascada"}),s.jsx("p",{className:"text-slate-600 text-sm",children:"Práctica de suprimir los resultados de antibióticos de amplio espectro cuando un aislado es susceptible a un agente de espectro más estrecho y terapéuticamente equivalente. Esto guía al clínico a usar el fármaco más dirigido, preservando los de amplio espectro."})]}),s.jsxs("div",{children:[s.jsx("h4",{className:"font-semibold text-slate-800",children:"Reporte Selectivo"}),s.jsx("p",{className:"text-slate-600 text-sm",children:"Consiste en suprimir el resultado de un antibiótico que es clínicamente ineficaz para un tipo de infección específico, sin importar el resultado in vitro. Ejemplo: suprimir el resultado de daptomicina para un S. aureus de origen respiratorio, ya que es inactivado por el surfactante pulmonar."})]})]})]})]})]})]})},Nt={MILD:1,MODERATE:2,SEVERE:3,CRITICAL:4},dl={HIGH_ESBL_RATE:"high_esbl",ICU_ADMISSION:"icu",IMMUNOCOMPROMISED:"immunocompromised"},pl={LOW_ESBL_RATE:.15,HIGH_ESBL_RATE:.3},vd={esblRate:{enterobacterales:.12,klebsiella:.18,escherichia:.08,enterobacter:.25},carbapenemResistance:{enterobacterales:.03,klebsiella:.05,acinetobacter:.25,pseudomonas:.15},mrsaRate:.35,vreRate:.15},nb={"Skin and soft tissues":Nt.MILD,Genitourinary:Nt.MILD,Respiratory:Nt.MODERATE,Gastrointestinal:Nt.MODERATE,"Bone tissue":Nt.MODERATE,Cardiovascular:Nt.SEVERE,"Central nervous system":Nt.SEVERE,"Bacteremia/Sepsis":Nt.SEVERE},Be={CNS_CRITICAL:{type:"CNS_critical",description:"Blood-brain barrier penetration essential",excellent:["Ceftriaxone","Ceftazidime","Meropenem","Metronidazole","Linezolid"],good:["Ciprofloxacin","Levofloxacin","Penicillin G"],moderate:["Vancomycin"],poor:["Cefazolin","Oxacillin","Gentamicin","Tobramycin","Amikacin"],avoid:["First-generation cephalosporins","Most aminoglycosides"]},BONE_SPECIFIC:{type:"bone_specific",description:"Bone tissue penetration essential",excellent:["Ciprofloxacin","Levofloxacin","Clindamycin","Rifampin"],good:["Linezolid","Doxycycline","Minocycline"],moderate:["Vancomycin","Ceftriaxone"],poor:["Gentamicin","Tobramycin","Amikacin"],avoid:["Aminoglycosides for oral sequential therapy"]},URINARY_SPECIFIC:{type:"urinary_specific",description:"Urinary concentration more important than serum",excellent:["Nitrofurantoin","Fosfomycin","Ciprofloxacin"],good:["Levofloxacin","Ceftriaxone","Ceftazidime"],moderate:["Ampicillin","Cefazolin"],poor:["Clindamycin","Vancomycin"],avoid:["Antibiotics without urinary concentration"]},PROSTATE_SPECIFIC:{type:"prostate_specific",description:"Prostate tissue penetration essential",excellent:["Ciprofloxacin","Levofloxacin","Trimethoprim-sulfamethoxazole"],good:["Doxycycline","Minocycline"],moderate:["Ceftriaxone"],poor:["Vancomycin","Gentamicin","Cefazolin"],avoid:["Most beta-lactams","Aminoglycosides"]},SYSTEMIC:{type:"systemic",description:"Good systemic distribution required",excellent:["Most IV antibiotics with good tissue distribution"],good:["Standard parenteral antibiotics"],moderate:[],poor:[],avoid:["Topical-only agents"]},GOOD:{type:"good",description:"Standard tissue penetration adequate",excellent:["Most antibiotics"],good:[],moderate:[],poor:[],avoid:[]}},Hs={ANAEROBIC_ESSENTIAL:{required:["Metronidazole","Clindamycin","Piperacillin-tazobactam","Meropenem"]},ATYPICAL_COVERAGE:{required:["Azithromycin","Clarithromycin","Doxycycline","Levofloxacin","Moxifloxacin"]},ANTI_PSEUDOMONAS:{required:["Piperacillin-tazobactam","Ceftazidime","Cefepime","Meropenem","Ciprofloxacin"]},BIOFILM_ACTIVITY:{required:["Rifampin","Daptomycin","Linezolid"]}},sb={bacteriumName:"Citrobacter freundii",aliases:["Citrobacter freundii"],lastUpdated:"2024-07-30",clsiCategory:"Enterobacterales (excluding Salmonella/Shigella)",classification:{gramStain:"Gram negative",morphology:"Bacilli",respiration:"Facultative anaerobe",notes:["Grows aerobically and anaerobically."]},strainDetails:[],biochemicalTests:"Gram-negative rod, motile, lactose fermenter (variable/slow), H2S +, indole variable, citrate +, urease variable, lysine decarboxylase –."},ob={summary:"Citrobacter species cause a variety of infections ranging from uncomplicated urinary tract infections to life-threatening infections of the abdomen, skin and soft tissue, lung, CNS and other sites in both normal and immuno-compromised hosts.",pathophysiologyPearls:["Citrobacter freundii predicably encodes an inducible ampC chromosomal gene that is de-repressed during clinical therapy with Ceftriaxone, Cefotaxime, Ceftazidime, Aztreonam, or Piperacillin-tazobactam.","Hence, initial in vitro susceptibility may indicate susceptibility to extended spectrum cephalosporins as the ampC gene is repressed.","With treatment, the ampC gene is de-repressed and patients may fail to respond clinically.","With de-repression, in vitro susceptibility now indicates resistance to beta lactams."],keySignsAndSymptoms:[],clinicalSyndromes:[{syndromeName:"Urinary Tract Infections (UTI)",description:"Can range from uncomplicated cystitis to complicated pyelonephritis."},{syndromeName:"Intra-abdominal Infections",description:"Infections within the abdominal cavity, often polymicrobial."},{syndromeName:"Skin and Soft Tissue Infections",description:"Infections of the skin, subcutaneous tissue, fascia, or muscle."},{syndromeName:"Pneumonia",description:"Infection of the lungs, often seen in hospitalized or immunocompromised patients."},{syndromeName:"Central Nervous System (CNS) Infections",description:"Life-threatening infections such as meningitis or brain abscesses."}],stagesOfIllness:[],highRiskPopulations:["Immuno-compromised hosts"],transmissionVectors:[],prognosisNotes:["It is best to avoid extended spectrum cephalosporins (cefepime is the exception), aztreonam, and piperacillin-tazobactam therapy for Citrobacter freundii regardless of the results of in vitro susceptibility due to risk of AmpC de-repression.","Citrobacter strains can also produce extended-spectrum beta-lactamases (ESBLs), which destroy the antibacterial activity of most extended-spectrum cephalosporins, penicillins, and aztreonam.","Strains often exhibit concomitant resistance to fluoroquinolones, aminoglycosides, and TMP/SMX."]},rb={groupIntrinsicResistance:[],intrinsicResistance:[{drugOrClass:"Multiple Beta-Lactams",notes:"Citrobacter freundii predicably encodes an inducible ampC chromosomal gene. It is de-repressed during clinical therapy with Ceftriaxone, Cefotaxime, Ceftazidime, Aztreonam, or Piperacillin-tazobactam, leading to clinical failure."}],majorMechanisms:[{mechanismName:"AmpC Beta-Lactamase Production",mechanismType:"Enzymatic Inactivation",description:"A chromosomal ampC gene may be present but repressed. Administration of a cephalosporin or other beta-lactams can derepress the gene, leading to the production of AmpC enzymes that hydrolyze the antibiotic."},{mechanismName:"Extended-Spectrum Beta-Lactamase (ESBL) Production",mechanismType:"Enzymatic Inactivation",description:"ESBLs destroy the antibacterial activity of most extended-spectrum cephalosporins, penicillins, and aztreonam. Cefepime may be an exception."},{mechanismName:"Carbapenemase Production (e.g., KPC)",mechanismType:"Enzymatic Inactivation",description:"Enzymes like Klebsiella pneumoniae carbapenemases (KPC) hydrolyze carbapenems and most other beta-lactams."},{mechanismName:"Metallo-beta-lactamase (MBL) Production",mechanismType:"Enzymatic Inactivation",description:"Enzymes that require zinc for activity and hydrolyze a broad range of beta-lactams including carbapenems. They are not inhibited by avibactam."},{mechanismName:"Porin Closure",mechanismType:"Reduced Permeability",description:"Reduced permeability of the outer cell wall, preventing antibiotics from reaching their target."},{mechanismName:"Efflux Pumps",mechanismType:"Antibiotic Efflux",description:"Active transport systems that pump antibiotics out of the bacterial cell."}],clinicalAlerts:[{alertTitle:"Inducible AmpC Resistance",details:"Until a Citrobacter isolate is speciated, assume it could be C. freundii. Avoid empiric third-generation cephalosporin, aztreonam, or piperacillin-tazobactam therapy regardless of initial in vitro susceptibility results due to the risk of de-repression of the AmpC gene and subsequent clinical failure."}]},lb={generalNotes:["Choice of empiric regimen depends on local resistance patterns, fragility of the patient, and the severity of the infection. Specific therapy is directed by the results of in vitro susceptibility testing.","For uncomplicated cystitis, see Cystitis, adult female guidelines.","For further discussion on resistance, see Gram-Negative Bacilli, Beta-lactam Resistance, Overview."],drugsToAvoid:[{drugOrClass:"Ceftriaxone, Cefotaxime, Ceftazidime, Aztreonam, Piperacillin-tazobactam",condition:"All serious infections",reason:"Risk of inducing AmpC beta-lactamase expression, leading to resistance and clinical failure, even if the initial isolate appears susceptible. Cefepime is a notable exception due to its stability."}],adjunctiveTherapies:[],regimens:[{context:{type:"Empiric",condition:"Suspected Citrobacter freundii infection, susceptibility pending",patientPopulation:["Patients in regions with local rate of ESBL <10-15%"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Cefepime",dose:"2 gm",route:"IV",frequency:"q8-12h",comments:"Infuse over 3 hours. Cefepime is the most stable cephalosporin in the presence of AmpC."}]}]}]},{context:{type:"Empiric",condition:"Suspected Citrobacter freundii infection, susceptibility pending",patientPopulation:["Patients in regions with local rate of ESBL >15%"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",comments:null}]}]},{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",comments:null}]}]}]},{context:{type:"Directed",condition:"Infection with C. freundii, IV therapy indicated",patientPopulation:["Isolates with no in vitro resistance detected"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Cefepime",dose:"2 gm",route:"IV",frequency:"q8h",comments:"Preferred beta-lactam due to stability against AmpC."}]}]},{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ciprofloxacin",dose:"400 mg",route:"IV",frequency:"q12h",comments:null},{drugName:"Levofloxacin",dose:"750 mg",route:"IV",frequency:"once daily",comments:null}]}]}]},{context:{type:"Directed",condition:"Uncomplicated UTI (Cystitis), PO therapy",patientPopulation:["Isolates with no in vitro resistance detected"],isolateSource:"Urine"},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Cefixime",dose:"Varies by formulation",route:"PO",frequency:"Varies",comments:"Dose depends on specific product and indication."},{drugName:"Cefdinir",dose:"Varies by formulation",route:"PO",frequency:"Varies",comments:"Dose depends on specific product and indication."},{drugName:"Fosfomycin",dose:"3 gm",route:"PO",frequency:"x 1 dose",comments:"Activity against Citrobacter can be variable; check susceptibility."}]}]}]},{context:{type:"Directed",condition:"ESBL producer or derepressed AmpC",patientPopulation:["Isolates with resistance to aztreonam, ceftriaxone, cefotaxime"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",comments:null}]}]},{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",comments:null}]}]}]},{context:{type:"Directed",condition:"Klebsiella pneumoniae carbapenemase (KPC) producer",patientPopulation:["Isolates resistant to carbapenems, cephalosporins, penicillins, fluoroquinolones, and aminoglycosides"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Meropenem-vaborbactam",dose:"4 gm",route:"IV",frequency:"q8h",comments:"Infused over 3 hours."}]}]},{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",comments:"Infused over 2 hours."},{drugName:"Imipenem-cilastatin-relebactam",dose:"1.25 gm",route:"IV",frequency:"q6h",comments:"Infused over 30 min. For patients with CrCl > 90 mL/min."}]}]}]},{context:{type:"Directed",condition:"Metallo-beta-lactamase (MBL) producer",patientPopulation:["Isolates resistant to meropenem-vaborbactam, ceftazidime-avibactam, carbapenems, and other beta-lactams"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",comments:"Infused over 2 hours."},{drugName:"Aztreonam",dose:"2 gm",route:"IV",frequency:"q8h",comments:"Infused over 2 hours. Must be given with Ceftazidime-avibactam."}]}]},{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Cefiderocol",dose:"2 gm",route:"IV",frequency:"q8h",comments:"Infused over 3 hours."}]}]}]},{context:{type:"Directed",condition:"Pan-resistant infection",patientPopulation:["Isolates resistant to all tested classes of FDA approved anti-infectives"],isolateSource:null},recommendations:[{preference:"Salvage",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Cefiderocol",dose:"2 gm",route:"IV",frequency:"q8h",comments:"Infused over 3 hours, if susceptible."},{drugName:"Fosfomycin",dose:"Varies",route:"IV/PO",frequency:"Varies",comments:"Use where available and based on susceptibility. IV formulation may be required for systemic infections."}]}]}]},{context:{type:"Alternative",condition:"Complicated UTI",patientPopulation:["ESBL Producers"],isolateSource:"Urine"},recommendations:[{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Cefepime-enmetazobactam",dose:"2.5 g",route:"IV",frequency:"q8h",comments:"Recently FDA approved for complicated UTIs, including ESBL producers."}]}]}]},{context:{type:"Alternative",condition:"Infection with AmpC and/or ESBL producer",patientPopulation:[],isolateSource:null},recommendations:[{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ceftolozane-tazobactam",dose:"1.5 gm",route:"IV",frequency:"q8h",comments:"Infused over 1h. De-repressed AmpC producers may be resistant."},{drugName:"Temocillin",dose:"2 gm",route:"IV",frequency:"q12h",comments:"Availability limited (e.g., Belgium, UK)."}]}]}]}]},cb={testingIndications:["Until a Citrobacter isolate is speciated, it should be assumed it could be C. freundii, which warrants avoidance of empiric third-generation cephalosporins, piperacillin-tazobactam, or aztreonam due to the high risk of inducible AmpC-mediated resistance."],methodologyNotes:["Breakpoints for Fosfomycin apply only to E. coli urinary tract isolates and should not be extrapolated to Citrobacter freundii.","Disk diffusion and gradient diffusion methods should not be performed for Colistin or Polymyxin B; MIC testing is required."],recommendedPanel:[],specialTests:[{testName:"Carbapenemase Production Test (e.g., mCIM, CarbaNP)",trigger:"Resistance to one or more carbapenems (ertapenem, imipenem, meropenem).",purpose:"To detect the presence of carbapenemase enzymes, which has significant therapeutic and infection control implications."}],reportingRules:[{ruleType:"Conditional",drug:"Cefepime",condition:"Isolate demonstrates carbapenemase production.",details:"Cefepime S/SDD results should be suppressed or edited and reported as Resistant."},{ruleType:"Conditional",drug:"Meropenem-vaborbactam",condition:"An OXA-48-like gene or enzyme is detected.",details:"Results for meropenem-vaborbactam should be suppressed or reported as Resistant."}],antimicrobialBreakpoints:[{tier:1,tierDescription:"Appropriate for routine, primary testing and reporting.",agents:[{agentName:"Cefepime",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 25 mm",i_breakpoint:"19–24 mm",r_breakpoint:"≤ 18 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:"8 µg/mL",r_breakpoint:"≥ 16 µg/mL"},comments:["Due to the concern for inducible AmpC, Cefepime should be considered a Tier 1 agent for testing and reporting of C. freundii complex.","Cefepime S/SDD results should be reported as resistant if the isolate has a carbapenemase."]}]},{agentName:"Ampicillin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 17 mm",i_breakpoint:"14–16 mm",r_breakpoint:"≤ 13 mm"},mic:{s_breakpoint:"≤ 8 µg/mL",i_breakpoint:"16 µg/mL",r_breakpoint:"≥ 32 µg/mL"},comments:["Results can predict susceptibility to amoxicillin."]}]},{agentName:"Piperacillin-tazobactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"100/10 µg",s_breakpoint:"≥ 25 mm",i_breakpoint:"21–24 mm",r_breakpoint:"≤ 20 mm"},mic:{s_breakpoint:"≤ 8/4 µg/mL",i_breakpoint:"16/4 µg/mL",r_breakpoint:"≥ 32/4 µg/mL"},comments:[]}]},{agentName:"Ceftriaxone",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 26 mm",i_breakpoint:"20–22 mm",r_breakpoint:"≤ 19 mm"},mic:{s_breakpoint:"≤ 1 µg/mL",i_breakpoint:"2 µg/mL",r_breakpoint:"≥ 4 µg/mL"},comments:[]}]},{agentName:"Ciprofloxacin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"5 µg",s_breakpoint:"≥ 26 mm",i_breakpoint:"22–25 mm",r_breakpoint:"≤ 21 mm"},mic:{s_breakpoint:"≤ 0.25 µg/mL",i_breakpoint:"0.5 µg/mL",r_breakpoint:"≥ 1 µg/mL"},comments:[]}]},{agentName:"Levofloxacin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"5 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:"17–20 mm",r_breakpoint:"≤ 16 mm"},mic:{s_breakpoint:"≤ 0.5 µg/mL",i_breakpoint:"1 µg/mL",r_breakpoint:"≥ 2 µg/mL"},comments:[]}]},{agentName:"Tobramycin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 17 mm",i_breakpoint:"13–16 mm",r_breakpoint:"≤ 12 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:null,r_breakpoint:"≥ 8 µg/mL"},comments:[]}]},{agentName:"Gentamicin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 18 mm",i_breakpoint:"15–17 mm",r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:null,r_breakpoint:"≥ 8 µg/mL"},comments:[]}]},{agentName:"Amikacin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 19 mm",i_breakpoint:"17–19 mm",r_breakpoint:"≤ 16 mm"},mic:{s_breakpoint:"≤ 16 µg/mL",i_breakpoint:null,r_breakpoint:"≥ 32 µg/mL"},comments:[]}]},{agentName:"Trimethoprim-sulfamethoxazole",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"1.25/23.75 µg",s_breakpoint:"≥ 16 mm",i_breakpoint:"11–15 mm",r_breakpoint:"≤ 10 mm"},mic:{s_breakpoint:"≤ 2/38 µg/mL",i_breakpoint:null,r_breakpoint:"≥ 4/76 µg/mL"},comments:[]}]}]},{tier:2,tierDescription:"Appropriate for routine, primary testing, may be reported following cascade reporting rules.",agents:[{agentName:"Ertapenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 22 mm",i_breakpoint:"19–21 mm",r_breakpoint:"≤ 18 mm"},mic:{s_breakpoint:"≤ 0.5 µg/mL",i_breakpoint:"1 µg/mL",r_breakpoint:"≥ 2 µg/mL"},comments:[]}]},{agentName:"Imipenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 23 mm",i_breakpoint:"20–22 mm",r_breakpoint:"≤ 19 mm"},mic:{s_breakpoint:"≤ 1 µg/mL",i_breakpoint:"2 µg/mL",r_breakpoint:"≥ 4 µg/mL"},comments:[]}]},{agentName:"Meropenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 23 mm",i_breakpoint:"20–22 mm",r_breakpoint:"≤ 19 mm"},mic:{s_breakpoint:"≤ 1 µg/mL",i_breakpoint:"2 µg/mL",r_breakpoint:"≥ 4 µg/mL"},comments:[]}]}]},{tier:3,tierDescription:"Appropriate for high-risk MDRO patients, subject to cascade reporting.",agents:[{agentName:"Ceftazidime-avibactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30/20 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:"—",r_breakpoint:"≤ 20 mm"},mic:{s_breakpoint:"≤ 8/4 µg/mL",i_breakpoint:"—",r_breakpoint:"≥ 16/4 µg/mL"},comments:["Confirmatory MIC testing is indicated for isolates with disk diffusion zones of 20–22 mm."]}]},{agentName:"Meropenem-vaborbactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"20/10 µg",s_breakpoint:"≥ 18 mm",i_breakpoint:"15–17 mm",r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 4/8 µg/mL",i_breakpoint:"8/8 µg/mL",r_breakpoint:"≥ 16/8 µg/mL"},comments:["If an OXA-48-like gene or enzyme is detected, results for meropenem-vaborbactam should be suppressed or reported as resistant."]}]},{agentName:"Imipenem-relebactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10/25 µg",s_breakpoint:"≥ 25 mm",i_breakpoint:"21–24 mm",r_breakpoint:"≤ 20 mm"},mic:{s_breakpoint:"≤ 1/4 µg/mL",i_breakpoint:"2/4 µg/mL",r_breakpoint:"≥ 4/4 µg/mL"},comments:[]}]},{agentName:"Cefiderocol",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 16 mm",i_breakpoint:"9–15 mm",r_breakpoint:"≤ 8 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:null,r_breakpoint:"≥ 8 µg/mL"},comments:[]}]},{agentName:"Plazomicin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 18 mm",i_breakpoint:"15–17 mm",r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 2 µg/mL",i_breakpoint:null,r_breakpoint:"≥ 4 µg/mL"},comments:[]}]}]},{tier:4,tierDescription:"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available.",agents:[{agentName:"Aztreonam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:"18–20 mm",r_breakpoint:"≤ 17 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:"8 µg/mL",r_breakpoint:"≥ 16 µg/mL"},comments:[]}]},{agentName:"Ceftazidime",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:"18–20 mm",r_breakpoint:"≤ 17 mm"},mic:{s_breakpoint:"≤ 8 µg/mL",i_breakpoint:"16 µg/mL",r_breakpoint:"≥ 32 µg/mL"},comments:[]}]},{agentName:"Ceftolozane-tazobactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30/10 µg",s_breakpoint:"≥ 22 mm",i_breakpoint:"19–21 mm",r_breakpoint:"≤ 18 mm"},mic:{s_breakpoint:"≤ 2/4 µg/mL",i_breakpoint:null,r_breakpoint:"≥ 4/4 µg/mL"},comments:[]}]},{agentName:"Colistin or Polymyxin B",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:null,s_breakpoint:null,i_breakpoint:null,r_breakpoint:null},mic:{s_breakpoint:"≤ 2 µg/mL",i_breakpoint:"—",r_breakpoint:"≥ 4 µg/mL"},comments:["Disk diffusion and gradient diffusion methods should not be performed for these agents."]}]}]},{tier:9,tierDescription:"Urine Only Tier: Designated for reporting only on organisms isolated from the urinary tract.",agents:[{agentName:"Cefazolin",breakpointSets:[{condition:"Uncomplicated UTI only",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 15 mm",i_breakpoint:"—",r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 16 µg/mL",i_breakpoint:"—",r_breakpoint:"≥ 32 µg/mL"},comments:["Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."]}]},{agentName:"Nitrofurantoin",breakpointSets:[{condition:"Urine Only",diskDiffusion:{diskContent:"300 µg",s_breakpoint:"≥ 17 mm",i_breakpoint:"15–16 mm",r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 32 µg/mL",i_breakpoint:"64 µg/mL",r_breakpoint:"≥ 128 µg/mL"},comments:[]}]}]}]},mb={diagnosticNotes:{summary:"",biosafetyWarning:"",methods:[]},preventionAndScreening:[],treatmentLifecycle:[],antimicrobialStewardship:["Reserve carbapenems for Citrobacter infections that in addition need anaerobic coverage or for treatment of ESBL producing strains.","Reserve Meropenem-vaborbactam and Ceftazidime-avibactam for patients with documented KPC infections."],drugSpecificPearls:[{drugName:"Cefepime",pearl:"Cefepime is a weak inducer of AmpC and is the most stable cephalosporin in its presence. However, strains with Cefepime MICs of 4-8 mcg/ml have dose-dependent susceptibility and may co-produce ESBL; caution is advised. Use higher doses (e.g., 2 gm IV over 3h q8-12h) for strains with MICs in this range."},{drugName:"Ceftazidime-avibactam + Aztreonam",pearl:"This combination is used for metallo-beta-lactamase (MBL) producers. Aztreonam is stable against MBLs, while avibactam inhibits other co-produced beta-lactamases (like ESBLs, KPC, AmpC) that would otherwise inactivate aztreonam. This combination has been shown to reduce mortality in MBL infections."},{drugName:"Cefiderocol",pearl:"FDA-approved for patients with complicated UTI with limited or no alternative treatment options. An open-label randomized trial comparing it to best available therapy for severe infections showed a non-statistically significant trend towards higher all-cause mortality with cefiderocol (24.8% vs 18.4%)."},{drugName:"Plazomicin",pearl:"Approved for complicated UTI. There is limited observational experience for its use in combination with Tigecycline or Meropenem for MDR bacteremia or ventilator-associated pneumonia."}],guidelineReferences:[{source:"IDSA",citation:"Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clin Infect Dis. Published online July 13, 2023:ciad428.",summaryOrNote:"Provides an updated framework for treating infections caused by multidrug-resistant Enterobacterales, including those producing ESBL, AmpC, and carbapenemases."},{source:"Clinical Infectious Diseases",citation:"Karaiskos I, et al. Ceftazidime-avibactam plus Aztreonam for Metallo-β-lactamase-producing Enterobacterales: A Prospective, Observational, Multicenter Study (REJUVENATE). Clin Infect Dis. 2024; 78:1111.",summaryOrNote:"Presents prospective observational trial data showing reduced 30-day mortality with ceftazidime-avibactam plus aztreonam versus colistin-based regimens for infections due to metallo-beta-lactamase-producing Enterobacterales."},{source:"Antimicrobial Agents and Chemotherapy",citation:"Marshall S, Hujer AM, Rojas LJ, et al. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae? Antimicrob Agents Chemother. 2017;61(4):e02243-16.",summaryOrNote:"Details the in-vitro and in-vivo rationale for combining ceftazidime-avibactam with aztreonam to treat infections caused by MBL-producing bacteria."},{source:"New England Journal of Medicine",citation:"De la Torre A, et al. Plazomicin for Ventilator-Associated Pneumonia. N Engl J Med 2019; 380: 791",summaryOrNote:"Provides limited observational experience on Plazomicin for MDR bacteremia or ventilator-associated pneumonia."}]},ub={identity:sb,clinicalProfile:ob,resistanceProfile:rb,treatment:lb,laboratoryProfile:cb,additionalInformation:mb},db={bacteriumName:"Citrobacter koseri",aliases:["Citrobacter diversus"],lastUpdated:"2025-01-17",clsiCategory:"Enterobacterales (excluding Salmonella/Shigella)",classification:{gramStain:"Gram negative",morphology:"Bacilli",respiration:"Facultative anaerobe",notes:["Grows aerobically and anaerobically."]},strainDetails:[],biochemicalTests:"Gram-negative rod, motile, lactose fermenter, H2S –, indole +, citrate +, lysine decarboxylase +, ornithine decarboxylase +."},pb={summary:"Citrobacter species cause a variety of infections ranging from uncomplicated urinary tract infections to life-threatening infections of the abdomen, skin and soft tissue, lung, CNS and other sites in both normal and immuno-compromised hosts.",pathophysiologyPearls:["Unlike Citrobacter freundii, Citrobacter koseri does not have repressed chromosomal ampC genes. Hence it is safe to use ceftriaxone if the isolate is both speciated as C. koseri and is susceptible in vitro."],keySignsAndSymptoms:[],clinicalSyndromes:[{syndromeName:"Urinary Tract Infections (UTI)",description:"Can range from uncomplicated cystitis to complicated infections."},{syndromeName:"Intra-abdominal Infections",description:"Infections within the abdominal cavity."},{syndromeName:"Skin and Soft Tissue Infections",description:"Infections involving the skin and underlying structures."},{syndromeName:"Pneumonia",description:"Infection of the lungs."},{syndromeName:"Central Nervous System (CNS) Infections",description:"Life-threatening infections of the central nervous system, particularly in neonates."}],stagesOfIllness:[],highRiskPopulations:["Immuno-compromised hosts","Neonates"],transmissionVectors:[],prognosisNotes:[]},fb={groupIntrinsicResistance:[],intrinsicResistance:[{drugOrClass:"Multiple Beta-Lactams",notes:"Citrobacter koseri predicably encodes an inducible ampC chromosomal gene. It is de-repressed during clinical therapy with Ceftriaxone, Cefotaxime, Ceftazidime, Aztreonam, or Piperacillin-tazobactam, leading to clinical failure."}],majorMechanisms:[{mechanismName:"Extended-Spectrum Beta-Lactamases (ESBLs)",mechanismType:"Enzymatic Inactivation",description:"Citrobacter strains can produce ESBLs, which destroy the antibacterial activity of most extended-spectrum cephalosporins, penicillins, and aztreonam, though Cefepime may be an exception."},{mechanismName:"Serine Carbapenemases (KPC)",mechanismType:"Enzymatic Inactivation",description:"Resistance to all carbapenems, cephalosporins, penicillins, fluoroquinolones, and aminoglycosides can be consistent with the production of Klebsiella-producing serine based carbapenemases (KPCs)."},{mechanismName:"Metallo-Carbapenemase (MBL)",mechanismType:"Enzymatic Inactivation",description:"Resistance to meropenem-vaborbactam, ceftazidime-avibactam, all carbapenems, and other beta-lactams is consistent with production of metallo-carbapenemase."}],clinicalAlerts:[{alertTitle:"Absence of Inducible AmpC",details:"A critical distinction is that C. koseri does not house the inducible ampC gene, unlike C. freundii. Therefore, third-generation cephalosporins (e.g., ceftriaxone) are safe and effective if the isolate is confirmed as C. koseri and tests susceptible in vitro. If the lab report only specifies 'Citrobacter species,' cephalosporins should be avoided regardless of susceptibility results due to the risk of AmpC induction with C. freundii."},{alertTitle:"Co-resistance",details:"Strains often exhibit concomitant resistance to fluoroquinolones, aminoglycosides, and TMP/SMX."}]},bb={generalNotes:["Choice of empiric regimen depends on local resistance patterns, the fragility of the patient, and the severity of the infection.","Specific therapy is directed by the results of in vitro susceptibility testing.","For uncomplicated cystitis, see Cystitis, adult female guidelines."],drugsToAvoid:[],adjunctiveTherapies:[],regimens:[{context:{type:"Empiric",condition:"Citrobacter koseri identified, susceptibility pending",patientPopulation:["Local rate of ESBL <10-15%"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Piperacillin-tazobactam",dose:"4.5 gm",route:"IV",frequency:"q6h",comments:"Infused over 4 hr."},{drugName:"Ceftriaxone",dose:"2 gm",route:"IV",frequency:"daily",comments:"Safe to use as C. koseri does not have inducible ampC genes."}]}]}]},{context:{type:"Empiric",condition:"Citrobacter koseri identified, susceptibility pending",patientPopulation:["Local rate of ESBL >15%"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",comments:""},{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",comments:""}]}]}]},{context:{type:"Directed",condition:"No in vitro resistance detected",patientPopulation:[],isolateSource:"Systemic (IV therapy)"},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Piperacillin-tazobactam",dose:"4.5 gm (infused over 4 hr)",route:"IV",frequency:"q6h",comments:""},{drugName:"Ciprofloxacin",dose:"400 mg",route:"IV",frequency:"q12h",comments:""},{drugName:"Levofloxacin",dose:"750 mg",route:"IV",frequency:"once daily",comments:""},{drugName:"Ceftriaxone",dose:"2 gms",route:"IV",frequency:"daily",comments:""}]}]}]},{context:{type:"Directed",condition:"No in vitro resistance detected",patientPopulation:[],isolateSource:"Urine (PO therapy)"},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Cefixime",dose:"Varies",route:"PO",frequency:"Varies",comments:""},{drugName:"Cefdinir",dose:"Varies",route:"PO",frequency:"Varies",comments:""},{drugName:"Fosfomycin",dose:"3 gm po x 1 dose",route:"PO",frequency:"Single dose",comments:"For uncomplicated cystitis. Note: CLSI breakpoints are only validated for E. coli."}]}]}]},{context:{type:"Directed",condition:"ESBL Producer",patientPopulation:["Resistance to aztreonam, ceftriaxone, cefotaxime"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",comments:""},{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",comments:""}]}]},{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ceftolozane-tazobactam",dose:"1.5 gm",route:"IV",frequency:"q8h",comments:"Infuse over 3h."},{drugName:"Temocillin",dose:"2 gm",route:"IV",frequency:"q12h",comments:"Availability is limited."}]}]}]},{context:{type:"Directed",condition:"Serine Carbapenemase (KPC) Producer",patientPopulation:["Resistant to carbapenems but susceptible to newer beta-lactamase inhibitor combinations"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Meropenem-vaborbactam",dose:"4 gm",route:"IV",frequency:"q8h",comments:"Infused over 3h."},{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",comments:"Infused over 2 hrs."},{drugName:"Imipenem-cilastatin-relebactam",dose:"1.25 gm",route:"IV",frequency:"q6h",comments:"Infused over 30 min (for CrCl > 90 mL/min)."}]}]}]},{context:{type:"Directed",condition:"Metallo-Carbapenemase (MBL) Producer",patientPopulation:["Resistant to meropenem-vaborbactam, ceftazidime-avibactam, and all carbapenems"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",comments:"Infused over 3 hrs. Must be given with Aztreonam."},{drugName:"Aztreonam",dose:"2 gm",route:"IV",frequency:"q8h",comments:"Infused over 3h. Must be given with Ceftazidime-avibactam."}]}]},{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Cefiderocol",dose:"2 gm",route:"IV",frequency:"q8h",comments:"Infuse over 3h."}]}]}]},{context:{type:"Directed",condition:"Pan-resistant infection",patientPopulation:["Resistant to all normally tested classes of FDA approved anti-infectives"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Fosfomycin",dose:"Varies",route:"IV",frequency:"Varies",comments:"IV formulation availability is limited."},{drugName:"Cefiderocol",dose:"2 gm",route:"IV",frequency:"q8h",comments:"Infused over 3h."}]}]}]}]},gb={clsiCategory:"Enterobacterales (excluding Salmonella/Shigella)",testingIndications:[],methodologyNotes:["For Citrobacter freundii complex, Enterobacter cloacae complex, Klebsiella aerogenes, Morganella morganii, Providencia spp., and Serratia marcescens, isolates that initially test susceptible to third-generation cephalosporins may develop resistance during therapy due to derepression of inducible AmpC β-lactamase. While C. koseri is not typically listed in this high-risk group, speciation is crucial to differentiate it from C. freundii."],recommendedPanel:[],specialTests:[],reportingRules:[{ruleType:"Surrogate",drug:"Cefazolin",condition:"Uncomplicated UTI",details:"For isolates from uncomplicated UTIs, cefazolin susceptibility can be used as a surrogate marker to predict susceptibility to oral cephalosporins like cephalexin, cefaclor, cefdinir, cefpodoxime, cefprozil, cefuroxime axetil, and loracarbef. This rule specifically applies to E. coli, K. pneumoniae, and P. mirabilis."},{ruleType:"Conditional",drug:"Fosfomycin",condition:"Isolate is not E. coli from a urinary tract source.",details:"Fosfomycin breakpoints (MIC and disk) are for E. coli from urinary tract isolates only and should not be used for other genera, including Citrobacter."},{ruleType:"Conditional",drug:"Colistin/Polymyxin B",condition:"Any isolate",details:"Disk diffusion and gradient diffusion methods are unreliable and should not be performed. Broth microdilution is the recommended method."}],antimicrobialBreakpoints:[{tier:1,tierDescription:"Appropriate for routine, primary testing and reporting.",agents:[{agentName:"Ampicillin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 17 mm",i_breakpoint:"14–16 mm",r_breakpoint:"≤ 13 mm"},mic:{s_breakpoint:"≤ 8 µg/mL",i_breakpoint:"16 µg/mL",r_breakpoint:"≥ 32 µg/mL"},comments:["Results can predict amoxicillin results."]}]},{agentName:"Amoxicillin-clavulanate",breakpointSets:[{condition:"Uncomplicated UTI only",diskDiffusion:{diskContent:"20/10 µg",s_breakpoint:"≥ 18 mm",i_breakpoint:"—",r_breakpoint:"≤ 17 mm"},mic:{s_breakpoint:"≤ 8/4 µg/mL",i_breakpoint:"16/4 µg/mL",r_breakpoint:"≥ 32/4 µg/mL"},comments:["Breakpoints apply for therapy of uncomplicated UTIs or for completion of therapy for systemic infection."]}]},{agentName:"Piperacillin-tazobactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"100/10 µg",s_breakpoint:"≥ 25 mm",i_breakpoint:"21–24 mm",r_breakpoint:"≤ 20 mm"},mic:{s_breakpoint:"≤ 8/4 µg/mL",i_breakpoint:"16/4 µg/mL",r_breakpoint:"≥ 32/4 µg/mL"},comments:[]}]},{agentName:"Ciprofloxacin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"5 µg",s_breakpoint:"≥ 26 mm",i_breakpoint:"22–25 mm",r_breakpoint:"≤ 21 mm"},mic:{s_breakpoint:"≤ 0.25 µg/mL",i_breakpoint:"0.5 µg/mL",r_breakpoint:"≥ 1 µg/mL"},comments:[]}]},{agentName:"Levofloxacin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"5 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:"17–20 mm",r_breakpoint:"≤ 16 mm"},mic:{s_breakpoint:"≤ 0.5 µg/mL",i_breakpoint:"1 µg/mL",r_breakpoint:"≥ 2 µg/mL"},comments:[]}]},{agentName:"Trimethoprim-sulfamethoxazole",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"1.25/23.75 µg",s_breakpoint:"≥ 16 mm",i_breakpoint:"11–15 mm",r_breakpoint:"≤ 10 mm"},mic:{s_breakpoint:"≤ 2/38 µg/mL",i_breakpoint:"—",r_breakpoint:"≥ 4/76 µg/mL"},comments:[]}]}]},{tier:2,tierDescription:"Appropriate for routine, primary testing, may be reported following cascade reporting rules.",agents:[{agentName:"Cefepime",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 25 mm",i_breakpoint:"19–24 mm",r_breakpoint:"≤ 18 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:"8 µg/mL",r_breakpoint:"≥ 16 µg/mL"},comments:["Cefepime S/SDD results should be suppressed or reported as resistant for isolates demonstrating carbapenemase production."]}]},{agentName:"Ertapenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 22 mm",i_breakpoint:"19–21 mm",r_breakpoint:"≤ 18 mm"},mic:{s_breakpoint:"≤ 0.5 µg/mL",i_breakpoint:"1 µg/mL",r_breakpoint:"≥ 2 µg/mL"},comments:[]}]},{agentName:"Meropenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 23 mm",i_breakpoint:"20–22 mm",r_breakpoint:"≤ 19 mm"},mic:{s_breakpoint:"≤ 1 µg/mL",i_breakpoint:"2 µg/mL",r_breakpoint:"≥ 4 µg/mL"},comments:[]}]}]},{tier:3,tierDescription:"Appropriate for high-risk MDRO patients, subject to cascade reporting.",agents:[{agentName:"Ceftazidime-avibactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30/20 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:"—",r_breakpoint:"≤ 20 mm"},mic:{s_breakpoint:"≤ 8/4 µg/mL",i_breakpoint:"—",r_breakpoint:"≥ 16/4 µg/mL"},comments:["Confirmatory MIC testing is indicated for isolates with disk diffusion zones of 20–22 mm."]}]},{agentName:"Meropenem-vaborbactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"20/10 µg",s_breakpoint:"≥ 18 mm",i_breakpoint:"15–17 mm",r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 4/8 µg/mL",i_breakpoint:"8/8 µg/mL",r_breakpoint:"≥ 16/8 µg/mL"},comments:["If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]},{agentName:"Imipenem-relebactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10/25 µg",s_breakpoint:"≥ 25 mm",i_breakpoint:"21–24 mm",r_breakpoint:"≤ 20 mm"},mic:{s_breakpoint:"≤ 1/4 µg/mL",i_breakpoint:"2/4 µg/mL",r_breakpoint:"≥ 4/4 µg/mL"},comments:["Breakpoints do not apply to the family Morganellaceae (Morganella, Proteus, and Providencia)."]}]}]},{tier:4,tierDescription:"May warrant testing and reporting by clinician request.",agents:[{agentName:"Ceftriaxone",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 26 mm",i_breakpoint:"20–22 mm",r_breakpoint:"≤ 19 mm"},mic:{s_breakpoint:"≤ 1 µg/mL",i_breakpoint:"2 µg/mL",r_breakpoint:"≥ 4 µg/mL"},comments:[]}]},{agentName:"Aztreonam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:"18–20 mm",r_breakpoint:"≤ 17 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:"8 µg/mL",r_breakpoint:"≥ 16 µg/mL"},comments:[]}]}]},{tier:0,tierDescription:"Urine Only Tier",agents:[{agentName:"Nitrofurantoin",breakpointSets:[{condition:"Urine Only",diskDiffusion:{diskContent:"300 µg",s_breakpoint:"≥ 17 mm",i_breakpoint:"15–16 mm",r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 32 µg/mL",i_breakpoint:"64 µg/mL",r_breakpoint:"≥ 128 µg/mL"},comments:[]}]},{agentName:"Cefazolin",breakpointSets:[{condition:"Uncomplicated UTI only",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 15 mm",i_breakpoint:"—",r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 16 µg/mL",i_breakpoint:"—",r_breakpoint:"≥ 32 µg/mL"},comments:["Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."]}]},{agentName:"Fosfomycin",breakpointSets:[{condition:"Urine Only",diskDiffusion:{diskContent:"200 µg",s_breakpoint:"≥ 16 mm",i_breakpoint:"13–15 mm",r_breakpoint:"≤ 12 mm"},mic:{s_breakpoint:"≤ 64 µg/mL",i_breakpoint:"128 µg/mL",r_breakpoint:"≥ 256 µg/mL"},comments:["Applies only to E. coli urinary tract isolates and should not be extrapolated to other Enterobacterales species. The 200 µg fosfomycin disk contains 50 µg glucose-6-phosphate."]}]}]}]},hb={diagnosticNotes:{summary:"",biosafetyWarning:"",methods:[]},preventionAndScreening:[],treatmentLifecycle:[],antimicrobialStewardship:["Reserve carbapenems for Citrobacter infections that in addition need anaerobic coverage or for treatment of ESBL producing strains.","Reserve Meropenem-vaborbactam, Imipenem-cilastatin-relebactam, and Ceftazidime-avibactam for patients with documented KPC infections."],drugSpecificPearls:[{drugName:"Cephalosporins",pearl:"C. koseri does not house the ampC gene, making third-generation cephalosporins safe and effective if the isolate is susceptible in vitro. This is a key difference from C. freundii, where cephalosporins should be avoided due to risk of inducible resistance."},{drugName:"Cefiderocol",pearl:"FDA-approved for patients with complicated UTI with limited or no alternative treatment options. In a trial comparing Cefiderocol to the Best Available Therapy (BAT) for serious infections, 28-day mortality was 24.8% for cefiderocol versus 18.4% for BAT (not statistically significant)."},{drugName:"Plazomicin",pearl:"Approved for complicated UTI. There is limited observational experience using it in combination with Tigecycline or Meropenem for MDR bacteremia or ventilator-associated pneumonia."}],guidelineReferences:[{source:"IDSA",citation:"IDSA 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections.",summaryOrNote:"Provides a framework for managing infections caused by resistant gram-negative organisms, including Citrobacter spp."},{source:"Antimicrobial Agents and Chemotherapy",citation:"Antimicrob Agents Chemother 2017 Mar 24; 61(4). pii:e02243-16.",summaryOrNote:"Discusses the rationale for combining Ceftazidime-avibactam with Aztreonam for treating MBL-producing bacteria."},{source:"New England Journal of Medicine",citation:"N Engl J Med 2019; 380: 791.",summaryOrNote:"Presents observational data on Plazomicin for MDR infections."}]},yb={identity:db,clinicalProfile:pb,resistanceProfile:fb,treatment:bb,laboratoryProfile:gb,additionalInformation:hb},vb={bacteriumName:"Enteroaggregative E. coli",aliases:["EAEC","EaggEC","E coli Enteroaggregative"],lastUpdated:"2025-07-10",clsiCategory:"Enterobacterales (excluding Salmonella/Shigella)",classification:{gramStain:"Gram-negative",morphology:"rod",respiration:"Facultative anaerobe",notes:["Gold standard for diagnosis is HEp-2 adherence assay, which is not generally available.","May be diagnosed by PCR detection of virulence genes aatA and aggR."]},strainDetails:[],biochemicalTests:"Biochemically indistinguishable from typical E. coli by routine tests. Identification requires molecular detection of aggregative adherence fimbriae (AAF) and other specific virulence factors."},kb={summary:"Enteroaggregative E. coli (EAEC) is a significant cause of acute and persistent watery diarrhea. It affects children and adults in developing nations, travelers to these areas, and has also been identified in patients with acute diarrhea in developed countries like the U.S. It is also associated with prolonged diarrhea in HIV-infected individuals.",pathophysiologyPearls:["While EAEC is consistently detected more frequently in patients with diarrhea than controls in various populations, it can also be detected in asymptomatic persons.","Molecular detection of EAEC virulence genes may not always correlate with symptomatic infection."],keySignsAndSymptoms:["Watery diarrhea","Abdominal pain","Low-grade fever","Occasional mucous or blood in stool"],clinicalSyndromes:[{syndromeName:"Acute Diarrhea",description:"A cause of acute, watery diarrhea in children and adults, particularly in less-developed countries and among travelers."},{syndromeName:"Persistent Diarrhea",description:"Can cause persistent diarrhea, especially in infants and HIV-infected patients."}],stagesOfIllness:[],highRiskPopulations:["Children and adults in less-developed countries","Travelers to less-developed countries","Infants (risk for persistent diarrhea)","HIV-infected patients"],transmissionVectors:[],prognosisNotes:["The infection is often self-limited, but treatment may be indicated for immunocompromised patients or those with prolonged illness."]},xb={groupIntrinsicResistance:[],intrinsicResistance:[],majorMechanisms:[],clinicalAlerts:[{alertTitle:"Diagnostic Uncertainty",details:"EAEC can be detected in asymptomatic individuals, and molecular detection (PCR) may not always correlate with symptomatic infection."}]},Sb={generalNotes:["Often self-limited, so antibiotics are not always necessary.","Treatment is probably indicated in immunocompromised patients and for prolonged illness.","Studies have shown response to antibiotics in general and specifically in HIV-infected patients.","Rifaximin appeared to improve the duration of symptoms in one study."],drugsToAvoid:[],adjunctiveTherapies:[],regimens:[{context:{type:"Directed",condition:"Diarrhea",patientPopulation:["General"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"As needed",drugs:[{drugName:"Hydration",dose:"N/A",route:"Oral or IV",frequency:"N/A",comments:"Supportive care is the mainstay of treatment."}]}],notes:[]},{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"3 days",drugs:[{drugName:"Ciprofloxacin",dose:"750 mg",route:"PO",frequency:"once daily",comments:""}]}],notes:[]},{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"3 days",drugs:[{drugName:"Rifaximin",dose:"200 mg",route:"PO",frequency:"tid",comments:""}]}],notes:["Rifaximin appeared to improve duration of symptoms. (Clin Gastroenterol Hepatol 2004;2(2):135)"]}]},{context:{type:"Directed",condition:"Diarrhea",patientPopulation:["AIDS patients"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"7 days",drugs:[{drugName:"Ciprofloxacin",dose:"500 mg",route:"PO",frequency:"bid",comments:""}]}],notes:["Antibiotics were effective in HIV infected patients with EAEC. (J Infect Dis 178:1369, 1998)"]}]}]},_b={testingIndications:["Patients with acute or persistent diarrhea, especially in high-risk populations (travelers, infants, immunocompromised)."],methodologyNotes:["The gold standard for diagnosis is the HEp-2 adherence assay, but it is a research tool and not generally available in clinical labs.","Commercial and research molecular assays (PCR) are used to detect specific virulence genes such as aatA and aggR."],recommendedPanel:[],specialTests:[{testName:"PCR for EAEC virulence genes",trigger:"Clinical suspicion of EAEC diarrhea, particularly in cases of persistent or severe illness, or in at-risk populations.",purpose:"To detect key virulence genes (e.g., aatA, aggR) for the diagnosis of EAEC infection."},{testName:"HEp-2 Adherence Assay",trigger:"Research settings or reference laboratories.",purpose:"To definitively identify the 'stacked-brick' adherence pattern characteristic of EAEC, considered the gold standard for identification."}],reportingRules:[],antimicrobialBreakpoints:[{tier:1,tierDescription:"Appropriate for routine, primary testing and reporting",agents:[{agentName:"Ampicillin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 17 mm",i_breakpoint:"14–16 mm",r_breakpoint:"≤ 13 mm"},mic:{s_breakpoint:"≤ 8 µg/mL",i_breakpoint:"16 µg/mL",r_breakpoint:"≥ 32 µg/mL"},comments:["Ampicillin test results can predict amoxicillin results."]}]},{agentName:"Cefazolin",breakpointSets:[{condition:"Urine Only - Uncomplicated UTI",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 15 mm",i_breakpoint:null,r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 16 µg/mL",i_breakpoint:null,r_breakpoint:"≥ 32 µg/mL"},comments:["Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."]}]},{agentName:"Amoxicillin-clavulanate",breakpointSets:[{condition:"Uncomplicated UTI only",diskDiffusion:{diskContent:"20/10 µg",s_breakpoint:"≥ 18 mm",i_breakpoint:null,r_breakpoint:"≤ 17 mm"},mic:{s_breakpoint:"≤ 8/4 µg/mL",i_breakpoint:"16/4 µg/mL",r_breakpoint:"≥ 32/4 µg/mL"},comments:[]}]},{agentName:"Piperacillin-tazobactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"100/10 µg",s_breakpoint:"≥ 25 mm",i_breakpoint:"21–24 mm",r_breakpoint:"≤ 20 mm"},mic:{s_breakpoint:"≤ 8/4 µg/mL",i_breakpoint:"16/4 µg/mL",r_breakpoint:"≥ 32/4 µg/mL"},comments:[]}]}]},{tier:2,tierDescription:"Appropriate for routine, primary testing, may be reported following cascade reporting rules",agents:[{agentName:"Cefepime",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 25 mm",i_breakpoint:"19–24 mm",r_breakpoint:"≤ 18 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:"8 µg/mL",r_breakpoint:"≥ 16 µg/mL"},comments:["Cefepime S/SDD results should be suppressed or reported as resistant for isolates demonstrating carbapenemase production."]}]},{agentName:"Ertapenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 22 mm",i_breakpoint:"19–21 mm",r_breakpoint:"≤ 18 mm"},mic:{s_breakpoint:"≤ 0.5 µg/mL",i_breakpoint:"1 µg/mL",r_breakpoint:"≥ 2 µg/mL"},comments:[]}]},{agentName:"Meropenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 23 mm",i_breakpoint:"20–22 mm",r_breakpoint:"≤ 19 mm"},mic:{s_breakpoint:"≤ 1 µg/mL",i_breakpoint:"2 µg/mL",r_breakpoint:"≥ 4 µg/mL"},comments:[]}]}]},{tier:3,tierDescription:"Appropriate for high-risk MDRO patients, subject to cascade reporting",agents:[{agentName:"Ceftazidime-avibactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30/20 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:null,r_breakpoint:"≤ 20 mm"},mic:{s_breakpoint:"≤ 8/4 µg/mL",i_breakpoint:null,r_breakpoint:"≥ 16/4 µg/mL"},comments:["Confirmatory MIC testing is indicated for isolates with zones of 20–22 mm."]}]},{agentName:"Meropenem-vaborbactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"20/10 µg",s_breakpoint:"≥ 18 mm",i_breakpoint:"15–17 mm",r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 4/8 µg/mL",i_breakpoint:"8/8 µg/mL",r_breakpoint:"≥ 16/8 µg/mL"},comments:["If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]}]},{tier:4,tierDescription:"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available",agents:[{agentName:"Aztreonam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:"18–20 mm",r_breakpoint:"≤ 17 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:"8 µg/mL",r_breakpoint:"≥ 16 µg/mL"},comments:[]}]},{agentName:"Ceftriaxone",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 26 mm",i_breakpoint:"20–22 mm",r_breakpoint:"≤ 19 mm"},mic:{s_breakpoint:"≤ 1 µg/mL",i_breakpoint:"2 µg/mL",r_breakpoint:"≥ 4 µg/mL"},comments:[]}]},{agentName:"Colistin or Polymyxin B",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:null,s_breakpoint:null,i_breakpoint:null,r_breakpoint:null},mic:{s_breakpoint:"≤ 2 µg/mL",i_breakpoint:null,r_breakpoint:"≥ 4 µg/mL"},comments:["Disk diffusion and gradient diffusion methods should not be performed."]}]}]}]},Cb={diagnosticNotes:{summary:"Gold standard is HEp-2 adherence which is not generally available. May be diagnosed by PCR detection of virulence genes aatA and aggR in some commercial and research assays.",biosafetyWarning:null,methods:[]},preventionAndScreening:[],treatmentLifecycle:[],antimicrobialStewardship:["Often self limited, so antibiotics not always necessary.","Treatment probably indicated in immunocompromised patients and prolonged illness.","One small study showed response to antibiotics (Clin Infect Dis 29:335, 1999) and antibiotics were effective in HIV infected patients with EAEC (J Infect Dis 178:1369, 1998). Rifaximin appeared to improve duration of symptoms Clin Gastroenterol Hepatol 2004;2(2):135."],drugSpecificPearls:[],guidelineReferences:[{source:"Clinical Infectious Diseases",citation:"Clin Infect Dis 2019;69:473",summaryOrNote:"Study detected EAEC frequently in Minnesota patients of all ages with acute diarrhea."},{source:"Clinical Infectious Diseases",citation:"Clin Infect Dis 29:335, 1999",summaryOrNote:"A small study showed a response to antibiotics for EAEC infection."},{source:"Journal of Infectious Diseases",citation:"J Infect Dis 178:1369, 1998",summaryOrNote:"Study showed antibiotics were effective in HIV-infected patients with EAEC."},{source:"Clinical Gastroenterology and Hepatology",citation:"Clin Gastroenterol Hepatol 2004;2(2):135",summaryOrNote:"Study suggests Rifaximin appeared to improve the duration of symptoms."},{source:"Clinical Microbiology Reviews",citation:"Clin Microbiol Rev 2014;27(3):614",summaryOrNote:"General review of EAEC."},{source:"Current Opinion in Gastroenterology",citation:"Current Opinion Gastroenterol 25:8, 2009",summaryOrNote:"General review of EAEC."},{source:"The Lancet Infectious Diseases",citation:"Lancet Infect Dis 1:304, 2001",summaryOrNote:"General review of EAEC."},{source:"JAMA",citation:"JAMA 2016 28;315(24):2712",summaryOrNote:"Review of persistent diarrhea, including EAEC."}]},Nb={identity:vb,clinicalProfile:kb,resistanceProfile:xb,treatment:Sb,laboratoryProfile:_b,additionalInformation:Cb},Ab={bacteriumName:"Escherichia coli",aliases:["E. coli"],lastUpdated:"2025-01-08",clsiCategory:"Enterobacterales (excluding Salmonella/Shigella)",classification:{gramStain:"Gram-negative",morphology:"Rod",respiration:"Facultative anaerobe",notes:["Motile","Lactose fermenter (pink on MacConkey agar)","Indole positive","VP negative","Citrate negative"]},strainDetails:[],biochemicalTests:"Gram-negative rod, motile, lactose fermenter (pink on MacConkey), indole +, VP –, citrate –, methyl red +, lysine decarboxylase +."},Eb={summary:"Escherichia coli causes a variety of infections ranging from uncomplicated urinary tract infections to life-threatening infections of the abdomen, skin and soft tissue, lung, CNS and other sites in both normal and immunocompromised hosts.",pathophysiologyPearls:[],keySignsAndSymptoms:[],clinicalSyndromes:[{syndromeName:"Urinary Tract Infections (UTI)",description:"Includes uncomplicated cystitis and pyelonephritis."},{syndromeName:"Intra-abdominal Infections",description:"Can cause peritonitis and abscesses."},{syndromeName:"Skin and Soft Tissue Infections",description:"Often occurs in surgical sites or wounds."},{syndromeName:"Pneumonia",description:"Hospital-acquired or ventilator-associated pneumonia."},{syndromeName:"Central Nervous System (CNS) Infections",description:"Can cause meningitis, especially in neonates."},{syndromeName:"Bacteremia",description:"Presence of bacteria in the bloodstream, can lead to sepsis."}],stagesOfIllness:[],highRiskPopulations:["Immunocompromised hosts","Patients with indwelling catheters","Neonates","Post-surgical patients"],transmissionVectors:["Endogenous flora","Contaminated food or water","Person-to-person (fecal-oral route)","Healthcare-associated transmission"],prognosisNotes:["E. coli may be susceptible to Piperacillin-tazobactam in vitro but may fail clinically, especially in bacteremia and other serious infections."]},jb={groupIntrinsicResistance:[],intrinsicResistance:[],majorMechanisms:[{mechanismName:"Extended-Spectrum Beta-Lactamase (ESBL)",mechanismType:"Enzymatic Inactivation",description:"Enzymes that confer resistance to most penicillins and cephalosporins, including third-generation cephalosporins and aztreonam."},{mechanismName:"Carbapenemase Production",mechanismType:"Enzymatic Inactivation",description:"Enzymes that hydrolyze carbapenems, as well as other beta-lactams. Includes Klebsiella pneumoniae carbapenemase (KPC) and metallo-beta-lactamases (e.g., NDM)."}],clinicalAlerts:[{alertTitle:"Piperacillin-Tazobactam Clinical Failure",details:"Despite in vitro susceptibility, Piperacillin-tazobactam is not recommended for bacteremia or other serious infections due to risk of treatment failure, possibly due to an inoculum effect. Ref: Clin Infect Dis 72:1109, 2021."},{alertTitle:"Emergence of Resistance",details:"Emergence of resistant mutants has been observed with agents like Ceftazidime-avibactam. See Clin Infect Dis 2019; 68:519; Antimicrob Agents Chemother. 2019;63:e01551-18 for discussion."}]},Rb={generalNotes:["Suggested treatment regimens are for parenteral therapy of more serious infections and based on status of pathogen detection and results of in vitro susceptibility.","Recommendations in the table below are for treatment of moderately severe or severe infections, particularly those in which resistance is a concern. For details see IDSA Guidance on the treatment of Antimicrobial Resistant Gram-Negative Infections.","For less severe and uncomplicated infections (e.g., UTI) caused by susceptible stains in addition to the agents below, treatment options include Amoxicillin-clavulanate, fluoroquinolones, oral and parenteral second- and third-generation cephalosporins. TMP-SMX is an option provided the strain is susceptible, but its utility as an empiric agent is limited because resistance is common. Nitrofurantoin and oral Fosfomycin are options for uncomplicated UTI.","For detailed discussion of beta-lactam drug resistance classes and mechanisms Gram Negative Bacilli, Resistance to Beta-lactams, Overview.","For treatment of uncomplicated urinary tract infections, see Cystitis (adult female) or Cystitis (adult male)."],drugsToAvoid:[{drugOrClass:"Piperacillin-tazobactam",condition:"Bacteremia, Serious Infections",reason:"Risk of clinical failure despite in vitro susceptibility, possibly due to inoculum effect."}],adjunctiveTherapies:[],regimens:[{context:{type:"Empiric",condition:"Isolation of E. coli, susceptibility results pending",patientPopulation:["Local rate of resistance <10%"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ceftriaxone",dose:"2 gm (age < 60 years) or 1 gm (age ≥ 65 years)",route:"IV",frequency:"q24h",comments:""},{drugName:"Ciprofloxacin",dose:"400 mg",route:"IV",frequency:"q12h",comments:""},{drugName:"Levofloxacin",dose:"750 mg",route:"IV",frequency:"q24h",comments:""},{drugName:"Piperacillin-tazobactam",dose:"4.5 gm",route:"IV",frequency:"q8h",comments:"Administer over 4 hours."}]}]}]},{context:{type:"Empiric",condition:"Isolation of E. coli, susceptibility results pending",patientPopulation:["Local rates of ESBL resistance >10%"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",comments:""},{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",comments:""}]}]}]},{context:{type:"Directed",condition:"ESBL-negative (Susceptible to Aztreonam, Ceftriaxone, Cefotaxime, Ceftazidime, or Cefepime)",patientPopulation:[],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ceftriaxone",dose:"2 gm (age < 60 years) or 1 gm (age ≥ 65 years)",route:"IV",frequency:"q24h",comments:""},{drugName:"Ciprofloxacin",dose:"400 mg",route:"IV",frequency:"q12h",comments:""},{drugName:"Levofloxacin",dose:"750 mg",route:"IV",frequency:"q24h",comments:""},{drugName:"Ampicillin",dose:"1-2 gm",route:"IV",frequency:"q4-6h",comments:"Use if susceptible."}]}]},{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Cefazolin",dose:"2 gm",route:"IV",frequency:"q8h",comments:""},{drugName:"TMP-SMX",dose:"10 mg/kg/d of TMP component",route:"IV or PO",frequency:"in 2-3 divided doses",comments:""},{drugName:"Amoxicillin-clavulanate",dose:"1.2-2.4 gm",route:"IV",frequency:"q8h",comments:"Where available; not available in US."},{drugName:"Ampicillin-sulbactam",dose:"3 gm",route:"IV",frequency:"q6h",comments:""},{drugName:"Gentamicin or Tobramycin",dose:"5-7 mg/kg",route:"IV",frequency:"q24h",comments:"Dose adjusted for renal function."}]}]}]},{context:{type:"Directed",condition:"ESBL producer, susceptible to carbapenems",patientPopulation:[],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",comments:"Consider higher dose infused over 3 hours q8h for more serious infections."},{drugName:"Imipenem-cilastatin",dose:"500 mg",route:"IV",frequency:"q6h",comments:""},{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",comments:""}]}],notes:["Consider use of Ceftolozane-tazobactam 3 gm IV infused over 3h q8h as a carbapenem-sparing alternative."]},{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ceftolozane-tazobactam",dose:"1.5 gm",route:"IV",frequency:"q8h",comments:""},{drugName:"Cefepime-enmetazobactam",dose:"Varies",route:"IV",frequency:"Varies",comments:"Recently FDA approved for treatment of complicated UTIs."},{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",comments:"Administer over 2 hours."},{drugName:"Temocillin",dose:"2 gm",route:"IV",frequency:"q12h",comments:"Available in Belgium and United Kingdom but not the US."},{drugName:"Gentamicin or Tobramycin",dose:"5-7 mg/kg",route:"IV",frequency:"q24h",comments:"Use if susceptible; dose adjusted for renal function."},{drugName:"Plazomicin",dose:"15 mg/kg",route:"IV",frequency:"once daily",comments:"Duration 4-7 days. FDA-approved for complicated UTI only. Use if available."}]}]}]},{context:{type:"Directed",condition:"Carbapenem-Resistant Enterobacterales (CRE) - KPC producer",patientPopulation:["Resistant to carbapenems, susceptible to Ceftazidime-avibactam, Meropenem-vaborbactam, and Imipenem-cilastatin-relebactam"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",comments:"Administer over 2 hours."},{drugName:"Meropenem-vaborbactam",dose:"4 gm",route:"IV",frequency:"q8h",comments:"Administer over 3 hours."}]}],notes:["Infectious diseases consultation recommended."]}]},{context:{type:"Directed",condition:"Carbapenem-Resistant Enterobacterales (CRE) - Metallo-carbapenemase producer",patientPopulation:["Resistant to agents above including Ceftazidime-avibactam, Meropenem-vaborbactam"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Imipenem-cilastatin-relebactam",dose:"1.25 gm",route:"IV",frequency:"q6h",comments:"Administer over 30 min. For use if CrCl > 90 mL/min."},{drugName:"Cefiderocol",dose:"2 gm",route:"IV",frequency:"q8h",comments:"Administer over 3 hours."}]}]},{preference:"Alternative",strategy:"Sequential",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",comments:"Administer over 3 hours."},{drugName:"Aztreonam",dose:"2 gm",route:"IV",frequency:"q6h",comments:"Administer over 3 hours. To be used in combination with Ceftazidime-avibactam."}]}],notes:["Infectious diseases consultation recommended.","Based on in vitro susceptibility, meropenem-vaborbactam plus aztreonam may be an option although efficacy unproven."]}]},{context:{type:"Directed",condition:"Uncomplicated Cystitis",patientPopulation:[],isolateSource:"Urine"},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"1 day",drugs:[{drugName:"Fosfomycin",dose:"3 gm",route:"PO",frequency:"x one dose",comments:""}]}]}]},{context:{type:"Directed",condition:"Pyelonephritis",patientPopulation:[],isolateSource:"Urine"},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Fosfomycin",dose:"6 gm",route:"IV",frequency:"q8h",comments:""}]}]}]}]},Tb=JSON.parse('{"testingIndications":[],"methodologyNotes":[],"recommendedPanel":[],"specialTests":[],"reportingRules":[{"ruleType":"Surrogate","drug":"Ampicillin","condition":"Standard","details":"Results of ampicillin testing can be used to predict results for amoxicillin."},{"ruleType":"Surrogate","drug":"Cefazolin","condition":"Uncomplicated UTIs due to E. coli, K. pneumoniae, and P. mirabilis","details":"Serves as a surrogate for oral cephalosporins."},{"ruleType":"Conditional","drug":"Cefepime","condition":"Carbapenemase production detected","details":"Susceptible/Susceptible-Dose Dependent (S/SDD) results should be suppressed or edited and reported as resistant."},{"ruleType":"Conditional","drug":"Meropenem-vaborbactam","condition":"OXA-48-like gene or enzyme detected","details":"Suppress or report as resistant, as the isolate may not respond in vivo despite in vitro susceptibility."}],"antimicrobialBreakpoints":[{"tier":1,"tierDescription":"Appropriate for routine, primary testing and reporting","agents":[{"agentName":"Ampicillin","breakpointSets":[{"condition":"Standard (Oral for uncomplicated UTI)","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥17","i_breakpoint":"14-16","r_breakpoint":"≤13"},"mic":{"s_breakpoint":"≤8","i_breakpoint":"16","r_breakpoint":"≥32"},"comments":["For oral use, breakpoints apply only for uncomplicated UTIs due to E. coli and Proteus mirabilis.","Results of ampicillin testing can be used to predict results for amoxicillin."]}]},{"agentName":"Cefazolin","breakpointSets":[{"condition":"Urine Only (Uncomplicated UTI)","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥15","i_breakpoint":null,"r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤16","i_breakpoint":null,"r_breakpoint":"≥32"},"comments":["Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis in uncomplicated UTIs."]},{"condition":"Standard (Parenteral)","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥23","i_breakpoint":"20-22","r_breakpoint":"≤19"},"mic":{"s_breakpoint":"≤2","i_breakpoint":"4","r_breakpoint":"≥8"},"comments":["For infections other than uncomplicated UTI, breakpoints apply to E. coli, K. pneumoniae, and P. mirabilis."]}]},{"agentName":"Amoxicillin-clavulanate","breakpointSets":[{"condition":"Uncomplicated UTI only","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥18","i_breakpoint":null,"r_breakpoint":"≤17"},"mic":{"s_breakpoint":"≤8/4","i_breakpoint":"16/4","r_breakpoint":"≥32/4"},"comments":["Breakpoints for oral use are also for completion of therapy for systemic infection."]}]},{"agentName":"Ampicillin-sulbactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10/10 µg","s_breakpoint":"≥15","i_breakpoint":"12-14","r_breakpoint":"≤11"},"mic":{"s_breakpoint":"≤8/4","i_breakpoint":"16/4","r_breakpoint":"≥32/4"},"comments":[]}]},{"agentName":"Piperacillin-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"100/10 µg","s_breakpoint":"≥25","i_breakpoint":"21-24","r_breakpoint":"≤20"},"mic":{"s_breakpoint":"≤8/4","i_breakpoint":"16/4","r_breakpoint":"≥32/4"},"comments":[]}]},{"agentName":"Gentamicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥18","i_breakpoint":"15-17","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"8","r_breakpoint":"≥16"},"comments":[]}]},{"agentName":"Tobramycin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥17","i_breakpoint":"13-16","r_breakpoint":"≤12"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"8","r_breakpoint":"≥16"},"comments":[]}]},{"agentName":"Amikacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥20","i_breakpoint":"17-19","r_breakpoint":"≤16"},"mic":{"s_breakpoint":"≤16","i_breakpoint":"32","r_breakpoint":"≥64"},"comments":[]}]},{"agentName":"Ciprofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥26","i_breakpoint":"22-25","r_breakpoint":"≤21"},"mic":{"s_breakpoint":"≤0.25","i_breakpoint":"0.5","r_breakpoint":"≥1"},"comments":[]}]},{"agentName":"Levofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥21","i_breakpoint":"17-20","r_breakpoint":"≤16"},"mic":{"s_breakpoint":"≤0.5","i_breakpoint":"1","r_breakpoint":"≥2"},"comments":[]}]},{"agentName":"Trimethoprim-sulfamethoxazole","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"1.25/23.75 µg","s_breakpoint":"≥16","i_breakpoint":"11-15","r_breakpoint":"≤10"},"mic":{"s_breakpoint":"≤2/38","i_breakpoint":"4/76","r_breakpoint":"≥8/152"},"comments":[]}]},{"agentName":"Nitrofurantoin","breakpointSets":[{"condition":"Urine only","diskDiffusion":{"diskContent":"300 µg","s_breakpoint":"≥17","i_breakpoint":"15-16","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤32","i_breakpoint":"64","r_breakpoint":"≥128"},"comments":["For uncomplicated urinary tract infections (UTI)."]}]},{"agentName":"Fosfomycin","breakpointSets":[{"condition":"Urine only","diskDiffusion":{"diskContent":"200 µg","s_breakpoint":"≥16","i_breakpoint":"13-15","r_breakpoint":"≤12"},"mic":{"s_breakpoint":"≤64","i_breakpoint":"128","r_breakpoint":"≥256"},"comments":["Applies only to E. coli urinary tract isolates.","The 200-µg fosfomycin disk contains 50 µg glucose-6-phosphate.","The only approved MIC testing method is agar dilution; broth dilution MIC testing should not be performed."]}]}]},{"tier":2,"tierDescription":"Appropriate for routine, primary testing, may be reported following cascade reporting rules","agents":[{"agentName":"Cefuroxime (parenteral)","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥18","i_breakpoint":"15-17","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤8","i_breakpoint":"16","r_breakpoint":"≥32"},"comments":[]}]},{"agentName":"Cefepime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥25","i_breakpoint":"19-24","r_breakpoint":"≤18"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"8","r_breakpoint":"≥16"},"comments":["Susceptible/Susceptible-Dose Dependent (S/SDD) results should be suppressed or edited and reported as resistant for isolates that demonstrate carbapenemase production."]}]},{"agentName":"Ertapenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥22","i_breakpoint":"19-21","r_breakpoint":"≤18"},"mic":{"s_breakpoint":"≤0.5","i_breakpoint":"1","r_breakpoint":"≥2"},"comments":[]}]},{"agentName":"Imipenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥23","i_breakpoint":"20-22","r_breakpoint":"≤19"},"mic":{"s_breakpoint":"≤1","i_breakpoint":"2","r_breakpoint":"≥4"},"comments":[]}]},{"agentName":"Meropenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥23","i_breakpoint":"20-22","r_breakpoint":"≤19"},"mic":{"s_breakpoint":"≤1","i_breakpoint":"2","r_breakpoint":"≥4"},"comments":[]}]}]},{"tier":3,"tierDescription":"Appropriate for high-risk MDRO patients, subject to cascade reporting","agents":[{"agentName":"Cefiderocol","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥16","i_breakpoint":"9-15","r_breakpoint":"≤8"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"8","r_breakpoint":"≥16"},"comments":["The accuracy and reproducibility of cefiderocol testing results by disk diffusion and broth microdilution are markedly affected by iron concentration and inoculum preparation and may vary by disk and media manufacturer."]}]},{"agentName":"Ceftazidime-avibactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/20 µg","s_breakpoint":"≥21","i_breakpoint":null,"r_breakpoint":"≤20"},"mic":{"s_breakpoint":"≤8/4","i_breakpoint":null,"r_breakpoint":"≥16/4"},"comments":["Confirmatory MIC testing is indicated for isolates with zones of 20–22 mm to avoid reporting false-susceptible or false-resistant results."]}]},{"agentName":"Imipenem-relebactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10/25 µg","s_breakpoint":"≥25","i_breakpoint":"21-24","r_breakpoint":"≤20"},"mic":{"s_breakpoint":"≤1/4","i_breakpoint":"2/4","r_breakpoint":"≥4/4"},"comments":["Breakpoints do not apply to the family Morganellaceae, which includes but is not limited to the genera Morganella, Proteus, and Providencia."]}]},{"agentName":"Meropenem-vaborbactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥18","i_breakpoint":"15-17","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤4/8","i_breakpoint":"8/8","r_breakpoint":"≥16/8"},"comments":["Enterobacterales that harbor OXA-48-like enzymes may test susceptible to meropenem-vaborbactam but may not respond in vivo. If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]},{"agentName":"Plazomicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥18","i_breakpoint":"15-17","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤2","i_breakpoint":"4","r_breakpoint":"≥8"},"comments":[]}]}]},{"tier":4,"tierDescription":"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available","agents":[{"agentName":"Aztreonam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥21","i_breakpoint":"18-20","r_breakpoint":"≤17"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"8","r_breakpoint":"≥16"},"comments":[]}]},{"agentName":"Ceftazidime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥21","i_breakpoint":"18-20","r_breakpoint":"≤17"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"8","r_breakpoint":"≥16"},"comments":[]}]},{"agentName":"Ceftriaxone","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥26","i_breakpoint":"20-22","r_breakpoint":"≤19"},"mic":{"s_breakpoint":"≤1","i_breakpoint":"2","r_breakpoint":"≥4"},"comments":[]}]},{"agentName":"Ceftolozane-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/20 µg","s_breakpoint":"≥22","i_breakpoint":"19-21","r_breakpoint":"≤18"},"mic":{"s_breakpoint":"≤2/4","i_breakpoint":"4/4","r_breakpoint":"≥8/4"},"comments":[]}]},{"agentName":"Colistin or Polymyxin B","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":null,"s_breakpoint":null,"i_breakpoint":null,"r_breakpoint":null},"mic":{"s_breakpoint":"≤2","i_breakpoint":null,"r_breakpoint":"≥4"},"comments":["Disk diffusion and gradient diffusion methods should not be performed.","When given systemically, these agents are likely effective for pneumonia."]}]}]}]}'),Db={diagnosticNotes:{summary:"",biosafetyWarning:"",methods:[]},preventionAndScreening:[],treatmentLifecycle:[],antimicrobialStewardship:["Carbapenems should be reserved for polymicrobial infections for which anaerobic coverage is required or for treatment of infections due to ESBL-producing strains","Although active against ESBLs and related beta-lactamases, use of Ceftazidime-avibactam, Imipenem-relebactam, and Meropenem-vaborbactam should be reserved for patients with documented carbapenemase mechanism of resistance."],drugSpecificPearls:[{drugName:"Aztreonam + Ceftazidime-avibactam",pearl:"Aztreonam is not hydrolyzed by metallocarbapenemases (ceftazidime is) but is inactivated by ESBLS which are often produced concomitantly with the carbapenemase. Avibactam inactivates ESBLs. This combination is a last resort recommendation based entirely on in vitro data and case reports. See Antimicrob Agents Chemother 2017 Mar 24; 61(4). pii:e02243-16 and J Antimicrob Chemother 2018; 73:1104."},{drugName:"Cefiderocol",pearl:"FDA-approved for patients with complicated UTI due to susceptible bacteria and with limited or no alternative treatment options. In an open label randomized trial vs Best Available Therapy (BAT) in patients with sepsis, pneumonia, bacteremia or cUTI, mortality at 28 days was 24.8% for cefiderocol pts. vs 18.4% for BAT pts (not statistically significant). Reference: Clin Infect Dis 2019; 69 (suppl.7): S519-S575."},{drugName:"Meropenem/Imipenem",pearl:"If Ertapenem resistance is noted, check for susceptibility to Meropenem or Imipenem; if the isolate is susceptible to both of the latter, either may be used."},{drugName:"Meropenem + Polymyxin B/Colistin",pearl:"This combination is not recommended for therapy of MDR gram-negative bacilli based on treatment failures in a controlled clinical trial (Lancet Infect Dis 2018; 18:391). Failures occurred in a randomized controlled trial where 77% of enrolled patients had infections due to Acinetobacter baumannii. Study was underpowered to assess comparative efficacy vs other carbapenemase producing gram-negative bacteria."},{drugName:"Meropenem-vaborbactam + Aztreonam",pearl:"This combination shows similar in vitro activity to aztreonam plus ceftazidime-avibactam against Enterobacterales producing NDM and other non-OXA serine ß-lactamases, but there is no clinical data (Antimicrob Agents Chemother 2019; 63: e01426-19)."},{drugName:"Plazomicin",pearl:"FDA approved for the treatment of complicated UTI and pyelonephritis (N Engl J Med 2019;380:729). There is limited observational experience with Plazomicin in combination with Tigecycline or Meropenem for treatment of MDR bloodstream infections or hospital-acquired or ventilator-associated pneumonia (N Engl J Med 2019; 380:791)."}],guidelineReferences:[{source:"IDSA Guidance",citation:"IDSA Guidance on the treatment of Antimicrobial Resistant Gram-Negative Infections. Updated 2024 IDSA Guidelines.",summaryOrNote:"Primary reference for treatment of moderately severe or severe infections due to resistant gram-negative organisms."},{source:"Clinical Infectious Diseases",citation:"Clin Infect Dis 72:1109, 2021",summaryOrNote:"Reference regarding clinical failure of Piperacillin-tazobactam for E. coli bacteremia."},{source:"Clinical Infectious Diseases",citation:"Clin Infect Dis 2019; 68:519",summaryOrNote:"Discussion on the emergence of resistant mutants with Ceftazidime-avibactam and similar agents."},{source:"Antimicrobial Agents and Chemotherapy",citation:"Antimicrob Agents Chemother. 2019;63:e01551-18",summaryOrNote:"Further discussion on emergence of resistance to novel beta-lactamase inhibitors."},{source:"The Lancet Infectious Diseases",citation:"Lancet Infect Dis 2018; 18:391",summaryOrNote:"Data on treatment failures with Meropenem + Polymyxin combination therapy."},{source:"New England Journal of Medicine",citation:"N Engl J Med 2019;380:729",summaryOrNote:"Data supporting FDA approval of Plazomicin for complicated UTI and pyelonephritis."}]},Lb={identity:Ab,clinicalProfile:Eb,resistanceProfile:jb,treatment:Rb,laboratoryProfile:Tb,additionalInformation:Db},Mb={bacteriumName:"Klebsiella aerogenes",aliases:["Enterobacter aerogenes"],lastUpdated:"2024-09-30",clsiCategory:"Enterobacterales (excluding Salmonella/Shigella)",classification:{gramStain:"Gram-negative",morphology:"Bacillus",respiration:"Facultative anaerobe",notes:["Motile (differentiates from other Klebsiella spp.)","Encodes an inducible chromosomal AmpC beta-lactamase."]},strainDetails:[],biochemicalTests:"Gram-negative rod, motile (differentiates from other Klebsiella), lactose fermenter, indole –, VP +, citrate +, ornithine decarboxylase +."},zb={summary:"Causes a range of infections including urinary tract infections (UTIs), bacteremia, pneumonia, and intra-abdominal infections. As a member of the Enterobacterales group, it is a common nosocomial pathogen. Its key clinical feature is the presence of an inducible AmpC beta-lactamase, which can lead to treatment failure with certain beta-lactam antibiotics, even if they appear susceptible in vitro.",pathophysiologyPearls:["Possesses an inducible chromosomal AmpC beta-lactamase gene. Expression is typically low but can be induced by exposure to certain beta-lactams (e.g., ampicillin, first- and second-generation cephalosporins).","Induction or selection of stably derepressed mutants can lead to clinical resistance to third-generation cephalosporins during therapy."],keySignsAndSymptoms:[],clinicalSyndromes:[{syndromeName:"Urinary Tract Infections (UTI)",description:"Can cause both uncomplicated cystitis and complicated UTIs, including pyelonephritis and catheter-associated UTIs."},{syndromeName:"Bloodstream Infections (BSI)",description:"A significant cause of nosocomial bacteremia, often associated with central lines, surgery, or other invasive procedures."},{syndromeName:"Pneumonia",description:"Typically occurs as hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP)."},{syndromeName:"Intra-abdominal Infections",description:"Can be isolated from peritonitis and abscesses, often as part of a polymicrobial infection."}],stagesOfIllness:[],highRiskPopulations:["Hospitalized patients","Immunocompromised individuals","Patients with indwelling medical devices (e.g., catheters, central lines)","Patients with recent antibiotic exposure"],transmissionVectors:["Contact with contaminated surfaces or equipment in healthcare settings","Hands of healthcare workers"],prognosisNotes:["Prognosis is highly dependent on the site of infection, severity of illness, and the presence of antimicrobial resistance.","Emergence of resistance to third-generation cephalosporins during therapy is a known risk due to AmpC induction."]},Ib={groupIntrinsicResistance:[],intrinsicResistance:[{drugOrClass:"Ampicillin, Amoxicillin, Amoxicillin-Clavulanate, First-generation Cephalosporins (e.g., Cefazolin), Cefoxitin",notes:"Resistance is mediated by the chromosomal AmpC beta-lactamase."}],majorMechanisms:[{mechanismName:"AmpC Beta-Lactamase",mechanismType:"Inducible Chromosomal Enzyme",description:"An inducible cephalosporinase that hydrolyzes penicillins, and first-, second-, and third-generation cephalosporins. Cefepime is more stable. Carbapenems are stable."},{mechanismName:"Extended-Spectrum Beta-Lactamase (ESBL)",mechanismType:"Plasmid-mediated Enzyme",description:"Confers resistance to most penicillins and cephalosporins (including third and fourth generation) and aztreonam. Susceptible to beta-lactamase inhibitors and carbapenems."},{mechanismName:"Carbapenemases (e.g., KPC, MBL)",mechanismType:"Plasmid-mediated Enzyme",description:"KPC (Klebsiella pneumoniae carbapenemase) hydrolyzes all beta-lactams including carbapenems; inhibited by avibactam and vaborbactam. MBLs (Metallo-beta-lactamases) are zinc-dependent enzymes that hydrolyze all beta-lactams except aztreonam; they are not inhibited by current clinical beta-lactamase inhibitors."}],clinicalAlerts:[{alertTitle:"Inducible AmpC Resistance",details:"Avoid using third-generation cephalosporins (e.g., ceftriaxone, ceftazidime) for serious infections, even if the isolate tests susceptible, due to the high risk of selecting for resistant mutants during therapy. Cefepime is the preferred cephalosporin."},{alertTitle:"Carbapenem-Resistant Enterobacterales (CRE)",details:"Infections caused by CRE strains (e.g., KPC or MBL producers) are associated with high mortality and require specialized treatment regimens and infectious diseases consultation."}]},qb={generalNotes:["The following recommendations apply to moderately severe or severe infections where resistance is a concern."],drugsToAvoid:[{drugOrClass:"Ceftriaxone, Cefotaxime, Ceftazidime",condition:"All serious infections",reason:"High risk of clinical failure due to induction of AmpC beta-lactamase, even with in vitro susceptibility."},{drugOrClass:"Piperacillin-tazobactam",condition:"All serious infections",reason:"Risk of in vivo resistance emergence due to AmpC."}],adjunctiveTherapies:[],regimens:[{context:{type:"Empiric",condition:"Klebsiella aerogenes identified, susceptibility pending",patientPopulation:["Local rate of ESBL resistance <10%"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Cefepime",dose:"1-2 gm",route:"IV",frequency:"q8-12h",comments:"Preferred due to stability against AmpC hydrolysis."}]}]},{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ciprofloxacin",dose:"400 mg",route:"IV",frequency:"bid",comments:"Use based on local susceptibility data."},{drugName:"Levofloxacin",dose:"750 mg",route:"IV",frequency:"q24h",comments:"Use based on local susceptibility data."}]}]}]},{context:{type:"Empiric",condition:"Klebsiella aerogenes identified, susceptibility pending",patientPopulation:["Local rate of ESBL resistance >10%"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",comments:""},{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",comments:""}]}]}]},{context:{type:"Directed",condition:"Non-ESBL producer",patientPopulation:["Susceptible to Aztreonam, Ceftriaxone, Cefotaxime, Ceftazidime, or Cefepime"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Cefepime",dose:"1-2 gm",route:"IV",frequency:"q8-12h",comments:"Preferred agent due to stability against AmpC."}]}]},{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ciprofloxacin",dose:"400 mg",route:"IV",frequency:"bid",comments:"If susceptible."},{drugName:"Levofloxacin",dose:"750 mg",route:"IV",frequency:"q24h",comments:"If susceptible."},{drugName:"TMP-SMX",dose:"10 mg/kg/day (TMP component)",route:"IV or PO",frequency:"in 2-3 divided doses",comments:"If susceptible."}]}]}]},{context:{type:"Directed",condition:"ESBL Producer / AmpC over-producer",patientPopulation:["Resistant to 3rd/4th generation cephalosporins, but susceptible to carbapenems"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",comments:"For serious infections, consider 2 gm infused over 3 hours q8h."},{drugName:"Imipenem-cilastatin",dose:"500 mg",route:"IV",frequency:"q6h",comments:""},{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",comments:"Generally avoid for bacteremia or pneumonia."}]}]},{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ceftolozane-tazobactam",dose:"1.5-3 gm",route:"IV",frequency:"q8h",comments:"Carbapenem-sparing option. Use 3 gm dose for severe infections like VAP."},{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"infused over 3 hrs q8h",comments:"Carbapenem-sparing option."}]}]}]},{context:{type:"Directed",condition:"Carbapenem-Resistant (KPC producer)",patientPopulation:["Resistant to carbapenems but susceptible to newer BL-BLI combinations"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"infused over 3 hrs q8h",comments:"Infectious diseases consultation strongly recommended."},{drugName:"Meropenem-vaborbactam",dose:"4 gm",route:"IV",frequency:"infused over 3 hrs q8h",comments:"Infectious diseases consultation strongly recommended."},{drugName:"Imipenem-cilastatin-relebactam",dose:"1.25 gm",route:"IV",frequency:"over 30 min q6h",comments:"Only for CrCl >90 mL/min. Infectious diseases consultation strongly recommended."}]}]}]},{context:{type:"Directed",condition:"Carbapenem-Resistant (MBL producer)",patientPopulation:["Resistant to carbapenems and newer beta-lactamase inhibitors like C/A, M/V, I/R"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"over 3h q8h",comments:"Must be given with Aztreonam."},{drugName:"Aztreonam",dose:"2 gm",route:"IV",frequency:"over 2 hrs q6h",comments:"Must be given with Ceftazidime-avibactam. Infectious diseases consultation strongly recommended."}]}]},{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Cefiderocol",dose:"2 gm",route:"IV",frequency:"over 3 hrs q8h",comments:"Infectious diseases consultation strongly recommended."}]}]}]}]},Ob=JSON.parse('{"testingIndications":["Susceptibility testing is indicated for all clinically significant isolates."],"methodologyNotes":["Broth dilution MIC testing should not be performed for fosfomycin; agar dilution with glucose-6-phosphate supplementation is the only validated method.","Disk diffusion and gradient diffusion methods for colistin or polymyxin B are unreliable and should not be performed."],"recommendedPanel":[],"specialTests":[{"testName":"Carbapenemase Production Test (e.g., mCIM, Carba NP)","trigger":"Resistance to one or more carbapenems.","purpose":"To detect the presence of a carbapenemase enzyme, which has significant therapeutic and infection control implications."}],"reportingRules":[{"ruleType":"Conditional","drug":"Cefepime","condition":"Isolate demonstrates carbapenemase production.","details":"Cefepime S/SDD results should be suppressed or reported as resistant."},{"ruleType":"Surrogate","drug":"Ampicillin","condition":"N/A","details":"Results of ampicillin testing can be used to predict results for amoxicillin."},{"ruleType":"Surrogate","drug":"Tetracycline","condition":"Isolate is susceptible to Tetracycline.","details":"Organisms susceptible to tetracycline are also considered susceptible to doxycycline and minocycline. However, some organisms that are intermediate or resistant to tetracycline may be susceptible to doxycycline, minocycline, or both."},{"ruleType":"Surrogate","drug":"Cefazolin (Urine)","condition":"Isolate is from an uncomplicated UTI.","details":"Serves as a surrogate for oral cephalosporins (e.g., cephalexin) for E. coli, K. pneumoniae, and P. mirabilis."}],"antimicrobialBreakpoints":[{"tier":1,"tierDescription":"Appropriate for routine, primary testing and reporting.","agents":[{"agentName":"Ampicillin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥17","i_breakpoint":"14-16","r_breakpoint":"≤13"},"mic":{"s_breakpoint":"≤8","i_breakpoint":"16","r_breakpoint":"≥32"},"comments":["Results can be used to predict results for amoxicillin."]}]},{"agentName":"Amoxicillin-clavulanate","breakpointSets":[{"condition":"Uncomplicated UTI only","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥18","i_breakpoint":"","r_breakpoint":"≤17"},"mic":{"s_breakpoint":"≤8/4","i_breakpoint":"16/8","r_breakpoint":"≥32/16"},"comments":["Breakpoints are only for therapy of uncomplicated UTIs."]}]},{"agentName":"Ampicillin-sulbactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10/10 µg","s_breakpoint":"≥15","i_breakpoint":"12-14","r_breakpoint":"≤11"},"mic":{"s_breakpoint":"≤8/4","i_breakpoint":"16/8","r_breakpoint":"≥32/16"},"comments":[]}]},{"agentName":"Piperacillin-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"100/10 µg","s_breakpoint":"≥25","i_breakpoint":"21-24","r_breakpoint":"≤20"},"mic":{"s_breakpoint":"≤8/4","i_breakpoint":"16/4","r_breakpoint":"≥32/4"},"comments":[]}]},{"agentName":"Gentamicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥18","i_breakpoint":"15-17","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"","r_breakpoint":"≥8"},"comments":[]}]},{"agentName":"Tobramycin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥17","i_breakpoint":"13-16","r_breakpoint":"≤12"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"","r_breakpoint":"≥8"},"comments":[]}]},{"agentName":"Amikacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥19","i_breakpoint":"17-18","r_breakpoint":"≤16"},"mic":{"s_breakpoint":"≤16","i_breakpoint":"","r_breakpoint":"≥32"},"comments":[]}]},{"agentName":"Ciprofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥26","i_breakpoint":"22-25","r_breakpoint":"≤21"},"mic":{"s_breakpoint":"≤0.25","i_breakpoint":"0.5","r_breakpoint":"≥1"},"comments":[]}]},{"agentName":"Levofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥21","i_breakpoint":"17-20","r_breakpoint":"≤16"},"mic":{"s_breakpoint":"≤0.5","i_breakpoint":"1","r_breakpoint":"≥2"},"comments":[]}]},{"agentName":"Trimethoprim-sulfamethoxazole","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"1.25/23.75 µg","s_breakpoint":"≥16","i_breakpoint":"11-15","r_breakpoint":"≤10"},"mic":{"s_breakpoint":"≤2/38","i_breakpoint":"","r_breakpoint":"≥4/76"},"comments":[]}]},{"agentName":"Cefotaxime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥26","i_breakpoint":"23-25","r_breakpoint":"≤22"},"mic":{"s_breakpoint":"≤1","i_breakpoint":"2","r_breakpoint":"≥4"},"comments":[]}]},{"agentName":"Ceftriaxone","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥23","i_breakpoint":"20-22","r_breakpoint":"≤19"},"mic":{"s_breakpoint":"≤1","i_breakpoint":"2","r_breakpoint":"≥4"},"comments":[]}]}]},{"tier":2,"tierDescription":"Appropriate for routine, primary testing, may be reported following cascade reporting rules.","agents":[{"agentName":"Cefuroxime (Parenteral)","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥18","i_breakpoint":"15-17","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤8","i_breakpoint":"16","r_breakpoint":"≥32"},"comments":[]}]},{"agentName":"Cefepime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥25","i_breakpoint":"19-24","r_breakpoint":"≤18"},"mic":{"s_breakpoint":"≤2","i_breakpoint":"4-8 (SDD)","r_breakpoint":"≥16"},"comments":["Cefepime S/SDD results should be suppressed or reported as resistant for isolates that demonstrate carbapenemase production."]}]},{"agentName":"Ertapenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥22","i_breakpoint":"19-21","r_breakpoint":"≤18"},"mic":{"s_breakpoint":"≤0.5","i_breakpoint":"1","r_breakpoint":"≥2"},"comments":[]}]},{"agentName":"Imipenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥23","i_breakpoint":"20-22","r_breakpoint":"≤19"},"mic":{"s_breakpoint":"≤1","i_breakpoint":"2","r_breakpoint":"≥4"},"comments":[]}]},{"agentName":"Meropenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥23","i_breakpoint":"20-22","r_breakpoint":"≤19"},"mic":{"s_breakpoint":"≤1","i_breakpoint":"2","r_breakpoint":"≥4"},"comments":[]}]},{"agentName":"Tetracycline","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥15","i_breakpoint":"12-14","r_breakpoint":"≤11"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"8","r_breakpoint":"≥16"},"comments":["Organisms susceptible to tetracycline are also considered susceptible to doxycycline and minocycline. However, some organisms that are intermediate or resistant to tetracycline may be susceptible to doxycycline, minocycline, or both."]}]}]},{"tier":3,"tierDescription":"Appropriate for high-risk Multi-Drug Resistant Organism (MDRO) patients, subject to cascade reporting.","agents":[{"agentName":"Cefiderocol","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥16","i_breakpoint":"9-15","r_breakpoint":"≤8"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"","r_breakpoint":"≥8"},"comments":[]}]},{"agentName":"Ceftazidime-avibactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/20 µg","s_breakpoint":"≥21","i_breakpoint":"","r_breakpoint":"≤20"},"mic":{"s_breakpoint":"≤8/4","i_breakpoint":"","r_breakpoint":"≥16/4"},"comments":["Confirmatory MIC testing is indicated for isolates with disk diffusion zones of 20–22 mm to avoid reporting false-susceptible or false-resistant results."]}]},{"agentName":"Imipenem-relebactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10/25 µg","s_breakpoint":"≥25","i_breakpoint":"21-24","r_breakpoint":"≤20"},"mic":{"s_breakpoint":"≤1/4","i_breakpoint":"2/4","r_breakpoint":"≥4/4"},"comments":["Breakpoints do not apply to the family Morganellaceae (Morganella, Proteus, and Providencia)."]}]},{"agentName":"Meropenem-vaborbactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥18","i_breakpoint":"15-17","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤4/8","i_breakpoint":"8/8","r_breakpoint":"≥16/8"},"comments":["If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]},{"agentName":"Plazomicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥18","i_breakpoint":"15-17","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤2","i_breakpoint":"","r_breakpoint":"≥4"},"comments":[]}]}]},{"tier":4,"tierDescription":"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available.","agents":[{"agentName":"Aztreonam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥21","i_breakpoint":"18-20","r_breakpoint":"≤17"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"8","r_breakpoint":"≥16"},"comments":[]}]},{"agentName":"Ceftazidime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥21","i_breakpoint":"18-20","r_breakpoint":"≤17"},"mic":{"s_breakpoint":"≤4","i_breakpoint":"8","r_breakpoint":"≥16"},"comments":[]}]},{"agentName":"Ceftolozane-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/10 µg","s_breakpoint":"≥22","i_breakpoint":"19-21","r_breakpoint":"≤18"},"mic":{"s_breakpoint":"≤2/4","i_breakpoint":"","r_breakpoint":"≥4/4"},"comments":[]}]},{"agentName":"Colistin (Polymyxin E)","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"","s_breakpoint":"","i_breakpoint":"","r_breakpoint":""},"mic":{"s_breakpoint":"≤2","i_breakpoint":"","r_breakpoint":"≥4"},"comments":["Disk diffusion and gradient diffusion methods should not be performed."]}]},{"agentName":"Polymyxin B","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"","s_breakpoint":"","i_breakpoint":"","r_breakpoint":""},"mic":{"s_breakpoint":"≤2","i_breakpoint":"","r_breakpoint":"≥4"},"comments":["Disk diffusion and gradient diffusion methods should not be performed."]}]}]},{"tier":99,"tierDescription":"Urine Only","agents":[{"agentName":"Cefazolin","breakpointSets":[{"condition":"Urine Only","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥15","i_breakpoint":"","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤16","i_breakpoint":"","r_breakpoint":"≥32"},"comments":["For uncomplicated UTI only. Serves as a surrogate for oral cephalosporins."]}]},{"agentName":"Nitrofurantoin","breakpointSets":[{"condition":"Urine Only","diskDiffusion":{"diskContent":"300 µg","s_breakpoint":"≥17","i_breakpoint":"15-16","r_breakpoint":"≤14"},"mic":{"s_breakpoint":"≤32","i_breakpoint":"64","r_breakpoint":"≥128"},"comments":[]}]},{"agentName":"Fosfomycin","breakpointSets":[{"condition":"Urine Only","diskDiffusion":{"diskContent":"200 µg","s_breakpoint":"≥16","i_breakpoint":"13-15","r_breakpoint":"≤12"},"mic":{"s_breakpoint":"≤64","i_breakpoint":"128","r_breakpoint":"≥256"},"comments":["Disk diffusion and MIC breakpoints for Fosfomycin apply ONLY to E. coli from urinary tract isolates and should not be extrapolated to other Enterobacterales species.","The only approved MIC method is agar dilution using media supplemented with 25 µg/mL of glucose-6-phosphate."]}]}]}]}'),Pb={diagnosticNotes:{summary:"",biosafetyWarning:"",methods:[]},preventionAndScreening:[],treatmentLifecycle:[],antimicrobialStewardship:["Infectious diseases consultation is strongly recommended for infections caused by carbapenem-resistant isolates.","Isolated Ertapenem resistance does not preclude the use of Meropenem or Imipenem if the isolate tests susceptible to them.","Avoid combination therapy with a carbapenem and a polymyxin for KPC-producing isolates; newer agents like ceftazidime-avibactam are superior."],drugSpecificPearls:[{drugName:"Cefepime",pearl:"Cefepime is a weak inducer of AmpC and is stable to hydrolysis by AmpC, making it the preferred cephalosporin for K. aerogenes. For isolates with MICs of 4-8 mcg/mL, a higher dose of 2 gm IV q8h infused over 3 hours is recommended for serious infections."},{drugName:"Ceftazidime-avibactam",pearl:"Showed superiority to colistin in an observational study for treating infections caused by carbapenem-resistant Enterobacterales."}],guidelineReferences:[]},Bb={identity:Mb,clinicalProfile:zb,resistanceProfile:Ib,treatment:qb,laboratoryProfile:Ob,additionalInformation:Pb},wb={bacteriumName:"Klebsiella species (oxytoca, pneumoniae, variicola)",aliases:["Klebsiella oxytoca","Klebsiella pneumoniae","Klebsiella variicola"],lastUpdated:"2025-01-08",clsiCategory:"Enterobacterales (excluding Salmonella/Shigella)",classification:{gramStain:"Gram-negative",morphology:"Bacilli",respiration:"Facultative anaerobe",notes:["Fermentative"]},strainDetails:[{type:"Complex",value:"Klebsiella pneumoniae complex",notes:"Includes K. pneumoniae and K. variicola."},{type:"Phenotype",value:"Hypermucoviscous Klebsiella",notes:"Increasingly recognized strains that can cause metastatic infections, like liver abscesses, in healthy hosts."}],biochemicalTests:"Gram-negative rod, non-motile, encapsulated, lactose fermenter (mucoid pink colonies on MacConkey agar), VP +, citrate +. K. oxytoca is indole +, while K. pneumoniae and K. variicola are indole –."},Vb={summary:"Klebsiella species cause a variety of infections, ranging from uncomplicated UTIs to life-threatening infections of the abdomen, skin/soft tissue, lungs, and CNS in both normal and immunocompromised hosts.",pathophysiologyPearls:["There is increasing recognition of hypermucoviscous strains that can cause metastatic infections, such as liver abscesses, even in healthy hosts."],keySignsAndSymptoms:[],clinicalSyndromes:[{syndromeName:"Urinary Tract Infections (UTI)",description:"Can be uncomplicated or complicated."},{syndromeName:"Intra-abdominal Infections",description:""},{syndromeName:"Skin and Soft Tissue Infections",description:""},{syndromeName:"Pneumonia",description:"Infection of the lungs."},{syndromeName:"Central Nervous System (CNS) Infections",description:"e.g., meningitis, brain abscess."},{syndromeName:"Liver Abscess",description:"Particularly associated with hypermucoviscous strains."}],stagesOfIllness:[],highRiskPopulations:["Immunocompromised hosts","Healthy hosts (for infections caused by hypermucoviscous strains)"],transmissionVectors:[],prognosisNotes:[]},Ub={groupIntrinsicResistance:[],intrinsicResistance:[],majorMechanisms:[{mechanismName:"Extended-Spectrum Beta-Lactamases (ESBLs)",mechanismType:"Enzymatic Inactivation",description:"A common resistance mechanism conferring resistance to third-generation cephalosporins and aztreonam. Piperacillin-tazobactam is not recommended for serious infections caused by ESBL producers, despite potential in vitro susceptibility, due to clinical failures."},{mechanismName:"Klebsiella pneumoniae carbapenemase (KPC)",mechanismType:"Enzymatic Inactivation",description:"A serine-based carbapenemase that confers resistance to carbapenems and most other beta-lactams."},{mechanismName:"Metallo-beta-lactamase (MBL)",mechanismType:"Enzymatic Inactivation",description:"A type of carbapenemase that confers resistance to carbapenems and newer beta-lactamase inhibitors like ceftazidime-avibactam and meropenem-vaborbactam."},{mechanismName:"OXA-48-like enzymes",mechanismType:"Enzymatic Inactivation",description:"A type of carbapenemase; if detected, meropenem-vaborbactam may not be effective and should be reported as resistant."}],clinicalAlerts:[{alertTitle:"Carbapenemase Production and Cefepime Reporting",details:"If carbapenemase production is identified in a Klebsiella isolate, any cefepime results indicating susceptibility should be suppressed or edited and reported as resistant."},{alertTitle:"Piperacillin-Tazobactam for ESBL",details:"Piperacillin-tazobactam is not recommended for serious infections caused by ESBL-producing Klebsiella despite potential in vitro susceptibility due to risk of clinical failures."}]},Hb={generalNotes:["Recommendations are for moderately severe or severe infections, especially where resistance is a concern.","For uncomplicated or less severe infections by susceptible strains, options include Amoxicillin-clavulanate, fluoroquinolones, and 2nd/3rd gen cephalosporins.","TMP-SMX is an option if the isolate is susceptible, but empiric use is limited by high rates of resistance.","Nitrofurantoin and oral Fosfomycin are options for uncomplicated UTIs."],drugsToAvoid:[{drugOrClass:"Piperacillin-tazobactam",condition:"Serious infections caused by ESBL-producers",reason:"Risk of clinical failure despite in vitro susceptibility."}],adjunctiveTherapies:[],regimens:[{context:{type:"Empiric",condition:"Suspected Klebsiella spp. infection",patientPopulation:["Local ESBL rate <10%"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ceftriaxone",dose:"2 gm",route:"IV",frequency:"q24h",comments:""},{drugName:"Piperacillin-tazobactam",dose:"4.5 gm",route:"IV",frequency:"q8h",comments:"Infuse over 4 hours."},{drugName:"Ciprofloxacin",dose:"400 mg",route:"IV",frequency:"bid",comments:""},{drugName:"Levofloxacin",dose:"750 mg",route:"IV",frequency:"q24h",comments:""}]}]}]},{context:{type:"Empiric",condition:"Suspected Klebsiella spp. infection",patientPopulation:["Local ESBL rate >10%"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",comments:""},{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",comments:""}]}]}]},{context:{type:"Directed",condition:"Non-ESBL Producer",patientPopulation:["Susceptible to Aztreonam, Ceftriaxone, Cefotaxime, Ceftazidime, or Cefepime"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ceftriaxone",dose:"2 gm",route:"IV",frequency:"q24h",comments:""},{drugName:"Piperacillin-tazobactam",dose:"4.5 gm",route:"IV",frequency:"q8h",comments:"Infuse over 4 hours."},{drugName:"Ciprofloxacin",dose:"400 mg",route:"IV",frequency:"bid",comments:""},{drugName:"Levofloxacin",dose:"750 mg",route:"IV",frequency:"q24h",comments:""}]}]},{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Cefazolin",dose:"1 gm",route:"IV",frequency:"q8h",comments:""},{drugName:"TMP-SMX",dose:"10 mg/kg/day (TMP component)",route:"IV/PO",frequency:"in 2-3 divided doses",comments:""},{drugName:"Amoxicillin-clavulanate",dose:"1.2-2.4 gm",route:"IV",frequency:"q8h",comments:"Where available"}]}]}]},{context:{type:"Directed",condition:"ESBL Producer",patientPopulation:["Resistant to ESBL-panel antibiotics but susceptible to carbapenems"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",comments:"For serious infections, consider 2 gm infused over 3 hours q8h."},{drugName:"Imipenem",dose:"500 mg",route:"IV",frequency:"q6h",comments:""},{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",comments:""}]}]},{preference:"Carbapenem-sparing Alternative (Non-Urinary Source)",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ceftolozane-tazobactam",dose:"1.5 gm",route:"IV",frequency:"q8h",comments:"Administer over 3 hrs."},{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",comments:"Infused over 3 hrs."}]}]},{preference:"Carbapenem-sparing Alternative (Urinary Tract Source)",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Temocillin",dose:"2 gm",route:"IV",frequency:"q12h",comments:"Where available."},{drugName:"Fosfomycin IV",dose:"6 gm",route:"IV",frequency:"q8h",comments:"Infuse over 60 minutes. Where available."}]}]}]},{context:{type:"Directed",condition:"KPC Producer",patientPopulation:["Resistant to carbapenems but susceptible to newer beta-lactamase inhibitors"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",comments:"Infused over 3 hrs."},{drugName:"Meropenem-vaborbactam",dose:"4 gm",route:"IV",frequency:"q8h",comments:"Infused over 3 hrs."},{drugName:"Imipenem-cilastatin-relebactam",dose:"1.25 gm",route:"IV",frequency:"q6h",comments:"Infused over 30 min (for CrCl >90 mL/min)."}]}],notes:["Infectious diseases consultation is strongly recommended."]}]},{context:{type:"Directed",condition:"MBL Producer",patientPopulation:["Resistant to carbapenems and newer beta-lactamase inhibitors"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",comments:"Infuse over 3 hours."},{drugName:"Aztreonam",dose:"2 gm",route:"IV",frequency:"q6h",comments:"Infuse over 2 hours. Must be given with Ceftazidime-avibactam."}]}]},{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Cefiderocol",dose:"2 gm",route:"IV",frequency:"q8h",comments:"Infuse over 3 hours."}]}],notes:["Infectious diseases consultation is strongly recommended. Meropenem-vaborbactam plus Aztreonam may also be effective based on in vitro data."]}]},{context:{type:"Directed",condition:"Carbapenemase (MBL) Producer with Complicated UTI",patientPopulation:[],isolateSource:"Urine"},recommendations:[{preference:"Salvage",strategy:"Concurrent",steps:[{step:1,duration:"4-7 days",drugs:[{drugName:"Plazomicin",dose:"15 mg/kg",route:"IV",frequency:"once daily",comments:"May be an option for complicated UTI only."}]}]}]}]},Gb=JSON.parse('{"testingIndications":[],"methodologyNotes":[],"recommendedPanel":[],"specialTests":[],"reportingRules":[{"ruleType":"Exception","drug":"Fosfomycin","condition":"Isolate is not E. coli from a urinary tract source.","details":"Breakpoints for Fosfomycin apply only to E. coli and should not be extrapolated to Klebsiella species."},{"ruleType":"Conditional","drug":"Cefepime","condition":"Carbapenemase production is identified.","details":"Cefepime results indicating susceptibility should be suppressed or reported as resistant."},{"ruleType":"Conditional","drug":"Meropenem-vaborbactam","condition":"An OXA-48-like gene or enzyme is detected.","details":"Results should be suppressed or reported as resistant as the isolate may not respond in vivo."},{"ruleType":"General","drug":"All","condition":"All Enterobacterales","details":"Cascade reporting protocols are followed. Results for broader-spectrum agents are typically reported only if the isolate shows resistance to primary agents."}],"antimicrobialBreakpoints":[{"tier":1,"tierDescription":"Appropriate for routine, primary testing and reporting.","agents":[{"agentName":"Ampicillin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"14–16 mm","r_breakpoint":"≤ 13 mm"},"mic":{"s_breakpoint":"≤ 8 µg/mL","i_breakpoint":"16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":["Results of ampicillin testing can predict results for amoxicillin."]}]},{"agentName":"Amoxicillin-clavulanate","breakpointSets":[{"condition":"Uncomplicated UTI only","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":null,"r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":"16/4 µg/mL","r_breakpoint":"≥ 32/4 µg/mL"},"comments":[]}]},{"agentName":"Piperacillin-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"100/10 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"21–24 mm","r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":"16/4 µg/mL","r_breakpoint":"≥ 32/4 µg/mL"},"comments":[]}]},{"agentName":"Gentamicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Tobramycin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"13–16 mm","r_breakpoint":"≤ 12 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Amikacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 19 mm","i_breakpoint":"17–18 mm","r_breakpoint":"≤ 16 mm"},"mic":{"s_breakpoint":"≤ 16 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 32 µg/mL"},"comments":[]}]},{"agentName":"Ciprofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥ 26 mm","i_breakpoint":"22–25 mm","r_breakpoint":"≤ 21 mm"},"mic":{"s_breakpoint":"≤ 0.25 µg/mL","i_breakpoint":"0.5 µg/mL","r_breakpoint":"≥ 1 µg/mL"},"comments":[]}]},{"agentName":"Levofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"17–20 mm","r_breakpoint":"≤ 16 mm"},"mic":{"s_breakpoint":"≤ 0.5 µg/mL","i_breakpoint":"1 µg/mL","r_breakpoint":"≥ 2 µg/mL"},"comments":[]}]},{"agentName":"Trimethoprim-sulfamethoxazole","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"1.25/23.75 µg","s_breakpoint":"≥ 16 mm","i_breakpoint":"11–15 mm","r_breakpoint":"≤ 10 mm"},"mic":{"s_breakpoint":"≤ 2/38 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4/76 µg/mL"},"comments":[]}]}]},{"tier":2,"tierDescription":"Appropriate for routine, primary testing, may be reported following cascade reporting rules.","agents":[{"agentName":"Cefuroxime (Parental)","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"15–22 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8–16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":[]}]},{"agentName":"Cefepime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"19–24 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8 µg/mL","r_breakpoint":"≥ 16 µg/mL"},"comments":["Cefepime S/SDD results should be suppressed or reported as resistant for isolates demonstrating carbapenemase production."]}]},{"agentName":"Ertapenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 22 mm","i_breakpoint":"19–21 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 0.5 µg/mL","i_breakpoint":"1 µg/mL","r_breakpoint":"≥ 2 µg/mL"},"comments":[]}]},{"agentName":"Imipenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]},{"agentName":"Meropenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]}]},{"tier":3,"tierDescription":"Appropriate for high-risk Multi-Drug Resistant Organism (MDRO) patients, subject to cascade reporting.","agents":[{"agentName":"Cefiderocol","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 20 mm","i_breakpoint":"9–15 mm","r_breakpoint":"≤ 8 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Ceftazidime-avibactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/20 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":null,"r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 16/4 µg/mL"},"comments":["Confirmatory MIC testing is indicated for isolates with disk diffusion zones of 20–22 mm."]}]},{"agentName":"Imipenem-relebactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10/25 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"21–24 mm","r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 1/4 µg/mL","i_breakpoint":"2/4 µg/mL","r_breakpoint":"≥ 4/4 µg/mL"},"comments":["These breakpoints apply to Klebsiella species as they are Enterobacterales but not Morganellaceae."]}]},{"agentName":"Meropenem-vaborbactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 4/8 µg/mL","i_breakpoint":"8/8 µg/mL","r_breakpoint":"≥ 16/8 µg/mL"},"comments":["If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]},{"agentName":"Plazomicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 2 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]}]},{"tier":4,"tierDescription":"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available.","agents":[{"agentName":"Aztreonam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"18–20 mm","r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8 µg/mL","r_breakpoint":"≥ 16 µg/mL"},"comments":[]}]},{"agentName":"Ceftriaxone","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 26 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]},{"agentName":"Ceftazidime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"18–20 mm","r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 8 µg/mL","i_breakpoint":"16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":[]}]},{"agentName":"Ceftolozane-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/10 µg","s_breakpoint":"≥ 22 mm","i_breakpoint":"19–21 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 2/4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4/4 µg/mL"},"comments":[]}]},{"agentName":"Colistin or Polymyxin B","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":null,"s_breakpoint":null,"i_breakpoint":null,"r_breakpoint":null},"mic":{"s_breakpoint":"≤ 2 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4 µg/mL"},"comments":["Disk diffusion and gradient diffusion methods should not be performed for these agents."]}]}]},{"tier":5,"tierDescription":"Urine Only Tier","agents":[{"agentName":"Cefazolin","breakpointSets":[{"condition":"Uncomplicated UTI only","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 15 mm","i_breakpoint":null,"r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 16 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 32 µg/mL"},"comments":["Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."]}]},{"agentName":"Nitrofurantoin","breakpointSets":[{"condition":"Urine Only","diskDiffusion":{"diskContent":"300 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"15–16 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 32 µg/mL","i_breakpoint":"64 µg/mL","r_breakpoint":"≥ 128 µg/mL"},"comments":[]}]},{"agentName":"Fosfomycin","breakpointSets":[{"condition":"Urine Only","diskDiffusion":{"diskContent":"200 µg","s_breakpoint":"≥ 16 mm","i_breakpoint":"13–15 mm","r_breakpoint":"≤ 12 mm"},"mic":{"s_breakpoint":"≤ 64 µg/mL","i_breakpoint":"128 µg/mL","r_breakpoint":"≥ 256 µg/mL"},"comments":["Important Note: Disk diffusion and MIC breakpoints for Fosfomycin apply only to E. coli urinary tract isolates and should not be extrapolated to other Enterobacterales species, including Klebsiella."]}]}]}]}'),Yb={diagnosticNotes:{summary:"",biosafetyWarning:"",methods:[]},preventionAndScreening:[],treatmentLifecycle:[],antimicrobialStewardship:["Reserve carbapenems for ESBL-producing strains or for mixed anaerobic/aerobic infections.","Reserve Ceftazidime-avibactam, Imipenem-relebactam, and Meropenem-vaborbactam for documented carbapenemase-producing infections."],drugSpecificPearls:[{drugName:"Ceftazidime-avibactam + Aztreonam",pearl:"This combination is recommended for metallo-beta-lactamase (MBL) producers because Aztreonam is not hydrolyzed by MBLs, and avibactam protects Aztreonam from other co-produced beta-lactamases like ESBLs or AmpC."},{drugName:"Cefiderocol",pearl:"FDA-approved for complicated UTIs with limited alternatives. In a key trial, 28-day mortality was not statistically different between cefiderocol and the best available therapy."},{drugName:"Ceftazidime-avibactam",pearl:"An observational study showed this drug was superior to Colistin for treating carbapenem-resistant Enterobacterales infections."},{drugName:"Meropenem + Polymyxin",pearl:"Combination therapy with Meropenem plus a polymyxin is not recommended for KPC producers based on a failed RCT, though the trial was underpowered for Enterobacterales."}],guidelineReferences:[]},Xb={identity:wb,clinicalProfile:Vb,resistanceProfile:Ub,treatment:Hb,laboratoryProfile:Gb,additionalInformation:Yb},Kb={bacteriumName:"Klebsiella sp. (rhinoscleromatis, ozaenae)",aliases:["Klebsiella rhinoscleromatis/ozaenae"],lastUpdated:"2024-09-09",clsiCategory:"Enterobacterales (excluding Salmonella/Shigella)",classification:{gramStain:"Gram-negative",morphology:"rod",respiration:"Facultative anaerobe",notes:["non-motile","encapsulated","Biochemically very inert compared to Klebsiella pneumoniae"]},strainDetails:[{type:"Subspecies",value:"Klebsiella rhinoscleromatis",notes:"Causative agent of Rhinoscleroma."},{type:"Subspecies",value:"Klebsiella ozaenae",notes:"Associated with Ozena (atrophic rhinitis)."}],biochemicalTests:"Gram-negative rod, non-motile, encapsulated. Biochemically very inert compared to K. pneumoniae. Typically indole –, citrate –, urease –, lysine –."},Qb={summary:"Causes two main chronic granulomatous diseases of the upper respiratory tract. Rhinoscleroma is a progressive disease more common in specific geographic regions (Africa, Eastern Europe, South America, Southeast Asia) and presents with purulent nasal discharge and nodule formation leading to obstruction. Ozena, or chronic atrophic rhinitis, typically affects elderly patients and presents with a classic triad of fetid nasal discharge, crusting, and nasal atrophy.",pathophysiologyPearls:[],keySignsAndSymptoms:[],clinicalSyndromes:[{syndromeName:"Rhinoscleroma",description:"A chronic granulomatous disease of the upper respiratory tract, presenting with purulent nasal discharge and nodule formation with obstruction."},{syndromeName:"Ozena (Atrophic Rhinitis)",description:"Chronic atrophic rhinitis or sinusitis, characterized by a triad of fetid nasal discharge, crusting, and atrophy. K. ozaenae is often isolated from affected patients."}],stagesOfIllness:[],highRiskPopulations:["Individuals in or from Africa, Eastern Europe, South America, and Southeast Asia (for Rhinoscleroma)","Elderly patients (for Ozena)"],transmissionVectors:[],prognosisNotes:["Relapses can occur in Rhinoscleroma, even after prolonged treatment.","The causative role of K. ozaenae in ozena is controversial."]},Zb={groupIntrinsicResistance:[{drugOrClass:"Ampicillin",notes:"Most Klebsiella species possess a chromosomal SHV-1 β-lactamase conferring intrinsic resistance to ampicillin, amoxicillin, ticarcillin, and carbenicillin."}],intrinsicResistance:[],majorMechanisms:[],clinicalAlerts:[{alertTitle:"Potential for Relapse",details:"Relapses can occur in Rhinoscleroma even after a long course of antibiotic therapy."}]},Jb={generalNotes:["For Ozena, the role of infection is controversial. Topical moistening agents and nasal irrigation are recommended as initial therapy, with antibiotics reserved for documented superinfection."],drugsToAvoid:[],adjunctiveTherapies:[],regimens:[{context:{type:"Directed",condition:"Rhinoscleroma",patientPopulation:["Adults"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Monotherapy",steps:[{step:1,duration:"2-3 months",drugs:[{drugName:"Ciprofloxacin",dose:"750 mg",route:"po",frequency:"bid",comments:null}]}],notes:[]},{preference:"Primary",strategy:"Monotherapy",steps:[{step:1,duration:"2-3 months",drugs:[{drugName:"Levofloxacin",dose:"750 mg",route:"po",frequency:"once daily",comments:null}]}],notes:["Relapses can occur after treatment is complete."]}]},{context:{type:"Directed",condition:"Ozena (for superinfection)",patientPopulation:["Elderly Patients"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Monotherapy",steps:[{step:1,duration:"8 weeks",drugs:[{drugName:"Ciprofloxacin",dose:"750 mg",route:"po",frequency:"bid",comments:null}]}],notes:[]},{preference:"Primary",strategy:"Monotherapy",steps:[{step:1,duration:"8 weeks",drugs:[{drugName:"Levofloxacin",dose:"750 mg",route:"po",frequency:"once daily",comments:null}]}],notes:["The role of infection in ozena is controversial; topical moistening agents are recommended as initial therapy, with antibiotics reserved for superinfection."]}]}]},Fb={testingIndications:["Isolation of the organism via culture from nasal specimens is required for diagnosis.","For Rhinoscleroma, histological examination of biopsy specimens is crucial to identify characteristic Mikulicz cells."],methodologyNotes:[],recommendedPanel:[],specialTests:[],reportingRules:[],antimicrobialBreakpoints:[{tier:1,tierDescription:"Appropriate for routine, primary testing and reporting.",agents:[{agentName:"Ampicillin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 17 mm",i_breakpoint:"14–16 mm",r_breakpoint:"≤ 13 mm"},mic:{s_breakpoint:"≤ 8 µg/mL",i_breakpoint:"16 µg/mL",r_breakpoint:"≥ 32 µg/mL"},comments:["Results of ampicillin testing can be used to predict results for amoxicillin."]}]},{agentName:"Cefazolin",breakpointSets:[{condition:"Urine Only - Uncomplicated UTI",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 15 mm",i_breakpoint:null,r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 16 µg/mL",i_breakpoint:null,r_breakpoint:"≥ 32 µg/mL"},comments:["Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."]}]},{agentName:"Amoxicillin-clavulanate",breakpointSets:[{condition:"Urine Only - Uncomplicated UTI",diskDiffusion:{diskContent:"20/10 µg",s_breakpoint:"≥ 18 mm",i_breakpoint:null,r_breakpoint:"≤ 17 mm"},mic:{s_breakpoint:"≤ 8/4 µg/mL",i_breakpoint:"16/4 µg/mL",r_breakpoint:"≥ 32/4 µg/mL"},comments:[]}]},{agentName:"Piperacillin-tazobactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"100/10 µg",s_breakpoint:"≥ 25 mm",i_breakpoint:"21–24 mm",r_breakpoint:"≤ 20 mm"},mic:{s_breakpoint:"≤ 8/4 µg/mL",i_breakpoint:"16/4 µg/mL",r_breakpoint:"≥ 32/4 µg/mL"},comments:[]}]}]},{tier:2,tierDescription:"Appropriate for routine, primary testing, may be reported following cascade reporting rules.",agents:[{agentName:"Cefepime",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 25 mm",i_breakpoint:"19–24 mm",r_breakpoint:"≤ 18 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:"8 µg/mL",r_breakpoint:"≥ 16 µg/mL"},comments:["Cefepime S/SDD results should be suppressed or reported as resistant for isolates that demonstrate carbapenemase production."]}]},{agentName:"Ertapenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 22 mm",i_breakpoint:"19–21 mm",r_breakpoint:"≤ 18 mm"},mic:{s_breakpoint:"≤ 0.5 µg/mL",i_breakpoint:"1 µg/mL",r_breakpoint:"≥ 2 µg/mL"},comments:[]}]},{agentName:"Meropenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 23 mm",i_breakpoint:"20–22 mm",r_breakpoint:"≤ 19 mm"},mic:{s_breakpoint:"≤ 1 µg/mL",i_breakpoint:"2 µg/mL",r_breakpoint:"≥ 4 µg/mL"},comments:[]}]}]},{tier:3,tierDescription:"Appropriate for high-risk MDRO patients, subject to cascade reporting.",agents:[{agentName:"Ceftazidime-avibactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30/20 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:null,r_breakpoint:"≤ 20 mm"},mic:{s_breakpoint:"≤ 8/4 µg/mL",i_breakpoint:null,r_breakpoint:"≥ 16/4 µg/mL"},comments:["Confirmatory MIC testing is indicated for isolates with zones of 20–22 mm."]}]},{agentName:"Meropenem-vaborbactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"20/10 µg",s_breakpoint:"≥ 18 mm",i_breakpoint:"15–17 mm",r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 4/8 µg/mL",i_breakpoint:"8/8 µg/mL",r_breakpoint:"≥ 16/8 µg/mL"},comments:["If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]}]},{tier:4,tierDescription:"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available.",agents:[{agentName:"Aztreonam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:"18–20 mm",r_breakpoint:"≤ 17 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:"8 µg/mL",r_breakpoint:"≥ 16 µg/mL"},comments:[]}]},{agentName:"Ceftriaxone",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 26 mm",i_breakpoint:"20–22 mm",r_breakpoint:"≤ 19 mm"},mic:{s_breakpoint:"≤ 1 µg/mL",i_breakpoint:"2 µg/mL",r_breakpoint:"≥ 4 µg/mL"},comments:[]}]},{agentName:"Colistin or Polymyxin B",breakpointSets:[{condition:"Standard",diskDiffusion:null,mic:{s_breakpoint:"≤ 2 µg/mL",i_breakpoint:null,r_breakpoint:"≥ 4 µg/mL"},comments:["Disk diffusion and gradient diffusion methods should not be performed."]}]}]}]},$b={diagnosticNotes:{summary:"Diagnosis is confirmed by isolation of the organism via culture from the upper respiratory tract. For Rhinoscleroma, histopathology showing Mikulicz cells is characteristic.",biosafetyWarning:null,methods:[{methodName:"Culture",details:"Isolation from purulent nasal discharge or tissue biopsy."},{methodName:"Histology",details:"For Rhinoscleroma, biopsy showing chronic granulomatous inflammation with numerous plasma cells and characteristic large vacuolated macrophages (Mikulicz cells) containing the bacteria."}]},preventionAndScreening:[],treatmentLifecycle:[],antimicrobialStewardship:["In cases of Ozena, antibiotics should be reserved for superinfection. Initial therapy should focus on topical moistening agents and nasal irrigation to manage crusting and atrophy."],drugSpecificPearls:[],guidelineReferences:[]},Wb={identity:Kb,clinicalProfile:Qb,resistanceProfile:Zb,treatment:Jb,laboratoryProfile:Fb,additionalInformation:$b},eg={bacteriumName:"Morganella morganii",aliases:["Morganella sp."],lastUpdated:"2025-01-17",clsiCategory:"Enterobacterales (excluding Salmonella/Shigella)",classification:{gramStain:"Gram negative",morphology:"Bacilli",respiration:"Facultative anaerobe",notes:["Enteric bacterium."]},strainDetails:[],biochemicalTests:"Gram-negative rod, motile, lactose –, H2S –, indole +, citrate –, urease +, phenylalanine deaminase +, ornithine decarboxylase +."},tg={summary:"Morganella morganii can cause various infections, but it is most commonly identified as the cause of urinary tract and post-operative wound infections. It is typically a nosocomial pathogen.",pathophysiologyPearls:["Like other SPACE-M organisms, M. morganii may initially test susceptible to third-generation cephalosporins but can become resistant during therapy due to derepression of an inducible AmpC β-lactamase.","The risk of AmpC derepression during therapy is noted as less frequent for M. morganii compared to other organisms like Enterobacter cloacae complex or Citrobacter freundii complex."],keySignsAndSymptoms:[],clinicalSyndromes:[{syndromeName:"Urinary Tract Infections (UTI)",description:"A common manifestation, particularly in hospital settings. For UTIs, it's crucial to remove indwelling Foley catheters if possible and ensure no urinary obstruction."},{syndromeName:"Post-operative Wound Infections",description:"Infections occurring at the site of a surgical incision."}],stagesOfIllness:[],highRiskPopulations:["Hospitalized patients (nosocomial infections)"],transmissionVectors:[],prognosisNotes:[]},ig={groupIntrinsicResistance:[],intrinsicResistance:[{drugOrClass:"Polymyxins (Colistin, Polymyxin B)",notes:"Isolates are intrinsically resistant."},{drugOrClass:"Penicillins (Penicillin, Ampicillin, Amoxicillin-clavulanate)",notes:"Isolates are intrinsically resistant."},{drugOrClass:"Ampicillin/sulbactam",notes:"Isolates are intrinsically resistant."},{drugOrClass:"1st and 2nd Generation Cephalosporins",notes:"Isolates are intrinsically resistant."},{drugOrClass:"Nitrofurantoin",notes:"Isolates are intrinsically resistant."},{drugOrClass:"Fosfomycin",notes:"Isolates are intrinsically resistant."}],majorMechanisms:[{mechanismName:"Inducible AmpC β-lactamase",mechanismType:"Enzymatic Inactivation",description:"M. morganii possesses an inducible AmpC gene that can be derepressed during therapy with third-generation cephalosporins, leading to resistance, although this is less frequent than in other AmpC-producers."},{mechanismName:"Carbapenemase Production",mechanismType:"Enzymatic Inactivation",description:"Isolates may produce carbapenemases, including serine-carbapenemases (like KPC) or metallo-beta-lactamases (MBLs)."},{mechanismName:"Plasmid-mediated Resistance",mechanismType:"Various",description:"Strains may acquire plasmid-mediated resistance to aminoglycosides and fluoroquinolones."}],clinicalAlerts:[{alertTitle:"Potential for Inducible AmpC Resistance",details:"Although the risk is lower than with other organisms, M. morganii can develop resistance to third-generation cephalosporins during treatment. For high-inoculum infections, Cefepime may be a more stable option than Ceftriaxone."}]},ag={generalNotes:["Recommendations are generally for moderately severe or severe infections.","For uncomplicated infections with susceptible strains, options can include fluoroquinolones and third-generation cephalosporins.","TMP-SMX is an option only if the strain is susceptible, as resistance is common.","Imipenem is noted to be less active than other carbapenems against M. morganii."],drugsToAvoid:[],adjunctiveTherapies:[],regimens:[{context:{type:"Empiric",condition:"Suspected Morganella sp. infection, susceptibility pending",patientPopulation:["Local ESBL rate <10-15%"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Piperacillin-tazobactam",dose:"4.5 gm",route:"IV",frequency:"q8h",comments:"Infuse over 4 hours."}]}]},{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ceftriaxone",dose:"1-2 gm",route:"IV",frequency:"q24h",comments:""},{drugName:"Cefepime",dose:"1-2 gm",route:"IV",frequency:"q8h-q12h",comments:""},{drugName:"Aztreonam",dose:"2 gm",route:"IV",frequency:"q8h",comments:""},{drugName:"Ciprofloxacin",dose:"400 mg",route:"IV",frequency:"q12h",comments:""},{drugName:"Levofloxacin",dose:"750 mg",route:"IV",frequency:"once daily",comments:""}]}]},{preference:"For Life-Threatening Illness",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",comments:""}]}]}]},{context:{type:"Empiric",condition:"Suspected Morganella sp. infection, susceptibility pending",patientPopulation:["Local ESBL rate >15%"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",comments:""},{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",comments:""}]}]}]},{context:{type:"Directed",condition:"No ESBL or constitutive AmpC production",patientPopulation:["Isolate susceptible to 3rd-gen cephalosporins, TMP-SMX, fluoroquinolones"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ceftriaxone",dose:"1-2 gm",route:"IV",frequency:"q24h",comments:""},{drugName:"Cefepime",dose:"1-2 gm",route:"IV",frequency:"q8h-q12h",comments:"May be preferred over Ceftriaxone for high inoculum infections."},{drugName:"Ciprofloxacin",dose:"400 mg",route:"IV",frequency:"q12h",comments:""},{drugName:"Levofloxacin",dose:"750 mg",route:"IV",frequency:"once daily",comments:""},{drugName:"TMP-SMX",dose:"10 mg/kg/day (TMP component)",route:"IV",frequency:"in 2-3 divided doses",comments:""}]}]}]},{context:{type:"Directed",condition:"ESBL and/or AmpC overproduction",patientPopulation:["Isolate resistant to aztreonam, ceftriaxone, cefotaxime, ceftazidime"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",comments:""},{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",comments:""}]}]},{preference:"Alternative (if susceptible)",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ciprofloxacin",dose:"400 mg",route:"IV",frequency:"q12h",comments:""},{drugName:"Levofloxacin",dose:"750 mg",route:"IV",frequency:"once daily",comments:""},{drugName:"TMP-SMX",dose:"10 mg/kg/day (TMP component)",route:"IV",frequency:"in 2-3 divided doses",comments:""}]}]}]},{context:{type:"Directed",condition:"Serine-carbapenemase (e.g., KPC) producer",patientPopulation:["Resistant to carbapenems but susceptible to newer beta-lactamase inhibitor combos"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",comments:"Infuse over 3 hours. Use if susceptible in vitro."},{drugName:"Meropenem-vaborbactam",dose:"4 gm",route:"IV",frequency:"q8h",comments:"Infuse over 3 hours."}]}]}]},{context:{type:"Directed",condition:"Metallo-beta-lactamase (MBL) producer",patientPopulation:["Pan-resistant to most tested beta-lactams and other agents"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",comments:"Infuse over 3 hours."},{drugName:"Aztreonam",dose:"2 gm",route:"IV",frequency:"q6h",comments:"Infuse over 3 hours. Must be given with Ceftazidime-avibactam."}]}]},{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Cefiderocol",dose:"2 gm",route:"IV",frequency:"q8h",comments:"Infuse over 3 hours."}]}]}]}]},ng={testingIndications:["If resistance to third-generation cephalosporins develops during therapy, subsequent testing of the isolate may be clinically warranted to guide further treatment."],methodologyNotes:["The approach to testing and reporting AST results for organisms with inducible resistance, like M. morganii, should be determined in consultation with the institutional antimicrobial stewardship team."],recommendedPanel:[],specialTests:[],reportingRules:[{ruleType:"Exception",drug:"Imipenem-relebactam",condition:"Isolate is identified as a member of the family Morganellaceae (Morganella, Proteus, Providencia).",details:"The defined CLSI breakpoints for Imipenem-relebactam do not apply to Morganella morganii. This agent should not be reported using these breakpoints for this organism."}],antimicrobialBreakpoints:[{tier:1,tierDescription:"Appropriate for routine, primary testing and reporting.",agents:[{agentName:"Piperacillin-tazobactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"100/10 µg",s_breakpoint:"≥ 22 mm",i_breakpoint:"18–21 mm",r_breakpoint:"≤ 17 mm"},mic:{s_breakpoint:"≤ 16/4 µg/mL",i_breakpoint:"32/4 µg/mL",r_breakpoint:"≥ 64/4 µg/mL"},comments:["Note: These breakpoints are specific to Morganella, Proteus, and Providencia species and differ from other Enterobacterales."]}]},{agentName:"Gentamicin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 18 mm",i_breakpoint:"15–17 mm",r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:"—",r_breakpoint:"≥ 8 µg/mL"},comments:[]}]},{agentName:"Tobramycin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 17 mm",i_breakpoint:"13–16 mm",r_breakpoint:"≤ 12 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:"—",r_breakpoint:"≥ 8 µg/mL"},comments:[]}]},{agentName:"Amikacin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 19 mm",i_breakpoint:"17–18 mm",r_breakpoint:"≤ 16 mm"},mic:{s_breakpoint:"≤ 16 µg/mL",i_breakpoint:"—",r_breakpoint:"≥ 32 µg/mL"},comments:[]}]},{agentName:"Ciprofloxacin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"5 µg",s_breakpoint:"≥ 26 mm",i_breakpoint:"22–25 mm",r_breakpoint:"≤ 21 mm"},mic:{s_breakpoint:"≤ 0.25 µg/mL",i_breakpoint:"0.5 µg/mL",r_breakpoint:"≥ 1 µg/mL"},comments:[]}]},{agentName:"Levofloxacin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"5 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:"17–20 mm",r_breakpoint:"≤ 16 mm"},mic:{s_breakpoint:"≤ 0.5 µg/mL",i_breakpoint:"1 µg/mL",r_breakpoint:"≥ 2 µg/mL"},comments:[]}]},{agentName:"Trimethoprim-sulfamethoxazole",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"1.25/23.75 µg",s_breakpoint:"≥ 16 mm",i_breakpoint:"11–15 mm",r_breakpoint:"≤ 10 mm"},mic:{s_breakpoint:"≤ 2/38 µg/mL",i_breakpoint:"—",r_breakpoint:"≥ 4/76 µg/mL"},comments:[]}]}]},{tier:2,tierDescription:"Appropriate for routine, primary testing, may be reported following cascade reporting rules.",agents:[{agentName:"Cefepime",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 25 mm",i_breakpoint:"19–24 mm",r_breakpoint:"≤ 18 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:"8 µg/mL",r_breakpoint:"≥ 16 µg/mL"},comments:["Cefepime S/SDD results should be suppressed or reported as resistant for isolates demonstrating carbapenemase production."]}]},{agentName:"Ertapenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 22 mm",i_breakpoint:"19–21 mm",r_breakpoint:"≤ 18 mm"},mic:{s_breakpoint:"≤ 0.5 µg/mL",i_breakpoint:"1 µg/mL",r_breakpoint:"≥ 2 µg/mL"},comments:[]}]},{agentName:"Imipenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 23 mm",i_breakpoint:"20–22 mm",r_breakpoint:"≤ 19 mm"},mic:{s_breakpoint:"≤ 1 µg/mL",i_breakpoint:"2 µg/mL",r_breakpoint:"≥ 4 µg/mL"},comments:[]}]},{agentName:"Meropenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 23 mm",i_breakpoint:"20–22 mm",r_breakpoint:"≤ 19 mm"},mic:{s_breakpoint:"≤ 1 µg/mL",i_breakpoint:"2 µg/mL",r_breakpoint:"≥ 4 µg/mL"},comments:[]}]}]},{tier:3,tierDescription:"Appropriate for high-risk MDRO patients, subject to cascade reporting.",agents:[{agentName:"Cefiderocol",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 20 mm",i_breakpoint:"9–15 mm",r_breakpoint:"≤ 8 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:"—",r_breakpoint:"≥ 8 µg/mL"},comments:[]}]},{agentName:"Ceftazidime-avibactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30/20 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:"—",r_breakpoint:"≤ 20 mm"},mic:{s_breakpoint:"≤ 8/4 µg/mL",i_breakpoint:"—",r_breakpoint:"≥ 16/4 µg/mL"},comments:["Confirmatory MIC testing is indicated for isolates with disk diffusion zones of 20–22 mm."]}]},{agentName:"Meropenem-vaborbactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"20/10 µg",s_breakpoint:"≥ 18 mm",i_breakpoint:"15–17 mm",r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 4/8 µg/mL",i_breakpoint:"8/8 µg/mL",r_breakpoint:"≥ 16/8 µg/mL"},comments:["If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]},{agentName:"Plazomicin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 18 mm",i_breakpoint:"15–17 mm",r_breakpoint:"≤ 14 mm"},mic:{s_breakpoint:"≤ 2 µg/mL",i_breakpoint:"—",r_breakpoint:"≥ 4 µg/mL"},comments:[]}]}]},{tier:4,tierDescription:"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available.",agents:[{agentName:"Aztreonam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:"18–20 mm",r_breakpoint:"≤ 17 mm"},mic:{s_breakpoint:"≤ 4 µg/mL",i_breakpoint:"8 µg/mL",r_breakpoint:"≥ 16 µg/mL"},comments:[]}]},{agentName:"Ceftriaxone",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 26 mm",i_breakpoint:"20–22 mm",r_breakpoint:"≤ 19 mm"},mic:{s_breakpoint:"≤ 1 µg/mL",i_breakpoint:"2 µg/mL",r_breakpoint:"≥ 4 µg/mL"},comments:[]}]},{agentName:"Ceftazidime",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 21 mm",i_breakpoint:"18–20 mm",r_breakpoint:"≤ 17 mm"},mic:{s_breakpoint:"≤ 8 µg/mL",i_breakpoint:"16 µg/mL",r_breakpoint:"≥ 32 µg/mL"},comments:[]}]},{agentName:"Ceftolozane-tazobactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30/10 µg",s_breakpoint:"≥ 22 mm",i_breakpoint:"19–21 mm",r_breakpoint:"≤ 18 mm"},mic:{s_breakpoint:"≤ 2/4 µg/mL",i_breakpoint:"—",r_breakpoint:"≥ 4/4 µg/mL"},comments:["Note: These breakpoints are specific to Morganella, Proteus, and Providencia species and differ from other Enterobacterales."]}]}]}]},sg={diagnosticNotes:{summary:"For UTIs, remove indwelling Foley catheter if possible and ensure no urinary obstruction. Note the intrinsic lack of activity of nitrofurantoin and fosfomycin.",biosafetyWarning:"",methods:[]},preventionAndScreening:[],treatmentLifecycle:[],antimicrobialStewardship:["For ESBL-producing strains, Piperacillin-tazobactam should be avoided even if it is reported as susceptible in vitro.","Susceptibility should be checked for all carbapenems individually; resistance to imipenem does not predict resistance to meropenem.","Tigecycline may show in vitro activity against MDR/XDR strains, but its clinical efficacy is questionable due to low serum levels.","For metallo-beta-lactamase (MBL) producers, Aztreonam is not hydrolyzed by the MBL enzyme, but co-production of other beta-lactamases that can hydrolyze it is common. Combining Ceftazidime-avibactam with Aztreonam can protect Aztreonam and has been successful in case reports."],drugSpecificPearls:[{drugName:"Cefiderocol",pearl:"This drug is FDA-approved for complicated UTIs with limited or no other treatment options. In one trial, 28-day mortality was 24.8% for cefiderocol vs 18.4% for the best available therapy, a difference that was not statistically significant."}],guidelineReferences:[{source:"IDSA",citation:"Updated 2024 IDSA Guideline on treatment of ESBL, AmpC, and carbapenemase producers.",summaryOrNote:"Provides comprehensive guidance for treating infections caused by resistant gram-negative organisms."}]},og={identity:eg,clinicalProfile:tg,resistanceProfile:ig,treatment:ag,laboratoryProfile:ng,additionalInformation:sg},rg={bacteriumName:"Proteus sp.",aliases:["Proteus mirabilis","Proteus penneri","Proteus vulgaris"],lastUpdated:"2025-01-08",clsiCategory:"Enterobacterales (excluding Salmonella/Shigella)",classification:{gramStain:"Gram negative",morphology:"bacilli",respiration:"Facultative anaerobe",notes:["motile (swarming on culture plate)"]},strainDetails:[{type:"Complex Member",value:"Proteus mirabilis",notes:"indole negative"},{type:"Complex Member",value:"Proteus penneri",notes:"indole negative"},{type:"Complex Member",value:"Proteus vulgaris",notes:"indole positive"}],biochemicalTests:"Gram-negative rod, highly motile (swarming), lactose –, urease strongly +, phenylalanine deaminase +, H2S + (P. mirabilis, P. vulgaris)."},lg={summary:"Proteus sp. cause a variety of infections from uncomplicated UTIs to life-threatening infections of the abdomen, skin, soft tissue, and lungs in both normal and immunocompromised hosts. UTIs are the most common and are often catheter-associated.",pathophysiologyPearls:["Known for biofilm formation and producing a potent urease enzyme, which leads to alkaline urine and the formation of struvite stones (magnesium ammonium phosphate)."],keySignsAndSymptoms:[],clinicalSyndromes:[{syndromeName:"Urinary Tract Infections (UTI)",description:"Most common infection type, frequently catheter-associated and can be complicated by the formation of struvite stones due to urease production."},{syndromeName:"Intra-abdominal Infections",description:"Can cause life-threatening infections of the abdomen."},{syndromeName:"Skin and Soft Tissue Infections",description:"Can cause life-threatening infections of the skin and soft tissue."},{syndromeName:"Pneumonia",description:"Can cause life-threatening infections of the lungs."}],stagesOfIllness:[],highRiskPopulations:["Immunocompromised hosts","Patients with urinary catheters"],transmissionVectors:[],prognosisNotes:["Diagnostic imaging is recommended for upper tract or recurrent infections to assess for stones or obstructive uropathy."]},cg={groupIntrinsicResistance:[],intrinsicResistance:[{drugOrClass:"Polymyxins",notes:"Proteus species are intrinsically resistant to polymyxins (Colistin, Polymyxin B)."},{drugOrClass:"Nitrofurantoin",notes:"Proteus spp. are intrinsically resistant to Nitrofurantoin."}],majorMechanisms:[{mechanismName:"ESBL (Extended-Spectrum Beta-Lactamase)",mechanismType:"Enzymatic",description:"Confers resistance to most penicillins and cephalosporins. Indole positive species (P. vulgaris) may overproduce ESBLs."},{mechanismName:"AmpC Beta-Lactamase",mechanismType:"Enzymatic",description:"Resistance to aztreonam, ceftriaxone, and/or cefotaxime may indicate overproduction of AmpC."},{mechanismName:"KPC (Klebsiella pneumoniae carbapenemase)",mechanismType:"Enzymatic",description:"A serine-based carbapenemase conferring resistance to all carbapenems. Can be overcome by new beta-lactamase inhibitor combinations like meropenem-vaborbactam or ceftazidime-avibactam."},{mechanismName:"MBL (Metallo-Beta-Lactamase)",mechanismType:"Enzymatic",description:"Confers resistance to all carbapenems and newer beta-lactamase inhibitors (vaborbactam, avibactam). Requires alternative strategies like ceftazidime-avibactam + aztreonam or cefiderocol."}],clinicalAlerts:[{alertTitle:"ESBL Production and Piperacillin-Tazobactam",details:"Do not use piperacillin-tazobactam for suspected or proven ESBL production, as it may fail clinically despite in vitro susceptibility."},{alertTitle:"Carbapenem Activity Variability",details:"Imipenem is noted to be less active against Proteus spp. compared to other carbapenems. Check susceptibility of all carbapenems if considering their use."}]},mg={generalNotes:["The recommendations in the table are for moderately severe or severe infections.","For less severe infections, options include Amoxicillin-clavulanate, fluoroquinolones, and second/third-gen cephalosporins.","Amoxicillin may be active against P. mirabilis but not P. vulgaris.","TMP-SMX can be used if susceptible.","Proteus spp. are intrinsically resistant to Nitrofurantoin.","Imipenem is less active than other carbapenems.","Fosfomycin susceptibility is variable and should only be used for uncomplicated UTI if susceptible."],drugsToAvoid:[{drugOrClass:"Nitrofurantoin",condition:"All infections",reason:"Intrinsic resistance."},{drugOrClass:"Polymyxins (Colistin, Polymyxin B)",condition:"All infections",reason:"Intrinsic resistance."},{drugOrClass:"Piperacillin-tazobactam",condition:"Suspected or proven ESBL-producing infections",reason:"Reported clinical failures despite in vitro susceptibility."},{drugOrClass:"Imipenem-relebactam",condition:"All infections",reason:"CLSI breakpoints do not apply to the family Morganellaceae, which includes Proteus."}],adjunctiveTherapies:[],regimens:[{context:{type:"Empiric",condition:"Moderately severe or severe infection",patientPopulation:["Areas with local ESBL rate <15%"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"pending susceptibilities",drugs:[{drugName:"Piperacillin-tazobactam",dose:"4.5 gm",route:"IV",frequency:"q8h",comments:"Administer over 4 hours."}]}]},{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"pending susceptibilities",drugs:[{drugName:"Ciprofloxacin",dose:"400 mg",route:"IV",frequency:"bid",comments:""}]}]},{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"pending susceptibilities",drugs:[{drugName:"Levofloxacin",dose:"750 mg",route:"IV",frequency:"q24h",comments:""}]}]},{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"pending susceptibilities",drugs:[{drugName:"Cefazolin",dose:"1 gm",route:"IV",frequency:"q12h",comments:""}]}]},{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"pending susceptibilities",drugs:[{drugName:"Ceftriaxone",dose:"1-2 gm",route:"IV",frequency:"q24h",comments:""}]}]}]},{context:{type:"Empiric",condition:"Moderately severe or severe infection",patientPopulation:["Areas with local ESBL rate >15%"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"pending susceptibilities",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",comments:"See alternative regimens for other options."}]}]}]},{context:{type:"Directed",condition:"Indole positive Proteus (e.g., vulgaris) with resistance to aztreonam, ceftriaxone, and/or cefotaxime",patientPopulation:["Patients with isolates consistent with overproduction of ESBL and/or AmpC"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Course of therapy",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",comments:"Higher percentage of in vitro resistance to Imipenem compared to other carbapenems. Avoid Pip/tazo if ESBL production is suspected."}]}]},{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"Course of therapy",drugs:[{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24hr",comments:"See other alternatives if needed."}]}]}]},{context:{type:"Directed",condition:"Carbapenem resistance, KPC suspected",patientPopulation:["Isolates resistant to all carbapenems but susceptible to meropenem-vaborbactam and ceftazidime-avibactam"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Course of therapy",drugs:[{drugName:"Meropenem-vaborbactam",dose:"4 gm",route:"IV",frequency:"q8h",comments:"Administer over 3 hours. Infectious Diseases consultation recommended."}]}]},{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"Course of therapy",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",comments:"Administer over 2 hours. Infectious Diseases consultation recommended."}]}]}]},{context:{type:"Directed",condition:"Carbapenem resistance, Metallo-beta-lactamase (MBL) suspected",patientPopulation:["Isolates resistant to all carbapenems, meropenem-vaborbactam, and ceftazidime-avibactam"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Course of therapy",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",comments:"Administer over 3 hours."},{drugName:"Aztreonam",dose:"2 gm",route:"IV",frequency:"q6h",comments:"Administer over 3 hours. Infectious Diseases consultation strongly recommended."}]}]},{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"Course of therapy",drugs:[{drugName:"Cefiderocol",dose:"2 gm",route:"IV",frequency:"q8h",comments:"Administer over 3 hours. Infectious Diseases consultation strongly recommended."}]}]}]},{context:{type:"Directed",condition:"Less severe infection, no evidence of ESBL or plasmid-based AmpC production",patientPopulation:[],isolateSource:null},recommendations:[{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"Course of therapy",drugs:[{drugName:"Cefixime",dose:"Varies",route:"PO",frequency:"Varies",comments:""},{drugName:"Cefpodoxime",dose:"Varies",route:"PO",frequency:"Varies",comments:""},{drugName:"Cefdinir",dose:"Varies",route:"PO",frequency:"Varies",comments:""}]}]},{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"1 dose",drugs:[{drugName:"Fosfomycin",dose:"3 gm",route:"PO",frequency:"x1",comments:"For UTI only. Use is discouraged for Proteus sp. as breakpoints are only for E.coli."}]}]}]},{context:{type:"Directed",condition:"Any infection",patientPopulation:["Patients with a severe beta-lactam allergy"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Course of therapy",drugs:[{drugName:"Aztreonam",dose:"Varies",route:"IV",frequency:"Varies",comments:""}]}]}]},{context:{type:"Directed",condition:"ESBL-producing infection",patientPopulation:["Patient cannot receive a carbapenem"],isolateSource:null},recommendations:[{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"Course of therapy",drugs:[{drugName:"Aminoglycoside",dose:"Varies",route:"IV",frequency:"Varies",comments:"If susceptible."},{drugName:"Fluoroquinolone",dose:"Varies",route:"IV/PO",frequency:"Varies",comments:"If susceptible."},{drugName:"Ceftolozane-tazobactam",dose:"1.5 gm",route:"IV",frequency:"q8h",comments:"Administer over 3 hours."},{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",comments:"Administer over 3 hours."},{drugName:"Cefepime-enmetazobactam",dose:"Varies",route:"IV",frequency:"Varies",comments:""},{drugName:"Temocillin",dose:"2 gm",route:"IV",frequency:"q12h",comments:"Where available."}]}]}]},{context:{type:"Directed",condition:"Pan-resistant infection",patientPopulation:[],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Course of therapy",drugs:[{drugName:"Plazomicin",dose:"15 mg/kg",route:"IV",frequency:"once daily",comments:"If available. Infectious Diseases consultation needed."}]}]}]}]},ug=JSON.parse(`{"testingIndications":["Cultures obtained from suspected sites of infection, such as urine, blood, wounds, or respiratory specimens."],"methodologyNotes":["Proteus species are known for their characteristic 'swarming' motility on non-inhibitory agar plates, which can sometimes complicate the isolation of other organisms in a mixed culture."],"recommendedPanel":[],"specialTests":[{"testName":"Indole Test","trigger":"Isolation of Proteus sp.","purpose":"To differentiate between Proteus species. P. vulgaris is indole positive, while P. mirabilis and P. penneri are indole negative. This can have treatment implications as P. vulgaris may have different resistance patterns."}],"reportingRules":[{"ruleType":"Surrogate","drug":"Ampicillin","condition":"All isolates","details":"Results of ampicillin testing can be used to predict results for amoxicillin."},{"ruleType":"Surrogate","drug":"Cefazolin","condition":"Uncomplicated UTI caused by P. mirabilis","details":"Cefazolin can be used as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."},{"ruleType":"Surrogate","drug":"Tetracycline","condition":"All isolates","details":"Organisms susceptible to tetracycline are also considered susceptible to doxycycline and minocycline."},{"ruleType":"Conditional","drug":"Cefepime","condition":"Isolate demonstrates carbapenemase production.","details":"Cefepime S/SDD results should be suppressed or reported as resistant."},{"ruleType":"Conditional","drug":"Meropenem-vaborbactam","condition":"An OXA-48-like gene or enzyme is detected.","details":"Results should be suppressed or reported as resistant."},{"ruleType":"Exclusion","drug":"Fosfomycin","condition":"Any Proteus sp. isolate","details":"Disk diffusion and MIC breakpoints for Fosfomycin apply only to E. coli urinary tract isolates and should not be extrapolated to other Enterobacterales species, including Proteus sp."},{"ruleType":"Exclusion","drug":"Imipenem-relebactam","condition":"Any Proteus sp. isolate","details":"Breakpoints for imipenem-relebactam are explicitly stated not to apply to the family Morganellaceae, which includes Proteus."},{"ruleType":"General","drug":"All","condition":"All isolates","details":"Laboratories generally follow cascade reporting rules, meaning that results for broader-spectrum agents (Tier 2 or 3) are often only reported if the isolate is resistant to primary, narrower-spectrum agents (Tier 1)."}],"antimicrobialBreakpoints":[{"tier":1,"tierDescription":"Appropriate for routine, primary testing and reporting.","agents":[{"agentName":"Ampicillin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"14–16 mm","r_breakpoint":"≤ 13 mm"},"mic":{"s_breakpoint":"≤ 8 µg/mL","i_breakpoint":"16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":["Results of ampicillin testing can predict results for amoxicillin."]}]},{"agentName":"Amoxicillin-clavulanate","breakpointSets":[{"condition":"Uncomplicated UTI only","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":null,"r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":"16/4 µg/mL","r_breakpoint":"≥ 32/4 µg/mL"},"comments":["Breakpoints when oral amoxicillin-clavulanate is used are only for therapy of uncomplicated UTIs due to E. coli and Proteus mirabilis."]}]},{"agentName":"Ampicillin-sulbactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10/10 µg","s_breakpoint":"≥ 15 mm","i_breakpoint":"12–14 mm","r_breakpoint":"≤ 11 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":"16/4 µg/mL","r_breakpoint":"≥ 32/16 µg/mL"},"comments":[]}]},{"agentName":"Piperacillin-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"100/10 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"21–24 mm","r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":"16/4 µg/mL","r_breakpoint":"≥ 32/4 µg/mL"},"comments":[]}]},{"agentName":"Gentamicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Tobramycin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"13–16 mm","r_breakpoint":"≤ 12 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Amikacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 19 mm","i_breakpoint":"17–19 mm","r_breakpoint":"≤ 16 mm"},"mic":{"s_breakpoint":"≤ 16 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 32 µg/mL"},"comments":[]}]},{"agentName":"Ciprofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥ 26 mm","i_breakpoint":"22–25 mm","r_breakpoint":"≤ 21 mm"},"mic":{"s_breakpoint":"≤ 0.25 µg/mL","i_breakpoint":"0.5 µg/mL","r_breakpoint":"≥ 1 µg/mL"},"comments":[]}]},{"agentName":"Levofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"17–20 mm","r_breakpoint":"≤ 16 mm"},"mic":{"s_breakpoint":"≤ 0.5 µg/mL","i_breakpoint":"1 µg/mL","r_breakpoint":"≥ 2 µg/mL"},"comments":[]}]},{"agentName":"Trimethoprim-sulfamethoxazole","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"1.25/23.75 µg","s_breakpoint":"≥ 16 mm","i_breakpoint":"11–15 mm","r_breakpoint":"≤ 10 mm"},"mic":{"s_breakpoint":"≤ 2/38 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4/76 µg/mL"},"comments":[]}]},{"agentName":"Cefotaxime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 26 mm","i_breakpoint":"23–25 mm","r_breakpoint":"≤ 22 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]},{"agentName":"Ceftriaxone","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 26 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]}]},{"tier":2,"tierDescription":"Appropriate for routine, primary testing, may be reported following cascade reporting rules.","agents":[{"agentName":"Cefuroxime (Parenteral)","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"18–22 mm","r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8–16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":[]}]},{"agentName":"Cefepime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"19–24 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8 µg/mL","r_breakpoint":"≥ 16 µg/mL"},"comments":["Cefepime S/SDD results should be suppressed or reported as resistant for isolates demonstrating carbapenemase production."]}]},{"agentName":"Ertapenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 22 mm","i_breakpoint":"19–21 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 0.5 µg/mL","i_breakpoint":"1 µg/mL","r_breakpoint":"≥ 2 µg/mL"},"comments":[]}]},{"agentName":"Imipenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]},{"agentName":"Meropenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]},{"agentName":"Cefotetan","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"13–15 mm","r_breakpoint":"≤ 12 mm"},"mic":{"s_breakpoint":"≤ 16 µg/mL","i_breakpoint":"32 µg/mL","r_breakpoint":"≥ 64 µg/mL"},"comments":[]}]},{"agentName":"Cefoxitin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 16 µg/mL","i_breakpoint":"32 µg/mL","r_breakpoint":"≥ 64 µg/mL"},"comments":[]}]},{"agentName":"Tetracycline","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 15 mm","i_breakpoint":"12–14 mm","r_breakpoint":"≤ 11 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8 µg/mL","r_breakpoint":"≥ 16 µg/mL"},"comments":["Organisms susceptible to tetracycline are also considered susceptible to doxycycline and minocycline."]}]}]},{"tier":3,"tierDescription":"Appropriate for high-risk Multi-Drug Resistant Organism (MDRO) patients, subject to cascade reporting.","agents":[{"agentName":"Cefiderocol","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 16 mm","i_breakpoint":"9–15 mm","r_breakpoint":"≤ 8 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Ceftazidime-avibactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/20 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":null,"r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 16/4 µg/mL"},"comments":["Confirmatory MIC testing is indicated for isolates with disk diffusion zones of 20–22 mm."]}]},{"agentName":"Imipenem-relebactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10/25 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"21–24 mm","r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 1/4 µg/mL","i_breakpoint":"2/4 µg/mL","r_breakpoint":"≥ 4/4 µg/mL"},"comments":["Important Comment for Proteus sp.: These breakpoints do not apply to the family Morganellaceae, which includes but is not limited to the genera Morganella, Proteus, and Providencia."]}]},{"agentName":"Meropenem-vaborbactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 4/8 µg/mL","i_breakpoint":"8/8 µg/mL","r_breakpoint":"≥ 16/8 µg/mL"},"comments":["If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]},{"agentName":"Plazomicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 2 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]}]},{"tier":4,"tierDescription":"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available.","agents":[{"agentName":"Aztreonam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"18–20 mm","r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8 µg/mL","r_breakpoint":"≥ 16 µg/mL"},"comments":[]}]},{"agentName":"Ceftazidime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"18–20 mm","r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 8 µg/mL","i_breakpoint":"16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":[]}]},{"agentName":"Ceftolozane-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/10 µg","s_breakpoint":"≥ 22 mm","i_breakpoint":"19–21 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 2/4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4/4 µg/mL"},"comments":[]}]},{"agentName":"Colistin or Polymyxin B","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":null,"s_breakpoint":null,"i_breakpoint":null,"r_breakpoint":null},"mic":{"s_breakpoint":"≤ 2 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4 µg/mL"},"comments":["Disk diffusion and gradient diffusion methods should not be performed for these agents. Note: Proteus is intrinsically resistant."]}]}]},{"tier":5,"tierDescription":"Urine Only Tier: Designated for reporting only on organisms isolated from the urinary tract.","agents":[{"agentName":"Cefazolin","breakpointSets":[{"condition":"Uncomplicated UTI only","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 15 mm","i_breakpoint":null,"r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 16 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 32 µg/mL"},"comments":["Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."]}]},{"agentName":"Nitrofurantoin","breakpointSets":[{"condition":"Urine Only","diskDiffusion":{"diskContent":"300 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"15–16 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 32 µg/mL","i_breakpoint":"64 µg/mL","r_breakpoint":"≥ 128 µg/mL"},"comments":["Note: Proteus is intrinsically resistant."]}]},{"agentName":"Fosfomycin","breakpointSets":[{"condition":"Urine Only","diskDiffusion":{"diskContent":"200 µg","s_breakpoint":"≥ 16 mm","i_breakpoint":"13–15 mm","r_breakpoint":"≤ 12 mm"},"mic":{"s_breakpoint":"≤ 64 µg/mL","i_breakpoint":"128 µg/mL","r_breakpoint":"≥ 256 µg/mL"},"comments":["Important Note: Disk diffusion and MIC breakpoints for Fosfomycin apply only to E. coli urinary tract isolates and should not be extrapolated to other Enterobacterales species, which includes Proteus sp."]}]}]}]}`),dg={diagnosticNotes:{summary:"Diagnostic imaging is recommended for upper tract or recurrent infections to assess for stones or obstructive uropathy.",biosafetyWarning:"",methods:[]},preventionAndScreening:[],treatmentLifecycle:[],antimicrobialStewardship:["Reserve carbapenems for mixed infections or for documented ESBL-producing strains.","Reserve ceftazidime-avibactam and meropenem-vaborbactam for documented carbapenemase producers.","Check susceptibility of all carbapenems if use is considered."],drugSpecificPearls:[{drugName:"Piperacillin-tazobactam",pearl:"Do not use for suspected or proven ESBL production due to reported clinical failures."},{drugName:"Ceftazidime-avibactam + Aztreonam",pearl:"The rationale for this combination is to use aztreonam (which is not hydrolyzed by MBLs) and protect it with avibactam from other co-produced beta-lactamases (e.g., ESBLs, AmpC, KPCs)."},{drugName:"Cefiderocol",pearl:"FDA-approved for complicated UTI with limited alternatives. A trial showed no statistically significant difference in mortality vs best available therapy (BAT)."},{drugName:"Aztreonam-avibactam",pearl:"This combination is in late stages of development and may be a future option."}],guidelineReferences:[{source:"IDSA",citation:"IDSA Guideline on treatment of ESBL, AmpC, and carbapenemase producers: Updated 2024 IDSA Guidelines.",summaryOrNote:"Referenced for treatment strategies against resistant phenotypes."}]},pg={identity:rg,clinicalProfile:lg,resistanceProfile:cg,treatment:mg,laboratoryProfile:ug,additionalInformation:dg},fg={bacteriumName:"Providencia species",aliases:["Providencia stuartii","Providencia rettgeri","Providencia alcalifaciens","Providencia rustigianii"],lastUpdated:"2025-01-17",clsiCategory:"Enterobacterales (excluding Salmonella/Shigella)",classification:{gramStain:"Gram negative",morphology:"Bacilli",respiration:"Facultative anaerobe",notes:[]},strainDetails:[{type:"Species",value:"Providencia stuartii",notes:"Generally the most resistant species, frequently produces ESBLs, and 50% or more of isolates are resistant to aminoglycosides and fluoroquinolones."},{type:"Species",value:"Providencia rettgeri",notes:"Susceptibility falls between that of P. stuartii and P. alcalifaciens."},{type:"Species",value:"Providencia alcalifaciens",notes:"More often susceptible to penicillins and older cephalosporins."},{type:"Species",value:"Providencia rustigianii",notes:"More often susceptible to penicillins and older cephalosporins."}],biochemicalTests:"Gram-negative rod, motile, lactose –, H2S –, indole +, citrate +, urease +, phenylalanine deaminase +."},bg={summary:"Providencia species are typically nosocomial pathogens isolated from urine, blood, or wounds, causing a range of infections. They are known for several resistance mechanisms.",pathophysiologyPearls:["Providencia spp. may initially test susceptible to third-generation cephalosporins (like ceftriaxone) but have the potential to develop resistance during therapy due to the derepression of an inducible AmpC β-lactamase.","The risk of AmpC derepression during therapy appears to be less frequent with Providencia spp. compared to organisms like C. freundii complex or E. cloacae complex."],keySignsAndSymptoms:[],clinicalSyndromes:[{syndromeName:"Urinary Tract Infections (UTI)",description:"Common infection site, especially in nosocomial settings. Isolates are often multidrug-resistant."},{syndromeName:"Bacteremia",description:"Bloodstream infections, often originating from another site like the urinary tract."},{syndromeName:"Wound Infections",description:"Can colonize and infect surgical or traumatic wounds."}],stagesOfIllness:[],highRiskPopulations:["Hospitalized patients"],transmissionVectors:[],prognosisNotes:[]},gg={groupIntrinsicResistance:[],intrinsicResistance:[{drugOrClass:"Polymyxins",notes:"Providencia species are intrinsically resistant to polymyxins."},{drugOrClass:"Nitrofurantoin",notes:"Usually resistant."},{drugOrClass:"Tigecycline",notes:"May have in vitro activity but its clinical efficacy is questionable due to low serum levels."}],majorMechanisms:[{mechanismName:"Inducible AmpC β-lactamase",mechanismType:"Enzymatic Inactivation",description:"Organisms can develop resistance during therapy with third-generation cephalosporins due to derepression of an inducible AmpC gene, though this is less frequent than in other SPACE-M organisms."},{mechanismName:"Extended-Spectrum Beta-Lactamases (ESBLs)",mechanismType:"Enzymatic Inactivation",description:"Frequently produced, especially by P. stuartii. For ESBL producers, piperacillin-tazobactam should be avoided even if susceptible in vitro due to risk of clinical failures."},{mechanismName:"Serine-based Carbapenemase (e.g., KPC)",mechanismType:"Enzymatic Inactivation",description:"Production of enzymes like KPC can lead to resistance to carbapenems, fluoroquinolones, and aminoglycosides."},{mechanismName:"Metallo-carbapenemase (MBL)",mechanismType:"Enzymatic Inactivation",description:"Production results in a resistance pattern that includes newer agents like ceftazidime-avibactam and meropenem-vaborbactam."}],clinicalAlerts:[{alertTitle:"Species-Dependent Resistance",details:"Resistance patterns vary significantly by species. P. stuartii is generally the most resistant, while P. alcalifaciens is often more susceptible."}]},hg={generalNotes:["Recommendations are for moderately severe or severe infections where resistance is a concern.","For uncomplicated or less severe infections with susceptible strains, options include Amoxicillin-clavulanate, fluoroquinolones, and second/third-generation cephalosporins.","TMP-SMX is an option only if susceptible, as resistance is common.","Imipenem is less active than other carbapenems.","Oral Fosfomycin is an option for uncomplicated UTI."],drugsToAvoid:[{drugOrClass:"Piperacillin-tazobactam",condition:"ESBL-producing infections",reason:"Risk of clinical failures despite in vitro susceptibility."}],adjunctiveTherapies:[],regimens:[{context:{type:"Empiric",condition:"Suspected Providencia sp. infection",patientPopulation:["Local ESBL rate <10-15%"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Piperacillin-tazobactam",dose:"4.5 gm",route:"IV",frequency:"q8h",comments:"Infuse over 4 hours."},{drugName:"Ceftriaxone",dose:"1-2 gm",route:"IV",frequency:"q24h",comments:""},{drugName:"Cefepime",dose:"1-2 gm",route:"IV",frequency:"q8h-q12h",comments:""},{drugName:"Ciprofloxacin",dose:"400 mg IV or 750 mg PO",route:"IV/PO",frequency:"q12h",comments:""}]}],notes:["For life-threatening infection, consider Meropenem 2 gm over 3h IV q8h."]}]},{context:{type:"Empiric",condition:"Suspected Providencia sp. infection",patientPopulation:["Local ESBL rate >15%"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",comments:""}]}],notes:["For life-threatening infection, consider Meropenem 2 gm over 3h IV q8h."]}]},{context:{type:"Directed",condition:"Broadly susceptible isolate",patientPopulation:["Susceptible to aztreonam, ceftriaxone, ceftazidime, cefepime, piperacillin-tazobactam"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Piperacillin-tazobactam",dose:"4.5 gm",route:"IV",frequency:"q8h",comments:"Infuse over 4 hours."},{drugName:"Ceftriaxone",dose:"1-2 gm",route:"IV",frequency:"q24h",comments:""},{drugName:"Cefepime",dose:"1-2 gm",route:"IV",frequency:"q8h to q12h",comments:"May be considered over Ceftriaxone for high inoculum infections or if source control is limited due to its greater stability to AmpC."},{drugName:"Ciprofloxacin",dose:"400 mg IV or 750 mg PO",route:"IV/PO",frequency:"q12h",comments:""},{drugName:"Aztreonam",dose:"2 gm",route:"IV",frequency:"q6-8h",comments:"Option for patients with penicillin allergy."}]}]}]},{context:{type:"Directed",condition:"ESBL Producer",patientPopulation:["Resistant to Aztreonam, Ceftriaxone, Cefotaxime, Ceftazidime, or Cefepime"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",comments:""},{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",comments:""}]}]},{preference:"Alternative (if susceptible)",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ciprofloxacin",dose:"400 mg IV or 750 mg PO",route:"IV/PO",frequency:"bid",comments:""},{drugName:"Levofloxacin",dose:"750 mg",route:"IV/PO",frequency:"once daily",comments:""}]}]}]},{context:{type:"Directed",condition:"Serine-based Carbapenemase (e.g., KPC) Producer",patientPopulation:["Resistant to carbapenems, fluoroquinolones, and aminoglycosides"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",comments:"Infuse over 3 hours."},{drugName:"Meropenem-vaborbactam",dose:"4 gm",route:"IV",frequency:"q8h",comments:"Infuse over 3 hours."}]}],notes:["Infectious diseases consultation recommended."]}]},{context:{type:"Directed",condition:"Metallo-carbapenemase (MBL) Producer",patientPopulation:["Resistant to KPC-inhibitors, fluoroquinolones, aminoglycosides, TMP-SMX"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",comments:"Infuse over 3 hours."},{drugName:"Aztreonam",dose:"2 gm",route:"IV",frequency:"q8h",comments:"Infuse over 3 hours. Must be given with Ceftazidime-avibactam."}]}]},{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Cefiderocol",dose:"2 gm",route:"IV",frequency:"q8h",comments:"Infuse over 3 hours."}]}],notes:["Infectious diseases consult recommended. Based on in vitro susceptibility, meropenem-vaborbactam plus aztreonam may prove effective."]}]},{context:{type:"Alternative",condition:"Severe IgE-mediated allergy to beta-lactams",patientPopulation:["Isolate is susceptible in vitro"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Aztreonam",dose:"2 gm",route:"IV",frequency:"q6-8h",comments:""},{drugName:"Ciprofloxacin",dose:"400 mg IV or 750 mg po",route:"IV/PO",frequency:"bid",comments:""},{drugName:"Levofloxacin",dose:"750 mg",route:"IV/PO",frequency:"once daily",comments:""}]}]}]},{context:{type:"Alternative",condition:"ESBL and/or AmpC producing strains",patientPopulation:[],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ceftolozane-tazobactam",dose:"1.5 gm",route:"IV",frequency:"q8h",comments:"Infuse over 3 hours."},{drugName:"Temocillin",dose:"2 gm",route:"IV",frequency:"q12h",comments:"Where available."}]}]}]},{context:{type:"Salvage",condition:"Pan-resistant infection",patientPopulation:[],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ceftazidime-avibactam + Aztreonam",dose:"Varies",route:"IV",frequency:"Varies",comments:"Combination therapy."},{drugName:"Fosfomycin IV",dose:"Varies",route:"IV",frequency:"Varies",comments:"Where available, requires emergency IND from FDA."},{drugName:"Plazomicin",dose:"15 mg/kg",route:"IV",frequency:"q24h",comments:"For complicated UTIs only."}]}],notes:["Infectious Diseases consultation suggested."]}]}]},yg=JSON.parse('{"testingIndications":[],"methodologyNotes":[],"recommendedPanel":[],"specialTests":[],"reportingRules":[{"ruleType":"Exception","drug":"Imipenem-relebactam","condition":"Isolate is identified as Providencia species.","details":"CLSI breakpoints for Imipenem-relebactam do not apply to the family Morganellaceae, which includes Providencia. Testing or reporting this agent is not recommended based on these breakpoints."},{"ruleType":"Exception","drug":"Fosfomycin","condition":"Isolate is not E. coli from a urinary tract source.","details":"Breakpoints for Fosfomycin apply only to E. coli and should not be extrapolated to Providencia species."},{"ruleType":"Conditional","drug":"Cefepime","condition":"Carbapenemase production is identified.","details":"Cefepime S/SDD results should be suppressed or reported as resistant."},{"ruleType":"General","drug":"Third-generation cephalosporins","condition":"Isolate is Providencia species.","details":"Providencia spp. can derepress inducible AmpC β-lactamase, potentially leading to resistance during therapy despite initial susceptibility to agents like ceftriaxone."}],"antimicrobialBreakpoints":[{"tier":1,"tierDescription":"Appropriate for routine, primary testing and reporting.","agents":[{"agentName":"Ampicillin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"14–16 mm","r_breakpoint":"≤ 13 mm"},"mic":{"s_breakpoint":"≤ 8 µg/mL","i_breakpoint":"16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":["Results of ampicillin testing can predict results for amoxicillin."]}]},{"agentName":"Amoxicillin-clavulanate","breakpointSets":[{"condition":"Uncomplicated UTI only","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":null,"r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":"16/4 µg/mL","r_breakpoint":"≥ 32/4 µg/mL"},"comments":["Breakpoints apply for therapy of uncomplicated UTIs or for completion of therapy for systemic infection."]}]},{"agentName":"Piperacillin-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"100/10 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"21–24 mm","r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":"16/4 µg/mL","r_breakpoint":"≥ 32/4 µg/mL"},"comments":[]}]},{"agentName":"Gentamicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Tobramycin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"13–16 mm","r_breakpoint":"≤ 12 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Amikacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 19 mm","i_breakpoint":"17–18 mm","r_breakpoint":"≤ 16 mm"},"mic":{"s_breakpoint":"≤ 16 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 32 µg/mL"},"comments":[]}]},{"agentName":"Ciprofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥ 26 mm","i_breakpoint":"22–25 mm","r_breakpoint":"≤ 21 mm"},"mic":{"s_breakpoint":"≤ 0.25 µg/mL","i_breakpoint":"0.5 µg/mL","r_breakpoint":"≥ 1 µg/mL"},"comments":[]}]},{"agentName":"Levofloxacin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"5 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"17–20 mm","r_breakpoint":"≤ 16 mm"},"mic":{"s_breakpoint":"≤ 0.5 µg/mL","i_breakpoint":"1 µg/mL","r_breakpoint":"≥ 2 µg/mL"},"comments":[]}]},{"agentName":"Trimethoprim-sulfamethoxazole","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"1.25/23.75 µg","s_breakpoint":"≥ 16 mm","i_breakpoint":"11–15 mm","r_breakpoint":"≤ 10 mm"},"mic":{"s_breakpoint":"≤ 2/38 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4/76 µg/mL"},"comments":[]}]}]},{"tier":2,"tierDescription":"Appropriate for routine, primary testing, may be reported following cascade reporting rules.","agents":[{"agentName":"Cefuroxime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"15–22 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8–16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":[]}]},{"agentName":"Cefepime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 25 mm","i_breakpoint":"19–24 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8 µg/mL","r_breakpoint":"≥ 16 µg/mL"},"comments":["Cefepime S/SDD results should be suppressed or reported as resistant for isolates demonstrating carbapenemase production."]}]},{"agentName":"Ertapenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 22 mm","i_breakpoint":"19–21 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 0.5 µg/mL","i_breakpoint":"1 µg/mL","r_breakpoint":"≥ 2 µg/mL"},"comments":[]}]},{"agentName":"Imipenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]},{"agentName":"Meropenem","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"10 µg","s_breakpoint":"≥ 23 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]}]},{"tier":3,"tierDescription":"Appropriate for high-risk MDRO patients, subject to cascade reporting.","agents":[{"agentName":"Cefiderocol","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 20 mm","i_breakpoint":"9–15 mm","r_breakpoint":"≤ 8 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 8 µg/mL"},"comments":[]}]},{"agentName":"Ceftazidime-avibactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/20 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":null,"r_breakpoint":"≤ 20 mm"},"mic":{"s_breakpoint":"≤ 8/4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 16/4 µg/mL"},"comments":["Confirmatory MIC testing is indicated for isolates with disk diffusion zones of 20–22 mm."]}]},{"agentName":"Imipenem-relebactam","breakpointSets":[{"condition":"Standard","diskDiffusion":null,"mic":null,"comments":["Important Note: The breakpoints for Imipenem-relebactam do not apply to the family Morganellaceae, which includes Morganella, Proteus, and Providencia. Therefore, testing or reporting for Providencia with this agent using these breakpoints is not recommended by CLSI."]}]},{"agentName":"Meropenem-vaborbactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"20/10 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 4/8 µg/mL","i_breakpoint":"8/8 µg/mL","r_breakpoint":"≥ 16/8 µg/mL"},"comments":["If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]},{"agentName":"Plazomicin","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 18 mm","i_breakpoint":"15–17 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 2 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]}]},{"tier":4,"tierDescription":"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available.","agents":[{"agentName":"Aztreonam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"18–20 mm","r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 4 µg/mL","i_breakpoint":"8 µg/mL","r_breakpoint":"≥ 16 µg/mL"},"comments":[]}]},{"agentName":"Ceftriaxone","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 26 mm","i_breakpoint":"20–22 mm","r_breakpoint":"≤ 19 mm"},"mic":{"s_breakpoint":"≤ 1 µg/mL","i_breakpoint":"2 µg/mL","r_breakpoint":"≥ 4 µg/mL"},"comments":[]}]},{"agentName":"Ceftazidime","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 21 mm","i_breakpoint":"18–20 mm","r_breakpoint":"≤ 17 mm"},"mic":{"s_breakpoint":"≤ 8 µg/mL","i_breakpoint":"16 µg/mL","r_breakpoint":"≥ 32 µg/mL"},"comments":[]}]},{"agentName":"Ceftolozane-tazobactam","breakpointSets":[{"condition":"Standard","diskDiffusion":{"diskContent":"30/10 µg","s_breakpoint":"≥ 22 mm","i_breakpoint":"19–21 mm","r_breakpoint":"≤ 18 mm"},"mic":{"s_breakpoint":"≤ 2/4 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4/4 µg/mL"},"comments":[]}]},{"agentName":"Colistin or Polymyxin B","breakpointSets":[{"condition":"Standard","diskDiffusion":null,"mic":{"s_breakpoint":"≤ 2 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 4 µg/mL"},"comments":["Disk diffusion and gradient diffusion methods should not be performed for these agents.","Note: Providencia is intrinsically resistant."]}]}]},{"tier":5,"tierDescription":"Urine Only Tier","agents":[{"agentName":"Cefazolin","breakpointSets":[{"condition":"Uncomplicated UTI only","diskDiffusion":{"diskContent":"30 µg","s_breakpoint":"≥ 15 mm","i_breakpoint":null,"r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 16 µg/mL","i_breakpoint":null,"r_breakpoint":"≥ 32 µg/mL"},"comments":["Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."]}]},{"agentName":"Nitrofurantoin","breakpointSets":[{"condition":"Urine Only","diskDiffusion":{"diskContent":"300 µg","s_breakpoint":"≥ 17 mm","i_breakpoint":"15–16 mm","r_breakpoint":"≤ 14 mm"},"mic":{"s_breakpoint":"≤ 32 µg/mL","i_breakpoint":"64 µg/mL","r_breakpoint":"≥ 128 µg/mL"},"comments":["Note: Providencia is usually resistant."]}]},{"agentName":"Fosfomycin","breakpointSets":[{"condition":"Urine Only","diskDiffusion":null,"mic":null,"comments":["Important Note: Disk diffusion and MIC breakpoints for Fosfomycin apply only to E. coli urinary tract isolates and should not be extrapolated to other Enterobacterales species."]}]}]}]}'),vg={diagnosticNotes:{summary:"",biosafetyWarning:"",methods:[]},preventionAndScreening:[],treatmentLifecycle:[],antimicrobialStewardship:["For ESBL producers, avoid piperacillin-tazobactam even if susceptible in vitro due to clinical failures.","Providencia sp. are intrinsically resistant to Polymyxins and usually resistant to nitrofurantoin.","Tigecycline may have in vitro activity but its clinical efficacy is questionable due to low serum levels.","If the source of infection is the urinary tract, Providencia sp. are usually multidrug-resistant."],drugSpecificPearls:[{drugName:"Cefiderocol",pearl:"FDA-approved for complicated UTI with limited or no alternative treatment options. In a trial, mortality at 28 days was 24.8% for cefiderocol vs 18.4% for Best Available Therapy (not statistically significant)."}],guidelineReferences:[{source:"IDSA",citation:"IDSA Guideline on treatment of ESBL, AmpC, and carbapenemase producers: Updated 2024 IDSA Guidelines.",summaryOrNote:"Provides a framework for treating infections caused by resistant gram-negative organisms."}]},kg={identity:fg,clinicalProfile:bg,resistanceProfile:gg,treatment:hg,laboratoryProfile:yg,additionalInformation:vg},xg={bacteriumName:"Serratia marcescens",aliases:["Serratia sp."],lastUpdated:"2025-01-08",clsiCategory:"Enterobacterales (excluding Salmonella/Shigella)",classification:{gramStain:"Gram-negative",morphology:"Bacilli",respiration:"Facultative anaerobe",notes:["Motile","May produce a characteristic red pigment (prodigiosin), especially at room temperature."]},strainDetails:[],biochemicalTests:"Gram-negative rod, motile, lactose – (or slow), ONPG +, oxidase –, catalase +, citrate +, VP +, DNase +, gelatinase +, lysine +, ornithine +, esculin +, urease variable, may produce red pigment (prodigiosin) at room temperature."},Sg={summary:"Serratia marcescens is an opportunistic pathogen that causes a variety of nosocomial and healthcare-associated infections, including urinary tract infections, pneumonia, bloodstream infections, and surgical site infections. Both immunocompetent and immunocompromised individuals can be affected. The increasing prevalence of multi-drug resistant (MDR) strains poses a significant therapeutic challenge.",pathophysiologyPearls:["Produces several virulence factors including proteases, lipases, and DNase, which contribute to tissue damage.","The red pigment, prodigiosin, has immunosuppressive and cytotoxic properties.","Forms biofilms on medical devices, contributing to catheter-related infections and antibiotic resistance."],keySignsAndSymptoms:["Fever, chills, and leukocytosis in cases of bacteremia.","Dysuria, frequency, and urgency in urinary tract infections.","Cough, dyspnea, and purulent sputum in pneumonia.","Erythema, purulent discharge, and pain at surgical or wound sites."],clinicalSyndromes:[{syndromeName:"Catheter-Associated Urinary Tract Infection (CAUTI)",description:"One of the most common infections caused by S. marcescens, often associated with indwelling urinary catheters."},{syndromeName:"Ventilator-Associated Pneumonia (VAP)",description:"A significant cause of nosocomial pneumonia in intubated patients in intensive care units."},{syndromeName:"Catheter-Related Bloodstream Infection (CRBSI)",description:"Often linked to central venous catheters, particularly in patients receiving parenteral nutrition."},{syndromeName:"Surgical Site Infection (SSI)",description:"Can contaminate surgical wounds, leading to postoperative infections."},{syndromeName:"Neonatal Sepsis and Meningitis",description:"Causes outbreaks in neonatal intensive care units (NICUs), leading to severe systemic infections."}],stagesOfIllness:[],highRiskPopulations:["Hospitalized patients, especially in intensive care units (ICUs)","Neonates","Immunocompromised individuals","Patients with indwelling medical devices (e.g., catheters, ventilators)","Intravenous drug users"],transmissionVectors:["Contaminated medical equipment and solutions","Hands of healthcare workers","Person-to-person transmission in hospital settings"],prognosisNotes:["The prevalence of multi-drug resistant (MDR) strains is increasing, which can complicate treatment and worsen outcomes.","Infections with carbapenemase-producing strains are associated with high mortality rates."]},_g={groupIntrinsicResistance:[],intrinsicResistance:[{drugOrClass:"Polymyxins (Colistin)",notes:"Chromosomally-mediated resistance."},{drugOrClass:"Ampicillin",notes:""},{drugOrClass:"Ampicillin-sulbactam",notes:""},{drugOrClass:"Amoxicillin-clavulanate",notes:""},{drugOrClass:"Cefazolin",notes:""},{drugOrClass:"Cephamycins (e.g., Cefoxitin, Cefotetan)",notes:""},{drugOrClass:"Nitrofurantoin",notes:""}],majorMechanisms:[{mechanismName:"AmpC Beta-Lactamase",mechanismType:"Enzymatic Inactivation",description:"Serratia marcescens possesses a chromosomal AmpC beta-lactamase that is typically inducible but can be constitutively overexpressed, conferring resistance to penicillins, early-generation cephalosporins, and cephamycins. Clinical significance of induction is less common than in Enterobacter."},{mechanismName:"Extended-Spectrum Beta-Lactamases (ESBLs)",mechanismType:"Enzymatic Inactivation",description:"Acquired plasmid-mediated enzymes (e.g., CTX-M, SHV, TEM) that hydrolyze most penicillins and cephalosporins, including 3rd and 4th generation cephalosporins, and aztreonam."},{mechanismName:"Carbapenemases",mechanismType:"Enzymatic Inactivation",description:"Can acquire genes for serine carbapenemases (e.g., KPC) or metallo-beta-lactamases (e.g., NDM, VIM, IMP), leading to resistance to nearly all beta-lactam agents, including carbapenems."},{mechanismName:"Aminoglycoside-Modifying Enzymes",mechanismType:"Enzymatic Inactivation",description:"Enzymes that acetylate, phosphorylate, or adenylate aminoglycosides, preventing them from binding to the ribosome."}],clinicalAlerts:[{alertTitle:"Potential for Multi-Drug Resistance",details:"Serratia marcescens frequently acquires resistance genes, leading to ESBL, AmpC, and carbapenemase production. Susceptibility testing is essential to guide therapy."},{alertTitle:"AmpC Stability Considerations",details:"For serious infections, cefepime may be preferred over third-generation cephalosporins (e.g., ceftriaxone) due to its greater stability against hydrolysis by AmpC beta-lactamases, particularly in high-inoculum infections."}]},Cg={generalNotes:["The following recommendations are for moderately severe or severe infections. For uncomplicated infections, options may include second and third-generation cephalosporins if susceptible.","TMP-SMX is a viable option if the isolate is proven susceptible.","Serratia marcescens is intrinsically resistant to Nitrofurantoin.","Susceptibility to Fosfomycin is variable and requires testing."],drugsToAvoid:[{drugOrClass:"Polymyxins (Colistin)",condition:"All infections",reason:"Intrinsic resistance."},{drugOrClass:"Ampicillin, Amoxicillin-clavulanate, Cefazolin, Cephamycins",condition:"All infections",reason:"Intrinsic resistance."}],adjunctiveTherapies:[],regimens:[{context:{type:"Empiric",condition:"Suspected Serratia marcescens infection",patientPopulation:["Areas with local resistance rates <10-15% to 3rd-generation cephalosporins"]},recommendations:[{preference:"Primary",strategy:"Monotherapy",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Piperacillin-tazobactam",dose:"4.5 gm",route:"IV",frequency:"q8h",comments:"infused over 4 hr"},{drugName:"Cefepime",dose:"1-2 gm",route:"IV",frequency:"q8h-q12h",comments:""},{drugName:"Ceftriaxone",dose:"1-2 gm",route:"IV",frequency:"q24h",comments:""},{drugName:"Aztreonam",dose:"2 gm",route:"IV",frequency:"q8h",comments:""},{drugName:"Ciprofloxacin",dose:"400 mg",route:"IV",frequency:"q12h",comments:""},{drugName:"Levofloxacin",dose:"750 mg",route:"IV",frequency:"once daily",comments:""}]}]}]},{context:{type:"Empiric",condition:"Suspected Serratia marcescens infection, severe illness",patientPopulation:["Areas with local resistance rates >15% to 3rd-generation cephalosporins","Critically ill patients","Recent antibiotic exposure"]},recommendations:[{preference:"Primary",strategy:"Monotherapy",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",comments:""},{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",comments:"Not for Pseudomonas coverage if a mixed infection is suspected."}]}],notes:["Reserve carbapenems for mixed infections or for documented ESBL-producing strains."]}]},{context:{type:"Directed",condition:"Serratia marcescens infection, susceptible to 3rd-generation cephalosporins",patientPopulation:["All"],isolateSource:"Any"},recommendations:[{preference:"Primary",strategy:"Monotherapy",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ceftriaxone",dose:"1-2 gm",route:"IV",frequency:"once daily",comments:""},{drugName:"Cefepime",dose:"1-2 gm",route:"IV",frequency:"q8h-q12h",comments:""},{drugName:"Piperacillin-tazobactam",dose:"Dose based on susceptibility report",route:"IV",frequency:"",comments:""},{drugName:"Ciprofloxacin",dose:"400 mg",route:"IV",frequency:"q12h",comments:"If susceptible."},{drugName:"Levofloxacin",dose:"750 mg",route:"IV",frequency:"once daily",comments:"If susceptible."},{drugName:"TMP-SMX",dose:"8-10 mg/kg/day (TMP component)",route:"IV",frequency:"divided q6h",comments:"If susceptible."}]}],notes:["IDSA guidance suggests selecting treatment based on AST results. Cefepime may be preferred over Ceftriaxone for high inoculum infections due to its greater stability to AmpC."]}]},{context:{type:"Directed",condition:"ESBL and/or AmpC-producing Serratia marcescens infection",patientPopulation:["All"],isolateSource:"Any"},recommendations:[{preference:"Primary",strategy:"Monotherapy",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",comments:""},{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",comments:"Not for Pseudomonas coverage or CNS infections."}]}]},{preference:"Alternative",strategy:"Monotherapy",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ciprofloxacin",dose:"400 mg IV q12h or 750 mg po bid",route:"IV/PO",frequency:"q12h/bid",comments:"Only if susceptible."},{drugName:"Levofloxacin",dose:"750 mg",route:"IV/PO",frequency:"once daily",comments:"Only if susceptible."},{drugName:"TMP-SMX",dose:"8-10 mg/kg/day (TMP component)",route:"IV",frequency:"divided q6h",comments:"Only if susceptible."},{drugName:"Ceftolozane-tazobactam",dose:"1.5 gm",route:"IV",frequency:"q8h",comments:"infused over 3h; limited clinical data vs Serratia"},{drugName:"Temocillin",dose:"2 gm",route:"IV",frequency:"q12h",comments:"Where available"},{drugName:"Cefepime",dose:"2 gm",route:"IV",frequency:"q8h",comments:"For mild/moderate infection with controlled source and MIC <=2 mcg/mL."}]}],notes:["Ceftazidime-avibactam has in vitro activity but limited clinical data for this specific resistance pattern."]}]},{context:{type:"Directed",condition:"KPC-producing carbapenem-resistant Serratia marcescens infection",patientPopulation:["All"],isolateSource:"Any"},recommendations:[{preference:"Primary",strategy:"Monotherapy",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",comments:"infused over 3 hrs"},{drugName:"Meropenem-vaborbactam",dose:"4 gm",route:"IV",frequency:"q8h",comments:"infused over 3 hrs"}]}],notes:["Infectious diseases consultation recommended."]}]},{context:{type:"Directed",condition:"Metallo-beta-lactamase (MBL)-producing carbapenem-resistant Serratia marcescens infection",patientPopulation:["All"],isolateSource:"Any"},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",comments:"infused over 3 hrs"},{drugName:"Aztreonam",dose:"2 gm",route:"IV",frequency:"q6h",comments:"infused over 3h"}]}],notes:["Aztreonam is stable to MBLs, while avibactam protects aztreonam from co-produced ESBLs/AmpC."]},{preference:"Alternative",strategy:"Monotherapy",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Cefiderocol",dose:"2 gm",route:"IV",frequency:"q8h",comments:"infused over 3 hrs"},{drugName:"Plazomicin",dose:"15 mg/kg",route:"IV",frequency:"once daily",comments:"For complicated UTI only, if available."}]}],notes:["Infectious diseases consultation is essential as there is no proven effective therapy."]}]},{context:{type:"Directed",condition:"Serratia marcescens infection",patientPopulation:["Severe IgE-mediated beta-lactam allergy"]},recommendations:[{preference:"Alternative",strategy:"Monotherapy",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Aztreonam",dose:"2 gm",route:"IV",frequency:"q6h",comments:"Generally safe, but check for cross-reactivity if allergy is to ceftazidime."},{drugName:"Ciprofloxacin",dose:"400 mg IV or 750 mg po",route:"IV/PO",frequency:"q12h/bid",comments:"If susceptible."},{drugName:"Levofloxacin",dose:"750 mg",route:"IV/PO",frequency:"once daily",comments:"If susceptible."},{drugName:"Gentamicin or Tobramycin",dose:"7 mg/kg loading dose then 5.1 mg/kg",route:"IV",frequency:"q24h",comments:"Therapeutic drug monitoring required."}]}]}]}]},Ng={testingIndications:["Susceptibility testing should be performed on all clinically significant isolates of Serratia marcescens."],methodologyNotes:["Broth microdilution is the recommended method for susceptibility testing, especially for critical agents like polymyxins. Disk diffusion may be unreliable for some agent/organism combinations."],recommendedPanel:["Primary panel should include agents from Tier 1 and Tier 2. Tier 3 and 4 agents should be tested based on institutional epidemiology, patient risk factors, or on isolates resistant to primary agents."],specialTests:[{testName:"Carbapenemase Production Test (e.g., mCIM, CarbaNP)",trigger:"Resistance to one or more carbapenems (ertapenem, meropenem).",purpose:"To detect the presence of carbapenemase enzymes, which has significant therapeutic and infection control implications."},{testName:"ESBL Phenotypic Test",trigger:"Elevated MICs to ceftazidime or ceftriaxone, though often performed reflexively.",purpose:"To detect the presence of ESBL enzymes."}],reportingRules:[{ruleType:"Conditional",drug:"Cefepime",condition:"Isolate demonstrates carbapenemase production.",details:"Cefepime Susceptible/SDD results should be suppressed or edited and reported as Resistant."}],antimicrobialBreakpoints:[{tier:1,tierDescription:"Appropriate for routine, primary testing and reporting",agents:[{agentName:"Ampicillin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 17",i_breakpoint:"14–16",r_breakpoint:"≤ 13"},mic:{s_breakpoint:"≤ 8",i_breakpoint:"16",r_breakpoint:"≥ 32"},comments:["Results of ampicillin testing can be used to predict results for amoxicillin."]}]},{agentName:"Cefazolin",breakpointSets:[{condition:"Urine Only (Uncomplicated UTI)",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 15",i_breakpoint:"—",r_breakpoint:"≤ 14"},mic:{s_breakpoint:"≤ 16",i_breakpoint:"—",r_breakpoint:"≥ 32"},comments:["Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis. Note: Serratia is intrinsically resistant to cefazolin for systemic infections."]}]},{agentName:"Amoxicillin-clavulanate",breakpointSets:[{condition:"Uncomplicated UTI only",diskDiffusion:{diskContent:"20/10 µg",s_breakpoint:"≥ 18",i_breakpoint:"—",r_breakpoint:"≤ 17"},mic:{s_breakpoint:"≤ 8/4",i_breakpoint:"16/4",r_breakpoint:"≥ 32/4"},comments:[]}]},{agentName:"Piperacillin-tazobactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"100/10 µg",s_breakpoint:"≥ 25",i_breakpoint:"21–24",r_breakpoint:"≤ 20"},mic:{s_breakpoint:"≤ 8/4",i_breakpoint:"16/4",r_breakpoint:"≥ 32/4"},comments:[]}]}]},{tier:2,tierDescription:"Appropriate for routine, primary testing, may be reported following cascade reporting rules",agents:[{agentName:"Cefepime",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 25",i_breakpoint:"19–24",r_breakpoint:"≤ 18"},mic:{s_breakpoint:"≤ 4",i_breakpoint:"8",r_breakpoint:"≥ 16"},comments:["Cefepime S/SDD results should be suppressed or edited and reported as resistant for isolates that demonstrate carbapenemase production."]}]},{agentName:"Ertapenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 22",i_breakpoint:"19–21",r_breakpoint:"≤ 18"},mic:{s_breakpoint:"≤ 0.5",i_breakpoint:"1",r_breakpoint:"≥ 2"},comments:[]}]},{agentName:"Meropenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 23",i_breakpoint:"20–22",r_breakpoint:"≤ 19"},mic:{s_breakpoint:"≤ 1",i_breakpoint:"2",r_breakpoint:"≥ 4"},comments:[]}]}]},{tier:3,tierDescription:"Appropriate for high-risk MDRO patients, subject to cascade reporting",agents:[{agentName:"Ceftazidime-avibactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30/20 µg",s_breakpoint:"≥ 21",i_breakpoint:"—",r_breakpoint:"≤ 20"},mic:{s_breakpoint:"≤ 8/4",i_breakpoint:"—",r_breakpoint:"≥ 16/4"},comments:["Confirmatory MIC testing is indicated for isolates with zones of 20–22 mm."]}]},{agentName:"Meropenem-vaborbactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"20/10 µg",s_breakpoint:"≥ 18",i_breakpoint:"15–17",r_breakpoint:"≤ 14"},mic:{s_breakpoint:"≤ 4/8",i_breakpoint:"8/8",r_breakpoint:"≥ 16/8"},comments:["If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]}]},{tier:4,tierDescription:"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available",agents:[{agentName:"Aztreonam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 21",i_breakpoint:"18–20",r_breakpoint:"≤ 17"},mic:{s_breakpoint:"≤ 4",i_breakpoint:"8",r_breakpoint:"≥ 16"},comments:[]}]},{agentName:"Ceftriaxone",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 26",i_breakpoint:"20–22",r_breakpoint:"≤ 19"},mic:{s_breakpoint:"≤ 1",i_breakpoint:"2",r_breakpoint:"≥ 4"},comments:[]}]},{agentName:"Colistin or Polymyxin B",breakpointSets:[{condition:"Standard",diskDiffusion:null,mic:{s_breakpoint:"≤ 2",i_breakpoint:"—",r_breakpoint:"≥ 4"},comments:["Disk diffusion and gradient diffusion methods should not be performed.","Serratia is intrinsically resistant to polymyxins; testing is generally not indicated."]}]}]}]},Ag={diagnosticNotes:{summary:"Identification is typically performed using automated systems (e.g., VITEK, MicroScan) or MALDI-TOF MS. Conventional biochemical tests confirm identity. The ability to produce red pigment (prodigiosin) is a classic but variable characteristic. Non-pigmented strains are common in clinical settings.",biosafetyWarning:"BSL-2: Serratia marcescens is a Biosafety Level 2 organism. Standard laboratory precautions should be followed.",methods:[{methodName:"Culture",details:"Grows well on standard laboratory media like Blood Agar and MacConkey Agar. Colonies are non-lactose fermenting (or slow) and may show red pigmentation, especially after incubation at room temperature (22-25°C)."},{methodName:"MALDI-TOF Mass Spectrometry",details:"Provides rapid and accurate identification to the species level."}]},preventionAndScreening:[{type:"Infection Control",details:"Strict adherence to hand hygiene is paramount. Contact precautions are recommended for patients colonized or infected with MDR strains. Environmental cleaning and disinfection are crucial to prevent outbreaks.",targetPopulation:"Healthcare facilities, especially ICUs and NICUs"}],treatmentLifecycle:[],antimicrobialStewardship:["Reserve carbapenems for documented mixed infections or for infections due to confirmed ESBL-producing strains to limit selective pressure for carbapenem resistance.","Reserve Meropenem-vaborbactam and Ceftazidime-avibactam for documented KPC-producing CRE infections.","Avoid using polymyxins (colistin) due to intrinsic resistance."],drugSpecificPearls:[{drugName:"Aztreonam + Ceftazidime-avibactam",pearl:"This combination is a key strategy for MBL-producing CRE. Aztreonam is not hydrolyzed by metallo-carbapenemases but is inactivated by co-produced ESBLs and AmpC; avibactam protects aztreonam by inhibiting these other beta-lactamases."},{drugName:"Cefiderocol",pearl:"A siderophore cephalosporin used as a last-line agent for CRE. In a trial of severely ill patients with carbapenem-resistant infections, all-cause mortality was numerically higher in the cefiderocol arm compared to the best available therapy arm (24.8% vs 18.4%), although this was not statistically significant. Use should be reserved for patients with limited or no other treatment options."}],guidelineReferences:[{source:"IDSA",citation:"Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections (2024 Update or latest version)",summaryOrNote:"Provides evidence-based recommendations for the management of infections caused by ESBL-producing, AmpC-producing, and carbapenem-resistant Enterobacterales."}]},Eg={identity:xg,clinicalProfile:Sg,resistanceProfile:_g,treatment:Cg,laboratoryProfile:Ng,additionalInformation:Ag},jg={bacteriumName:"Enterobacter cloacae complex",aliases:["Enterobacter spp."],lastUpdated:"2025-01-02",clsiCategory:"Enterobacterales (excluding Salmonella/Shigella)",classification:{gramStain:"Negative",morphology:"Bacillus",respiration:"Facultative Anaerobe",notes:[]},strainDetails:[{type:"Complex Member",value:"Enterobacter cloacae",notes:""},{type:"Complex Member",value:"Enterobacter hormaechei",notes:""}],biochemicalTests:"Gram-negative rod, motile, lactose fermenter, indole –, VP +, citrate +, ornithine decarboxylase +, arginine dihydrolase +."},Rg={summary:"The Enterobacter cloacae complex causes a variety of infections in both normal and immunocompromised hosts and is a frequent cause of nosocomial infections, including bacteremia, pneumonia, and intra-abdominal infections.",pathophysiologyPearls:["Exposure to 3rd-generation cephalosporins can select for de-repressed ampC mutants, with emergence of resistance during therapy in 5-20% of treatment courses."],keySignsAndSymptoms:[],clinicalSyndromes:[{syndromeName:"Systemic Infections",description:"Can cause bacteremia, pneumonia, intra-abdominal infections, and skin and soft tissue infections."}],stagesOfIllness:[],highRiskPopulations:["Hospitalized patients","Immunocompromised hosts"],transmissionVectors:[],prognosisNotes:["Emergence of resistance during therapy with 3rd-generation cephalosporins occurs in 5-20% of treatment courses due to de-repression of the ampC gene."]},Tg={groupIntrinsicResistance:[],intrinsicResistance:[],majorMechanisms:[{mechanismName:"AmpC (Chromosomal)",mechanismType:"Cephalosporinase",description:"Virtually all isolates carry an inducible, chromosomal ampC gene that is normally repressed. It is not inhibited by clavulanate, sulbactam, or tazobactam, but is inhibited by avibactam."},{mechanismName:"ESBL",mechanismType:"Beta-lactamase",description:"Can acquire plasmid-encoded Extended-Spectrum Beta-Lactamases, which are not readily distinguishable phenotypically from de-repressed AmpC."},{mechanismName:"Carbapenemases",mechanismType:"Beta-lactamase",description:"Can acquire plasmid-encoded carbapenemases, including serine carbapenemases (KPC) and metallo-beta-lactamases (MBL)."},{mechanismName:"Other MDR Mechanisms",mechanismType:"Multiple",description:"Multi-drug resistance can also be mediated by over-expression of drug efflux pumps, target alterations, and outer membrane protein mutations affecting drug permeability."}],clinicalAlerts:[{alertTitle:"Inducible AmpC Resistance",details:"Exposure to 3rd-generation cephalosporins (e.g., ceftriaxone, ceftazidime) can select for de-repressed mutants that over-express AmpC, leading to clinical failure even if initial testing shows susceptibility. These agents should be avoided for serious infections."}]},Dg={generalNotes:["Recommendations are for treatment of moderately severe or severe infections.","For uncomplicated UTI, options include fluoroquinolones, TMP-SMX, or nitrofurantoin if susceptible. Third-generation cephalosporins can be used for uncomplicated UTI but should be avoided otherwise."],drugsToAvoid:[{drugOrClass:"3rd Generation Cephalosporins (Ceftriaxone, Ceftazidime, etc.)",condition:"Serious infections",reason:"High risk of selecting for de-repressed AmpC mutants and subsequent treatment failure."},{drugOrClass:"Piperacillin-tazobactam",condition:"Serious infections",reason:"Risk of clinical failure despite potential in-vitro susceptibility, especially for ESBL-producers."},{drugOrClass:"Meropenem + Polymyxin",condition:"All infections",reason:"Combination therapy is not recommended based on a failed randomized controlled trial (Lancet Infect Dis 2018;18:391)."}],adjunctiveTherapies:[],regimens:[{context:{type:"Empiric",condition:"Systemic Infection (Low Local ESBL Rate <10-15%)",patientPopulation:["Adult"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Cefepime",dose:"1-2 gm",route:"IV",frequency:"q8-12h",comments:"Infuse over 3 hours."},{drugName:"Ciprofloxacin",dose:"400 mg",route:"IV",frequency:"q12h",comments:""},{drugName:"Levofloxacin",dose:"750 mg",route:"IV",frequency:"q24h",comments:""}]}]}]},{context:{type:"Empiric",condition:"Systemic Infection (High Local ESBL Rate >15% or Severe Illness)",patientPopulation:["Adult"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",comments:""},{drugName:"Ertapenem",dose:"1 gm",route:"IV",frequency:"q24h",comments:""}]}]}]},{context:{type:"Directed",condition:"ESBL or AmpC Overproducer",patientPopulation:["Adult"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Meropenem",dose:"1-2 gm",route:"IV",frequency:"q8h",comments:"Consider 2 gm infused over 3 hours for more serious infections."}]}]},{preference:"Alternative (If susceptible)",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ciprofloxacin",dose:"400 mg",route:"IV",frequency:"q12h",comments:""},{drugName:"Levofloxacin",dose:"750 mg",route:"IV",frequency:"q24h",comments:""},{drugName:"TMP-SMX",dose:"10 mg/kg/day (TMP component)",route:"IV",frequency:"in 2-3 divided doses",comments:""}]}]}]},{context:{type:"Directed",condition:"KPC Producer (Carbapenem-Resistant)",patientPopulation:["Adult"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",comments:"Infuse over 3 hours."},{drugName:"Meropenem-vaborbactam",dose:"4 gm",route:"IV",frequency:"q8h",comments:"Infuse over 3 hours."},{drugName:"Imipenem-cilastatin-relebactam",dose:"1.25 gm",route:"IV",frequency:"q6h",comments:"Infuse over 30 min. For CrCl > 90 mL/min."}]}]}]},{context:{type:"Directed",condition:"Metallo-beta-lactamase (MBL) Producer",patientPopulation:["Adult"],isolateSource:null},recommendations:[{preference:"Primary",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Ceftazidime-avibactam",dose:"2.5 gm",route:"IV",frequency:"q8h",comments:"Infuse over 3 hours."},{drugName:"Aztreonam",dose:"2 gm",route:"IV",frequency:"q6h",comments:"Infuse over 3 hours."}]}],notes:["This combination is recommended because Aztreonam is not hydrolyzed by MBLs, while Avibactam protects Aztreonam from co-produced ESBLs or AmpC enzymes."]},{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Cefiderocol",dose:"2 gm",route:"IV",frequency:"q8h",comments:"Infuse over 3 hours."}]}]}]},{context:{type:"Directed",condition:"ESBL Producer",patientPopulation:["Adult"],isolateSource:"Urinary Tract"},recommendations:[{preference:"Alternative",strategy:"Concurrent",steps:[{step:1,duration:"Variable",drugs:[{drugName:"Cefepime-enmetazobactam",dose:"2.5 gm",route:"IV",frequency:"q8h",comments:"Recently FDA approved for complicated UTIs, including ESBL producers."},{drugName:"Plazomicin",dose:"15 mg/kg",route:"IV",frequency:"q24h",comments:"For complicated UTIs."},{drugName:"Fosfomycin",dose:"3 gm",route:"PO",frequency:"x 1 dose",comments:"For uncomplicated cystitis only."}]}]}]}]},Lg={testingIndications:[],methodologyNotes:["For Polymyxins, disk diffusion and gradient diffusion methods should not be performed; MIC testing is required."],recommendedPanel:["Cefepime should be considered a Tier 1 agent for testing and/or reporting."],specialTests:[],reportingRules:[{ruleType:"Conditional",drug:"Cefepime",condition:"Isolate demonstrates carbapenemase production.",details:"Cefepime S/SDD results should be suppressed or edited and reported as resistant."}],antimicrobialBreakpoints:[{tier:1,tierDescription:"Appropriate for routine, primary testing and reporting.",agents:[{agentName:"Ampicillin",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 17",i_breakpoint:"14–16",r_breakpoint:"≤ 13"},mic:{s_breakpoint:"≤ 8",i_breakpoint:"16",r_breakpoint:"≥ 32"},comments:["Results of ampicillin testing can be used to predict results for amoxicillin."]}]},{agentName:"Cefazolin",breakpointSets:[{condition:"Urine Only (Uncomplicated UTI)",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 15",i_breakpoint:"—",r_breakpoint:"≤ 14"},mic:{s_breakpoint:"≤ 16",i_breakpoint:"—",r_breakpoint:"≥ 32"},comments:["Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."]}]},{agentName:"Amoxicillin-clavulanate",breakpointSets:[{condition:"Uncomplicated UTI only",diskDiffusion:{diskContent:"20/10 µg",s_breakpoint:"≥ 18",i_breakpoint:"—",r_breakpoint:"≤ 17"},mic:{s_breakpoint:"≤ 8/4",i_breakpoint:"16/4",r_breakpoint:"≥ 32/4"},comments:[]}]},{agentName:"Piperacillin-tazobactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"100/10 µg",s_breakpoint:"≥ 25",i_breakpoint:"21–24",r_breakpoint:"≤ 20"},mic:{s_breakpoint:"≤ 8/4",i_breakpoint:"16/4",r_breakpoint:"≥ 32/4"},comments:[]}]}]},{tier:2,tierDescription:"Appropriate for routine, primary testing, may be reported following cascade reporting rules.",agents:[{agentName:"Cefepime",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 25",i_breakpoint:"19–24",r_breakpoint:"≤ 18"},mic:{s_breakpoint:"≤ 4",i_breakpoint:"8",r_breakpoint:"≥ 16"},comments:["Cefepime S/SDD results should be suppressed or edited and reported as resistant for isolates that demonstrate carbapenemase production."]}]},{agentName:"Ertapenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 22",i_breakpoint:"19–21",r_breakpoint:"≤ 18"},mic:{s_breakpoint:"≤ 0.5",i_breakpoint:"1",r_breakpoint:"≥ 2"},comments:[]}]},{agentName:"Meropenem",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"10 µg",s_breakpoint:"≥ 23",i_breakpoint:"20–22",r_breakpoint:"≤ 19"},mic:{s_breakpoint:"≤ 1",i_breakpoint:"2",r_breakpoint:"≥ 4"},comments:[]}]}]},{tier:3,tierDescription:"Appropriate for high-risk MDRO patients, subject to cascade reporting.",agents:[{agentName:"Ceftazidime-avibactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30/20 µg",s_breakpoint:"≥ 21",i_breakpoint:"—",r_breakpoint:"≤ 20"},mic:{s_breakpoint:"≤ 8/4",i_breakpoint:"—",r_breakpoint:"≥ 16/4"},comments:["Confirmatory MIC testing is indicated for isolates with zones of 20–22 mm."]}]},{agentName:"Meropenem-vaborbactam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"20/10 µg",s_breakpoint:"≥ 18",i_breakpoint:"15–17",r_breakpoint:"≤ 14"},mic:{s_breakpoint:"≤ 4/8",i_breakpoint:"8/8",r_breakpoint:"≥ 16/8"},comments:["If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."]}]}]},{tier:4,tierDescription:"May warrant testing and reporting by clinician request if optimal agents in other tiers are not available.",agents:[{agentName:"Aztreonam",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 21",i_breakpoint:"18–20",r_breakpoint:"≤ 17"},mic:{s_breakpoint:"≤ 4",i_breakpoint:"8",r_breakpoint:"≥ 16"},comments:[]}]},{agentName:"Ceftriaxone",breakpointSets:[{condition:"Standard",diskDiffusion:{diskContent:"30 µg",s_breakpoint:"≥ 26",i_breakpoint:"20–22",r_breakpoint:"≤ 19"},mic:{s_breakpoint:"≤ 1",i_breakpoint:"2",r_breakpoint:"≥ 4"},comments:[]}]},{agentName:"Colistin or Polymyxin B",breakpointSets:[{condition:"Standard",diskDiffusion:null,mic:{s_breakpoint:"≤ 2",i_breakpoint:"—",r_breakpoint:"≥ 4"},comments:["Disk diffusion and gradient diffusion methods should not be performed."]}]}]}]},Mg={diagnosticNotes:null,preventionAndScreening:[],treatmentLifecycle:[],antimicrobialStewardship:["Carbapenems should be reserved for mixed infections or for treatment of confirmed ESBL-producing strains.","Novel beta-lactam/beta-lactamase inhibitor combinations (e.g., Ceftazidime-avibactam) should be reserved for documented carbapenemase-producing organisms."],drugSpecificPearls:[{drugName:"Cefepime",pearl:"Cefepime is a weak inducer of chromosomal AmpC and more resistant to its hydrolysis than other cephalosporins. For strains with MICs of 4-8 mcg/ml, dose-dependent susceptibility is noted; the recommended dose is 2 gm IV q8h infused over 3 hours."},{drugName:"Cefiderocol",pearl:"FDA-approved for cUTI with limited options. An open-label trial in patients with serious carbapenem-resistant infections showed numerically higher all-cause mortality with cefiderocol vs. best available therapy, warranting caution."},{drugName:"Ceftazidime-avibactam + Aztreonam",pearl:"The rationale for this combination for MBL producers is that Aztreonam is stable against MBLs, and Avibactam protects Aztreonam from co-produced serine beta-lactamases (ESBL, AmpC, KPC)."},{drugName:"Fosfomycin (IV)",pearl:"In the US, it may be possible to obtain IV Fosfomycin as a single-patient emergency IND from the FDA's Division of Anti-infective Products."}],guidelineReferences:[{source:"IDSA 2024",citation:"Updated 2024 IDSA Guidelines on treatment of ESBL, AmpC, and carbapenemase producers.",summaryOrNote:"Provides comprehensive guidance on treating resistant gram-negative infections."},{source:"Clinical Infectious Diseases",citation:"Clin Infect Dis 2019;69:1446",summaryOrNote:"Primer on AmpC beta-lactamases."}]},zg={identity:jg,clinicalProfile:Rg,resistanceProfile:Tg,treatment:Dg,laboratoryProfile:Lg,additionalInformation:Mg},gl={citrobacterfreundii:ub,citrobacterkoseri:yb,ecolienteroaggregative:Nb,escherichiacoli:Lb,klebsiellaaerogenes:Bb,klebsiellaspoxytocapneumoniaevariicola:Xb,klebsiellasprhinoscleromatisozaenae:Wb,morganellamorganii:og,proteusspmirabilispennerivulgaris:pg,providenciaspstuartiirettgerialcalificiens:kg,serratiamarcescens:Eg,enterobactercloacaecomplex:zg},Ig=m=>m.toLowerCase().replace(/[^a-z0-9\s]/g,"").replace(/\s+/g,"_").replace(/_{2,}/g,"_").replace(/^_|_$/g,"");Object.values(gl).forEach(m=>{var c;(c=m.identity)!=null&&c.bacteriumName&&Ig(m.identity.bacteriumName)});const xd=()=>Object.keys(gl).length;console.log("📊 Loaded",xd(),"Enterobacterales organisms");let fl=null,kd=null;const qg=m=>{const c=JSON.stringify(Object.keys(m));if(fl&&kd===c)return fl;const d=Object.entries(m).map(([u,_])=>{var B,Q,H,Y,M,V,X,Z,K,G,F,se,w,ue,le,W,re,de,ce,x,D,$,fe,f,R,T,C,I,U;const E=[(B=_.identity)==null?void 0:B.bacteriumName,_.name,(Q=_.taxonomy)==null?void 0:Q.genus,(H=_.taxonomy)==null?void 0:H.species,(M=(Y=_.identity)==null?void 0:Y.classification)==null?void 0:M.gramStain,(V=_.identity)==null?void 0:V.clsiCategory].filter(Boolean).map(ee=>ee.toLowerCase()),O=(((X=_.identity)==null?void 0:X.aliases)||[]).map(ee=>ee.toLowerCase()),P=(((Z=_.clinicalProfile)==null?void 0:Z.clinicalSyndromes)||[]).map(ee=>{var Te;return(Te=ee.syndromeName)==null?void 0:Te.toLowerCase()}).filter(Boolean),L=(((K=_.resistanceProfile)==null?void 0:K.majorMechanisms)||[]).map(ee=>{var Te;return(Te=ee.mechanismName)==null?void 0:Te.toLowerCase()}).filter(Boolean),y=[...E,...O,...P,...L],z=((G=_.identity)==null?void 0:G.bacteriumName)||_.name||"Unknown",q=((F=_.taxonomy)==null?void 0:F.genus)||z.split(" ")[0]||"",ie=((se=_.taxonomy)==null?void 0:se.species)||z.split(" ")[1]||"";return{id:u,name:z,gramStain:((ue=(w=_.identity)==null?void 0:w.classification)==null?void 0:ue.gramStain)||"unknown",clinicalSignificance:2,significance:2,taxonomy:{genus:q,species:ie,family:((le=_.taxonomy)==null?void 0:le.family)||"",order:((W=_.taxonomy)==null?void 0:W.order)||"",class:((re=_.taxonomy)==null?void 0:re.class)||"",phylum:((de=_.taxonomy)==null?void 0:de.phylum)||"",domain:((ce=_.taxonomy)==null?void 0:ce.domain)||"Bacteria"},clsiCategory:(x=_.identity)==null?void 0:x.clsiCategory,aliases:((D=_.identity)==null?void 0:D.aliases)||[],clinicalSyndromes:(($=_.clinicalProfile)==null?void 0:$.clinicalSyndromes)||[],resistanceMechanisms:((fe=_.resistanceProfile)==null?void 0:fe.majorMechanisms)||[],clinicalAlerts:((f=_.resistanceProfile)==null?void 0:f.clinicalAlerts)||[],searchTerms:y,_indexed:{name:z.toLowerCase(),genus:q.toLowerCase(),gramStain:((C=(T=(R=_.identity)==null?void 0:R.classification)==null?void 0:T.gramStain)==null?void 0:C.toLowerCase())||"",clsiCategory:((U=(I=_.identity)==null?void 0:I.clsiCategory)==null?void 0:U.toLowerCase())||""}}});return fl=d,kd=c,d},Sd=gl;console.log(`✅ Loaded ${xd()} Enterobacterales organisms from generated index`);console.log("🦠 Available organisms:",Object.keys(Sd).sort());const Jt=()=>Sd,Og=()=>{const m=Jt();return qg(m)};class Pg{constructor(c,d,u=vd){this.patient=c,this.bacterium=d,this.epidemiology=u,this.susceptibilityResults=c.susceptibilityResults||{}}getOptimalRegimen(){try{const c=this.assessPatientSeverity(),d=this.assessResistanceRisk(),u=this.detectResistanceMechanisms(),_=this.assessEpidemiologyRisk();return{regimen:this.matchClinicalContext(c,d,u,_),rationale:this.generateRationale(c,d,u,_),severity:c,resistanceRisk:d,mechanisms:u,epidemiologyRisk:_}}catch(c){return console.error("Clinical Decision Engine error:",c),this.getFallbackRecommendation()}}assessPatientSeverity(){var L;let c=0;const d=[],_={CNS_meningitis:3,CNS_encephalitis:3,CNS_brain_abscess:3,CNS_subdural_empyema:3,CV_endocarditis_native:3,CV_endocarditis_prosthetic:3,CV_endocarditis_CIED:3,CV_mycotic_aneurysm:3,CV_pericarditis:2,RESP_CAP:2,RESP_HAP:2,RESP_VAP:3,RESP_empyema:2,RESP_lung_abscess:2,RESP_bronchitis_acute:1,GU_UTI_uncomplicated:1,GU_UTI_complicated:2,GU_UTI_catheter:2,GU_pyelonephritis:2,GU_prostatitis_acute:2,GU_prostatitis_chronic:1,SST_cellulitis_simple:1,SST_cellulitis_severe:2,SST_necrotizing_fasciitis:3,SST_abscess:1,SST_diabetic_foot:2,SST_surgical_site:2,BJ_osteomyelitis_acute:2,BJ_osteomyelitis_chronic:2,BJ_prosthetic_joint:2,BJ_septic_arthritis:2,BJ_vertebral_osteomyelitis:2,BJ_diabetic_foot_osteo:2,IA_peritonitis_secondary:2,IA_peritonitis_primary:2,IA_intra_abdominal:2,IA_cholangitis:2,IA_liver_abscess:2,IA_appendicitis:2,BS_bacteremia_primary:2,BS_CLABSI:2,BS_sepsis:3,BS_septic_shock:3,BS_neutropenic_fever:2}[this.patient.location]||nb[this.patient.location]||Nt.MILD;c+=_;const E=(L=this.patient.location)!=null&&L.includes("_")?"Syndrome-specific":this.patient.location;d.push(`${E}: (+${_})`),parseFloat(this.patient.age)>65&&(c+=1,d.push("Age >65 years (+1)")),this.patient.showSeverityAssessment&&(this.patient.isICU&&(c+=3,d.push("ICU admission (+3)")),this.patient.isImmunocompromised&&(c+=2,d.push("Immunocompromised (+2)")),this.patient.priorAntibiotics&&(c+=1,d.push("Prior antibiotics (+1)")),this.patient.hasOrganDysfunction&&(c+=2,d.push("Organ dysfunction (+2)")),this.patient.hasSepsis&&(c+=3,d.push("Sepsis/septic shock (+3)")),this.patient.hemodynamicStatus==="shock"?(c+=3,d.push("Hemodynamic shock (+3)")):this.patient.hemodynamicStatus==="hypotension"&&(c+=2,d.push("Hypotension (+2)")),this.patient.respiratoryStatus==="mechanical"?(c+=2,d.push("Mechanical ventilation (+2)")):this.patient.respiratoryStatus==="oxygen"&&(c+=1,d.push("Oxygen supplementation (+1)")));let P;return c<=2?P="MILD":c<=5?P="MODERATE":c<=8?P="SEVERE":P="CRITICAL",{score:c,level:Nt[P],levelName:P,factors:d,description:this.getSeverityDescription(P),objective:this.patient.showSeverityAssessment}}assessResistanceRisk(){var O,P;const c=[];let d=0;const u=((P=(O=this.bacterium.taxonomy)==null?void 0:O.genus)==null?void 0:P.toLowerCase())||"unknown",_=this.getLocalESBLRate(u);_>pl.HIGH_ESBL_RATE&&(c.push(dl.HIGH_ESBL_RATE),d+=3),this.patient.isICU&&(c.push(dl.ICU_ADMISSION),d+=2),this.patient.isImmunocompromised&&(c.push(dl.IMMUNOCOMPROMISED),d+=1);const E=this.assessSyndromeSpecificResistanceRisk();return d+=E.score,c.push(...E.factors),{score:d,level:this.categorizeRiskLevel(d),factors:c,localESBLRate:_,syndromeSpecificRisks:E.syndromeRisks,description:this.getRiskDescription(d)}}assessSyndromeSpecificResistanceRisk(){const c=[],d=[];let u=0;const _=this.patient.location;switch(["RESP_HAP","RESP_VAP","BS_CLABSI","GU_UTI_catheter","SST_surgical_site","CV_endocarditis_CIED","BJ_prosthetic_joint"].includes(_)&&(u+=2,d.push("Healthcare-associated infection (+2)"),c.push("Higher MDR pathogen risk")),["BS_CLABSI","GU_UTI_catheter","CV_endocarditis_CIED","BJ_prosthetic_joint","CV_endocarditis_prosthetic"].includes(_)&&(u+=1,d.push("Device-associated infection (+1)"),c.push("Biofilm-forming pathogens likely")),_){case"RESP_VAP":u+=2,d.push("VAP: High Pseudomonas/Acinetobacter risk (+2)"),c.push("Consider anti-Pseudomonas coverage");break;case"BS_neutropenic_fever":u+=2,d.push("Neutropenic fever: MDR gram-negative risk (+2)"),c.push("Broad-spectrum empiric therapy essential");break;case"BJ_osteomyelitis_chronic":u+=1,d.push("Chronic osteomyelitis: Small colony variants (+1)"),c.push("Consider biofilm-active agents");break;case"SST_diabetic_foot":u+=1,d.push("Diabetic foot: Polymicrobial + MRSA risk (+1)"),c.push("Consider MRSA and anaerobic coverage");break;case"IA_peritonitis_secondary":d.push("Peritonitis: Polymicrobial infection expected"),c.push("Anaerobic coverage essential");break;case"GU_UTI_complicated":case"GU_UTI_catheter":u+=1,d.push("Complicated UTI: ESBL risk increased (+1)"),c.push("Consider carbapenem if ESBL suspected");break;case"CNS_meningitis":d.push("Meningitis: Penetration more critical than resistance"),c.push("Prioritize CNS penetration over spectrum");break}return this.patient.institutionType==="tertiary"&&(u+=1,d.push("Tertiary care center (+1)"),c.push("Higher baseline resistance rates")),{score:u,factors:d,syndromeRisks:c}}assessCoverageRequirements(){const c=this.patient.location,d=[],u=[];switch(["IA_peritonitis_secondary","IA_peritonitis_primary","IA_intra_abdominal","IA_liver_abscess","IA_appendicitis","RESP_lung_abscess","SST_diabetic_foot"].includes(c)&&(d.push({type:"ANAEROBIC_ESSENTIAL",description:"Anaerobic coverage essential",agents:Hs.ANAEROBIC_ESSENTIAL.required,priority:"Essential"}),u.push("Consider metronidazole, clindamycin, or beta-lactam/beta-lactamase inhibitor")),["RESP_CAP"].includes(c)&&(d.push({type:"ATYPICAL_COVERAGE",description:"Atypical pathogen coverage recommended",agents:Hs.ATYPICAL_COVERAGE.required,priority:"Recommended"}),u.push("Consider macrolide, fluoroquinolone, or tetracycline for atypical coverage")),["RESP_HAP","RESP_VAP","BS_neutropenic_fever","BJ_osteomyelitis_chronic"].includes(c)&&(d.push({type:"ANTI_PSEUDOMONAS",description:"Anti-Pseudomonas coverage recommended",agents:Hs.ANTI_PSEUDOMONAS.required,priority:"Recommended"}),u.push("Consider anti-pseudomonal beta-lactam or fluoroquinolone")),["BJ_prosthetic_joint","CV_endocarditis_CIED","CV_endocarditis_prosthetic","BJ_osteomyelitis_chronic","BS_CLABSI"].includes(c)&&(d.push({type:"BIOFILM_ACTIVITY",description:"Biofilm-active agents preferred",agents:Hs.BIOFILM_ACTIVITY.required,priority:"Preferred"}),u.push("Consider rifampin combinations, daptomycin, or linezolid")),["SST_cellulitis_severe","SST_necrotizing_fasciitis","SST_diabetic_foot","BJ_osteomyelitis_acute","BJ_prosthetic_joint","CV_endocarditis_native"].includes(c)&&this.patient.isICU&&(d.push({type:"MRSA_COVERAGE",description:"MRSA coverage consideration",agents:["Vancomycin","Linezolid","Daptomycin","Ceftaroline"],priority:"Consider"}),u.push("Consider MRSA coverage based on local epidemiology and risk factors")),c){case"CNS_meningitis":d.push({type:"CNS_PENETRATION",description:"Blood-brain barrier penetration essential",agents:["Ceftriaxone","Vancomycin","Meropenem"],priority:"Essential"}),u.push("Bactericidal agents preferred; high-dose regimens required");break;case"GU_UTI_uncomplicated":d.push({type:"UTI_SPECIFIC",description:"UTI-specific agents preferred",agents:["Nitrofurantoin","Fosfomycin","Trimethoprim-sulfamethoxazole"],priority:"Preferred"}),u.push("Short course therapy (3 days) appropriate");break;case"GU_prostatitis_acute":d.push({type:"PROSTATE_PENETRATION",description:"Prostate penetration essential",agents:["Ciprofloxacin","Levofloxacin","Trimethoprim-sulfamethoxazole"],priority:"Essential"}),u.push("Extended duration therapy (2-4 weeks) required");break}return{requirements:d,recommendations:u,summary:d.length>0?`${d.length} special coverage consideration${d.length>1?"s":""}`:"Standard spectrum adequate"}}detectResistanceMechanisms(){const c={esbl:this.detectESBL(),ampC:this.detectAmpC(),carbapenemase:this.detectCarbapenemase()};return{...c,summary:this.summarizeMechanisms(c),coverageRequirements:this.assessCoverageRequirements()}}detectESBL(){const c=["Ceftriaxone","Ceftazidime","Cefotaxime"].filter(_=>this.susceptibilityResults[_]==="R").length>=2,d=["Meropenem","Ertapenem"].some(_=>this.susceptibilityResults[_]==="S"),u=c&&d;return{suspected:u,pattern:c?"Classic ESBL pattern":"Atypical pattern",implications:u?"Avoid cephalosporins, consider carbapenems":"Standard therapy may be appropriate"}}detectAmpC(){var O,P;const c=["enterobacter","citrobacter","serratia"],d=((P=(O=this.bacterium.taxonomy)==null?void 0:O.genus)==null?void 0:P.toLowerCase())||"";if(!c.includes(d))return{suspected:!1,reason:"Not an AmpC-producing genus"};const u=["Ceftriaxone","Ceftazidime"].some(L=>this.susceptibilityResults[L]==="R"),_=["Meropenem","Ertapenem"].some(L=>this.susceptibilityResults[L]==="S"),E=u&&_;return{suspected:E,pattern:E?"AmpC overproduction pattern":"No AmpC pattern",implications:E?"Avoid 3rd gen cephalosporins, use cefepime or carbapenems":"Standard therapy appropriate"}}detectCarbapenemase(){const c=["Meropenem","Imipenem","Ertapenem"],d=c.filter(u=>this.susceptibilityResults[u]==="R");return d.length===0?{suspected:!1,type:"None detected"}:{suspected:!0,confidence:d.length/c.length,type:"Carbapenemase suspected",implications:"Extremely limited options"}}assessEpidemiologyRisk(){var E,O;const c=((O=(E=this.bacterium.taxonomy)==null?void 0:E.genus)==null?void 0:O.toLowerCase())||"unknown",d=this.getLocalESBLRate(c);let u="LOW";const _=[];return d>pl.HIGH_ESBL_RATE?(u="HIGH",_.push(`High local ESBL rate: ${(d*100).toFixed(1)}%`)):d>pl.LOW_ESBL_RATE&&(u="MODERATE",_.push(`Moderate local ESBL rate: ${(d*100).toFixed(1)}%`)),{level:u,esblRate:d,factors:_,recommendation:this.getEpidemiologyRecommendation(u)}}matchClinicalContext(c,d,u,_){var z;const E=((z=this.bacterium.treatment)==null?void 0:z.regimens)||[];if(E.length===0)return this.getFallbackRecommendation();const P=E.map(q=>({regimen:q,score:this.calculateRegimenScore(q,c,d,u,_)})).sort((q,ie)=>ie.score-q.score),L=P[0],y=this.findSuitableAntibiotics(L.regimen);if(y.length===0){for(let q=1;q<P.length;q++){const ie=P[q],B=this.findSuitableAntibiotics(ie.regimen);if(B.length>0)return{...ie,suitableOptions:B,note:"Alternative regimen selected due to resistance/allergies"}}return this.getFallbackRecommendation()}return{...L,suitableOptions:y,allRegimens:P}}calculateRegimenScore(c,d,u,_,E){var L,y,z,q,ie,B,Q,H,Y,M,V,X,Z,K;let O=0;const P=c.context||{};return((y=(L=c.recommendations)==null?void 0:L[0])==null?void 0:y.preference)==="Primary"&&(O+=10),d.level>=Nt.SEVERE?(((z=P.condition)!=null&&z.includes("Severe")||(q=P.condition)!=null&&q.includes("High Local ESBL")||(ie=P.condition)!=null&&ie.includes("Carbapenem"))&&(O+=15),(B=P.condition)!=null&&B.includes("Low Local ESBL")&&(O-=15)):(Q=P.condition)!=null&&Q.includes("Low Local ESBL")&&!_.esbl.suspected&&(O+=10),E.level==="HIGH"&&((H=P.condition)!=null&&H.includes("High Local ESBL")&&(O+=12),(Y=P.condition)!=null&&Y.includes("Low Local ESBL")&&(O-=10)),_.esbl.suspected&&(((M=P.condition)!=null&&M.includes("ESBL")||(V=P.condition)!=null&&V.includes("High Local ESBL"))&&(O+=20),(X=P.condition)!=null&&X.includes("Low Local ESBL")&&(O-=25)),_.carbapenemase.suspected&&((Z=P.condition)!=null&&Z.includes("KPC")||(K=P.condition)!=null&&K.includes("Carbapenem-Resistant")?O+=25:O-=30),Math.max(0,O)}findSuitableAntibiotics(c){const d=c.recommendations||[],u=[];for(const _ of d){const E=_.steps||[];for(const O of E){const P=O.drugs||[];for(const L of P)if(this.isAntibioticSuitable(L.drugName)){const y=this.assessPenetrationSuitability(L.drugName);u.push({...L,preference:_.preference,strategy:_.strategy,penetrationScore:y.score,penetrationLevel:y.level,penetrationWarnings:y.warnings})}}}return u.sort((_,E)=>_.penetrationScore!==E.penetrationScore?E.penetrationScore-_.penetrationScore:_.preference==="Primary"&&E.preference!=="Primary"?-1:E.preference==="Primary"&&_.preference!=="Primary"?1:0)}assessPenetrationSuitability(c){const d=this.getPenetrationRequirement();if(!d)return{score:5,level:"Standard",warnings:[]};const u=[];let _=0,E="Poor";return d.excellent.includes(c)?(_=10,E="Excellent"):d.good.includes(c)?(_=8,E="Good"):d.moderate.includes(c)?(_=5,E="Moderate",d.type==="CNS_critical"&&u.push("Consider high-dose regimen for CNS penetration")):d.poor.includes(c)?(_=2,E="Poor",u.push(`Poor ${d.description.toLowerCase()}`)):d.avoid.some(O=>c.includes(O)||O.includes(c))?(_=0,E="Avoid",u.push(`Avoid: ${d.description}`)):(_=5,E="Unknown"),{score:_,level:E,warnings:u}}getPenetrationRequirement(){return{CNS_meningitis:Be.CNS_CRITICAL,CNS_encephalitis:Be.CNS_CRITICAL,CNS_brain_abscess:Be.CNS_CRITICAL,CNS_subdural_empyema:Be.CNS_CRITICAL,BJ_osteomyelitis_acute:Be.BONE_SPECIFIC,BJ_osteomyelitis_chronic:Be.BONE_SPECIFIC,BJ_prosthetic_joint:Be.BONE_SPECIFIC,BJ_vertebral_osteomyelitis:Be.BONE_SPECIFIC,BJ_diabetic_foot_osteo:Be.BONE_SPECIFIC,GU_UTI_uncomplicated:Be.URINARY_SPECIFIC,GU_prostatitis_acute:Be.PROSTATE_SPECIFIC,GU_prostatitis_chronic:Be.PROSTATE_SPECIFIC,GU_UTI_complicated:Be.SYSTEMIC,GU_UTI_catheter:Be.SYSTEMIC,GU_pyelonephritis:Be.SYSTEMIC,BS_bacteremia_primary:Be.SYSTEMIC,BS_CLABSI:Be.SYSTEMIC,BS_sepsis:Be.SYSTEMIC,BS_septic_shock:Be.SYSTEMIC}[this.patient.location]||Be.GOOD}isAntibioticSuitable(c){return this.susceptibilityResults[c]==="S"}getLocalESBLRate(c){return this.epidemiology.esblRate[c]||this.epidemiology.esblRate.enterobacterales||vd.esblRate.enterobacterales}generateRationale(c,d,u,_){return{summary:`Recommendation based on ${c.levelName.toLowerCase()} patient severity, ${d.level.toLowerCase()} resistance risk, and ${_.level.toLowerCase()} local epidemiology.`,factors:[`Severity: ${c.levelName} (${c.score})`,`Resistance risk: ${d.level}`,`ESBL rate: ${(d.localESBLRate*100).toFixed(1)}%`,`Mechanisms: ${u.summary}`],warnings:u.esbl.suspected?["ESBL detected - avoid cephalosporins"]:[],considerations:[]}}getSeverityDescription(c){return{MILD:"Paciente estable con infección no complicada (puntuación ≤2)",MODERATE:"Paciente con enfermedad moderada que requiere vigilancia (puntuación 3-5)",SEVERE:"Paciente gravemente enfermo que requiere terapia intensiva (puntuación 6-8)",CRITICAL:"Paciente en estado crítico con riesgo vital inmediato (puntuación >8)"}[c]||"Severidad no determinada"}getRiskDescription(c){return c>=4?"Riesgo alto de resistencia":c>=2?"Riesgo moderado de resistencia":"Riesgo bajo de resistencia"}categorizeRiskLevel(c){return c>=4?"HIGH":c>=2?"MODERATE":"LOW"}getEpidemiologyRecommendation(c){return{LOW:"Standard empiric therapy appropriate",MODERATE:"Consider enhanced empiric coverage",HIGH:"Broad-spectrum empiric therapy recommended"}[c]||"Assessment needed"}summarizeMechanisms(c){const d=[];return c.esbl.suspected&&d.push("ESBL"),c.ampC.suspected&&d.push("AmpC"),c.carbapenemase.suspected&&d.push("Carbapenemase"),d.length>0?d.join(", "):"None detected"}getFallbackRecommendation(){return{regimen:null,score:0,suitableOptions:[],note:"No suitable treatment regimen identified. Infectious diseases consultation recommended.",rationale:{summary:"Complex resistance pattern prevents standard therapy",factors:["Multiple resistance mechanisms or contraindications"],warnings:["Requires expert consultation"],considerations:["Consider combination therapy"]}}}}function Bg(m,c,d){return new Pg(m,c,d).getOptimalRegimen()}const wi={PENICILLIN:"penicillin",BETALACTAM:"betalactam",CARBAPENEM:"carbapenem",GLYCOPEPTIDE:"glycopeptide"},Vi={TIME_DEPENDENT:"Time > MIC",AUC_DEPENDENT:"AUC/MIC"},Ui={B:"Category B - No evidence of risk in humans",C:"Category C - Risk cannot be ruled out"},wg={Oxacillin:{classification:{family:wi.PENICILLIN,subclass:"Antistaphylococcal penicillin",generation:null},mechanism:{target:"Penicillin-binding proteins (PBPs)",action:"Inhibits cell wall synthesis",bactericidal:!0,pkpdIndex:Vi.TIME_DEPENDENT},spectrum:{gramPositive:["MSSA","Streptococcus spp.","Non-enterococcal Group D strep"],gramNegative:[],anaerobes:["Clostridium spp."],atypicals:[],notes:"Narrow spectrum, MSSA-specific"},dosing:{adult:{standard:"2g IV q4h",severe:"2g IV q4h (12g/day maximum)",renal:{normal:"≥50 mL/min - No adjustment",mild:"30-49 mL/min - No adjustment",moderate:"10-29 mL/min - 50% dose reduction",severe:"<10 mL/min - 25-50% dose reduction"},hepatic:"No adjustment required",infusion:"Administer over 30 minutes"},pediatric:{standard:"150-200 mg/kg/day IV divided q6h",maximum:"12g/day",neonatal:"Adjust based on gestational age"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:["Beta-lactamase production","PBP alterations"],crossResistance:["Penicillin","Ampicillin","Amoxicillin"],testing:"Cefoxitin disk screening for mecA"},safety:{pregnancyCategory:Ui.B,lactation:"Compatible",blackBoxWarning:!1,majorAdverseEffects:["Hypersensitivity reactions","Clostridioides difficile-associated diarrhea","Thrombophlebitis"],contraindications:["Penicillin allergy"],monitoring:["Signs of allergic reaction","CBC with prolonged use"]},interactions:{drugDrug:["Probenecid - increases serum levels","Warfarin - may enhance anticoagulant effect"],foodDrug:[]},stewardship:{preferredFor:["MSSA infections","Skin and soft tissue infections"],avoid:["MRSA","Gram-negative infections"],deEscalation:"Preferred over vancomycin for MSSA",resistance:"Low resistance development risk"}},"Penicillin G":{classification:{family:wi.PENICILLIN,subclass:"Natural penicillin",generation:null},mechanism:{target:"Penicillin-binding proteins (PBPs)",action:"Inhibits cell wall synthesis",bactericidal:!0,pkpdIndex:Vi.TIME_DEPENDENT},spectrum:{gramPositive:["Streptococcus spp.","Non-beta-lactamase producing staphylococci"],gramNegative:["Neisseria meningitidis","Neisseria gonorrhoeae (if susceptible)"],anaerobes:["Clostridium spp.","Peptostreptococcus","Fusobacterium"],spirochetes:["Treponema pallidum","Borrelia burgdorferi"],notes:"Narrow spectrum, activity against spirochetes"},dosing:{adult:{standard:"2-4 million units IV q4-6h",severe:"18-24 million units/day continuous infusion",meningitis:"24 million units/day divided q4h",syphilis:"18-24 million units/day for 10-14 days",renal:{normal:"≥50 mL/min - No adjustment",mild:"30-49 mL/min - No adjustment",moderate:"10-29 mL/min - Reduce dose by 25-50%",severe:"<10 mL/min - Reduce dose by 50-75%"},hepatic:"No adjustment required"},pediatric:{standard:"100,000-400,000 units/kg/day divided q4-6h",meningitis:"450,000 units/kg/day divided q4h",maximum:"24 million units/day"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement"},resistance:{mechanisms:["Beta-lactamase production"],crossResistance:["Ampicillin","Amoxicillin"],prevalence:"High resistance in S. aureus (>90%)"},safety:{pregnancyCategory:Ui.B,lactation:"Compatible",blackBoxWarning:!1,majorAdverseEffects:["Hypersensitivity reactions","CNS toxicity (high doses)","Electrolyte disturbances (potassium/sodium load)"],contraindications:["Penicillin allergy"],monitoring:["Electrolytes with high doses","Signs of allergic reaction"]},interactions:{drugDrug:["Probenecid - increases serum levels","Methotrexate - may increase toxicity"],foodDrug:[]},stewardship:{preferredFor:["Neurosyphilis","Group A/B/C streptococcal infections","Clostridial infections"],avoid:["Most staphylococcal infections","Gram-negative infections"],deEscalation:"Narrow spectrum preferred when appropriate",resistance:"Consider local resistance patterns"}},"Piperacillin-Tazobactam":{classification:{family:wi.BETALACTAM,subclass:"Antipseudomonal penicillin with beta-lactamase inhibitor",generation:null},mechanism:{target:"Penicillin-binding proteins (PBPs)",action:"Inhibits cell wall synthesis; tazobactam inhibits beta-lactamases",bactericidal:!0,pkpdIndex:Vi.TIME_DEPENDENT},spectrum:{gramPositive:["MSSA","Streptococcus spp.","Enterococcus faecalis"],gramNegative:["Escherichia coli","Klebsiella spp.","Proteus spp.","Pseudomonas aeruginosa","Enterobacter spp.","Citrobacter spp.","Serratia marcescens","Haemophilus influenzae"],anaerobes:["Bacteroides fragilis group","Prevotella","Peptostreptococcus"],atypicals:[],notes:"Broad spectrum including antipseudomonal activity"},dosing:{adult:{standard:"4.5g IV q6h or q8h",extendedInfusion:"4.5g IV over 4 hours q8h (preferred for P. aeruginosa)",severe:"4.5g IV q6h (extended infusion)",renal:{normal:"≥40 mL/min - No adjustment",mild:"20-39 mL/min - 3.375g q6h",moderate:"<20 mL/min - 2.25g q6h",hemodialysis:"2.25g q8h + 0.75g after each dialysis"},hepatic:"No adjustment required"},pediatric:{standard:"300-400 mg/kg/day (piperacillin component) divided q6-8h",maximum:"18g/day piperacillin component",neonatal:"Adjust based on gestational age"}},monitoring:{levels:!1,parameters:[],targets:{efficacy:"≥50% fT>MIC for bacteriostatic effect",optimal:"≥100% fT>MIC for bactericidal effect"},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:["ESBL production (limited protection)","AmpC beta-lactamases","Carbapenemases","Efflux pumps (P. aeruginosa)"],crossResistance:["Other penicillins"],surveillance:"Monitor for ESBL and carbapenemase producers"},safety:{pregnancyCategory:Ui.B,lactation:"Compatible",blackBoxWarning:!1,majorAdverseEffects:["Hypersensitivity reactions","Clostridioides difficile-associated diarrhea","Thrombocytopenia","Bleeding (platelet dysfunction)"],contraindications:["Penicillin allergy"],monitoring:["CBC","Platelet function","Signs of bleeding"]},interactions:{drugDrug:["Vancomycin - potential nephrotoxicity","Aminoglycosides - physical incompatibility","Warfarin - enhanced anticoagulant effect"],foodDrug:[]},stewardship:{preferredFor:["Hospital-acquired pneumonia","Complicated intra-abdominal infections","Febrile neutropenia","Pseudomonas aeruginosa infections"],avoid:["Uncomplicated community-acquired infections"],deEscalation:"Consider narrower spectrum based on cultures",resistance:"High resistance development risk with monotherapy"}},Cefazolin:{classification:{family:wi.BETALACTAM,subclass:"First-generation cephalosporin",generation:1},mechanism:{target:"Penicillin-binding proteins (PBPs)",action:"Inhibits cell wall synthesis",bactericidal:!0,pkpdIndex:Vi.TIME_DEPENDENT},spectrum:{gramPositive:["MSSA","Streptococcus spp.","Non-enterococcal Group D strep"],gramNegative:["E. coli","Klebsiella pneumoniae","Proteus mirabilis"],anaerobes:[],atypicals:[],notes:"Narrow spectrum, excellent staphylococcal activity"},dosing:{adult:{standard:"1-2g IV q8h",severe:"2g IV q6-8h",prophylaxis:"1-2g IV 30-60 minutes before incision",renal:{normal:"≥55 mL/min - No adjustment",mild:"35-54 mL/min - No adjustment",moderate:"11-34 mL/min - 50% dose or q12h",severe:"≤10 mL/min - 25% dose or q24h"},hepatic:"No adjustment required"},pediatric:{standard:"100-150 mg/kg/day divided q8h",maximum:"6g/day",prophylaxis:"30 mg/kg IV pre-operatively"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement"},resistance:{mechanisms:["Beta-lactamase production (limited spectrum)"],crossResistance:["Other first-generation cephalosporins"],stability:"Stable against most gram-positive beta-lactamases"},safety:{pregnancyCategory:Ui.B,lactation:"Compatible",blackBoxWarning:!1,majorAdverseEffects:["Hypersensitivity reactions","Clostridioides difficile-associated diarrhea","Thrombophlebitis"],contraindications:["Cephalosporin allergy"],monitoring:["Signs of allergic reaction"]},interactions:{drugDrug:["Probenecid - increases serum levels"],foodDrug:[]},stewardship:{preferredFor:["Surgical prophylaxis","MSSA skin/soft tissue infections"],avoid:["MRSA","Enterococcal infections","Gram-negative infections beyond basic spectrum"],deEscalation:"Excellent de-escalation choice for susceptible organisms",resistance:"Low resistance development risk"}},Ceftriaxone:{classification:{family:wi.BETALACTAM,subclass:"Third-generation cephalosporin",generation:3},mechanism:{target:"Penicillin-binding proteins (PBPs)",action:"Inhibits cell wall synthesis",bactericidal:!0,pkpdIndex:Vi.TIME_DEPENDENT},spectrum:{gramPositive:["MSSA","Streptococcus spp.","S. pneumoniae"],gramNegative:["E. coli","Klebsiella spp.","Proteus spp.","Enterobacter spp.","H. influenzae","N. gonorrhoeae","N. meningitidis"],anaerobes:["Limited activity"],atypicals:[],notes:"Broad gram-negative spectrum, excellent CNS penetration"},dosing:{adult:{standard:"1-2g IV q24h",meningitis:"2g IV q12h",gonorrhea:"500mg IM single dose",renal:{normal:"≥10 mL/min - No adjustment",severe:"<10 mL/min - Consider dose reduction if concurrent hepatic impairment"},hepatic:"Max 2g/day if severe hepatic impairment + renal impairment"},pediatric:{standard:"50-75 mg/kg/day IV q24h",meningitis:"100 mg/kg/day IV divided q12h",maximum:"4g/day"}},monitoring:{levels:!1,parameters:[],targets:{},clinicalResponse:"Monitor for clinical improvement"},resistance:{mechanisms:["ESBL production","AmpC beta-lactamases"],crossResistance:["Other third-generation cephalosporins"],surveillance:"Monitor for ESBL producers"},safety:{pregnancyCategory:Ui.B,lactation:"Compatible",blackBoxWarning:!1,majorAdverseEffects:["Hypersensitivity reactions","Biliary sludging/pseudolithiasis","Clostridioides difficile-associated diarrhea"],contraindications:["Cephalosporin allergy","Neonates with hyperbilirubinemia"],monitoring:["Hepatic function with prolonged use"]},interactions:{drugDrug:["Calcium-containing solutions - precipitation","Probenecid - increases serum levels"],foodDrug:[]},stewardship:{preferredFor:["Community-acquired pneumonia","Meningitis","Gonorrhea"],avoid:["ESBL producers","Enterococcal infections","Pseudomonas"],deEscalation:"Good de-escalation choice for susceptible gram-negatives",resistance:"Monitor for ESBL emergence"}},Meropenem:{classification:{family:wi.CARBAPENEM,subclass:"Carbapenem",generation:null},mechanism:{target:"Penicillin-binding proteins (PBPs)",action:"Inhibits cell wall synthesis",bactericidal:!0,pkpdIndex:Vi.TIME_DEPENDENT},spectrum:{gramPositive:["MSSA","Streptococcus spp.","Enterococcus faecalis"],gramNegative:["E. coli","Klebsiella spp.","Enterobacter spp.","Citrobacter spp.","Pseudomonas aeruginosa","Acinetobacter spp.","ESBL producers"],anaerobes:["Bacteroides fragilis group","Clostridium spp."],atypicals:[],notes:"Broadest beta-lactam spectrum, excellent for ESBL producers"},dosing:{adult:{standard:"1g IV q8h",severe:"2g IV q8h",extendedInfusion:"1-2g IV over 3-4 hours q8h (preferred)",meningitis:"2g IV q8h",renal:{normal:"≥50 mL/min - No adjustment",mild:"26-49 mL/min - 1g q12h",moderate:"10-25 mL/min - 500mg q12h",severe:"<10 mL/min - 500mg q24h"},hepatic:"No adjustment required"},pediatric:{standard:"60 mg/kg/day divided q8h",meningitis:"120 mg/kg/day divided q8h",maximum:"6g/day"}},monitoring:{levels:!1,parameters:[],targets:{efficacy:"≥40% fT>MIC for bacteriostatic effect",optimal:"≥100% fT>MIC for bactericidal effect"},clinicalResponse:"Monitor for clinical improvement within 48-72 hours"},resistance:{mechanisms:["Carbapenemase production (KPC, NDM, OXA-48)","Porin loss + ESBL/AmpC","Efflux pumps"],crossResistance:["Other carbapenems"],surveillance:"Monitor for carbapenemase producers (CRE)"},safety:{pregnancyCategory:Ui.B,lactation:"Compatible",blackBoxWarning:!1,majorAdverseEffects:["Seizures (especially with renal impairment)","Hypersensitivity reactions","Clostridioides difficile-associated diarrhea"],contraindications:["Carbapenem allergy"],monitoring:["Neurological status","Renal function"]},interactions:{drugDrug:["Valproic acid - decreases levels significantly","Probenecid - increases serum levels"],foodDrug:[]},stewardship:{preferredFor:["ESBL producers","Severe hospital-acquired infections","Polymicrobial intra-abdominal infections"],avoid:["Uncomplicated infections","MRSA","Enterococcus faecium"],deEscalation:"Reserved for multidrug-resistant organisms",resistance:"Extremely high resistance development risk - use judiciously"}},Vancomycin:{classification:{family:wi.GLYCOPEPTIDE,subclass:"Glycopeptide",generation:null},mechanism:{target:"D-alanyl-D-alanine terminus of peptidoglycan",action:"Inhibits cell wall synthesis",bactericidal:!0,pkpdIndex:Vi.AUC_DEPENDENT},spectrum:{gramPositive:["MRSA","MSSA","Streptococcus spp.","Enterococcus faecalis","C. difficile (oral)","Coagulase-negative staphylococci"],gramNegative:[],anaerobes:["Clostridium spp."],atypicals:[],notes:"Gram-positive only, MRSA drug of choice"},dosing:{adult:{loading:"25-30 mg/kg IV (max 3g)",maintenance:"15-20 mg/kg IV q8-12h",continuous:"Loading dose then 1.5-2g/day continuous infusion",oral:"125-500mg PO q6h (C. difficile only)",renal:{normal:"≥60 mL/min - q8-12h based on levels",mild:"40-59 mL/min - q12-24h based on levels",moderate:"20-39 mL/min - q24-48h based on levels",severe:"<20 mL/min - Loading dose then individualize"},hepatic:"No adjustment required"},pediatric:{standard:"40-60 mg/kg/day divided q6-8h",severe:"60-80 mg/kg/day divided q6h",maximum:"No established maximum"}},monitoring:{levels:!0,parameters:["AUC24","Trough (if AUC unavailable)"],targets:{auc24:"400-600 μg•hr/mL",trough:"15-20 μg/mL (complicated infections)",troughAlternative:"10-15 μg/mL (uncomplicated infections)"},frequency:"Daily until stable, then 2-3 times weekly"},resistance:{mechanisms:["vanA/vanB gene clusters","Thickened cell wall (VISA)"],crossResistance:["Teicoplanin (vanA)"],surveillance:"Monitor for VISA/VRSA"},safety:{pregnancyCategory:Ui.C,lactation:"Compatible",blackBoxWarning:!1,majorAdverseEffects:["Nephrotoxicity","Ototoxicity","Red man syndrome (infusion-related)","Thrombocytopenia"],contraindications:["Previous serious hypersensitivity"],monitoring:["Renal function","Hearing assessment","Drug levels"]},interactions:{drugDrug:["Aminoglycosides - enhanced nephrotoxicity","Piperacillin-tazobactam - potential nephrotoxicity","Loop diuretics - enhanced ototoxicity"],foodDrug:[]},stewardship:{preferredFor:["MRSA infections","C. difficile colitis (oral)"],avoid:["MSSA (use beta-lactam instead)","Empiric therapy without MRSA risk"],deEscalation:"Switch to beta-lactam if MSSA identified",resistance:"Monitor for heteroresistance (VISA)"}}},Mt={CNS:{label:"Sistema Nervioso Central",color:"bg-red-50 border-red-200",options:[{value:"CNS_meningitis",label:"Meningitis bacteriana",penetration:"CNS_critical",severity:3},{value:"CNS_encephalitis",label:"Encefalitis",penetration:"CNS_critical",severity:3},{value:"CNS_brain_abscess",label:"Absceso cerebral",penetration:"CNS_critical",severity:3},{value:"CNS_subdural_empyema",label:"Empiema subdural",penetration:"CNS_critical",severity:3}]},Cardiovascular:{label:"Cardiovascular",color:"bg-purple-50 border-purple-200",options:[{value:"CV_endocarditis_native",label:"Endocarditis válvula nativa",penetration:"moderate",severity:3},{value:"CV_endocarditis_prosthetic",label:"Endocarditis válvula protésica",penetration:"moderate",severity:3},{value:"CV_endocarditis_CIED",label:"Infección dispositivo cardiaco (CIED)",penetration:"moderate",severity:3},{value:"CV_pericarditis",label:"Pericarditis bacteriana",penetration:"moderate",severity:2},{value:"CV_mycotic_aneurysm",label:"Aneurisma micótico",penetration:"moderate",severity:3}]},Respiratory:{label:"Respiratorio",color:"bg-blue-50 border-blue-200",options:[{value:"RESP_CAP",label:"Neumonía adquirida en comunidad (NAC)",penetration:"good",severity:2},{value:"RESP_HAP",label:"Neumonía nosocomial (NAH)",penetration:"good",severity:2},{value:"RESP_VAP",label:"Neumonía asociada a ventilador (NAV)",penetration:"good",severity:3},{value:"RESP_empyema",label:"Empiema pleural",penetration:"good",severity:2},{value:"RESP_lung_abscess",label:"Absceso pulmonar",penetration:"good",severity:2},{value:"RESP_bronchitis_acute",label:"Bronquitis aguda",penetration:"good",severity:1}]},GU:{label:"Genitourinario",color:"bg-green-50 border-green-200",options:[{value:"GU_UTI_uncomplicated",label:"ITU no complicada (mujer)",penetration:"urinary_specific",severity:1},{value:"GU_UTI_complicated",label:"ITU complicada",penetration:"systemic",severity:2},{value:"GU_UTI_catheter",label:"ITU asociada a catéter",penetration:"systemic",severity:2},{value:"GU_pyelonephritis",label:"Pielonefritis aguda",penetration:"systemic",severity:2},{value:"GU_prostatitis_acute",label:"Prostatitis aguda",penetration:"prostate_specific",severity:2},{value:"GU_prostatitis_chronic",label:"Prostatitis crónica",penetration:"prostate_specific",severity:1}]},Skin_Soft_Tissue:{label:"Piel y Tejidos Blandos",color:"bg-yellow-50 border-yellow-200",options:[{value:"SST_cellulitis_simple",label:"Celulitis simple",penetration:"good",severity:1},{value:"SST_cellulitis_severe",label:"Celulitis severa/eritema",penetration:"good",severity:2},{value:"SST_necrotizing_fasciitis",label:"Fascitis necrotizante",penetration:"good",severity:3},{value:"SST_abscess",label:"Absceso cutáneo",penetration:"good",severity:1},{value:"SST_diabetic_foot",label:"Pie diabético infectado",penetration:"moderate",severity:2},{value:"SST_surgical_site",label:"Infección sitio quirúrgico",penetration:"good",severity:2}]},Bone_Joint:{label:"Hueso y Articulaciones",color:"bg-orange-50 border-orange-200",options:[{value:"BJ_osteomyelitis_acute",label:"Osteomielitis aguda",penetration:"bone_specific",severity:2},{value:"BJ_osteomyelitis_chronic",label:"Osteomielitis crónica",penetration:"bone_specific",severity:2},{value:"BJ_prosthetic_joint",label:"Infección prótesis articular",penetration:"bone_specific",severity:2},{value:"BJ_septic_arthritis",label:"Artritis séptica",penetration:"good",severity:2},{value:"BJ_vertebral_osteomyelitis",label:"Osteomielitis vertebral",penetration:"bone_specific",severity:2},{value:"BJ_diabetic_foot_osteo",label:"Osteomielitis pie diabético",penetration:"bone_specific",severity:2}]},Intra_Abdominal:{label:"Intraabdominal",color:"bg-indigo-50 border-indigo-200",options:[{value:"IA_peritonitis_secondary",label:"Peritonitis secundaria",penetration:"good",severity:2},{value:"IA_peritonitis_primary",label:"Peritonitis primaria/espontánea",penetration:"good",severity:2},{value:"IA_intra_abdominal",label:"Infección intraabdominal complicada",penetration:"good",severity:2},{value:"IA_cholangitis",label:"Colangitis",penetration:"good",severity:2},{value:"IA_liver_abscess",label:"Absceso hepático",penetration:"good",severity:2},{value:"IA_appendicitis",label:"Apendicitis complicada",penetration:"good",severity:2}]},Bacteremia_Sepsis:{label:"Bacteriemia y Sepsis",color:"bg-red-50 border-red-200",options:[{value:"BS_bacteremia_primary",label:"Bacteriemia primaria",penetration:"systemic",severity:2},{value:"BS_CLABSI",label:"Bacteriemia asociada a catéter central",penetration:"systemic",severity:2},{value:"BS_sepsis",label:"Sepsis",penetration:"systemic",severity:3},{value:"BS_septic_shock",label:"Shock séptico",penetration:"systemic",severity:3},{value:"BS_neutropenic_fever",label:"Fiebre neutropénica",penetration:"systemic",severity:2}]}},Vg=({children:m,title:c})=>s.jsxs("div",{className:"bg-white shadow-2xl rounded-2xl overflow-hidden w-full max-w-4xl mx-auto",children:[s.jsx("div",{className:"bg-gray-800 text-white p-4 sm:p-6",children:s.jsx("h2",{className:"text-xl sm:text-2xl font-bold",children:c})}),s.jsx("div",{className:"p-4 sm:p-8 space-y-6",children:m})]}),Lt=({label:m,name:c,value:d,onChange:u,type:_="number",placeholder:E,unit:O})=>s.jsxs("div",{children:[s.jsx("label",{htmlFor:c,className:"block text-sm font-medium text-gray-700 mb-1",children:m}),s.jsxs("div",{className:"flex items-center",children:[s.jsx("input",{type:_,name:c,id:c,value:d,onChange:u,placeholder:E,className:"mt-1 block w-full px-4 py-2 bg-white border border-gray-300 rounded-md shadow-sm focus:outline-none focus:ring-indigo-500 focus:border-indigo-500",min:"0",step:_==="number"?"0.01":void 0}),O&&s.jsx("span",{className:"ml-3 text-gray-500",children:O})]})]}),Zt=({label:m,name:c,value:d,onChange:u,options:_,placeholder:E,required:O})=>s.jsxs("div",{children:[s.jsx("label",{htmlFor:c,className:"block text-sm font-medium text-gray-700 mb-1",children:m}),s.jsxs("select",{name:c,id:c,value:d,onChange:u,required:O,className:"mt-1 block w-full pl-3 pr-10 py-2 text-base border-gray-300 focus:outline-none focus:ring-indigo-500 focus:border-indigo-500 sm:text-sm rounded-md",children:[s.jsx("option",{value:"",children:E}),_.map(P=>s.jsx("option",{value:P.value,children:P.label},P.value))]})]}),Ug=({current:m,total:c})=>s.jsx("div",{className:"w-full bg-gray-200 rounded-full h-2.5 mb-8",children:s.jsx("div",{className:"bg-indigo-600 h-2.5 rounded-full",style:{width:`${m/c*100}%`,transition:"width 0.5s ease-in-out"}})}),Hg=({data:m,onChange:c,calculations:d})=>s.jsxs("div",{children:[s.jsx("h3",{className:"text-xl font-semibold text-gray-800 mb-4",children:"Datos del Paciente"}),s.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-6",children:[s.jsx(Lt,{label:"Edad",name:"age",value:m.age,onChange:c,unit:"años",placeholder:"e.g., 55"}),s.jsx(Zt,{label:"Sexo",name:"gender",value:m.gender,onChange:c,options:[{value:"Female",label:"Femenino"},{value:"Male",label:"Masculino"}]}),s.jsx(Lt,{label:"Peso",name:"weight",value:m.weight,onChange:c,unit:"kg",placeholder:"e.g., 70"}),s.jsx(Lt,{label:"Talla",name:"height",value:m.height,onChange:c,unit:"cm",placeholder:"e.g., 175"})]}),m.gender==="Female"&&m.age>=15&&m.age<=50&&s.jsx("div",{className:"mt-6 border-t pt-6",children:s.jsxs("label",{className:"flex items-center space-x-3 cursor-pointer",children:[s.jsx("input",{type:"checkbox",name:"isPregnantOrFertile",checked:m.isPregnantOrFertile,onChange:c,className:"h-5 w-5 text-indigo-600 rounded focus:ring-indigo-500"}),s.jsx("span",{className:"text-gray-800 font-medium",children:"¿Paciente embarazada, en lactancia o en edad fértil?"})]})}),s.jsxs("div",{className:"mt-6 border-t pt-6",children:[s.jsx("h4",{className:"font-semibold text-gray-800",children:"Función Renal"}),s.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-6 mt-2",children:[s.jsx(Lt,{label:"Creatinina Sérica",name:"creatinine",value:m.creatinine,onChange:c,unit:"mg/dL",placeholder:"e.g., 1.2"}),m.age>=18&&s.jsxs("div",{children:[s.jsxs("label",{className:"flex items-center space-x-3 cursor-pointer mt-2",children:[s.jsx("input",{type:"checkbox",name:"useCystatinC",checked:m.useCystatinC,onChange:c,className:"h-5 w-5 text-indigo-600 rounded"}),s.jsx("span",{className:"font-medium",children:"Usar Cistatina C"})]}),m.useCystatinC&&s.jsx(Lt,{label:"Cistatina C",name:"cystatinC",value:m.cystatinC,onChange:c,unit:"mg/L"})]}),s.jsx(Zt,{label:"Terapia de Reemplazo Renal",name:"rrt",value:m.rrt,onChange:c,options:[{value:"None",label:"Ninguna"},{value:"HD",label:"Hemodiálisis (HD)"},{value:"CRRT",label:"CRRT"},{value:"SLED",label:"SLED"},{value:"CAPD",label:"DPAC"}],placeholder:"-- Seleccione --"})]})]}),s.jsx("div",{className:"mt-6 border-t pt-6",children:s.jsxs("label",{className:"flex items-center space-x-3 cursor-pointer",children:[s.jsx("input",{type:"checkbox",name:"hasHepaticDisease",checked:m.hasHepaticDisease,onChange:c,className:"h-5 w-5 text-indigo-600 rounded"}),s.jsx("span",{className:"font-medium",children:"¿Enfermedad Hepática?"})]})}),m.hasHepaticDisease&&s.jsxs("div",{className:"mt-4 p-4 bg-indigo-50 rounded-lg space-y-4 animate-fade-in",children:[s.jsx("h4",{className:"font-semibold text-indigo-800",children:"Cálculo de Child-Pugh"}),s.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-3 gap-4",children:[s.jsx(Lt,{label:"Bilirrubina Total",name:"bilirubin",value:m.bilirubin,onChange:c,unit:"mg/dL"}),s.jsx(Lt,{label:"Albúmina Sérica",name:"albumin",value:m.albumin,onChange:c,unit:"g/dL"}),s.jsx(Lt,{label:"INR",name:"inr",value:m.inr,onChange:c}),s.jsx(Zt,{label:"Ascitis",name:"ascites",value:m.ascites,onChange:c,options:[{value:1,label:"Ninguna"},{value:2,label:"Leve"},{value:3,label:"Moderada/Severa"}]}),s.jsx(Zt,{label:"Encefalopatía",name:"encephalopathy",value:m.encephalopathy,onChange:c,options:[{value:1,label:"Ninguna"},{value:2,label:"Grado 1-2"},{value:3,label:"Grado 3-4"}]})]})]}),s.jsxs("div",{className:"mt-6 border-t pt-6",children:[s.jsxs("div",{className:"flex items-center justify-between",children:[s.jsx("h4",{className:"font-semibold text-gray-800",children:"Evaluación de Severidad Clínica"}),s.jsxs("button",{type:"button",onClick:()=>c({target:{name:"showSeverityAssessment",type:"checkbox",checked:!m.showSeverityAssessment}}),className:"text-sm text-indigo-600 hover:text-indigo-800 font-medium",children:[m.showSeverityAssessment?"Ocultar":"Mostrar"," evaluación avanzada"]})]}),s.jsx("div",{className:"mt-3 text-xs text-gray-600",children:s.jsxs("p",{children:[s.jsx("strong",{children:"Nota:"})," La evaluación de severidad mejora la precisión de las recomendaciones mediante criterios objetivos específicos."]})}),m.showSeverityAssessment&&s.jsx("div",{className:"mt-4 p-4 bg-yellow-50 rounded-lg space-y-4 animate-fade-in",children:s.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-4",children:[s.jsxs("div",{children:[s.jsx("label",{className:"block text-sm font-medium text-gray-700 mb-2",children:"Criterios de Severidad Objetivos"}),s.jsxs("div",{className:"space-y-2",children:[s.jsxs("label",{className:"flex items-center space-x-3 cursor-pointer",children:[s.jsx("input",{type:"checkbox",name:"isICU",checked:m.isICU||!1,onChange:c,className:"h-4 w-4 text-indigo-600 rounded focus:ring-indigo-500"}),s.jsx("span",{className:"text-sm font-medium text-gray-700",children:"UCI o cuidados intensivos"})]}),s.jsxs("label",{className:"flex items-center space-x-3 cursor-pointer",children:[s.jsx("input",{type:"checkbox",name:"isImmunocompromised",checked:m.isImmunocompromised||!1,onChange:c,className:"h-4 w-4 text-indigo-600 rounded focus:ring-indigo-500"}),s.jsx("span",{className:"text-sm font-medium text-gray-700",children:"Inmunocomprometido"})]}),s.jsxs("label",{className:"flex items-center space-x-3 cursor-pointer",children:[s.jsx("input",{type:"checkbox",name:"priorAntibiotics",checked:m.priorAntibiotics||!1,onChange:c,className:"h-4 w-4 text-indigo-600 rounded focus:ring-indigo-500"}),s.jsx("span",{className:"text-sm font-medium text-gray-700",children:"Antibióticos previos (últimos 90 días)"})]}),s.jsxs("label",{className:"flex items-center space-x-3 cursor-pointer",children:[s.jsx("input",{type:"checkbox",name:"hasOrganDysfunction",checked:m.hasOrganDysfunction||!1,onChange:c,className:"h-4 w-4 text-indigo-600 rounded focus:ring-indigo-500"}),s.jsx("span",{className:"text-sm font-medium text-gray-700",children:"Disfunción orgánica"})]}),s.jsxs("label",{className:"flex items-center space-x-3 cursor-pointer",children:[s.jsx("input",{type:"checkbox",name:"hasSepsis",checked:m.hasSepsis||!1,onChange:c,className:"h-4 w-4 text-indigo-600 rounded focus:ring-indigo-500"}),s.jsx("span",{className:"text-sm font-medium text-gray-700",children:"Sepsis o shock séptico"})]})]})]}),s.jsxs("div",{children:[s.jsx(Zt,{label:"Estado Hemodinámico",name:"hemodynamicStatus",value:m.hemodynamicStatus,onChange:c,options:[{value:"stable",label:"Estable"},{value:"hypotension",label:"Hipotensión"},{value:"shock",label:"Shock/vasopresores"}],placeholder:"-- Seleccione --"}),s.jsx("div",{className:"mt-3",children:s.jsx(Zt,{label:"Función Respiratoria",name:"respiratoryStatus",value:m.respiratoryStatus,onChange:c,options:[{value:"normal",label:"Normal"},{value:"oxygen",label:"Oxígeno suplementario"},{value:"mechanical",label:"Ventilación mecánica"}],placeholder:"-- Seleccione --"})})]})]})})]}),s.jsxs("div",{className:"mt-6 border-t pt-6",children:[s.jsxs("div",{className:"flex items-center justify-between",children:[s.jsx("h4",{className:"font-semibold text-gray-800",children:"Epidemiología Local"}),s.jsxs("button",{type:"button",onClick:()=>c({target:{name:"showEpidemiologyData",type:"checkbox",checked:!m.showEpidemiologyData}}),className:"text-sm text-indigo-600 hover:text-indigo-800 font-medium",children:[m.showEpidemiologyData?"Ocultar":"Personalizar"," datos epidemiológicos"]})]}),s.jsx("div",{className:"mt-3 text-xs text-gray-600",children:s.jsxs("p",{children:[s.jsx("strong",{children:"Nota:"})," Los datos epidemiológicos locales mejoran la precisión de las recomendaciones. Si no se especifican, se utilizarán valores por defecto basados en literatura."]})}),m.showEpidemiologyData&&s.jsx("div",{className:"mt-4 p-4 bg-blue-50 rounded-lg space-y-4 animate-fade-in",children:s.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-3 gap-4",children:[s.jsx(Lt,{label:"Tasa ESBL Local (%)",name:"localESBLRate",value:m.localESBLRate,onChange:c,type:"number",placeholder:"ej. 15",unit:"%"}),s.jsx(Lt,{label:"Resistencia a Carbapenémicos (%)",name:"localCarbapenemResistance",value:m.localCarbapenemResistance,onChange:c,type:"number",placeholder:"ej. 3",unit:"%"}),s.jsx(Zt,{label:"Tipo de Institución",name:"institutionType",value:m.institutionType,onChange:c,options:[{value:"community",label:"Hospital Comunitario"},{value:"academic",label:"Centro Académico"},{value:"tertiary",label:"Centro de Referencia"}],placeholder:"-- Seleccione tipo --"})]})})]}),s.jsxs("div",{className:"mt-8 p-6 bg-gray-50 rounded-lg space-y-3",children:[s.jsx("h4",{className:"text-lg font-semibold text-gray-700",children:"Valores Calculados:"}),s.jsxs("p",{children:[s.jsx("strong",{children:"TFG:"})," ",d.tfg?`${d.tfg.value} mL/min/1.73m²`:"N/A"," ",s.jsxs("span",{className:"text-sm text-gray-500",children:["(",d.tfg?d.tfg.formula:"N/A",")"]})]}),s.jsxs("p",{children:[s.jsx("strong",{children:"IMC:"})," ",d.bmi?`${d.bmi} kg/m²`:"N/A",d.bmiZScore!==null&&s.jsxs("span",{className:"text-sm text-blue-600 ml-2",children:["(Z-score: ",d.bmiZScore.toFixed(2),")"]}),s.jsx("br",{}),s.jsx("span",{className:"text-sm text-gray-600",children:d.obesityClass||"N/A"}),d.bmiZScore!==null&&s.jsxs(s.Fragment,{children:[s.jsx("br",{}),s.jsx("span",{className:"text-xs text-blue-500",children:"📊 Clasificación pediátrica basada en estándares WHO con z-score edad/sexo específico"})]})]}),parseFloat(m.age)<5&&parseFloat(m.age)>0&&s.jsxs("div",{className:"mt-3 p-3 bg-blue-50 rounded-md border border-blue-200",children:[s.jsx("h5",{className:"text-sm font-semibold text-blue-800 mb-2",children:"📈 Indicadores de Crecimiento WHO (menores de 5 años)"}),d.heightForAgeZScore!==null&&s.jsxs("p",{className:"text-sm text-blue-700",children:[s.jsx("strong",{children:"Talla para la edad:"})," Z-score ",d.heightForAgeZScore.toFixed(2),s.jsxs("span",{className:"ml-2 text-xs font-medium",children:["(",d.heightForAgeClass,")"]})]}),d.weightForAgeZScore!==null&&s.jsxs("p",{className:"text-sm text-blue-700 mt-1",children:[s.jsx("strong",{children:"Peso para la edad:"})," Z-score ",d.weightForAgeZScore.toFixed(2),s.jsxs("span",{className:"ml-2 text-xs font-medium",children:["(",d.weightForAgeClass,")"]})]}),s.jsxs("p",{className:"text-xs text-blue-600 mt-2",children:[s.jsx("strong",{children:"Nota:"})," Los indicadores de crecimiento ayudan a identificar desnutrición, retraso en el crecimiento, y otros factores que pueden afectar el dosaje de antibióticos."]})]}),m.hasHepaticDisease&&s.jsxs("p",{children:[s.jsx("strong",{children:"Child-Pugh Score:"})," ",d.childPugh?`${d.childPugh.score} (Clase ${d.childPugh.class})`:"Datos incompletos"]}),d.severityAssessment&&s.jsxs("div",{className:"p-3 bg-yellow-100 rounded-md",children:[s.jsxs("p",{children:[s.jsx("strong",{children:"Severidad Clínica:"})," ",d.severityAssessment.level," (Puntuación: ",d.severityAssessment.score,")"]}),s.jsxs("p",{className:"text-sm text-gray-600 mt-1",children:[s.jsx("strong",{children:"Factores:"})," ",d.severityAssessment.factors.join(", ")]})]}),d.epidemiologyRisk&&s.jsxs("div",{className:"p-3 bg-blue-100 rounded-md",children:[s.jsxs("p",{children:[s.jsx("strong",{children:"Riesgo Epidemiológico:"})," ",d.epidemiologyRisk.level]}),s.jsxs("p",{className:"text-sm text-gray-600 mt-1",children:[s.jsx("strong",{children:"Factores:"})," ",d.epidemiologyRisk.factors.join(", ")]})]})]})]}),Gg=({data:m,onChange:c})=>{var _;const[d,u]=_e.useState(null);return _e.useEffect(()=>{if(m.location&&m.location.includes("_")){const E=Object.keys(Mt).find(O=>Mt[O].options.some(P=>P.value===m.location));E&&u(E)}},[m.location]),s.jsxs("div",{children:[s.jsx("h3",{className:"text-xl font-semibold text-gray-800 mb-4",children:"Síndrome Infeccioso"}),s.jsx("p",{className:"text-sm text-gray-600 mb-4",children:"Seleccione el síndrome clínico específico para optimizar la interpretación del antibiograma, requerimientos de penetración y recomendaciones de tratamiento."}),!m.location&&s.jsx("div",{className:"mb-4 p-3 bg-blue-50 border border-blue-200 rounded-lg",children:s.jsxs("p",{className:"text-sm text-blue-700",children:["💡 ",s.jsx("strong",{children:"Consejo:"})," Haga clic en cualquier categoría anatómica para ver los síndromes específicos disponibles."]})}),s.jsx("div",{className:"space-y-3",children:Object.entries(Mt).map(([E,O])=>{const P=d===E,L=O.options.some(y=>y.value===m.location);return s.jsxs("div",{className:`rounded-lg border transition-all duration-200 ${L?`${O.color} border-2`:P?`${O.color}`:"bg-gray-50 border-gray-200 hover:bg-gray-100"}`,children:[s.jsxs("button",{type:"button",onClick:()=>u(P?null:E),className:"w-full p-4 text-left flex items-center justify-between focus:outline-none",children:[s.jsxs("div",{className:"flex items-center space-x-3",children:[s.jsx("h4",{className:"font-semibold text-gray-800",children:O.label}),L&&s.jsx("span",{className:"text-xs px-2 py-1 bg-indigo-100 text-indigo-700 rounded-full",children:"Seleccionado"})]}),s.jsx("svg",{className:`w-5 h-5 text-gray-500 transition-transform duration-200 ${P?"rotate-180":""}`,fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:s.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M19 9l-7 7-7-7"})})]}),P&&s.jsx("div",{className:"px-4 pb-4 animate-fade-in",children:s.jsx("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-2",children:O.options.map(y=>s.jsxs("label",{className:"flex items-center space-x-3 cursor-pointer p-2 rounded hover:bg-white hover:bg-opacity-60",children:[s.jsx("input",{type:"radio",name:"location",value:y.value,checked:m.location===y.value,onChange:z=>{c(z),u(E)},className:"h-4 w-4 text-indigo-600 focus:ring-indigo-500"}),s.jsxs("div",{children:[s.jsx("span",{className:"text-sm font-medium text-gray-800",children:y.label}),s.jsxs("div",{className:"flex items-center space-x-2 mt-1",children:[s.jsxs("span",{className:`text-xs px-2 py-1 rounded ${y.severity===3?"bg-red-100 text-red-700":y.severity===2?"bg-yellow-100 text-yellow-700":"bg-green-100 text-green-700"}`,children:["Severidad: ",y.severity===3?"Alta":y.severity===2?"Moderada":"Leve"]}),s.jsxs("span",{className:"text-xs text-gray-500",children:["Penetración: ",y.penetration==="CNS_critical"?"Barrera hematoencefálica crítica":y.penetration==="bone_specific"?"Penetración ósea específica":y.penetration==="urinary_specific"?"Concentración urinaria":y.penetration==="prostate_specific"?"Penetración prostática":y.penetration==="systemic"?"Sistémica":"Buena"]})]})]})]},y.value))})})]},E)})}),m.location&&s.jsxs("div",{className:"mt-6 p-4 bg-blue-50 border border-blue-200 rounded-lg",children:[s.jsx("h4",{className:"font-semibold text-blue-800 mb-2",children:"Consideraciones Clínicas"}),s.jsx("div",{className:"text-sm text-blue-700",children:((_=Mt[Object.keys(Mt).find(E=>Mt[E].options.some(O=>O.value===m.location))])==null?void 0:_.options.find(E=>E.value===m.location))&&(()=>{const E=Mt[Object.keys(Mt).find(P=>Mt[P].options.some(L=>L.value===m.location))].options.find(P=>P.value===m.location);return{CNS_meningitis:"• Penetración de barrera hematoencefálica esencial • Altas dosis requeridas • Actividad bactericida preferida",CNS_brain_abscess:"• Penetración de barrera hematoencefálica esencial • Tratamiento prolongado • Considerar drenaje quirúrgico",GU_UTI_uncomplicated:"• Concentración urinaria más importante que sérica • Considerar fosfomicina, nitrofurantoína • Duración corta (3 días)",GU_UTI_complicated:"• Penetración sistémica requerida • Descartar complicaciones estructurales • Duración 7-14 días",GU_prostatitis_acute:"• Penetración prostática esencial • Fluoroquinolonas, TMP-SMX preferidos • Duración 2-4 semanas",BJ_osteomyelitis_chronic:"• Penetración ósea esencial • Tratamiento prolongado (6-12 semanas) • Considerar terapia oral secuencial",BJ_prosthetic_joint:"• Actividad anti-biofilm importante • Combinaciones sinérgicas • Evaluar retención vs remoción",RESP_VAP:"• Cobertura anti-Pseudomonas • Resistencia nosocomial alta • Considerar terapia combinada",IA_peritonitis_secondary:"• Cobertura anaeróbica esencial • Infección polimicrobiana • Control quirúrgico del foco",BS_septic_shock:"• Inicio precoz (<1 hora) • Cobertura empírica amplia • Desescalamiento basado en cultivos"}[E.value]||"• Consideraciones específicas del síndrome seleccionado aplicarán"})()})]})]})},Yg=({data:m,onChange:c})=>{var B,Q,H,Y,M,V,X,Z,K,G,F,se,w,ue,le,W,re,de,ce,x,D,$,fe,f,R,T;const[d,u]=_e.useState(""),[_,E]=_e.useState(""),[O,P]=_e.useState(""),L=Og(),y=_e.useMemo(()=>{let C=L;return d&&(C=C.filter(I=>I.name.toLowerCase().includes(d.toLowerCase())||I.searchTerms.includes(d.toLowerCase()))),_&&(C=C.filter(I=>I.gramStain.toLowerCase().includes(_.toLowerCase()))),O&&(C=C.filter(I=>I.clinicalSignificance>=parseInt(O))),C},[d,_,O,L]),z=C=>{c({target:{name:"bacteriumId",value:C}}),u("")},q=m.bacteriumId?Jt()[m.bacteriumId]:null,ie=({level:C})=>{const I={3:"bg-red-100 text-red-800 border-red-300",2:"bg-orange-100 text-orange-800 border-orange-300",1:"bg-yellow-100 text-yellow-800 border-yellow-300",0:"bg-gray-100 text-gray-800 border-gray-300"},U={3:"Patógeno Primario",2:"Oportunista",1:"Colonizador",0:"Contaminante"};return s.jsx("span",{className:`inline-flex items-center px-2 py-1 rounded-full text-xs font-medium border ${I[C]}`,children:U[C]})};return s.jsxs("div",{className:"space-y-6",children:[s.jsxs("div",{children:[s.jsx("h3",{className:"text-xl font-semibold text-gray-800 mb-4",children:"Identificación del Microorganismo"}),s.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-3 gap-4 mb-4",children:[s.jsx("div",{className:"relative",children:s.jsx("input",{type:"text",value:d,onChange:C=>u(C.target.value),placeholder:"Buscar por nombre, características...",className:"w-full px-4 py-2 bg-white border border-gray-300 rounded-md shadow-sm focus:outline-none focus:ring-indigo-500 focus:border-indigo-500"})}),s.jsx(Zt,{label:"",name:"gramFilter",value:_,onChange:C=>E(C.target.value),options:[{value:"",label:"Todas las bacterias"},{value:"Gram-positive",label:"Gram positivas"},{value:"Gram-negative",label:"Gram negativas"}],placeholder:"Filtrar por Gram"}),s.jsx(Zt,{label:"",name:"significanceFilter",value:O,onChange:C=>P(C.target.value),options:[{value:"",label:"Cualquier significancia"},{value:"3",label:"Solo patógenos primarios"},{value:"2",label:"Patógenos y oportunistas"},{value:"1",label:"Incluir colonizadores"}],placeholder:"Filtrar por relevancia clínica"})]}),d&&s.jsx("div",{className:"bg-white border border-gray-300 rounded-md shadow-lg max-h-80 overflow-y-auto",children:y.length>0?y.map(C=>{var I,U;return s.jsx("div",{onClick:()=>z(C.id),className:"px-4 py-3 cursor-pointer hover:bg-indigo-50 border-b border-gray-100 last:border-b-0",children:s.jsxs("div",{className:"flex items-center justify-between",children:[s.jsxs("div",{children:[s.jsx("h4",{className:"font-medium text-gray-900",children:C.name}),s.jsxs("p",{className:"text-sm text-gray-600",children:[C.gramStain," • ",C.clsiCategory]}),s.jsxs("p",{className:"text-xs text-gray-500 mt-1",children:[(I=C.taxonomy)==null?void 0:I.genus," ",(U=C.taxonomy)==null?void 0:U.species]})]}),s.jsx(ie,{level:C.clinicalSignificance})]})},C.id)}):s.jsx("div",{className:"px-4 py-2 text-gray-500",children:"No se encontraron resultados"})})]}),q&&s.jsxs("div",{className:"bg-white border border-gray-200 rounded-lg shadow-sm overflow-hidden",children:[s.jsx("div",{className:"bg-indigo-50 px-6 py-4 border-b border-gray-200",children:s.jsxs("div",{className:"flex items-center justify-between",children:[s.jsxs("div",{children:[s.jsx("h4",{className:"text-lg font-bold text-gray-900",children:((B=q.identity)==null?void 0:B.bacteriumName)||q.name}),s.jsxs("p",{className:"text-sm text-gray-600 mt-1",children:[s.jsx("strong",{children:"Taxonomía:"})," ",(Q=q.taxonomy)==null?void 0:Q.genus," ",(H=q.taxonomy)==null?void 0:H.species]})]}),s.jsx(ie,{level:q.clinicalSignificance||2})]})}),s.jsxs("div",{className:"p-6 space-y-6",children:[s.jsxs("div",{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:[s.jsxs("div",{className:"space-y-3",children:[s.jsx("h5",{className:"font-semibold text-gray-800 flex items-center",children:"🔬 Características Microscópicas"}),s.jsxs("div",{className:"bg-gray-50 p-3 rounded-md space-y-2",children:[s.jsxs("div",{className:"flex justify-between",children:[s.jsx("span",{className:"text-sm font-medium",children:"Tinción de Gram:"}),s.jsx("span",{className:"text-sm",children:((M=(Y=q.identity)==null?void 0:Y.classification)==null?void 0:M.gramStain)||"N/A"})]}),s.jsxs("div",{className:"flex justify-between",children:[s.jsx("span",{className:"text-sm font-medium",children:"Morfología:"}),s.jsx("span",{className:"text-sm",children:((X=(V=q.identity)==null?void 0:V.classification)==null?void 0:X.morphology)||"N/A"})]}),s.jsxs("div",{className:"flex justify-between",children:[s.jsx("span",{className:"text-sm font-medium",children:"Respiración:"}),s.jsx("span",{className:"text-sm",children:((K=(Z=q.identity)==null?void 0:Z.classification)==null?void 0:K.respiration)||"N/A"})]})]})]}),s.jsxs("div",{className:"space-y-3",children:[s.jsx("h5",{className:"font-semibold text-gray-800 flex items-center",children:"🧪 Pruebas Bioquímicas"}),s.jsx("div",{className:"bg-gray-50 p-3 rounded-md space-y-1",children:(G=q.identity)!=null&&G.biochemicalTests?s.jsx("div",{className:"text-sm text-gray-600",children:q.identity.biochemicalTests}):s.jsx("div",{className:"text-sm text-gray-500",children:"No disponible"})})]})]}),s.jsxs("div",{className:"space-y-3",children:[s.jsx("h5",{className:"font-semibold text-gray-800 flex items-center",children:"📋 Información Clínica"}),s.jsxs("div",{className:"bg-gray-50 p-3 rounded-md",children:[s.jsxs("div",{className:"text-sm text-gray-600",children:[s.jsx("strong",{children:"Categoría CLSI:"})," ",((F=q.identity)==null?void 0:F.clsiCategory)||"N/A"]}),s.jsxs("div",{className:"text-sm text-gray-600 mt-2",children:[s.jsx("strong",{children:"Resumen:"})," ",((se=q.clinicalProfile)==null?void 0:se.summary)||"No disponible"]})]})]}),s.jsxs("div",{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:[((w=q.clinicalProfile)==null?void 0:w.clinicalSyndromes)&&s.jsxs("div",{className:"space-y-3",children:[s.jsx("h5",{className:"font-semibold text-gray-800 flex items-center",children:"🦠 Síndromes Clínicos"}),s.jsx("div",{className:"bg-blue-50 p-3 rounded-md",children:s.jsx("ul",{className:"text-sm space-y-1",children:q.clinicalProfile.clinicalSyndromes.slice(0,5).map((C,I)=>s.jsxs("li",{className:"text-blue-800",children:["• ",s.jsxs("strong",{children:[C.syndromeName,":"]})," ",C.description]},I))})})]}),((ue=q.resistanceProfile)==null?void 0:ue.majorMechanisms)&&s.jsxs("div",{className:"space-y-3",children:[s.jsx("h5",{className:"font-semibold text-gray-800 flex items-center",children:"🛡️ Mecanismos de Resistencia"}),s.jsx("div",{className:"bg-orange-50 p-3 rounded-md",children:s.jsx("ul",{className:"text-sm space-y-1",children:q.resistanceProfile.majorMechanisms.slice(0,3).map((C,I)=>s.jsxs("li",{className:"text-orange-800",children:["• ",s.jsxs("strong",{children:[C.mechanismName,":"]})," ",C.description]},I))})})]})]}),(((W=(le=q.resistanceProfile)==null?void 0:le.intrinsicResistance)==null?void 0:W.length)>0||((de=(re=q.resistanceProfile)==null?void 0:re.groupIntrinsicResistance)==null?void 0:de.length)>0)&&s.jsxs("div",{className:"p-3 bg-yellow-50 border-l-4 border-yellow-400 rounded-md",children:[s.jsx("h5",{className:"font-semibold text-yellow-800 mb-2",children:"⚠️ Resistencia Intrínseca"}),s.jsxs("div",{className:"space-y-3",children:[((x=(ce=q.resistanceProfile)==null?void 0:ce.groupIntrinsicResistance)==null?void 0:x.length)>0&&s.jsxs("div",{children:[s.jsx("div",{className:"text-xs font-medium text-yellow-800 mb-1",children:"Resistencia de Grupo:"}),q.resistanceProfile.groupIntrinsicResistance.map((C,I)=>s.jsxs("div",{className:"text-sm text-yellow-700 pl-2",children:[s.jsx("span",{className:"font-medium",children:C.drugOrClass}),C.notes&&s.jsxs("div",{className:"text-yellow-600 text-xs mt-1 ml-2",children:["📝 ",C.notes]})]},`group-${I}`))]}),(($=(D=q.resistanceProfile)==null?void 0:D.intrinsicResistance)==null?void 0:$.length)>0&&s.jsxs("div",{children:[((f=(fe=q.resistanceProfile)==null?void 0:fe.groupIntrinsicResistance)==null?void 0:f.length)>0&&s.jsx("div",{className:"text-xs font-medium text-yellow-800 mb-1",children:"Resistencia Específica:"}),q.resistanceProfile.intrinsicResistance.map((C,I)=>s.jsxs("div",{className:"text-sm text-yellow-700 pl-2",children:[s.jsx("span",{className:"font-medium",children:C.drugOrClass}),C.notes&&s.jsxs("div",{className:"text-yellow-600 text-xs mt-1 ml-2",children:["📝 ",C.notes]})]},`individual-${I}`))]})]})]}),((T=(R=q.clinicalProfile)==null?void 0:R.highRiskPopulations)==null?void 0:T.length)>0&&s.jsxs("div",{className:"bg-gray-50 p-3 rounded-md",children:[s.jsx("h5",{className:"font-semibold text-gray-800 mb-2",children:"👥 Poblaciones de Alto Riesgo"}),s.jsx("div",{className:"text-sm text-gray-600",children:q.clinicalProfile.highRiskPopulations.join(", ")})]})]})]})]})},Xg=({data:m,onChange:c})=>{var q,ie;const d=m.bacteriumId?Jt()[m.bacteriumId]:null;if(!d)return s.jsx("div",{className:"text-center text-gray-600 p-4 bg-gray-100 rounded-md",children:"Por favor, seleccione un microorganismo en el paso anterior."});const u=(B,Q)=>{var Y,M;const H={...m.micValues,[B]:Q};if(c({target:{name:"micValues",value:H}}),Q&&!isNaN(parseFloat(Q))){const V=parseFloat(Q),X=P.flatMap(K=>K.agents).find(K=>K.agentName===B),Z=(M=(Y=X==null?void 0:X.breakpointSets)==null?void 0:Y[0])==null?void 0:M.mic;if(Z){const K=ue=>{if(!ue)return NaN;const W=ue.replace("≤ ","").replace("≥ ","").replace("> ","").split("/")[0];return parseFloat(W)},G=K(Z.s_breakpoint),F=K(Z.i_breakpoint),se=K(Z.r_breakpoint);let w="I";if(isNaN(G)||(Z.s_breakpoint.includes("≤")&&V<=G||Z.s_breakpoint.includes("≥")&&V>=G)&&(w="S"),!isNaN(se)&&w!=="S"&&(Z.r_breakpoint.includes("≥")&&V>=se||Z.r_breakpoint.includes("≤")&&V<=se)&&(w="R"),!isNaN(F)&&w==="I"&&Z.i_breakpoint&&typeof Z.i_breakpoint=="string")if(Z.i_breakpoint.includes("–")){const[ue,le]=Z.i_breakpoint.split("–").map(W=>parseFloat(W.trim()));V>=ue&&V<=le&&(w="I")}else V===F&&(w="I");c({target:{name:"susceptibilityResults",value:{...m.susceptibilityResults,[B]:w}}})}}},_=(B,Q)=>{const H={...m.micValues};delete H[B],c({target:{name:"micValues",value:H}}),c({target:{name:"susceptibilityResults",value:{...m.susceptibilityResults,[B]:Q}}})},E=(B,Q)=>{var Y,M;const H=(M=(Y=B==null?void 0:B.breakpointSets)==null?void 0:Y[0])==null?void 0:M.mic;if(!H)return"";switch(Q){case"S":return H.s_breakpoint||"";case"I":return H.i_breakpoint||"";case"R":return H.r_breakpoint||"";default:return""}},O=B=>{var M;const Q=(M=B==null?void 0:B.breakpointSets)==null?void 0:M[0];if(!Q)return null;const H=Q.comments||[],Y=Q.condition||"";return H.length===0&&!Y?null:{condition:Y!=="Standard"?Y:"",comments:H}},P=((q=d.laboratoryProfile)==null?void 0:q.antimicrobialBreakpoints)||[],L=B=>{if(B===1)return!0;const Q=P.filter(M=>M.tier<B);let H=0,Y=0;for(const M of Q)for(const V of M.agents){const X=m.susceptibilityResults[V.agentName];X&&(Y++,(X==="R"||X==="I")&&H++)}if(Y>0){const M=H/Y;if(B===2)return["Ceftriaxone","Ceftazidime","Cefepime","Gentamicin"].some(X=>m.susceptibilityResults[X]==="R")||M>=.5;if(B===3){const V=["Meropenem","Imipenem","Ertapenem"].some(Z=>m.susceptibilityResults[Z]==="R"),X=m.susceptibilityResults.Ceftazidime==="R"&&m.susceptibilityResults.Ceftriaxone==="R";return V||X||M>=.6}if(B===4){const V=M>=.7,X=["Meropenem","Imipenem"].every(Z=>m.susceptibilityResults[Z]==="R");return V||X}}return!1},z=(()=>{var V,X,Z,K;const B=((V=d.identity)==null?void 0:V.bacteriumName)||d.name,Q=d.taxonomy,H=((X=d.resistanceProfile)==null?void 0:X.intrinsicResistance)||[],Y=((Z=d.resistanceProfile)==null?void 0:Z.resistanceMechanisms)||[],M=((K=d.clinicalSignificance)==null?void 0:K.epidemiology)||{};return{bacteriumName:B,taxonomy:Q,intrinsicResistance:H,resistanceMechanisms:Y,epidemiology:M}})();return s.jsxs("div",{className:"space-y-6",children:[s.jsxs("div",{children:[s.jsxs("h3",{className:"text-xl font-semibold text-gray-800 mb-2",children:["Interpretación del Antibiograma Escalonado - ",((ie=d.identity)==null?void 0:ie.bacteriumName)||d.name]}),s.jsx("p",{className:"text-sm text-gray-600 mb-4",children:"Ingrese valores MIC (se interpreta automáticamente) o seleccione S/I/R directamente. Los niveles superiores se desbloquean según CLSI M100."})]}),s.jsxs("div",{className:"bg-blue-50 rounded-lg border border-blue-200 p-6",children:[s.jsxs("h4",{className:"text-lg font-semibold text-blue-900 mb-4 flex items-center",children:[s.jsx("span",{className:"text-xl mr-2",children:"🧬"}),"Perfil de Resistencia Específico del Patógeno"]}),s.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-6",children:[s.jsxs("div",{className:"bg-white p-4 rounded-lg border",children:[s.jsxs("h5",{className:"font-semibold text-gray-800 mb-3 flex items-center",children:[s.jsx("span",{className:"text-orange-500 mr-2",children:"🔒"}),"Resistencia Intrínseca"]}),z.intrinsicResistance.length>0?s.jsxs("div",{className:"space-y-2",children:[z.intrinsicResistance.map((B,Q)=>s.jsxs("div",{className:"flex items-center",children:[s.jsx("span",{className:"w-2 h-2 bg-orange-400 rounded-full mr-2"}),s.jsx("span",{className:"text-sm text-gray-700",children:B.drugOrClass||B})]},Q)),s.jsx("div",{className:"mt-3 p-2 bg-orange-50 rounded text-xs text-orange-700",children:"💡 Estos antibióticos no son efectivos independientemente del resultado del antibiograma"})]}):s.jsx("p",{className:"text-sm text-gray-500",children:"Sin resistencia intrínseca conocida"})]}),s.jsxs("div",{className:"bg-white p-4 rounded-lg border",children:[s.jsxs("h5",{className:"font-semibold text-gray-800 mb-3 flex items-center",children:[s.jsx("span",{className:"text-red-500 mr-2",children:"⚙️"}),"Mecanismos de Resistencia Comunes"]}),z.resistanceMechanisms.length>0?s.jsxs("div",{className:"space-y-2",children:[z.resistanceMechanisms.slice(0,3).map((B,Q)=>s.jsxs("div",{className:"flex items-start",children:[s.jsx("span",{className:"w-2 h-2 bg-red-400 rounded-full mr-2 mt-1"}),s.jsxs("div",{children:[s.jsx("span",{className:"text-sm font-medium text-gray-800",children:B.mechanism}),B.description&&s.jsx("div",{className:"text-xs text-gray-600 mt-1",children:B.description})]})]},Q)),s.jsx("div",{className:"mt-3 p-2 bg-red-50 rounded text-xs text-red-700",children:"🔍 Considere estas resistencias al interpretar patrones inusuales"})]}):s.jsx("p",{className:"text-sm text-gray-500",children:"Información de mecanismos no disponible"})]})]}),z.epidemiology&&Object.keys(z.epidemiology).length>0&&s.jsxs("div",{className:"mt-4 bg-white p-4 rounded-lg border",children:[s.jsxs("h5",{className:"font-semibold text-gray-800 mb-3 flex items-center",children:[s.jsx("span",{className:"text-teal-500 mr-2",children:"📊"}),"Contexto Epidemiológico"]}),s.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-4",children:[z.epidemiology.prevalence&&s.jsxs("div",{className:"text-sm",children:[s.jsx("span",{className:"font-medium text-gray-700",children:"Prevalencia:"}),s.jsx("span",{className:"ml-2 text-gray-600",children:z.epidemiology.prevalence})]}),z.epidemiology.riskFactors&&s.jsxs("div",{className:"text-sm",children:[s.jsx("span",{className:"font-medium text-gray-700",children:"Factores de Riesgo:"}),s.jsx("span",{className:"ml-2 text-gray-600",children:z.epidemiology.riskFactors})]})]})]})]}),s.jsxs("div",{className:"bg-purple-50 rounded-lg border border-purple-200 p-6",children:[s.jsxs("h4",{className:"text-lg font-semibold text-purple-900 mb-4 flex items-center",children:[s.jsx("span",{className:"text-xl mr-2",children:"🔗"}),"Detección de Patrones de Resistencia Cruzada"]}),s.jsxs("div",{className:"space-y-4",children:[(()=>{if(m.susceptibilityResults.Ceftriaxone==="R"||m.susceptibilityResults.Ceftazidime==="R"||m.susceptibilityResults.Cefotaxime==="R")return s.jsxs("div",{className:"bg-red-100 p-4 rounded-lg border border-red-300",children:[s.jsxs("h5",{className:"font-semibold text-red-800 mb-2 flex items-center",children:[s.jsx("span",{className:"text-red-500 mr-2",children:"🧬"}),"Patrón ESBL (Beta-lactamasa de Espectro Extendido) Detectado"]}),s.jsxs("div",{className:"text-sm text-red-700 space-y-2",children:[s.jsxs("p",{children:[s.jsx("strong",{children:"Resistencia cruzada implícita:"})," Todas las penicilinas, cefalosporinas (1ra-4ta gen), y aztreonam"]}),s.jsxs("p",{children:[s.jsx("strong",{children:"Opciones terapéuticas:"})," Carbapenémicos, cefepime (si susceptible), piperacilina-tazobactam (evaluar con precaución)"]}),s.jsxs("p",{children:[s.jsx("strong",{children:"Recomendación:"})," Reportar como resistente a todos los beta-lactámicos excepto carbapenémicos"]})]})]})})(),(()=>{if(m.susceptibilityResults.Meropenem==="R"||m.susceptibilityResults.Imipenem==="R"||m.susceptibilityResults.Ertapenem==="R")return s.jsxs("div",{className:"bg-red-100 p-4 rounded-lg border border-red-300",children:[s.jsxs("h5",{className:"font-semibold text-red-800 mb-2 flex items-center",children:[s.jsx("span",{className:"text-red-500 mr-2",children:"🚨"}),"Patrón de Resistencia a Carbapenémicos Detectado"]}),s.jsxs("div",{className:"text-sm text-red-700 space-y-2",children:[s.jsxs("p",{children:[s.jsx("strong",{children:"Resistencia cruzada implícita:"})," Todos los beta-lactámicos (penicilinas, cefalosporinas, carbapenémicos)"]}),s.jsxs("p",{children:[s.jsx("strong",{children:"Opciones terapéuticas:"})," Colistina, ceftazidima-avibactam, meropenem-vaborbactam, fosfomicina (según pruebas)"]}),s.jsxs("p",{children:[s.jsx("strong",{children:"Alerta de salud pública:"})," Reportar inmediatamente al laboratorio de referencia"]})]})]})})(),(()=>{var Q,H;if((m.susceptibilityResults.Ceftriaxone==="R"||m.susceptibilityResults.Ceftazidime==="R")&&m.susceptibilityResults.Cefepime==="S"&&(((Q=z.taxonomy)==null?void 0:Q.family)==="Enterobacteriaceae"||((H=z.bacteriumName)==null?void 0:H.includes("Enterobacter"))))return s.jsxs("div",{className:"bg-orange-100 p-4 rounded-lg border border-orange-300",children:[s.jsxs("h5",{className:"font-semibold text-orange-800 mb-2 flex items-center",children:[s.jsx("span",{className:"text-orange-500 mr-2",children:"⚠️"}),"Patrón AmpC Cromosómica Detectado"]}),s.jsxs("div",{className:"text-sm text-orange-700 space-y-2",children:[s.jsxs("p",{children:[s.jsx("strong",{children:"Resistencia cruzada implícita:"})," Ampicilina, amoxicilina-clavulánico, cefalosporinas 1ra-3ra gen"]}),s.jsxs("p",{children:[s.jsx("strong",{children:"Opciones terapéuticas:"})," Cefepime, carbapenémicos, fluoroquinolonas (si susceptible)"]}),s.jsxs("p",{children:[s.jsx("strong",{children:"Precaución:"})," Puede desarrollar resistencia inducible durante el tratamiento"]})]})]})})(),(()=>{if(m.susceptibilityResults.Ciprofloxacin==="R"||m.susceptibilityResults.Levofloxacin==="R")return s.jsxs("div",{className:"bg-yellow-100 p-4 rounded-lg border border-yellow-300",children:[s.jsxs("h5",{className:"font-semibold text-yellow-800 mb-2 flex items-center",children:[s.jsx("span",{className:"text-yellow-500 mr-2",children:"🔄"}),"Resistencia Cruzada a Fluoroquinolonas"]}),s.jsxs("div",{className:"text-sm text-yellow-700 space-y-2",children:[s.jsxs("p",{children:[s.jsx("strong",{children:"Resistencia cruzada implícita:"})," Alta probabilidad para todas las fluoroquinolonas"]}),s.jsxs("p",{children:[s.jsx("strong",{children:"Recomendación:"})," No probar fluoroquinolonas adicionales"]}),s.jsxs("p",{children:[s.jsx("strong",{children:"Opciones alternativas:"})," Beta-lactámicos, aminoglucósidos, otros según patrón"]})]})]})})(),(()=>{var Q;if((m.susceptibilityResults.Cefoxitin==="R"||m.susceptibilityResults.Oxacillin==="R")&&((Q=z.bacteriumName)==null?void 0:Q.includes("Staphylococcus aureus")))return s.jsxs("div",{className:"bg-red-100 p-4 rounded-lg border border-red-300",children:[s.jsxs("h5",{className:"font-semibold text-red-800 mb-2 flex items-center",children:[s.jsx("span",{className:"text-red-500 mr-2",children:"🦠"}),"S. aureus Resistente a Meticilina (MRSA) Detectado"]}),s.jsxs("div",{className:"text-sm text-red-700 space-y-2",children:[s.jsxs("p",{children:[s.jsx("strong",{children:"Resistencia cruzada implícita:"})," Todos los beta-lactámicos (excepto ceftarolina)"]}),s.jsxs("p",{children:[s.jsx("strong",{children:"Opciones terapéuticas:"})," Vancomicina, daptomicina, linezolid, ceftarolina"]}),s.jsxs("p",{children:[s.jsx("strong",{children:"Recomendación:"})," Reportar como resistente a todos los beta-lactámicos"]})]})]})})(),(()=>{const B=Object.keys(m.susceptibilityResults||{}).length>0,Q=m.susceptibilityResults.Ceftriaxone==="R"||m.susceptibilityResults.Ceftazidime==="R"||m.susceptibilityResults.Meropenem==="R"||m.susceptibilityResults.Ciprofloxacin==="R"||m.susceptibilityResults.Cefoxitin==="R";if(B&&!Q)return s.jsxs("div",{className:"bg-green-100 p-4 rounded-lg border border-green-300",children:[s.jsxs("h5",{className:"font-semibold text-green-800 mb-2 flex items-center",children:[s.jsx("span",{className:"text-green-500 mr-2",children:"✅"}),"No se detectaron patrones de resistencia cruzada"]}),s.jsx("p",{className:"text-sm text-green-700",children:"Continue ingresando resultados. Los patrones de resistencia cruzada se detectarán automáticamente."})]});if(!B)return s.jsxs("div",{className:"bg-blue-100 p-4 rounded-lg border border-blue-300",children:[s.jsxs("h5",{className:"font-semibold text-blue-800 mb-2 flex items-center",children:[s.jsx("span",{className:"text-blue-500 mr-2",children:"📚"}),"Sistema de Detección de Resistencia Cruzada"]}),s.jsx("p",{className:"text-sm text-blue-700",children:"Este sistema detecta automáticamente patrones de resistencia cruzada como ESBL, AmpC, carbapenemasas, y MRSA. Comience ingresando los resultados del antibiograma para obtener interpretaciones inteligentes."})]})})()]})]}),P.map((B,Q)=>{const H=L(B.tier);return s.jsxs("div",{className:`rounded-lg border ${H?"border-indigo-200 bg-white shadow-sm":"border-gray-300 bg-gray-50 opacity-60"} overflow-hidden`,children:[s.jsx("div",{className:`px-6 py-4 border-b ${H?"bg-indigo-50 border-indigo-200":"bg-gray-100 border-gray-300"}`,children:s.jsxs("div",{className:"flex items-center justify-between",children:[s.jsxs("div",{children:[s.jsxs("h4",{className:"text-lg font-semibold text-gray-800",children:["Tier ",B.tier," - ",B.tierDescription||"Pruebas Rutinarias"]}),s.jsxs("p",{className:"text-sm text-gray-600 mt-1",children:[B.tier===1&&"Pruebas de primera línea (siempre disponibles)",B.tier===2&&"Se desbloquea con resistencia a cefalosporinas o aminoglucósidos",B.tier===3&&"Se desbloquea con resistencia a carbapenémicos o patrón ESBL",B.tier===4&&"Se desbloquea con resistencia extrema (MDR)"]})]}),s.jsx("div",{className:"flex items-center space-x-2",children:H?s.jsx("span",{className:"inline-flex items-center px-3 py-1 rounded-full text-sm font-medium bg-green-100 text-green-800",children:"🔓 Desbloqueado"}):s.jsx("span",{className:"inline-flex items-center px-3 py-1 rounded-full text-sm font-medium bg-gray-100 text-gray-600",children:"🔒 Bloqueado"})})]})}),s.jsx("div",{className:"p-6",children:H?s.jsx("div",{className:"overflow-x-auto -mx-6 px-6 sm:mx-0 sm:px-0",style:{WebkitOverflowScrolling:"touch",scrollbarWidth:"thin"},children:s.jsxs("table",{className:"w-full min-w-full",style:{minWidth:"600px"},children:[s.jsx("thead",{className:"bg-gray-50",children:s.jsxs("tr",{children:[s.jsx("th",{className:"px-2 sm:px-4 py-3 text-left text-xs font-medium text-gray-500 uppercase tracking-wider min-w-0",children:s.jsx("div",{className:"truncate",children:"Antibiótico"})}),s.jsx("th",{className:"px-2 sm:px-4 py-3 text-left text-xs font-medium text-gray-500 uppercase tracking-wider min-w-0",children:s.jsx("div",{className:"truncate",children:"Resultado (MIC o S/I/R)"})})]})}),s.jsx("tbody",{className:"bg-white divide-y divide-gray-200",children:B.agents.map((Y,M)=>{var K,G,F,se;const V=Y.agentName,X=(K=m.susceptibilityResults)==null?void 0:K[V],Z=(G=m.micValues)==null?void 0:G[V];return s.jsxs("tr",{className:"hover:bg-gray-50",children:[s.jsx("td",{className:"px-2 sm:px-4 py-3",children:s.jsxs("div",{children:[s.jsx("div",{className:"text-sm font-medium text-gray-900",children:V}),((se=(F=Y.breakpointSets)==null?void 0:F[0])==null?void 0:se.condition)&&Y.breakpointSets[0].condition!=="Standard"&&s.jsx("div",{className:"text-xs text-orange-600 mt-1",children:Y.breakpointSets[0].condition}),(()=>{const w=O(Y);return w&&(w.comments.length>0||w.condition)&&s.jsxs("div",{className:"text-xs text-blue-700 mt-1 space-y-1",children:[w.condition&&s.jsxs("div",{className:"text-orange-600",children:["📋 ",w.condition]}),w.comments.map((ue,le)=>s.jsxs("div",{className:"text-blue-600",children:["💡 ",ue]},le))]})})(),(()=>{if((z.intrinsicResistance||[]).some(le=>{const W=le.drugOrClass||le;return typeof W!="string"?!1:W.toLowerCase().includes(V.toLowerCase())||V.toLowerCase().includes(W.toLowerCase().replace(/[^a-z]/g,""))}))return s.jsx("div",{className:"text-xs text-red-600 mt-1 bg-red-50 p-1 rounded",children:"🔒 Resistencia intrínseca - No reportar"})})(),X==="S"&&Z&&s.jsx("div",{className:"text-xs text-blue-600 mt-1",children:"🎯 PK/PD optimizable"})]})}),s.jsx("td",{className:"px-2 sm:px-4 py-3",children:s.jsxs("div",{className:"flex flex-col sm:flex-row sm:items-center space-y-2 sm:space-y-0 sm:space-x-2",children:[s.jsx("input",{type:"text",placeholder:Z?"MIC":X&&E(Y,X)||"MIC",value:Z||"",onChange:w=>u(V,w.target.value),className:`w-20 sm:w-24 px-2 py-1 text-sm border border-gray-300 rounded focus:outline-none focus:ring-1 focus:ring-indigo-500 ${!Z&&X?"placeholder-gray-400 italic":""}`}),s.jsx("span",{className:"text-xs text-gray-400",children:"or"}),s.jsx("div",{className:"flex flex-wrap gap-1",children:["S","SDD","I","R"].map(w=>{const W=(z.intrinsicResistance||[]).some(re=>{const de=re.drugOrClass||re;return typeof de!="string"?!1:de.toLowerCase().includes(V.toLowerCase())||V.toLowerCase().includes(de.toLowerCase().replace(/[^a-z]/g,""))})&&(w==="S"||w==="SDD"||w==="I");return s.jsx("button",{onClick:()=>!W&&_(V,w),disabled:W,className:`px-2 py-1 text-xs rounded transition-colors ${W?"bg-gray-200 text-gray-400 cursor-not-allowed border border-gray-300":X===w?w==="S"?"bg-green-600 text-white border border-green-600":w==="SDD"?"bg-blue-600 text-white border border-blue-600":w==="I"?"bg-yellow-500 text-white border border-yellow-500":"bg-red-600 text-white border border-red-600":"bg-gray-100 text-gray-600 hover:bg-gray-200 border border-gray-300"}`,title:W?"Resistencia intrínseca - No seleccionar":"",children:w},w)})})]})})]},M)})})]})}):s.jsxs("div",{className:"text-center py-8",children:[s.jsx("div",{className:"text-gray-400 text-lg mb-2",children:"🔒"}),s.jsxs("p",{className:"text-gray-500 text-sm",children:["Complete las pruebas de Tier ",B.tier-1," para desbloquear este nivel"]})]})})]},Q)})]})},Kg=({data:m,onChange:c})=>{const d=["Penicilinas","Cefalosporinas","Carbapenémicos","Quinolonas","Sulfas","Macrólidos","Glicopéptidos","Aminoglucósidos","Lincosamidas"];return s.jsxs("div",{children:[s.jsx("h3",{className:"text-xl font-semibold text-gray-800 mb-4",children:"Hipersensibilidad del Paciente"}),s.jsxs("fieldset",{className:"space-y-2",children:[s.jsx("legend",{className:"text-base font-medium text-gray-900",children:"Marque las alergias conocidas:"}),d.map(u=>s.jsxs("div",{className:"relative flex items-start",children:[s.jsx("div",{className:"flex items-center h-5",children:s.jsx("input",{id:u,name:"hypersensitivities",type:"checkbox",value:u,checked:m.hypersensitivities.includes(u),onChange:c,className:"focus:ring-indigo-500 h-4 w-4 text-indigo-600 border-gray-300 rounded"})}),s.jsx("div",{className:"ml-3 text-sm",children:s.jsx("label",{htmlFor:u,className:"font-medium text-gray-700",children:u})})]},u))]})]})},Qg=({data:m,calculations:c,recommendation:d,alternatives:u,clinicalAnalysis:_})=>{var B,Q,H,Y;const[E,O]=_e.useState(""),[P,L]=_e.useState(""),y=M=>{for(const V of Object.values(Mt)){const X=V.options.find(Z=>Z.value===M);if(X)return X.label}return M||"No especificada"},z=()=>{var se;const M=m.bacteriumId?Jt()[m.bacteriumId]:null,V=M?((se=M.identity)==null?void 0:se.bacteriumName)||M.name:"No especificado",X=y(m.location);let Z=[];if(m.rrt&&m.rrt!=="None"&&Z.push(`TRR: ${m.rrt}`),m.hasHepaticDisease){const w=c.childPugh?`Child-Pugh ${c.childPugh.score} (Clase ${c.childPugh.class})`:"Datos incompletos";Z.push(`Enf. Hepática: ${w}`)}if(m.isPregnantOrFertile&&Z.push("Embarazo/Fertilidad: Sí"),m.showSeverityAssessment){let w=[];m.isICU&&w.push("UCI"),m.isImmunocompromised&&w.push("Inmunocomprometido"),m.priorAntibiotics&&w.push("ATB previos"),m.hasOrganDysfunction&&w.push("Disfunción orgánica"),m.hasSepsis&&w.push("Sepsis"),m.hemodynamicStatus&&w.push(`Estado hemodinámico: ${m.hemodynamicStatus}`),m.respiratoryStatus&&w.push(`Estado respiratorio: ${m.respiratoryStatus}`),w.length>0&&Z.push(`Severidad: ${w.join(", ")}`)}if(m.showEpidemiologyData){let w=[];m.localESBLRate&&w.push(`ESBL local: ${m.localESBLRate}%`),m.localCarbapenemResistance&&w.push(`Carbapenem resist. local: ${m.localCarbapenemResistance}%`),m.institutionType&&w.push(`Institución: ${m.institutionType}`),w.length>0&&Z.push(`Epidemiología: ${w.join(", ")}`)}const K=Z.length>0?`
FACTORES CLÍNICOS:
  - ${Z.join(`
  - `)}
`:`
`,G=`** RESUMEN DE CASO CLÍNICO **
---------------------------------
PACIENTE: ${m.age||"N/A"} años, Sexo: ${m.gender==="Female"?"Femenino":"Masculino"}, ${m.weight||"N/A"} kg, ${m.height||"N/A"} cm.
CÁLCULOS:
  - TFG: ${c.tfg?`${c.tfg.value} mL/min/1.73m² (${c.tfg.formula})`:"N/A"}
  - IMC: ${c.bmi||"N/A"} (${c.obesityClass||"N/A"})${K}---------------------------------
INFECCIÓN:
  - Localización: ${X}
  - Microorganismo: ${V}
---------------------------------
RESULTADOS:
  - Alergias: ${m.hypersensitivities.length>0?m.hypersensitivities.join(", "):"Ninguna"}.
  - TRATAMIENTO RECOMENDADO: ${d.antibiotic||"Ninguno adecuado"} (${d.tier||"N/A"})
  - Alternativas viables: ${u.length>0?u.join(", "):"Ninguna"}
---------------------------------`,F=document.createElement("textarea");F.value=G,F.style.position="fixed",F.style.left="-9999px",document.body.appendChild(F),F.focus(),F.select();try{document.execCommand("copy"),O("Copiado!"),setTimeout(()=>O(""),2e3)}catch{O("Error")}document.body.removeChild(F)},q=d.antibiotic?wg[d.antibiotic]:null,ie=d.dose?`${d.dose} ${d.route||"IV"} ${d.frequency||""}${d.comments?` - ${d.comments}`:""}`:q?m.age<18?q.pediatricDosage:q.adultDosage:"N/A";return s.jsxs("div",{className:"space-y-6",children:[s.jsxs("div",{className:"flex justify-between items-start",children:[s.jsx("h3",{className:"text-xl font-semibold text-gray-800",children:"Resumen y Recomendación Automática"}),s.jsxs("button",{onClick:z,className:"flex items-center gap-2 bg-gray-200 text-gray-800 font-semibold py-2 px-4 rounded-lg hover:bg-gray-300 transition duration-300",children:[s.jsx("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:s.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M8 16H6a2 2 0 01-2-2V6a2 2 0 012-2h8a2 2 0 012 2v2m-6 12h8a2 2 0 002-2v-8a2 2 0 00-2-2h-8a2 2 0 00-2 2v8a2 2 0 002 2z"})}),E||"Copiar Resumen"]})]}),s.jsxs("div",{className:"bg-blue-50 border-l-4 border-blue-500 p-4 rounded-md space-y-3",children:[s.jsx("h4",{className:"font-bold text-blue-800",children:"Resumen del Caso Completo"}),s.jsxs("p",{children:[s.jsx("strong",{children:"Paciente:"})," ",m.age||"N/A"," años, Sexo: ",m.gender==="Female"?"Femenino":"Masculino",", ",m.weight||"N/A"," kg, ",m.height||"N/A"," cm."]}),s.jsxs("p",{children:[s.jsx("strong",{children:"Valores Calculados:"})," TFG: ",c.tfg?`${c.tfg.value} mL/min/1.73m²`:"N/A"," (",c.tfg?c.tfg.formula:"N/A","), IMC: ",c.bmi||"N/A"," (",c.obesityClass||"N/A",")."]}),m.rrt&&m.rrt!=="None"&&s.jsxs("p",{children:[s.jsx("strong",{children:"Terapia de Reemplazo Renal:"})," ",m.rrt]}),m.hasHepaticDisease&&s.jsxs("p",{children:[s.jsx("strong",{children:"Enf. Hepática:"})," Child-Pugh ",c.childPugh?`${c.childPugh.score} (Clase ${c.childPugh.class})`:"Datos incompletos"]}),m.isPregnantOrFertile&&s.jsxs("p",{children:[s.jsx("strong",{children:"Embarazo/Fertilidad:"})," Consideraciones especiales requeridas"]}),m.showSeverityAssessment&&(()=>{let M=[];return m.isICU&&M.push("UCI"),m.isImmunocompromised&&M.push("Inmunocomprometido"),m.priorAntibiotics&&M.push("ATB previos"),m.hasOrganDysfunction&&M.push("Disfunción orgánica"),m.hasSepsis&&M.push("Sepsis"),m.hemodynamicStatus&&M.push(`Est. hemodinámico: ${m.hemodynamicStatus}`),m.respiratoryStatus&&M.push(`Est. respiratorio: ${m.respiratoryStatus}`),M.length>0?s.jsxs("p",{children:[s.jsx("strong",{children:"Factores de Severidad:"})," ",M.join(", ")]}):null})(),m.showEpidemiologyData&&(()=>{let M=[];return m.localESBLRate&&M.push(`ESBL local: ${m.localESBLRate}%`),m.localCarbapenemResistance&&M.push(`Carbapenem resistencia local: ${m.localCarbapenemResistance}%`),m.institutionType&&M.push(`Institución: ${m.institutionType}`),M.length>0?s.jsxs("p",{children:[s.jsx("strong",{children:"Datos Epidemiológicos:"})," ",M.join(", ")]}):null})(),s.jsxs("p",{children:[s.jsx("strong",{children:"Infección:"})," ",y(m.location),"."]}),s.jsxs("p",{children:[s.jsx("strong",{children:"Microorganismo:"})," ",m.bacteriumId?((B=Jt()[m.bacteriumId].identity)==null?void 0:B.bacteriumName)||Jt()[m.bacteriumId].name:"No especificado","."]}),s.jsxs("p",{children:[s.jsx("strong",{children:"Alergias:"})," ",m.hypersensitivities.length>0?m.hypersensitivities.join(", "):"Ninguna reportada","."]})]}),s.jsxs("div",{className:"p-4 rounded-lg bg-indigo-50 border border-indigo-200",children:[s.jsxs("div",{className:"flex justify-between items-start",children:[s.jsx("h4",{className:"text-lg font-semibold text-indigo-800",children:"Tratamiento Sugerido por Guía"}),d.antibiotic&&s.jsxs("button",{onClick:()=>{const M=`${d.antibiotic}
${d.tier}
${ie}`;navigator.clipboard.writeText(M).then(()=>{L("¡Copiado!"),setTimeout(()=>L(""),2e3)}).catch(()=>{L("Error"),setTimeout(()=>L(""),2e3)})},className:`flex items-center gap-2 px-3 py-1.5 text-sm font-medium rounded-lg transition-colors ${P?P==="Error"?"bg-red-600 text-white":"bg-green-600 text-white":"bg-indigo-600 text-white hover:bg-indigo-700"}`,title:"Copiar tratamiento",children:[s.jsx("svg",{className:"w-4 h-4",fill:"none",stroke:"currentColor",viewBox:"0 0 24 24",children:s.jsx("path",{strokeLinecap:"round",strokeLinejoin:"round",strokeWidth:2,d:"M8 16H6a2 2 0 01-2-2V6a2 2 0 012-2h8a2 2 0 012 2v2m-6 12h8a2 2 0 002-2v-8a2 2 0 00-2-2h-8a2 2 0 00-2 2v8a2 2 0 002 2z"})}),P||"Copiar"]})]}),d.antibiotic?s.jsxs("div",{children:[s.jsx("p",{className:"text-2xl font-bold text-indigo-600 mt-2",children:d.antibiotic}),s.jsx("p",{className:"text-sm font-medium text-indigo-700",children:d.tier}),((Q=d.context)==null?void 0:Q.condition)&&s.jsxs("p",{className:"text-sm text-gray-700 mt-1",children:[s.jsx("span",{className:"font-semibold",children:"Contexto Clínico:"})," ",d.context.condition]}),s.jsxs("p",{className:"text-md text-gray-800 mt-2",children:[s.jsx("span",{className:"font-semibold",children:"Dosis Sugerida:"})," ",ie]}),d.regimenNotes&&d.regimenNotes.length>0&&s.jsxs("div",{className:"mt-2 p-2 bg-yellow-50 border border-yellow-200 rounded",children:[s.jsx("p",{className:"text-sm font-semibold text-yellow-800",children:"Notas Importantes:"}),d.regimenNotes.map((M,V)=>s.jsxs("p",{className:"text-xs text-yellow-700 mt-1",children:["• ",M]},V))]}),s.jsx("p",{className:"text-xs text-gray-600 mt-1",children:"La duración del tratamiento es una decisión clínica."})]}):s.jsx("p",{className:"text-lg font-semibold text-red-600 mt-2",children:d.tier})]}),q&&s.jsxs("div",{className:"p-4 rounded-lg bg-gray-50 border border-gray-200 space-y-3",children:[s.jsx("h4",{className:"text-lg font-semibold text-gray-800",children:"Detalles Adicionales del Fármaco Recomendado"}),s.jsxs("div",{children:[s.jsx("strong",{children:"Ajuste Renal:"})," ",q.renalAdjustment]}),s.jsxs("div",{children:[s.jsx("strong",{children:"Ajuste Hepático:"})," ",q.hepaticAdjustment]}),m.isPregnantOrFertile&&s.jsxs("div",{children:[s.jsx("strong",{children:"Riesgo en Embarazo:"}),s.jsx("span",{className:"font-bold ml-2",children:q.pregnancyRisk})]})]}),s.jsxs("div",{className:"p-4 rounded-lg bg-gray-50 border border-gray-200",children:[s.jsx("h4",{className:"text-lg font-semibold text-gray-800",children:"Posibles Alternativas Terapéuticas"}),u.length>0?s.jsxs("p",{className:"text-gray-600 mt-2",children:["Otras opciones sensibles y sin contraindicación por alergia incluyen: ",s.jsx("span",{className:"font-semibold",children:u.join(", ")}),"."]}):s.jsx("p",{className:"text-gray-500 mt-2",children:"No se encontraron otras alternativas viables en el panel probado."})]}),m.bacteriumId&&((Y=(H=Jt()[m.bacteriumId])==null?void 0:H.treatment)==null?void 0:Y.generalNotes)&&s.jsxs("div",{className:"p-4 rounded-lg bg-blue-50 border border-blue-200",children:[s.jsx("h4",{className:"text-lg font-semibold text-blue-800",children:"Notas Generales de Tratamiento"}),s.jsx("div",{className:"mt-2 space-y-2",children:Jt()[m.bacteriumId].treatment.generalNotes.map((M,V)=>s.jsxs("p",{className:"text-sm text-blue-700",children:["• ",M]},V))})]}),_&&s.jsxs("div",{className:"p-4 rounded-lg bg-green-50 border border-green-200",children:[s.jsx("h4",{className:"text-lg font-semibold text-green-800",children:"Análisis Clínico Inteligente"}),s.jsxs("div",{className:"mt-3 space-y-3",children:[d.clinicalRationale&&s.jsxs("div",{children:[s.jsx("p",{className:"text-sm font-semibold text-green-700",children:"Justificación Clínica:"}),s.jsx("p",{className:"text-sm text-green-600",children:d.clinicalRationale})]}),d.severityAssessment&&s.jsxs("div",{children:[s.jsx("p",{className:"text-sm font-semibold text-green-700",children:"Evaluación de Severidad:"}),s.jsxs("p",{className:"text-sm text-green-600",children:[d.severityAssessment.levelName," (Puntuación: ",d.severityAssessment.score,")"]})]}),d.resistanceAssessment&&s.jsxs("div",{children:[s.jsx("p",{className:"text-sm font-semibold text-green-700",children:"Mecanismos de Resistencia Detectados:"}),s.jsx("p",{className:"text-sm text-green-600",children:d.resistanceAssessment.summary}),(d.resistanceAssessment.esbl.suspected||d.resistanceAssessment.ampC.suspected||d.resistanceAssessment.carbapenemase.suspected)&&s.jsxs("div",{className:"mt-2 p-2 bg-yellow-50 border border-yellow-200 rounded",children:[s.jsx("p",{className:"text-xs font-semibold text-yellow-800",children:"Alertas de Resistencia:"}),d.resistanceAssessment.esbl.suspected&&s.jsxs("p",{className:"text-xs text-yellow-700",children:["• ESBL detectado - ",d.resistanceAssessment.esbl.implications]}),d.resistanceAssessment.ampC.suspected&&s.jsxs("p",{className:"text-xs text-yellow-700",children:["• AmpC detectado - ",d.resistanceAssessment.ampC.implications]}),d.resistanceAssessment.carbapenemase.suspected&&s.jsxs("p",{className:"text-xs text-yellow-700",children:["• Carbapenemasa detectada - ",d.resistanceAssessment.carbapenemase.implications]})]})]})]})]}),s.jsxs("div",{className:"p-4 rounded-lg bg-teal-50 border border-teal-200",children:[s.jsxs("h4",{className:"text-lg font-semibold text-teal-800 mb-4 flex items-center",children:[s.jsx("span",{className:"text-xl mr-2",children:"🛡️"}),"Principios de Stewardship Antimicrobiano"]}),s.jsxs("div",{className:"space-y-4",children:[s.jsxs("div",{className:"bg-white p-4 rounded-lg border",children:[s.jsxs("h5",{className:"font-semibold text-teal-700 mb-2 flex items-center",children:[s.jsx("span",{className:"text-teal-500 mr-2",children:"🎯"}),"Recomendaciones de De-escalación"]}),s.jsx("div",{className:"text-sm text-teal-600 space-y-2",children:(()=>{const M=m.susceptibilityResults.Ceftriaxone==="R"||m.susceptibilityResults.Ceftazidime==="R",V=m.susceptibilityResults.Meropenem==="R"||m.susceptibilityResults.Imipenem==="R",X=m.susceptibilityResults.Ampicillin==="S"||m.susceptibilityResults.Penicillin==="S";return V?s.jsxs("div",{className:"p-3 bg-red-50 border border-red-200 rounded",children:[s.jsx("p",{className:"text-red-700 font-medium",children:"⚠️ Resistencia a carbapenémicos detectada"}),s.jsxs("p",{className:"text-red-600 text-xs mt-1",children:["• Consultar con infectología para terapia combinada",s.jsx("br",{}),"• Considerar colistina, ceftazidima-avibactam o fosfomicina",s.jsx("br",{}),"• Evaluar necesidad de aislamiento de contacto"]})]}):M?s.jsxs("div",{className:"p-3 bg-orange-50 border border-orange-200 rounded",children:[s.jsx("p",{className:"text-orange-700 font-medium",children:"🧬 Patrón ESBL detectado"}),s.jsxs("p",{className:"text-orange-600 text-xs mt-1",children:["• Evitar cefalosporinas y piperacilina-tazobactam",s.jsx("br",{}),"• Priorizar carbapenémicos para infecciones graves",s.jsx("br",{}),"• Considerar fosfomicina o nitrofurantoína para ITU"]})]}):X?s.jsxs("div",{className:"p-3 bg-green-50 border border-green-200 rounded",children:[s.jsx("p",{className:"text-green-700 font-medium",children:"✅ Opciones de espectro estrecho disponibles"}),s.jsxs("p",{className:"text-green-600 text-xs mt-1",children:["• Priorizar agentes de espectro estrecho cuando sea posible",s.jsx("br",{}),"• Evitar uso innecesario de carbapenémicos",s.jsx("br",{}),"• Considerar cambio a vía oral cuando sea apropiado"]})]}):s.jsxs("div",{className:"p-3 bg-blue-50 border border-blue-200 rounded",children:[s.jsx("p",{className:"text-blue-700 font-medium",children:"📋 Evaluación de de-escalación"}),s.jsxs("p",{className:"text-blue-600 text-xs mt-1",children:["• Revisar resultados de susceptibilidad completamente",s.jsx("br",{}),"• Evaluar evolución clínica a las 48-72 horas",s.jsx("br",{}),"• Considerar cambio a agente más específico si es posible"]})]})})()})]}),s.jsxs("div",{className:"bg-white p-4 rounded-lg border",children:[s.jsxs("h5",{className:"font-semibold text-teal-700 mb-2 flex items-center",children:[s.jsx("span",{className:"text-teal-500 mr-2",children:"⏱️"}),"Duración y Monitoreo"]}),s.jsxs("div",{className:"text-sm text-teal-600 space-y-2",children:[s.jsxs("p",{children:["• ",s.jsx("strong",{children:"Duración:"})," Usar la menor duración efectiva según guías clínicas"]}),s.jsxs("p",{children:["• ",s.jsx("strong",{children:"Monitoreo:"})," Evaluar respuesta clínica y microbiológica"]}),s.jsxs("p",{children:["• ",s.jsx("strong",{children:"Revisión:"})," Reevaluar necesidad de antibiótico cada 48-72 horas"]}),(q==null?void 0:q.therapeuticDrugMonitoring)&&s.jsxs("p",{children:["• ",s.jsx("strong",{children:"Niveles:"})," ",q.therapeuticDrugMonitoring.monitoring," (Objetivo: ",q.therapeuticDrugMonitoring.target,")"]})]})]}),(()=>{var V,X;if(m.susceptibilityResults.Meropenem==="R"||m.susceptibilityResults.Imipenem==="R"||((V=m.location)==null?void 0:V.includes("Endocarditis"))||((X=m.location)==null?void 0:X.includes("Meningitis"))||m.isICU)return s.jsxs("div",{className:"bg-white p-4 rounded-lg border",children:[s.jsxs("h5",{className:"font-semibold text-teal-700 mb-2 flex items-center",children:[s.jsx("span",{className:"text-teal-500 mr-2",children:"🔄"}),"Consideraciones de Terapia Combinada"]}),s.jsxs("div",{className:"text-sm text-teal-600 space-y-2",children:[s.jsxs("p",{children:["• ",s.jsx("strong",{children:"Indicaciones:"})," Infección grave, resistencia extrema, o sinergia requerida"]}),s.jsxs("p",{children:["• ",s.jsx("strong",{children:"Evaluación:"})," Evaluar beneficio vs. riesgo de toxicidad"]}),s.jsxs("p",{children:["• ",s.jsx("strong",{children:"Monitoreo:"})," Seguimiento estrecho de efectos adversos"]}),s.jsxs("p",{children:["• ",s.jsx("strong",{children:"Duración:"})," Limitar al período mínimo necesario"]})]})]})})(),s.jsxs("div",{className:"bg-white p-4 rounded-lg border",children:[s.jsxs("h5",{className:"font-semibold text-teal-700 mb-2 flex items-center",children:[s.jsx("span",{className:"text-teal-500 mr-2",children:"🔒"}),"Prevención de Resistencia"]}),s.jsxs("div",{className:"text-sm text-teal-600 space-y-2",children:[s.jsxs("p",{children:["• ",s.jsx("strong",{children:"Dosis óptima:"})," Usar dosis máximas recomendadas para infecciones graves"]}),s.jsxs("p",{children:["• ",s.jsx("strong",{children:"Cumplimiento:"})," Asegurar adherencia completa al tratamiento"]}),s.jsxs("p",{children:["• ",s.jsx("strong",{children:"Combinaciones:"})," Evitar monoterapia en infecciones por P. aeruginosa grave"]}),s.jsxs("p",{children:["• ",s.jsx("strong",{children:"Rotación:"})," Considerar políticas de rotación de antibióticos institucionales"]})]})]})]})]})]})},Zg=({onBackToLanding:m})=>{const[c,d]=_e.useState({age:"",weight:"",height:"",creatinine:"",gender:"Female",useCystatinC:!1,cystatinC:"",isPregnantOrFertile:!1,hasHepaticDisease:!1,bilirubin:"",albumin:"",inr:"1",ascites:"1",encephalopathy:"1",location:"",rrt:"None",bacteriumId:"",susceptibilityResults:{},micValues:{},hypersensitivities:[],showSeverityAssessment:!1,isICU:!1,isImmunocompromised:!1,priorAntibiotics:!1,hasOrganDysfunction:!1,hasSepsis:!1,hemodynamicStatus:"",respiratoryStatus:"",showEpidemiologyData:!1,localESBLRate:"",localCarbapenemResistance:"",institutionType:""}),[u,_]=_e.useState(1),E=6,O=()=>_(G=>Math.min(G+1,E)),P=()=>_(G=>Math.max(G-1,1)),L=()=>{d({age:"",weight:"",height:"",creatinine:"",gender:"Female",useCystatinC:!1,cystatinC:"",isPregnantOrFertile:!1,hasHepaticDisease:!1,bilirubin:"",albumin:"",inr:"1",ascites:"1",encephalopathy:"1",location:"",rrt:"None",bacteriumId:"",susceptibilityResults:{},micValues:{},hypersensitivities:[],showSeverityAssessment:!1,isICU:!1,isImmunocompromised:!1,priorAntibiotics:!1,hasOrganDysfunction:!1,hasSepsis:!1,hemodynamicStatus:"",respiratoryStatus:"",showEpidemiologyData:!1,localESBLRate:"",localCarbapenemResistance:"",institutionType:""}),_(1)},y=G=>{const{name:F,value:se,type:w,checked:ue}=G.target;if(F==="susceptibilityResults"||F==="micValues"||F==="bacteriumId")d(le=>({...le,[F]:se}));else if(F==="hypersensitivities")d(le=>({...le,hypersensitivities:ue?[...le.hypersensitivities,se]:le.hypersensitivities.filter(W=>W!==se)}));else{const le=w==="checkbox"?ue:se;d(W=>({...W,[F]:le}))}},z=(G,F,se)=>{if(F<24||F>228)return null;const w={Male:{24:{L:1,M:16,S:.11},60:{L:1,M:15.5,S:.13},120:{L:1,M:16.8,S:.15},180:{L:1,M:20.2,S:.14},216:{L:1,M:21.9,S:.13}},Female:{24:{L:1,M:15.8,S:.11},60:{L:1,M:15.2,S:.14},120:{L:1,M:16.9,S:.16},180:{L:1,M:20.7,S:.13},216:{L:1,M:21.4,S:.12}}},ue=w[se]||w.Male;let W=Object.keys(ue).map(Number).sort((x,D)=>x-D).reduce((x,D)=>Math.abs(D-F)<Math.abs(x-F)?D:x);const{L:re,M:de,S:ce}=ue[W];return re!==0?(Math.pow(G/de,re)-1)/(re*ce):Math.log(G/de)/ce},q=G=>G<-3?"Desnutrición severa (z-score < -3)":G<-2?"Desnutrición moderada (z-score -3 a -2)":G<-1?"Bajo peso (z-score -2 a -1)":G<=1?"Normal (z-score -1 a +1)":G<=2?"Sobrepeso (z-score +1 a +2)":G<=3?"Obesidad (z-score +2 a +3)":"Obesidad severa (z-score > +3)",ie=(G,F,se)=>{if(F<24||F>60)return null;const w={Male:{24:{L:1,M:87.1,S:.04},36:{L:1,M:96.1,S:.04},48:{L:1,M:103.3,S:.04},60:{L:1,M:110,S:.04}},Female:{24:{L:1,M:86.4,S:.04},36:{L:1,M:95.1,S:.04},48:{L:1,M:102.7,S:.04},60:{L:1,M:109.4,S:.04}}},ue=w[se]||w.Male;let W=Object.keys(ue).map(Number).sort((x,D)=>x-D).reduce((x,D)=>Math.abs(D-F)<Math.abs(x-F)?D:x);const{L:re,M:de,S:ce}=ue[W];return re!==0?(Math.pow(G/de,re)-1)/(re*ce):Math.log(G/de)/ce},B=(G,F,se)=>{if(F<24||F>60)return null;const w={Male:{24:{L:1,M:12.2,S:.15},36:{L:1,M:14.3,S:.15},48:{L:1,M:16.3,S:.14},60:{L:1,M:18.3,S:.14}},Female:{24:{L:1,M:11.5,S:.15},36:{L:1,M:13.9,S:.15},48:{L:1,M:15.7,S:.14},60:{L:1,M:17.7,S:.14}}},ue=w[se]||w.Male;let W=Object.keys(ue).map(Number).sort((x,D)=>x-D).reduce((x,D)=>Math.abs(D-F)<Math.abs(x-F)?D:x);const{L:re,M:de,S:ce}=ue[W];return re!==0?(Math.pow(G/de,re)-1)/(re*ce):Math.log(G/de)/ce},Q=G=>G<-3?"Talla baja severa (stunting severo)":G<-2?"Talla baja (stunting)":G<=2?"Talla normal":"Talla alta",H=G=>G<-3?"Bajo peso severo":G<-2?"Bajo peso":G<=2?"Peso normal":"Peso alto",Y=_e.useMemo(()=>{const G=parseFloat(c.age),F=parseFloat(c.height),se=parseFloat(c.creatinine),w=parseFloat(c.cystatinC),ue=parseFloat(c.weight);let le=null;if(G>0&&F>0){if(G<18)se>0&&(le={value:(.413*F/se).toFixed(2),formula:"Schwartz (Bedside)"});else if(c.useCystatinC&&w>0){let T;const I=w/.8<1?-.219:-.544;T=135*Math.pow(Math.min(w/.8,1),I)*Math.pow(Math.max(w/.8,1),-.544)*Math.pow(.9961,G),c.gender==="Female"&&(T*=.963),le={value:T.toFixed(2),formula:"CKD-EPI (Cistatina C)"}}else if(se>0){const T=c.gender==="Female"?.7:.9,C=c.gender==="Female"?-.241:-.302,I=c.gender==="Female"?1.012:1;le={value:(142*Math.pow(Math.min(se/T,1),C)*Math.pow(Math.max(se/T,1),-1.2)*Math.pow(.9938,G)*I).toFixed(2),formula:"CKD-EPI (Creatinina)"}}}let W=null,re="",de=null,ce=null,x="",D=null,$="";if(ue>0&&F>0)if(W=(ue/(F/100)**2).toFixed(2),G<18){const T=G*12;de=z(parseFloat(W),T,c.gender),de!==null?re=q(de):re="Z-score no disponible (requiere datos WHO)",G<5&&(ce=ie(F,T,c.gender),ce!==null&&(x=Q(ce)),D=B(ue,T,c.gender),D!==null&&($=H(D)))}else W<18.5?re="Bajo Peso":W<25?re="Normal":W<30?re="Sobrepeso":W<35?re="Obesidad Grado I":W<40?re="Obesidad Grado II":re="Obesidad Grado III";let fe=null;if(c.hasHepaticDisease){const T=parseFloat(c.bilirubin),C=parseFloat(c.albumin),I=parseFloat(c.inr);if(T>0&&C>0&&I>0){let U=0;T<2?U+=1:T<=3?U+=2:U+=3,C>3.5?U+=1:C>=2.8?U+=2:U+=3,I<1.7?U+=1:I<=2.3?U+=2:U+=3,U+=parseInt(c.ascites),U+=parseInt(c.encephalopathy);let ee="";U<=6?ee="A":U<=9?ee="B":ee="C",fe={score:U,class:ee}}}let f=null;if(c.showSeverityAssessment){let T=0;const C=[],U={CNS_meningitis:3,CNS_encephalitis:3,CNS_brain_abscess:3,CNS_subdural_empyema:3,CV_endocarditis_native:3,CV_endocarditis_prosthetic:3,CV_endocarditis_CIED:3,CV_mycotic_aneurysm:3,CV_pericarditis:2,RESP_CAP:2,RESP_HAP:2,RESP_VAP:3,RESP_empyema:2,RESP_lung_abscess:2,RESP_bronchitis_acute:1,GU_UTI_uncomplicated:1,GU_UTI_complicated:2,GU_UTI_catheter:2,GU_pyelonephritis:2,GU_prostatitis_acute:2,GU_prostatitis_chronic:1,SST_cellulitis_simple:1,SST_cellulitis_severe:2,SST_necrotizing_fasciitis:3,SST_abscess:1,SST_diabetic_foot:2,SST_surgical_site:2,BJ_osteomyelitis_acute:2,BJ_osteomyelitis_chronic:2,BJ_prosthetic_joint:2,BJ_septic_arthritis:2,BJ_vertebral_osteomyelitis:2,BJ_diabetic_foot_osteo:2,IA_peritonitis_secondary:2,IA_peritonitis_primary:2,IA_intra_abdominal:2,IA_cholangitis:2,IA_liver_abscess:2,IA_appendicitis:2,BS_bacteremia_primary:2,BS_CLABSI:2,BS_sepsis:3,BS_septic_shock:3,BS_neutropenic_fever:2,"Skin and soft tissues":1,Genitourinary:1,Respiratory:2,Gastrointestinal:2,"Bone tissue":2,Cardiovascular:3,"Central nervous system":3,"Bacteremia/Sepsis":3}[c.location]||0;if(U>0){T+=U;const je=c.location.includes("_")?"Síndrome específico":c.location;C.push(`${je} (+${U})`)}parseFloat(c.age)>65&&(T+=1,C.push("Edad >65 años (+1)")),c.isICU&&(T+=3,C.push("UCI (+3)")),c.isImmunocompromised&&(T+=2,C.push("Inmunocomprometido (+2)")),c.priorAntibiotics&&(T+=1,C.push("Antibióticos previos (+1)")),c.hasOrganDysfunction&&(T+=2,C.push("Disfunción orgánica (+2)")),c.hasSepsis&&(T+=3,C.push("Sepsis/shock séptico (+3)")),c.hemodynamicStatus==="shock"?(T+=3,C.push("Shock hemodinámico (+3)")):c.hemodynamicStatus==="hypotension"&&(T+=2,C.push("Hipotensión (+2)")),c.respiratoryStatus==="mechanical"?(T+=2,C.push("Ventilación mecánica (+2)")):c.respiratoryStatus==="oxygen"&&(T+=1,C.push("Oxígeno suplementario (+1)"));let Te;T<=2?Te="LEVE":T<=5?Te="MODERADO":T<=8?Te="GRAVE":Te="CRÍTICO",f={score:T,level:Te,factors:C}}let R=null;if(c.showEpidemiologyData){const T=parseFloat(c.localESBLRate),C=parseFloat(c.localCarbapenemResistance);let I="BAJO";const U=[];T>30?(I="ALTO",U.push(`ESBL alta (${T}%)`)):T>15?(I="MODERADO",U.push(`ESBL moderada (${T}%)`)):T>0&&U.push(`ESBL baja (${T}%)`),C>15?(I="ALTO",U.push(`Carbapenem alta (${C}%)`)):C>5?(I==="BAJO"&&(I="MODERADO"),U.push(`Carbapenem moderada (${C}%)`)):C>0&&U.push(`Carbapenem baja (${C}%)`),c.institutionType==="tertiary"?(I==="BAJO"&&(I="MODERADO"),U.push("Centro de referencia")):c.institutionType==="academic"?U.push("Centro académico"):c.institutionType==="community"&&U.push("Hospital comunitario"),R={level:I,factors:U.length>0?U:["Datos por defecto"]}}return{tfg:le,bmi:W,obesityClass:re,bmiZScore:de,heightForAgeZScore:ce,heightForAgeClass:x,weightForAgeZScore:D,weightForAgeClass:$,childPugh:fe,severityAssessment:f,epidemiologyRisk:R}},[c]),{recommendation:M,alternatives:V,clinicalAnalysis:X}=_e.useMemo(()=>{var w,ue,le;const{bacteriumId:G,location:F}=c,se=G?Jt()[G]:null;if(!se||!F)return{recommendation:{antibiotic:null,tier:"Información incompleta (bacteria o localización)."},alternatives:[],clinicalAnalysis:null};try{const W={esblRate:{enterobacterales:c.localESBLRate?parseFloat(c.localESBLRate)/100:.12,klebsiella:.18,escherichia:.08,enterobacter:.25},carbapenemResistance:{enterobacterales:c.localCarbapenemResistance?parseFloat(c.localCarbapenemResistance)/100:.03,klebsiella:.05,acinetobacter:.25,pseudomonas:.15},mrsaRate:.35,vreRate:.15},re=Bg(c,se,W),de=re.regimen;if(!de.regimen||!de.suitableOptions||de.suitableOptions.length===0)return{recommendation:{antibiotic:null,tier:de.note||"No se encontró opción adecuada con los datos actuales."},alternatives:[],clinicalAnalysis:re};const ce=de.suitableOptions[0],x=de.regimen,D={antibiotic:ce.drugName,tier:((w=x.context)==null?void 0:w.condition)||"Recomendación inteligente",dose:ce.dose,route:ce.route,frequency:ce.frequency,comments:ce.comments,context:x.context,regimenNotes:((le=(ue=x.recommendations)==null?void 0:ue[0])==null?void 0:le.notes)||[],clinicalRationale:re.rationale.summary,severityAssessment:re.severity,resistanceAssessment:re.mechanisms},$=de.suitableOptions.slice(1).map(fe=>fe.drugName);return{recommendation:D,alternatives:$,clinicalAnalysis:re}}catch(W){return console.error("Error in intelligent recommendation:",W),{recommendation:{antibiotic:null,tier:"Error en el análisis clínico. Consulte con especialista en infectología."},alternatives:[],clinicalAnalysis:null}}},[c]),Z=["Datos del Paciente","Localización de Infección","Selección de Microorganismo","Panel de Sensibilidad","Hipersensibilidad","Resumen y Recomendación"],K=()=>{switch(u){case 1:return s.jsx(Hg,{data:c,onChange:y,calculations:Y});case 2:return s.jsx(Gg,{data:c,onChange:y});case 3:return s.jsx(Yg,{data:c,onChange:y});case 4:return s.jsx(Xg,{data:c,onChange:y});case 5:return s.jsx(Kg,{data:c,onChange:y});case 6:return s.jsx(Qg,{data:c,calculations:Y,recommendation:M,alternatives:V,clinicalAnalysis:X});default:return s.jsx("div",{children:"Paso desconocido"})}};return s.jsxs("div",{className:"bg-gray-100 font-sans",style:{minHeight:"100vh",paddingBottom:"2rem"},children:[s.jsx("div",{className:"bg-white shadow-sm border-b border-gray-200 sticky top-0 z-10",children:s.jsxs("div",{className:"max-w-4xl mx-auto px-4 sm:px-8 py-4 flex items-center justify-between",children:[s.jsxs("button",{onClick:m,className:"flex items-center text-gray-600 hover:text-gray-800 transition-colors",children:[s.jsx("span",{className:"mr-2",children:"←"}),s.jsx("span",{className:"text-sm",children:"Volver al Inicio"})]}),s.jsxs("div",{className:"text-center",children:[s.jsx("h1",{className:"text-2xl font-bold text-gray-800",children:"Antibiograma Inteligente"}),s.jsx("p",{className:"text-sm text-gray-600",children:"Versión Alpha - Enterobacterales"})]}),s.jsx("div",{className:"w-24"})]})}),s.jsx("div",{className:"p-2 sm:p-4 lg:p-8 flex flex-col items-center",style:{minHeight:"calc(100vh - 100px)"},children:s.jsxs("div",{className:"w-full max-w-4xl pb-8",children:[s.jsx(Ug,{current:u,total:E}),s.jsxs(Vg,{title:Z[u-1],children:[s.jsx("form",{onSubmit:G=>G.preventDefault(),children:K()}),s.jsxs("div",{className:"mt-8 pt-6 border-t border-gray-200 flex justify-between items-center",children:[s.jsx("button",{onClick:P,disabled:u===1,className:"bg-gray-600 hover:bg-gray-700 text-white font-bold py-2 px-6 rounded-lg transition duration-300 disabled:opacity-50 disabled:cursor-not-allowed",children:"Anterior"}),u===E?s.jsx("button",{onClick:L,className:"bg-green-600 hover:bg-green-700 text-white font-bold py-2 px-6 rounded-lg transition duration-300",children:"Finalizar y Reiniciar"}):s.jsx("button",{onClick:O,className:"bg-indigo-600 hover:bg-indigo-700 text-white font-bold py-2 px-6 rounded-lg transition duration-300",children:"Siguiente"})]})]})]})})]})},Jg=({onBackToLanding:m})=>{const[c,d]=_e.useState("resumen"),[u,_]=_e.useState("p_aeruginosa"),[E,O]=_e.useState(null),[P,L]=_e.useState(null),y={topPathogens:{labels:["E. coli","S. aureus","K. pneumoniae","P. aeruginosa","A. baumannii"],data:[4e3,3100,2600,2e3,1500]},pathogens:{p_aeruginosa:{name:"Pseudomonas aeruginosa",burden:"4ta causa de muerte por RAM en Colombia (2,000 muertes en 2019). Prevalencia en UCI aumentó de 8% a 11% (2018-2021). 2do agente en Neumonía Asociada a Ventilador (20.7%) y Bacteriemia (10.5%) en UCI de adultos (2023).",resistance:{labels:["Pip/Tazo","Ceftazidima","Cefepime","Imipenem","Meropenem","Ciprofloxacina","Amikacina"],datasets:[{label:"% Resistencia",data:[35,30,30,28,28,30,30],backgroundColor:"rgba(13, 148, 136, 0.6)",borderColor:"rgba(13, 148, 136, 1)",borderWidth:1,sources:["GREBO 2018-21 (aumento sig.)","GREBO 2001-03 (>30%)","GREBO 2001-03 (>30%)","INS 2022 (23.9-27.9%)","INS 2022 (23.9-27.9%)","GREBO 2001-03 (>30%)","GREBO 2001-03 (>30%)"]}]},intrinsic:["Ampicilina","Amoxi/Clav","Cefalosp. 1ra/2da gen","Tetraciclinas","TMP/SMX","Cloranfenicol"],considerations:"TENDENCIA CRÍTICA: Se ha demostrado un aumento estadísticamente significativo en la resistencia a Piperacilina-Tazobactam y Carbapenems a nivel nacional (2018-2021). La eficacia de estas terapias clave está disminuyendo activamente."},e_coli:{name:"Escherichia coli",burden:"1ra causa de muerte por RAM en Colombia (4,000 muertes en 2019). Constituye 26-28% de todos los aislados bacterianos. Principal agente en ITU asociada a catéter en UCI (25.6% en 2023).",resistance:{labels:["Cefalosp. 3ra Gen","Ciprofloxacina"],datasets:[{label:"% Resistencia",data:[28.6,25],backgroundColor:"rgba(13, 148, 136, 0.6)",borderColor:"rgba(13, 148, 136, 1)",borderWidth:1,sources:["INS 2022 (28.6%)","GREBO 2001-03 (>20%)"]}]},intrinsic:[],considerations:"La resistencia a Cefalosporinas de 3ra Gen es un marcador de producción de BLEE. Datos de diferentes fuentes muestran tasas entre 20-28.6%, indicando una alta prevalencia de BLEE."},k_pneumoniae:{name:"Klebsiella pneumoniae",burden:"3ra causa de muerte por RAM en Colombia (2,600 muertes en 2019). Prevalencia en UCI aumentó de 15% a 18% (2018-2021). Agente predominante en Bacteriemia (19.9%) y NAV (29.8%) en UCI de adultos (2023).",resistance:{labels:["Ceftriaxona","Carbapenems"],datasets:[{label:"% Resistencia",data:[31,15],backgroundColor:"rgba(13, 148, 136, 0.6)",borderColor:"rgba(13, 148, 136, 1)",borderWidth:1,sources:["Expertos 2022 (31%) / GREBO 2001-03 (>30%)","INS/GREBO (variable, creciente)"]}]},intrinsic:["Ampicilina"],considerations:"La resistencia a carbapenems es una amenaza crítica y creciente a nivel nacional, a menudo mediada por carbapenemasas como KPC, cuya diseminación en Bogotá fue documentada desde 2008."},e_cloacae:{name:"Enterobacter cloacae complex",burden:"Causa frecuente de infecciones nosocomiales, especialmente en inmunocomprometidos. No está en el top 5 de mortalidad, pero es un patógeno de alta preocupación por su resistencia.",resistance:{labels:["Ceftriaxona","Cefepime","Pip/Tazo","Meropenem","Ciprofloxacina"],datasets:[{label:"% Resistencia (GREBO 2023)",data:[38,28.6,35.7,11.9,30.8],backgroundColor:"rgba(13, 148, 136, 0.6)",borderColor:"rgba(13, 148, 136, 1)",borderWidth:1,sources:["GREBO 2023","GREBO 2023","GREBO 2023","GREBO 2023","GREBO 2023"]}]},intrinsic:["Ampicilina","Amoxi/Clav","Cefalosp. 1ra Gen","Cefoxitina"],considerations:"La principal característica es la presencia de una β-lactamasa AmpC cromosómica inducible. La exposición a cefalosporinas de 1ra/2da/3ra gen puede seleccionar mutantes hiperproductoras, causando fracaso terapéutico. Cefepime es el agente de elección si es susceptible."},a_baumannii:{name:"Acinetobacter baumannii",burden:"5ta causa de muerte por RAM en Colombia (1,500 muertes en 2019). Patógeno formidable casi exclusivo de entornos de UCI.",resistance:{labels:["Carbapenems"],datasets:[{label:"% Resistencia",data:[45],backgroundColor:"rgba(13, 148, 136, 0.6)",borderColor:"rgba(13, 148, 136, 1)",borderWidth:1,sources:["INS 2022 (UCI Adultos)"]}]},intrinsic:["Ampicilina","Cefalosp. 1ra/2da gen","Ertapenem"],considerations:"Patógeno nosocomial con tasas de resistencia a carbapenémicos extremadamente altas (>45%), lo que limita severamente las opciones terapéuticas y lo convierte en una amenaza crítica."},s_aureus:{name:"Staphylococcus aureus",burden:"2da causa de muerte por RAM en Colombia (3,100 muertes en 2019). Constituye 10-11% de todos los aislados bacterianos.",resistance:{labels:["Infección Clínica","UCI Bogotá","Portadores Sanos"],datasets:[{label:"% Resistencia SARM",data:[43,62,20],backgroundColor:"rgba(13, 148, 136, 0.6)",borderColor:"rgba(13, 148, 136, 1)",borderWidth:1,sources:["Infección Clínica (Expertos 2022)","UCI Bogotá (GREBO 2001-03)","Portadores Sanos (Expertos 2022)"]}]},intrinsic:["Aztreonam","Polimixinas"],considerations:"La prevalencia de SARM es alta y depende del contexto: 43% en infecciones clínicas, pero puede superar el 60% en UCI. Esto requiere el uso empírico de terapias alternativas como vancomicina en pacientes críticos."},e_faecium:{name:"Enterococcus faecium",burden:"Patógeno de alta preocupación en UCI, especialmente por VRE.",resistance:{labels:["Vancomicina (ERV)","Vancomicina (ERV)"],datasets:[{label:"% Resistencia",data:[40.1,54.5],backgroundColor:"rgba(13, 148, 136, 0.6)",borderColor:"rgba(13, 148, 136, 1)",borderWidth:1,sources:["UCI Adultos (INS 2022)","UCI Neonatal (INS 2022)"]}]},intrinsic:["Cefalosporinas","Clindamicina","TMP/SMX"],considerations:"La resistencia a vancomicina (ERV) es muy preocupante, especialmente en E. faecium, superando el 40% en UCI de adultos y un alarmante 54% en UCI neonatales."},s_pneumoniae:{name:"Streptococcus pneumoniae",burden:"Principal causa de Neumonía Adquirida en la Comunidad, meningitis y bacteriemia. La resistencia complica el tratamiento de la enfermedad invasiva.",resistance:{labels:["Penicilina (Meningeo)","Ceftriaxona (Meningeo)","Penicilina (No Meningeo)","Ceftriaxona (No Meningeo)"],datasets:[{label:"% Resistencia o Susc. Disminuida",data:[41.3,21.7,28.2,24.2],backgroundColor:"rgba(13, 148, 136, 0.6)",borderColor:"rgba(13, 148, 136, 1)",borderWidth:1,sources:["IPD Pediátrica 2017-22","IPD Pediátrica 2017-22","IPD Pediátrica 2017-22","IPD Pediátrica 2017-22"]}]},intrinsic:["Aminoglucósidos (bajo nivel)"],considerations:"La resistencia está fuertemente ligada al serotipo 19A, no cubierto por la vacuna PCV10. Estos datos de vigilancia impulsaron el cambio de política nacional a la vacuna PCV13 para mejorar la cobertura."}},crossResistanceData:[{title:"Producción de BLEE (ESBL)",content:"<strong>En:</strong> E. coli, K. pneumoniae, P. mirabilis.<br><strong>Implica Resistencia a:</strong> Todas las penicilinas, todas las cefalosporinas (1ra-4ta gen), y aztreonam, sin importar el resultado in vitro.<br><strong>Nota Clínica:</strong> Reportar estos agentes como resistentes. Los carbapenems permanecen activos. La susceptibilidad a combinaciones con inhibidores (ej. Pip/Tazo) es variable."},{title:"Producción de Carbapenemasa (ej. KPC)",content:"<strong>En:</strong> Enterobacterales, P. aeruginosa, A. baumannii.<br><strong>Implica Resistencia a:</strong> Todos los beta-lactámicos (penicilinas, cefalosporinas, carbapenems).<br><strong>Nota Clínica:</strong> Hallazgo de salud pública crítico. El tratamiento requiere agentes noveles (ej. ceftazidima-avibactam) o terapia combinada."},{title:"S. aureus Meticilino-Resistente (SARM)",content:"<strong>En:</strong> S. aureus.<br><strong>Implica Resistencia a:</strong> Todos los beta-lactámicos (excepto ceftarolina).<br><strong>Nota Clínica:</strong> Usar Cefoxitin como marcador. Reportar como resistente a todos los beta-lactámicos. Opciones terapéuticas incluyen vancomicina, daptomicina, linezolid."},{title:"Resistencia a Fluoroquinolonas de Alto Nivel",content:"<strong>En:</strong> Enterobacterales, P. aeruginosa.<br><strong>Implica Resistencia a:</strong> Alta probabilidad de resistencia a todas las fluoroquinolonas (ciprofloxacina, levofloxacina, etc.).<br><strong>Nota Clínica:</strong> No se recomienda probar una segunda fluoroquinolona; la resistencia a una predice la resistencia de clase."},{title:"Resistencia Inducible a Clindamicina (Test D+)",content:"<strong>En:</strong> Estafilococos, S. pyogenes.<br><strong>Implica Resistencia a:</strong> Falla terapéutica con clindamicina in vivo a pesar de parecer susceptible in vitro.<br><strong>Nota Clínica:</strong> Si el test de aproximación de discos (D-test) es positivo, reportar clindamicina como resistente."}]};_e.useEffect(()=>{typeof window<"u"&&window.Chart&&z();const H=()=>{const Y=window.location.hash.replace("#","");["resumen","patogenos","principios"].includes(Y)&&d(Y)};return window.addEventListener("hashchange",H),H(),()=>{window.removeEventListener("hashchange",H)}},[c]);const z=()=>{if(c==="resumen"){const H=document.getElementById("topPathogensChart");if(H&&!P){const Y=new window.Chart(H,{type:"bar",data:{labels:y.topPathogens.labels,datasets:[{label:"Muertes Asociadas",data:y.topPathogens.data,backgroundColor:"rgba(13, 148, 136, 0.6)",borderColor:"rgba(13, 148, 136, 1)",borderWidth:1}]},options:{indexAxis:"y",responsive:!0,maintainAspectRatio:!1,plugins:{legend:{display:!1},tooltip:{callbacks:{label:M=>` ${M.raw.toLocaleString()} muertes`}}},scales:{x:{beginAtZero:!0,title:{display:!0,text:"Número de Muertes (Estimado 2019)"}}}}});L(Y)}}c==="patogenos"&&q()},q=()=>{const H=y.pathogens[u];if(!H)return;const Y=document.getElementById("resistanceChart");if(Y){E&&E.destroy();const M=new window.Chart(Y,{type:"bar",data:H.resistance,options:{responsive:!0,maintainAspectRatio:!1,scales:{y:{beginAtZero:!0,max:100,title:{display:!0,text:"% Resistencia"}}},plugins:{legend:{display:H.resistance.datasets.length>1},tooltip:{callbacks:{label:V=>` ${V.dataset.label||""}: ${V.raw}%`,afterLabel:V=>`Fuente: ${V.dataset.sources?V.dataset.sources[V.dataIndex]:""}`}}}}});O(M)}};_e.useEffect(()=>(c==="patogenos"&&u&&q(),()=>{E&&E.destroy(),P&&P.destroy()}),[u]);const ie=()=>s.jsxs("div",{className:"space-y-8",children:[s.jsxs("header",{className:"mb-8",children:[s.jsx("h2",{className:"text-3xl font-bold text-slate-900",children:"Panorama de la Resistencia Antimicrobiana en Colombia"}),s.jsx("p",{className:"mt-2 text-slate-600",children:"Un resumen del impacto, los patógenos clave y los sistemas de vigilancia que definen el desafío de la RAM en el país."})]}),s.jsxs("div",{className:"bg-white p-6 rounded-lg shadow-sm border border-slate-200",children:[s.jsx("h3",{className:"text-xl font-semibold text-slate-900 mb-4",children:"Carga de Mortalidad por RAM en Colombia (Datos 2019)"}),s.jsx("p",{className:"text-slate-600 mb-6",children:"La resistencia antimicrobiana es una de las principales causas de muerte en Colombia, superando la mortalidad combinada de varias enfermedades crónicas. Los datos del IHME de 2019 revelan la escala del problema."}),s.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-6",children:[s.jsxs("div",{className:"bg-red-50 p-6 rounded-lg border border-red-200",children:[s.jsx("h4",{className:"font-semibold text-red-800 mb-2",children:"Mortalidad Asociada a la RAM"}),s.jsx("p",{className:"text-4xl font-bold text-red-600",children:"18,200"}),s.jsx("p",{className:"text-red-700",children:"muertes en las que una infección resistente fue un factor contribuyente."})]}),s.jsxs("div",{className:"bg-red-50 p-6 rounded-lg border border-red-200",children:[s.jsx("h4",{className:"font-semibold text-red-800 mb-2",children:"Mortalidad Atribuible a la RAM"}),s.jsx("p",{className:"text-4xl font-bold text-red-700",children:"4,700"}),s.jsx("p",{className:"text-red-700",children:"muertes directamente causadas por la infección resistente."})]})]})]}),s.jsxs("div",{className:"bg-white p-6 rounded-lg shadow-sm border border-slate-200",children:[s.jsx("h3",{className:"text-xl font-semibold text-slate-900 mb-4",children:"Patógenos con Mayor Mortalidad Asociada en Colombia (2019)"}),s.jsx("div",{className:"chart-container",style:{position:"relative",height:"350px",maxHeight:"40vh"},children:s.jsx("canvas",{id:"topPathogensChart"})}),s.jsx("p",{className:"text-xs text-center text-slate-500 mt-2",children:"Fuente: IHME 2019. Pase el cursor sobre las barras para ver el número de muertes."})]}),s.jsxs("div",{className:"bg-white p-6 rounded-lg shadow-sm border border-slate-200",children:[s.jsx("h3",{className:"text-xl font-semibold text-slate-900 mb-4",children:"Arquitectura de la Vigilancia de la RAM en Colombia"}),s.jsx("p",{className:"text-slate-600 mb-6",children:'Colombia utiliza un enfoque de "Una Salud" y triangulación de datos, integrando información de múltiples niveles. Para un antibiograma local, es crucial priorizar datos locales (propios o de redes como GREBO), contextualizarlos con datos nacionales (INS/SIVIGILA) y compararlos con benchmarks regionales (PAHO/ReLAVRA+).'}),s.jsxs("div",{className:"grid grid-cols-1 sm:grid-cols-2 lg:grid-cols-3 gap-4 text-center",children:[s.jsxs("div",{className:"p-4 bg-teal-50 border border-teal-200 rounded-lg",children:[s.jsx("h4",{className:"font-semibold text-teal-800",children:"Local (GREBO)"}),s.jsx("p",{className:"text-sm text-teal-700",children:"Red de hospitales en Bogotá. Provee datos de alta granularidad, especialmente de UCI, que suelen mostrar tasas de resistencia más altas que el promedio nacional."})]}),s.jsxs("div",{className:"p-4 bg-blue-50 border border-blue-200 rounded-lg",children:[s.jsx("h4",{className:"font-semibold text-blue-800",children:"Nacional (INS/SIVIGILA)"}),s.jsxs("p",{className:"text-sm text-blue-700",children:["Sistema de reporte obligatorio nacional. Provee la data oficial del país.",s.jsx("strong",{className:"text-blue-900",children:" Nota:"})," Sufrió una brecha de reportes en 2020 durante la pandemia."]})]}),s.jsxs("div",{className:"p-4 bg-indigo-50 border border-indigo-200 rounded-lg",children:[s.jsx("h4",{className:"font-semibold text-indigo-800",children:"Regional (PAHO/ReLAVRA+)"}),s.jsx("p",{className:"text-sm text-indigo-700",children:"Red latinoamericana que agrega datos de 20 países. Permite la comparación y el benchmarking regional. Usa CLSI como estándar."})]})]})]})]}),B=()=>{var H,Y,M,V,X;return s.jsxs("div",{className:"space-y-6",children:[s.jsxs("header",{className:"mb-8",children:[s.jsx("h2",{className:"text-3xl font-bold text-slate-900",children:"Perfiles de Resistencia por Patógeno"}),s.jsx("p",{className:"mt-2 text-slate-600",children:"Seleccione un patógeno para visualizar su perfil de resistencia, carga epidemiológica y consideraciones clave, basado en la triangulación de datos de vigilancia colombianos."})]}),s.jsxs("div",{className:"mb-6 bg-white p-4 rounded-lg shadow-sm border border-slate-200",children:[s.jsx("label",{htmlFor:"pathogen-select",className:"block text-sm font-medium text-slate-700 mb-2",children:"Seleccionar Patógeno:"}),s.jsxs("select",{id:"pathogen-select",value:u,onChange:Z=>_(Z.target.value),className:"w-full md:w-1/2 p-2 border border-slate-300 rounded-md shadow-sm focus:ring-teal-500 focus:border-teal-500",children:[s.jsx("option",{value:"p_aeruginosa",children:"Pseudomonas aeruginosa"}),s.jsx("option",{value:"e_coli",children:"Escherichia coli"}),s.jsx("option",{value:"k_pneumoniae",children:"Klebsiella pneumoniae"}),s.jsx("option",{value:"e_cloacae",children:"Enterobacter cloacae complex"}),s.jsx("option",{value:"a_baumannii",children:"Acinetobacter baumannii"}),s.jsx("option",{value:"s_aureus",children:"Staphylococcus aureus"}),s.jsx("option",{value:"e_faecium",children:"Enterococcus faecium"}),s.jsx("option",{value:"s_pneumoniae",children:"Streptococcus pneumoniae"})]})]}),s.jsxs("div",{className:"grid grid-cols-1 lg:grid-cols-3 gap-6",children:[s.jsxs("div",{className:"lg:col-span-2 bg-white p-6 rounded-lg shadow-sm border border-slate-200",children:[s.jsxs("h3",{className:"text-xl font-semibold text-slate-900 mb-4",children:["Perfil de Resistencia para ",(H=y.pathogens[u])==null?void 0:H.name]}),s.jsx("div",{className:"chart-container",style:{position:"relative",height:"400px"},children:s.jsx("canvas",{id:"resistanceChart"})}),s.jsx("p",{className:"text-xs text-center text-slate-500 mt-2",children:"Pase el cursor sobre las barras para ver el porcentaje y la fuente del dato."})]}),s.jsxs("div",{className:"space-y-6",children:[s.jsxs("div",{className:"bg-white p-6 rounded-lg shadow-sm border border-slate-200",children:[s.jsx("h4",{className:"font-semibold text-slate-900 mb-2",children:"Carga Epidemiológica"}),s.jsx("p",{className:"text-sm text-slate-600",children:(Y=y.pathogens[u])==null?void 0:Y.burden})]}),s.jsxs("div",{className:"bg-white p-6 rounded-lg shadow-sm border border-slate-200",children:[s.jsx("h4",{className:"font-semibold text-slate-900 mb-2",children:"Consideraciones Clave y Tendencias"}),s.jsx("p",{className:"text-sm text-slate-600",children:(M=y.pathogens[u])==null?void 0:M.considerations})]}),s.jsxs("div",{className:"bg-white p-6 rounded-lg shadow-sm border border-slate-200",children:[s.jsx("h4",{className:"font-semibold text-slate-900 mb-2",children:"Resistencia Intrínseca"}),s.jsx("p",{className:"text-sm text-slate-600 mb-2",children:"Este patógeno es naturalmente resistente a los siguientes agentes. No deben ser usados."}),s.jsx("ul",{className:"list-disc list-inside text-sm text-slate-600 space-y-1",children:((X=(V=y.pathogens[u])==null?void 0:V.intrinsic)==null?void 0:X.length)>0?y.pathogens[u].intrinsic.map((Z,K)=>s.jsx("li",{children:Z},K)):s.jsx("li",{children:"Ninguna resistencia intrínseca común a destacar."})})]})]})]})]})},Q=()=>s.jsxs("div",{className:"space-y-8",children:[s.jsxs("header",{className:"mb-8",children:[s.jsx("h2",{className:"text-3xl font-bold text-slate-900",children:"Principios Clave y Hallazgos del Informe"}),s.jsx("p",{className:"mt-2 text-slate-600",children:"Conceptos y conclusiones fundamentales del análisis de la resistencia en Colombia para la interpretación y uso adecuado de los datos."})]}),s.jsxs("div",{className:"bg-white p-6 rounded-lg shadow-sm border border-slate-200",children:[s.jsx("h3",{className:"text-xl font-semibold text-slate-900 mb-4",children:"Hallazgos y Tendencias Críticas del Informe"}),s.jsx("p",{className:"text-slate-600 mb-6",children:"El análisis de los datos de vigilancia colombianos revela varias tendencias y conclusiones que son cruciales para la práctica clínica y la salud pública."}),s.jsxs("div",{className:"space-y-4",children:[s.jsxs("div",{className:"flex items-start gap-4 p-4 bg-amber-50 border-l-4 border-amber-500 rounded-r-lg",children:[s.jsx("span",{className:"text-2xl mt-1",children:"📈"}),s.jsxs("div",{children:[s.jsx("h4",{className:"font-bold text-amber-800",children:"Tendencia de Alarma: Resistencia Creciente en P. aeruginosa"}),s.jsxs("p",{className:"text-sm text-amber-700",children:["El hallazgo más consistente y estadísticamente significativo del período 2018-2021 fue el aumento de la resistencia de P. aeruginosa a ",s.jsx("strong",{children:"Piperacilina-Tazobactam y Carbapenems"}),". La eficacia de estas terapias de primera línea está disminuyendo activamente a nivel nacional."]})]})]}),s.jsxs("div",{className:"flex items-start gap-4 p-4 bg-sky-50 border-l-4 border-sky-500 rounded-r-lg",children:[s.jsx("span",{className:"text-2xl mt-1",children:"💉"}),s.jsxs("div",{children:[s.jsx("h4",{className:"font-bold text-sky-800",children:"Impacto de la Vigilancia en Políticas Públicas: Caso S. pneumoniae"}),s.jsx("p",{className:"text-sm text-sky-700",children:"La vigilancia demostró que la alta resistencia a penicilina y ceftriaxona en niños estaba ligada al serotipo 19A, no cubierto por la vacuna PCV10. Este dato fue fundamental para impulsar el cambio de la política nacional de vacunación a la PCV13, que sí cubre este serotipo."})]})]}),s.jsxs("div",{className:"flex items-start gap-4 p-4 bg-violet-50 border-l-4 border-violet-500 rounded-r-lg",children:[s.jsx("span",{className:"text-2xl mt-1",children:"🧩"}),s.jsxs("div",{children:[s.jsx("h4",{className:"font-bold text-violet-800",children:"El Imperativo de la Triangulación de Datos"}),s.jsxs("p",{className:"text-sm text-violet-700",children:["Un antibiograma local preciso no puede basarse en una sola fuente. Es esencial triangular la información: priorizar los ",s.jsx("strong",{children:"datos locales"})," (del propio hospital o de redes como GREBO), contextualizarlos con los ",s.jsx("strong",{children:"datos nacionales"})," (INS), y compararlos con los ",s.jsx("strong",{children:"benchmarks regionales"})," (PAHO/ReLAVRA+)."]})]})]})]})]}),s.jsxs("div",{className:"bg-white p-6 rounded-lg shadow-sm border border-slate-200",children:[s.jsx("h3",{className:"text-xl font-semibold text-slate-900 mb-4",children:"Resistencia Cruzada: Interpretando Fenotipos Complejos"}),s.jsx("p",{className:"text-slate-600 mb-4",children:"Un único mecanismo de resistencia puede conferir insensibilidad a múltiples fármacos. Reconocer estos fenotipos es clave para la interpretación. Haga clic en cada fenotipo para ver los detalles."}),s.jsx("div",{className:"space-y-2",children:y.crossResistanceData.map((H,Y)=>s.jsx(Fg,{title:H.title,content:H.content},Y))})]}),s.jsxs("div",{className:"bg-white p-6 rounded-lg shadow-sm border border-slate-200",children:[s.jsx("h3",{className:"text-xl font-semibold text-slate-900 mb-4",children:"Estrategias de Reporte Avanzadas (Stewardship)"}),s.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-6",children:[s.jsxs("div",{children:[s.jsx("h4",{className:"font-semibold text-slate-800",children:"Reporte en Cascada"}),s.jsx("p",{className:"text-slate-600 text-sm",children:"Práctica de suprimir los resultados de antibióticos de amplio espectro cuando un aislado es susceptible a un agente de espectro más estrecho y terapéuticamente equivalente. Esto guía al clínico a usar el fármaco más dirigido, preservando los de amplio espectro."})]}),s.jsxs("div",{children:[s.jsx("h4",{className:"font-semibold text-slate-800",children:"Reporte Selectivo"}),s.jsx("p",{className:"text-slate-600 text-sm",children:"Consiste en suprimir el resultado de un antibiótico que es clínicamente ineficaz para un tipo de infección específico, sin importar el resultado in vitro. Ejemplo: suprimir el resultado de daptomicina para un S. aureus de origen respiratorio, ya que es inactivado por el surfactante pulmonar."})]})]})]})]});return s.jsxs("div",{className:"min-h-full bg-slate-50 text-slate-800",children:[s.jsx("div",{className:"bg-white shadow-sm border-b border-slate-200 sticky top-0 z-10",children:s.jsx("div",{className:"max-w-7xl mx-auto px-4 sm:px-6 lg:px-8 py-4",children:s.jsxs("div",{className:"flex items-center justify-between",children:[s.jsxs("button",{onClick:m,className:"flex items-center text-gray-600 hover:text-gray-800 transition-colors",children:[s.jsx("span",{className:"mr-2",children:"←"}),s.jsx("span",{className:"text-sm",children:"Volver al Inicio"})]}),s.jsxs("div",{className:"text-center",children:[s.jsx("h1",{className:"text-2xl font-bold text-teal-700",children:"Guía RAM - Colombia"}),s.jsx("p",{className:"text-sm text-slate-600",children:"Atlas Epidemiológico Nacional"})]}),s.jsx("div",{className:"w-24"})]})})}),s.jsxs("div",{className:"flex flex-col md:flex-row",children:[s.jsx("aside",{className:"w-full md:w-64 bg-white md:border-r border-slate-200 p-4",children:s.jsxs("nav",{className:"flex flex-row md:flex-col gap-2",children:[s.jsxs("button",{onClick:()=>{d("resumen"),window.history.pushState(null,"","#resumen")},className:`nav-link flex items-center gap-3 p-3 rounded-lg text-sm font-medium transition-all ${c==="resumen"?"bg-teal-600 text-white":"text-slate-600 hover:bg-slate-100"}`,children:[s.jsx("span",{className:"text-xl",children:"🏠"}),s.jsx("span",{children:"Resumen Nacional"})]}),s.jsxs("button",{onClick:()=>{d("patogenos"),window.history.pushState(null,"","#patogenos")},className:`nav-link flex items-center gap-3 p-3 rounded-lg text-sm font-medium transition-all ${c==="patogenos"?"bg-teal-600 text-white":"text-slate-600 hover:bg-slate-100"}`,children:[s.jsx("span",{className:"text-xl",children:"🦠"}),s.jsx("span",{children:"Perfiles de Patógenos"})]}),s.jsxs("button",{onClick:()=>{d("principios"),window.history.pushState(null,"","#principios")},className:`nav-link flex items-center gap-3 p-3 rounded-lg text-sm font-medium transition-all ${c==="principios"?"bg-teal-600 text-white":"text-slate-600 hover:bg-slate-100"}`,children:[s.jsx("span",{className:"text-xl",children:"🔬"}),s.jsx("span",{children:"Principios Clave"})]})]})}),s.jsxs("main",{className:"flex-1 p-4 sm:p-6 lg:p-8",children:[s.jsx("div",{className:`view ${c==="resumen"?"active":""}`,style:{display:c==="resumen"?"block":"none",animation:c==="resumen"?"fadeIn 0.5s":"none"},children:c==="resumen"&&ie()}),s.jsx("div",{className:`view ${c==="patogenos"?"active":""}`,style:{display:c==="patogenos"?"block":"none",animation:c==="patogenos"?"fadeIn 0.5s":"none"},children:c==="patogenos"&&B()}),s.jsx("div",{className:`view ${c==="principios"?"active":""}`,style:{display:c==="principios"?"block":"none",animation:c==="principios"?"fadeIn 0.5s":"none"},children:c==="principios"&&Q()})]})]})]})},Fg=({title:m,content:c})=>{const[d,u]=_e.useState(!1),[_,E]=_e.useState("0"),O=()=>{u(!d),E(d?"0":"200px")};return s.jsxs("div",{className:"border border-slate-200 rounded-lg",children:[s.jsxs("button",{onClick:O,className:"w-full text-left p-4 bg-slate-100 hover:bg-slate-200 rounded-lg font-semibold flex justify-between items-center",children:[s.jsx("span",{children:m}),s.jsx("span",{className:`transform transition-transform duration-300 ${d?"rotate-180":""}`,children:"▼"})]}),s.jsx("div",{className:"accordion-content bg-white border-t border-slate-200 rounded-b-lg overflow-hidden",style:{maxHeight:_},children:s.jsx("div",{className:"p-4",children:s.jsx("div",{className:"text-sm text-slate-700",dangerouslySetInnerHTML:{__html:c}})})})]})},$g=()=>{const[m,c]=_e.useState("landing"),d=E=>{E==="antibiogram"?c("antibiogram"):E==="syndromes"&&c("syndromes")},u=()=>{c("landing")};return(()=>{switch(m){case"antibiogram":return s.jsx(Zg,{onBackToLanding:u});case"syndromes":return s.jsx(Jg,{onBackToLanding:u});case"landing":default:return s.jsx(ab,{onSelectSection:d})}})()};tb.createRoot(document.getElementById("root")).render(s.jsx(_e.StrictMode,{children:s.jsx($g,{})}));
